<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Méndez-Vidal, Cristina</style></author><author><style face="normal" font="default" size="100%">Bravo-Gil, Nereida</style></author><author><style face="normal" font="default" size="100%">Perez-Florido, Javier</style></author><author><style face="normal" font="default" size="100%">Marcos-Luque, Irene</style></author><author><style face="normal" font="default" size="100%">Fernández, Raquel M</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rueda, Jose Luis</style></author><author><style face="normal" font="default" size="100%">González-del Pozo, María</style></author><author><style face="normal" font="default" size="100%">Martín-Sánchez, Marta</style></author><author><style face="normal" font="default" size="100%">Fernández-Suárez, Elena</style></author><author><style face="normal" font="default" size="100%">Mena, Marcela</style></author><author><style face="normal" font="default" size="100%">Carmona, Rosario</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Borrego, Salud</style></author><author><style face="normal" font="default" size="100%">Antiňolo, Guillermo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A genomic strategy for precision medicine in rare diseases: integrating customized algorithms into clinical practice.</style></title><secondary-title><style face="normal" font="default" size="100%">J Transl Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">J Transl Med</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">High-Throughput Nucleotide Sequencing</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Precision Medicine</style></keyword><keyword><style  face="normal" font="default" size="100%">rare diseases</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2025 Jan 20</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">23</style></volume><pages><style face="normal" font="default" size="100%">86</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Despite the use of Next-Generation Sequencing (NGS) as the gold standard for the diagnosis of rare diseases, its clinical implementation has been challenging, limiting the cost-effectiveness of NGS and the understanding, control and safety essential for decision-making in clinical applications. Here, we describe a personalized NGS-based strategy integrating precision medicine into a public healthcare system and its implementation in the routine diagnosis process during a five-year pilot program.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;Our approach involved customized probe designs, the generation of virtual panels and the development of a personalized medicine module (PMM) for variant prioritization. This strategy was applied to 6500 individuals including 6267 index patients and 233 NGS-based carrier screenings.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Causative variants were identified in 2061 index patients (average 32.9%, ranging from 12 to 62% by condition). Also, 131 autosomal-recessive cases could be partially genetically diagnosed. These results led to over 5000 additional studies including carrier, prenatal and preimplantational tests or pharmacological and gene therapy treatments.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;This strategy has shown promising improvements in the diagnostic rate, facilitating timely diagnosis and gradually expanding our services portfolio for rare diseases. The steps taken towards the integration of clinical and genomic data are opening new possibilities for conducting both retrospective and prospective healthcare studies. Overall, this study represents a major milestone in the ongoing efforts to improve our understanding and clinical management of rare diseases, a crucial area of medical research and care.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martínez-Nava, Gabriela Angélica</style></author><author><style face="normal" font="default" size="100%">Altamirano-Molina, Efren</style></author><author><style face="normal" font="default" size="100%">Vázquez-Mellado, Janitzia</style></author><author><style face="normal" font="default" size="100%">Casimiro-Soriguer, Carlos S</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Lozada-Pérez, Carlos</style></author><author><style face="normal" font="default" size="100%">Herrera-López, Brígida</style></author><author><style face="normal" font="default" size="100%">Martínez-Gómez, Laura Edith</style></author><author><style face="normal" font="default" size="100%">Martínez-Armenta, Carlos</style></author><author><style face="normal" font="default" size="100%">Guido-Gómora, Dafne Lissete</style></author><author><style face="normal" font="default" size="100%">Valle-Gutiérrez, Sarahí</style></author><author><style face="normal" font="default" size="100%">Suarez-Ahedo, Carlos</style></author><author><style face="normal" font="default" size="100%">Camacho-Rea, María Del Carmen</style></author><author><style face="normal" font="default" size="100%">Martínez-García, Mireya</style></author><author><style face="normal" font="default" size="100%">Gutiérrez-Esparza, Guadalupe</style></author><author><style face="normal" font="default" size="100%">Amezcua-Guerra, Luis M</style></author><author><style face="normal" font="default" size="100%">Zamudio-Cuevas, Yessica</style></author><author><style face="normal" font="default" size="100%">Martínez-Flores, Karina</style></author><author><style face="normal" font="default" size="100%">Fernández-Torres, Javier</style></author><author><style face="normal" font="default" size="100%">Burguete-García, Ana I</style></author><author><style face="normal" font="default" size="100%">Orbe-Orihuela, Yaneth Citlalli</style></author><author><style face="normal" font="default" size="100%">Lagunas-Martínez, Alfredo</style></author><author><style face="normal" font="default" size="100%">Méndez-Salazar, Eder Orlando</style></author><author><style face="normal" font="default" size="100%">Francisco-Balderas, Adriana</style></author><author><style face="normal" font="default" size="100%">Palacios-González, Berenice</style></author><author><style face="normal" font="default" size="100%">Pineda, Carlos</style></author><author><style face="normal" font="default" size="100%">López-Reyes, Alberto</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Metatranscriptomic analysis reveals gut microbiome bacterial genes in pyruvate and amino acid metabolism associated with hyperuricemia and gout in humans.</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Sci Rep</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Amino Acids</style></keyword><keyword><style  face="normal" font="default" size="100%">Bacteria</style></keyword><keyword><style  face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Feces</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Gastrointestinal Microbiome</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Genes, Bacterial</style></keyword><keyword><style  face="normal" font="default" size="100%">Gout</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Hyperuricemia</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Pyruvic Acid</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcriptome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2025 Mar 22</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">9981</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Several pathologies with metabolic origin, such as hyperuricemia and gout, have been associated with the gut microbiota taxonomic profile. However, there is no evidence of which bacterial genes are being expressed in the gut microbiome, and of their potential effects on hyperuricemia and gout. We sequenced the RNA of 26 fecal samples from 10 healthy normouricemic controls, 10 with asymptomatic hyperuricemia (AH), and six gout patients. The coding sequences were mapped to KEGG orthologues (KO). We compared the expression levels using generalized linear models and validated the expression of four KO in a larger sample by qRT-PCR. A distinct genetic expression pattern was identified among groups. AH individuals and gout patients showed an over-expression of KOs mainly related to pyruvate metabolism (Log2foldchange &gt; 23, p-adj ≤ 3.56 × 10), the pentose pathway (Log2foldchange &gt; 24, p-adj &lt; 1.10 × 10) and purine metabolism (Log2foldchange &gt; 22, p-adj &lt; 1.25 × 10). AH subjects had lower expression of KO related to glycine metabolism (Log2foldchange=-18, p-adj &lt; 1.72 × 10) than controls. Gout patients had lower expression (Log2foldchange=-22.42, p-adj &lt; 3.31 × 10) of a KO involved in phenylalanine biosynthesis, in comparison to controls and AH subjects. The over-expression seen for the KO related to pyruvate metabolism and the pentose pathway in gout patients´ microbiome was validated. There is a differential gene expression pattern in the gut microbiome of normouricemic individuals, AH subjects and gout patients. These differences are mainly located in metabolic pathways involved in acetate precursors and bioavailability of amino acids.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Greene, Daniel</style></author><author><style face="normal" font="default" size="100%">De Wispelaere, Koenraad</style></author><author><style face="normal" font="default" size="100%">Lees, Jon</style></author><author><style face="normal" font="default" size="100%">Codina-Solà, Marta</style></author><author><style face="normal" font="default" size="100%">Jensson, Brynjar O.</style></author><author><style face="normal" font="default" size="100%">Hales, Emma</style></author><author><style face="normal" font="default" size="100%">Katrinecz, Andrea</style></author><author><style face="normal" font="default" size="100%">Nieto Molina, Esther</style></author><author><style face="normal" font="default" size="100%">Sevilla Porras, Marta</style></author><author><style face="normal" font="default" size="100%">Pascoal, Sonia</style></author><author><style face="normal" font="default" size="100%">Valenzuela, Irene</style></author><author><style face="normal" font="default" size="100%">Pfundt, Rolph</style></author><author><style face="normal" font="default" size="100%">Schot, Rachel</style></author><author><style face="normal" font="default" size="100%">Sleutels, Frank</style></author><author><style face="normal" font="default" size="100%">Wijngaard, Robin</style></author><author><style face="normal" font="default" size="100%">Arroyo Carrera, Ignacio</style></author><author><style face="normal" font="default" size="100%">Duat Rodríguez, Anna</style></author><author><style face="normal" font="default" size="100%">Atton, Giles</style></author><author><style face="normal" font="default" size="100%">Casas-Alba, Didac</style></author><author><style face="normal" font="default" size="100%">Donnelly, Deirdre</style></author><author><style face="normal" font="default" size="100%">Fernández Garoz, Bárbara</style></author><author><style face="normal" font="default" size="100%">Foulds, Nicola</style></author><author><style face="normal" font="default" size="100%">García-Navas Núñez, Deyanira</style></author><author><style face="normal" font="default" size="100%">González Alguacil, Elena</style></author><author><style face="normal" font="default" size="100%">Jarvis, Joanna</style></author><author><style face="normal" font="default" size="100%">Kant, Sarina G.</style></author><author><style face="normal" font="default" size="100%">Madrigal Bajo, Irene</style></author><author><style face="normal" font="default" size="100%">Martinez-Monseny, Antonio F.</style></author><author><style face="normal" font="default" size="100%">McKee, Shane</style></author><author><style face="normal" font="default" size="100%">Sariego Jamardo, Andrea</style></author><author><style face="normal" font="default" size="100%">Stefansson, Kari</style></author><author><style face="normal" font="default" size="100%">Rodríguez-Revenga Bodi, Laia</style></author><author><style face="normal" font="default" size="100%">Ortiz Cabrera, Nelmar Valentina</style></author><author><style face="normal" font="default" size="100%">Sulem, Patrick</style></author><author><style face="normal" font="default" size="100%">Suri, Mohnish</style></author><author><style face="normal" font="default" size="100%">Van Karnebeek, Clara</style></author><author><style face="normal" font="default" size="100%">Vasudevan, Pradeep</style></author><author><style face="normal" font="default" size="100%">Vega Pajares, Ana Isabel</style></author><author><style face="normal" font="default" size="100%">Carracedo, Ángel</style></author><author><style face="normal" font="default" size="100%">Engelen, Marc</style></author><author><style face="normal" font="default" size="100%">Lapunzina, Pablo</style></author><author><style face="normal" font="default" size="100%">Morgan, Natasha P.</style></author><author><style face="normal" font="default" size="100%">Morte, Beatriz</style></author><author><style face="normal" font="default" size="100%">Rump, Patrick</style></author><author><style face="normal" font="default" size="100%">Stirrups, Kathy</style></author><author><style face="normal" font="default" size="100%">Tizzano, Eduardo F.</style></author><author><style face="normal" font="default" size="100%">Barakat, Tahsin Stefan</style></author><author><style face="normal" font="default" size="100%">O’Donoghue, Michael</style></author><author><style face="normal" font="default" size="100%">Pérez-Jurado, Luis Alberto</style></author><author><style face="normal" font="default" size="100%">Freson, Kathleen</style></author><author><style face="normal" font="default" size="100%">Mumford, Andrew D.</style></author><author><style face="normal" font="default" size="100%">Turro, Ernest</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mutations in the small nuclear RNA gene RNU2-2 cause a severe neurodevelopmental disorder with prominent epilepsy</style></title><secondary-title><style face="normal" font="default" size="100%">Nature Genetics</style></secondary-title><short-title><style face="normal" font="default" size="100%">Nat Genet</style></short-title></titles><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Oct-04-2025</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.nature.com/articles/s41588-025-02159-5https://www.nature.com/articles/s41588-025-02159-5.pdfhttps://www.nature.com/articles/s41588-025-02159-5.pdfhttps://www.nature.com/articles/s41588-025-02159-5</style></url></web-urls></urls><language><style face="normal" font="default" size="100%">eng</style></language></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maillo, Alberto</style></author><author><style face="normal" font="default" size="100%">Huergo, Estefania</style></author><author><style face="normal" font="default" size="100%">Apellániz-Ruiz, María</style></author><author><style face="normal" font="default" size="100%">Urrutia-Lafuente, Edurne</style></author><author><style face="normal" font="default" size="100%">Miranda, María</style></author><author><style face="normal" font="default" size="100%">Salgado, Josefa</style></author><author><style face="normal" font="default" size="100%">Pasalodos-Sanchez, Sara</style></author><author><style face="normal" font="default" size="100%">Delgado-Mora, Luna</style></author><author><style face="normal" font="default" size="100%">Teijido, Óscar</style></author><author><style face="normal" font="default" size="100%">Goicoechea, Ibai</style></author><author><style face="normal" font="default" size="100%">Carmona, Rosario</style></author><author><style face="normal" font="default" size="100%">Perez-Florido, Javier</style></author><author><style face="normal" font="default" size="100%">Aquino, Virginia</style></author><author><style face="normal" font="default" size="100%">López-López, Daniel</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Beltran, Sergi</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Lasa, Iñigo</style></author><author><style face="normal" font="default" size="100%">Beloqui, Juan José</style></author><author><style face="normal" font="default" size="100%">Alonso, Ángel</style></author><author><style face="normal" font="default" size="100%">Gomez-Cabrero, David</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Characterization of the Common Genetic Variation in the Spanish Population of Navarre.</style></title><secondary-title><style face="normal" font="default" size="100%">Genes (Basel)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Genes (Basel)</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Exome</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Frequency</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Variation</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetics, Population</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome, Human</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style  face="normal" font="default" size="100%">Spain</style></keyword><keyword><style  face="normal" font="default" size="100%">Whole Genome Sequencing</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024 May 04</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Large-scale genomic studies have significantly increased our knowledge of genetic variability across populations. Regional genetic profiling is essential for distinguishing common benign variants from disease-causing ones. To this end, we conducted a comprehensive characterization of exonic variants in the population of Navarre (Spain), utilizing whole genome sequencing data from 358 unrelated individuals of Spanish origin. Our analysis revealed 61,410 biallelic single nucleotide variants (SNV) within the Navarrese cohort, with 35% classified as common (MAF &gt; 1%). By comparing allele frequency data from 1000 Genome Project (excluding the Iberian cohort of Spain, IBS), Genome Aggregation Database, and a Spanish cohort (including IBS individuals and data from Medical Genome Project), we identified 1069 SNVs common in Navarre but rare (MAF ≤ 1%) in all other populations. We further corroborated this observation with a second regional cohort of 239 unrelated exomes, which confirmed 676 of the 1069 SNVs as common in Navarre. In conclusion, this study highlights the importance of population-specific characterization of genetic variation to improve allele frequency filtering in sequencing data analysis to identify disease-causing variants.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Esteban-Medina, Marina</style></author><author><style face="normal" font="default" size="100%">de la Oliva Roque, Víctor Manuel</style></author><author><style face="normal" font="default" size="100%">Herráiz-Gil, Sara</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">drexml: A command line tool and Python package for drug repurposing.</style></title><secondary-title><style face="normal" font="default" size="100%">Comput Struct Biotechnol J</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Comput Struct Biotechnol J</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024 Dec</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">23</style></volume><pages><style face="normal" font="default" size="100%">1129-1143</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;We introduce drexml, a command line tool and Python package for rational data-driven drug repurposing. The package employs machine learning and mechanistic signal transduction modeling to identify drug targets capable of regulating a particular disease. In addition, it employs explainability tools to contextualize potential drug targets within the functional landscape of the disease. The methodology is validated in Fanconi Anemia and Familial Melanoma, two distinct rare diseases where there is a pressing need for solutions. In the Fanconi Anemia case, the model successfully predicts previously validated repurposed drugs, while in the Familial Melanoma case, it identifies a promising set of drugs for further investigation.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Niarakis, Anna</style></author><author><style face="normal" font="default" size="100%">Ostaszewski, Marek</style></author><author><style face="normal" font="default" size="100%">Mazein, Alexander</style></author><author><style face="normal" font="default" size="100%">Kuperstein, Inna</style></author><author><style face="normal" font="default" size="100%">Kutmon, Martina</style></author><author><style face="normal" font="default" size="100%">Gillespie, Marc E</style></author><author><style face="normal" font="default" size="100%">Funahashi, Akira</style></author><author><style face="normal" font="default" size="100%">Acencio, Marcio Luis</style></author><author><style face="normal" font="default" size="100%">Hemedan, Ahmed</style></author><author><style face="normal" font="default" size="100%">Aichem, Michael</style></author><author><style face="normal" font="default" size="100%">Klein, Karsten</style></author><author><style face="normal" font="default" size="100%">Czauderna, Tobias</style></author><author><style face="normal" font="default" size="100%">Burtscher, Felicia</style></author><author><style face="normal" font="default" size="100%">Yamada, Takahiro G</style></author><author><style face="normal" font="default" size="100%">Hiki, Yusuke</style></author><author><style face="normal" font="default" size="100%">Hiroi, Noriko F</style></author><author><style face="normal" font="default" size="100%">Hu, Finterly</style></author><author><style face="normal" font="default" size="100%">Pham, Nhung</style></author><author><style face="normal" font="default" size="100%">Ehrhart, Friederike</style></author><author><style face="normal" font="default" size="100%">Willighagen, Egon L</style></author><author><style face="normal" font="default" size="100%">Valdeolivas, Alberto</style></author><author><style face="normal" font="default" size="100%">Dugourd, Aurélien</style></author><author><style face="normal" font="default" size="100%">Messina, Francesco</style></author><author><style face="normal" font="default" size="100%">Esteban-Medina, Marina</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Rian, Kinza</style></author><author><style face="normal" font="default" size="100%">Soliman, Sylvain</style></author><author><style face="normal" font="default" size="100%">Aghamiri, Sara Sadat</style></author><author><style face="normal" font="default" size="100%">Puniya, Bhanwar Lal</style></author><author><style face="normal" font="default" size="100%">Naldi, Aurélien</style></author><author><style face="normal" font="default" size="100%">Helikar, Tomáš</style></author><author><style face="normal" font="default" size="100%">Singh, Vidisha</style></author><author><style face="normal" font="default" size="100%">Fernández, Marco Fariñas</style></author><author><style face="normal" font="default" size="100%">Bermudez, Viviam</style></author><author><style face="normal" font="default" size="100%">Tsirvouli, Eirini</style></author><author><style face="normal" font="default" size="100%">Montagud, Arnau</style></author><author><style face="normal" font="default" size="100%">Noël, Vincent</style></author><author><style face="normal" font="default" size="100%">Ponce-de-Leon, Miguel</style></author><author><style face="normal" font="default" size="100%">Maier, Dieter</style></author><author><style face="normal" font="default" size="100%">Bauch, Angela</style></author><author><style face="normal" font="default" size="100%">Gyori, Benjamin M</style></author><author><style face="normal" font="default" size="100%">Bachman, John A</style></author><author><style face="normal" font="default" size="100%">Luna, Augustin</style></author><author><style face="normal" font="default" size="100%">Piñero, Janet</style></author><author><style face="normal" font="default" size="100%">Furlong, Laura I</style></author><author><style face="normal" font="default" size="100%">Balaur, Irina</style></author><author><style face="normal" font="default" size="100%">Rougny, Adrien</style></author><author><style face="normal" font="default" size="100%">Jarosz, Yohan</style></author><author><style face="normal" font="default" size="100%">Overall, Rupert W</style></author><author><style face="normal" font="default" size="100%">Phair, Robert</style></author><author><style face="normal" font="default" size="100%">Perfetto, Livia</style></author><author><style face="normal" font="default" size="100%">Matthews, Lisa</style></author><author><style face="normal" font="default" size="100%">Rex, Devasahayam Arokia Balaya</style></author><author><style face="normal" font="default" size="100%">Orlic-Milacic, Marija</style></author><author><style face="normal" font="default" size="100%">Gomez, Luis Cristobal Monraz</style></author><author><style face="normal" font="default" size="100%">De Meulder, Bertrand</style></author><author><style face="normal" font="default" size="100%">Ravel, Jean Marie</style></author><author><style face="normal" font="default" size="100%">Jassal, Bijay</style></author><author><style face="normal" font="default" size="100%">Satagopam, Venkata</style></author><author><style face="normal" font="default" size="100%">Wu, Guanming</style></author><author><style face="normal" font="default" size="100%">Golebiewski, Martin</style></author><author><style face="normal" font="default" size="100%">Gawron, Piotr</style></author><author><style face="normal" font="default" size="100%">Calzone, Laurence</style></author><author><style face="normal" font="default" size="100%">Beckmann, Jacques S</style></author><author><style face="normal" font="default" size="100%">Evelo, Chris T</style></author><author><style face="normal" font="default" size="100%">D'Eustachio, Peter</style></author><author><style face="normal" font="default" size="100%">Schreiber, Falk</style></author><author><style face="normal" font="default" size="100%">Saez-Rodriguez, Julio</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Kuiper, Martin</style></author><author><style face="normal" font="default" size="100%">Valencia, Alfonso</style></author><author><style face="normal" font="default" size="100%">Wolkenhauer, Olaf</style></author><author><style face="normal" font="default" size="100%">Kitano, Hiroaki</style></author><author><style face="normal" font="default" size="100%">Barillot, Emmanuel</style></author><author><style face="normal" font="default" size="100%">Auffray, Charles</style></author><author><style face="normal" font="default" size="100%">Balling, Rudi</style></author><author><style face="normal" font="default" size="100%">Schneider, Reinhard</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">COVID-19 Disease Map Community</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches.</style></title><secondary-title><style face="normal" font="default" size="100%">Front Immunol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Front Immunol</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Computer Simulation</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">drug repositioning</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Systems biology</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">1282859</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;INTRODUCTION: &lt;/b&gt;The COVID-19 Disease Map project is a large-scale community effort uniting 277 scientists from 130 Institutions around the globe. We use high-quality, mechanistic content describing SARS-CoV-2-host interactions and develop interoperable bioinformatic pipelines for novel target identification and drug repurposing.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;Extensive community work allowed an impressive step forward in building interfaces between Systems Biology tools and platforms. Our framework can link biomolecules from omics data analysis and computational modelling to dysregulated pathways in a cell-, tissue- or patient-specific manner. Drug repurposing using text mining and AI-assisted analysis identified potential drugs, chemicals and microRNAs that could target the identified key factors.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Results revealed drugs already tested for anti-COVID-19 efficacy, providing a mechanistic context for their mode of action, and drugs already in clinical trials for treating other diseases, never tested against COVID-19.&lt;/p&gt;&lt;p&gt;&lt;b&gt;DISCUSSION: &lt;/b&gt;The key advance is that the proposed framework is versatile and expandable, offering a significant upgrade in the arsenal for virus-host interactions and other complex pathologies.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moura, David S</style></author><author><style face="normal" font="default" size="100%">Mondaza-Hernandez, Jose L</style></author><author><style face="normal" font="default" size="100%">Sanchez-Bustos, Paloma</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Cordero-Varela, Juan A</style></author><author><style face="normal" font="default" size="100%">Lopez-Alvarez, Maria</style></author><author><style face="normal" font="default" size="100%">Carrillo-Garcia, Jaime</style></author><author><style face="normal" font="default" size="100%">Martin-Ruiz, Marta</style></author><author><style face="normal" font="default" size="100%">Romero-Gonzalez, Pablo</style></author><author><style face="normal" font="default" size="100%">Renshaw-Calderon, Marta</style></author><author><style face="normal" font="default" size="100%">Ramos, Rafael</style></author><author><style face="normal" font="default" size="100%">Marcilla, David</style></author><author><style face="normal" font="default" size="100%">Alvarez-Alegret, Ramiro</style></author><author><style face="normal" font="default" size="100%">Agra-Pujol, Carolina</style></author><author><style face="normal" font="default" size="100%">Izquierdo, Francisco</style></author><author><style face="normal" font="default" size="100%">Ortega-Medina, Luis</style></author><author><style face="normal" font="default" size="100%">Martin-Davila, Francisco</style></author><author><style face="normal" font="default" size="100%">Hernandez-Leon, Carmen Nieves</style></author><author><style face="normal" font="default" size="100%">Romagosa, Cleofe</style></author><author><style face="normal" font="default" size="100%">Salgado, Maria Angeles Vaz</style></author><author><style face="normal" font="default" size="100%">Lavernia, Javier</style></author><author><style face="normal" font="default" size="100%">Bagué, Silvia</style></author><author><style face="normal" font="default" size="100%">Mayodormo-Aranda, Empar</style></author><author><style face="normal" font="default" size="100%">Alvarez, Rosa</style></author><author><style face="normal" font="default" size="100%">Valverde, Claudia</style></author><author><style face="normal" font="default" size="100%">Martinez-Trufero, Javier</style></author><author><style face="normal" font="default" size="100%">Castilla-Ramirez, Carolina</style></author><author><style face="normal" font="default" size="100%">Gutierrez, Antonio</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Hindi, Nadia</style></author><author><style face="normal" font="default" size="100%">Garcia-Foncillas, Jesus</style></author><author><style face="normal" font="default" size="100%">Martin-Broto, Javier</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.</style></title><secondary-title><style face="normal" font="default" size="100%">Cell Mol Life Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cell Mol Life Sci</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Antineoplastic Agents, Alkylating</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Line, Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Resistance, Neoplasm</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation, Neoplastic</style></keyword><keyword><style  face="normal" font="default" size="100%">HMGA1a Protein</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Leiomyosarcoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Sarcoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style  face="normal" font="default" size="100%">TOR Serine-Threonine Kinases</style></keyword><keyword><style  face="normal" font="default" size="100%">Trabectedin</style></keyword><keyword><style  face="normal" font="default" size="100%">Xenograft Model Antitumor Assays</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024 May 17</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">81</style></volume><pages><style face="normal" font="default" size="100%">219</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;HMGA1 is a structural epigenetic chromatin factor that has been associated with tumor progression and drug resistance. Here, we reported the prognostic/predictive value of HMGA1 for trabectedin in advanced soft-tissue sarcoma (STS) and the effect of inhibiting HMGA1 or the mTOR downstream pathway in trabectedin activity. The prognostic/predictive value of HMGA1 expression was assessed in a cohort of 301 STS patients at mRNA (n = 133) and protein level (n = 272), by HTG EdgeSeq transcriptomics and immunohistochemistry, respectively. The effect of HMGA1 silencing on trabectedin activity and gene expression profiling was measured in leiomyosarcoma cells. The effect of combining mTOR inhibitors with trabectedin was assessed on cell viability in vitro studies, whereas in vivo studies tested the activity of this combination. HMGA1 mRNA and protein expression were significantly associated with worse progression-free survival of trabectedin and worse overall survival in STS. HMGA1 silencing sensitized leiomyosarcoma cells for trabectedin treatment, reducing the spheroid area and increasing cell death. The downregulation of HGMA1 significantly decreased the enrichment of some specific gene sets, including the PI3K/AKT/mTOR pathway. The inhibition of mTOR, sensitized leiomyosarcoma cultures for trabectedin treatment, increasing cell death. In in vivo studies, the combination of rapamycin with trabectedin downregulated HMGA1 expression and stabilized tumor growth of 3-methylcholantrene-induced sarcoma-like models. HMGA1 is an adverse prognostic factor for trabectedin treatment in advanced STS. HMGA1 silencing increases trabectedin efficacy, in part by modulating the mTOR signaling pathway. Trabectedin plus mTOR inhibitors are active in preclinical models of sarcoma, downregulating HMGA1 expression levels and stabilizing tumor growth.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mavillard, Fabiola</style></author><author><style face="normal" font="default" size="100%">Perez-Florido, Javier</style></author><author><style face="normal" font="default" size="100%">Ortuno, Francisco M</style></author><author><style face="normal" font="default" size="100%">Valladares, Amador</style></author><author><style face="normal" font="default" size="100%">Álvarez-Villegas, Miren L</style></author><author><style face="normal" font="default" size="100%">Roldán, Gema</style></author><author><style face="normal" font="default" size="100%">Carmona, Rosario</style></author><author><style face="normal" font="default" size="100%">Soriano, Manuel</style></author><author><style face="normal" font="default" size="100%">Susarte, Santiago</style></author><author><style face="normal" font="default" size="100%">Fuentes, Pilar</style></author><author><style face="normal" font="default" size="100%">López-López, Daniel</style></author><author><style face="normal" font="default" size="100%">Nuñez-Negrillo, Ana María</style></author><author><style face="normal" font="default" size="100%">Carvajal, Alejandra</style></author><author><style face="normal" font="default" size="100%">Morgado, Yolanda</style></author><author><style face="normal" font="default" size="100%">Arteaga, Daniel</style></author><author><style face="normal" font="default" size="100%">Ufano, Rosa</style></author><author><style face="normal" font="default" size="100%">Mir, Pablo</style></author><author><style face="normal" font="default" size="100%">Gamella, Juan F</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Paradas, Carmen</style></author><author><style face="normal" font="default" size="100%">Cabrera-Serrano, Macarena</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Iberian Roma Population Variant Server (IRPVS).</style></title><secondary-title><style face="normal" font="default" size="100%">J Genet Genomics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">J Genet Genomics</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024 Mar 26</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">eng</style></language></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Casimiro-Soriguer, Carlos S</style></author><author><style face="normal" font="default" size="100%">Perez-Florido, Javier</style></author><author><style face="normal" font="default" size="100%">Robles, Enrique A</style></author><author><style face="normal" font="default" size="100%">Lara, María</style></author><author><style face="normal" font="default" size="100%">Aguado, Andrea</style></author><author><style face="normal" font="default" size="100%">Rodríguez Iglesias, Manuel A</style></author><author><style face="normal" font="default" size="100%">Lepe, Jose A</style></author><author><style face="normal" font="default" size="100%">García, Federico</style></author><author><style face="normal" font="default" size="100%">Pérez-Alegre, Mónica</style></author><author><style face="normal" font="default" size="100%">Andújar, Eloísa</style></author><author><style face="normal" font="default" size="100%">Jiménez, Victoria E</style></author><author><style face="normal" font="default" size="100%">Camino, Lola P</style></author><author><style face="normal" font="default" size="100%">Loruso, Nicola</style></author><author><style face="normal" font="default" size="100%">Ameyugo, Ulises</style></author><author><style face="normal" font="default" size="100%">Vazquez, Isabel María</style></author><author><style face="normal" font="default" size="100%">Lozano, Carlota M</style></author><author><style face="normal" font="default" size="100%">Chaves, J Alberto</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The integrated genomic surveillance system of Andalusia (SIEGA) provides a One Health regional resource connected with the clinic.</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Sci Rep</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Resistance, Bacterial</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome, Bacterial</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">One Health</style></keyword><keyword><style  face="normal" font="default" size="100%">Virulence Factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Whole Genome Sequencing</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024 Aug 19</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">19200</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The One Health approach, recognizing the interconnectedness of human, animal, and environmental health, has gained significance amid emerging zoonotic diseases and antibiotic resistance concerns. This paper aims to demonstrate the utility of a collaborative tool, the SIEGA, for monitoring infectious diseases across domains, fostering a comprehensive understanding of disease dynamics and risk factors, highlighting the pivotal role of One Health surveillance systems. Raw whole-genome sequencing is processed through different species-specific open software that additionally reports the presence of genes associated to anti-microbial resistances and virulence. The SIEGA application is a Laboratory Information Management System, that allows customizing reports, detect transmission chains, and promptly alert on alarming genetic similarities. The SIEGA initiative has successfully accumulated a comprehensive collection of more than 1900 bacterial genomes, including Salmonella enterica, Listeria monocytogenes, Campylobacter jejuni, Escherichia coli, Yersinia enterocolitica and Legionella pneumophila, showcasing its potential in monitoring pathogen transmission, resistance patterns, and virulence factors. SIEGA enables customizable reports and prompt detection of transmission chains, highlighting its contribution to enhancing vigilance and response capabilities. Here we show the potential of genomics in One Health surveillance when supported by an appropriate bioinformatic tool. By facilitating precise disease control strategies and antimicrobial resistance management, SIEGA enhances global health security and reduces the burden of infectious diseases. The integration of health data from humans, animals, and the environment, coupled with advanced genomics, underscores the importance of a holistic One Health approach in mitigating health threats.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Esteban-Medina, Marina</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Rian, Kinza</style></author><author><style face="normal" font="default" size="100%">Velasco, Sheyla</style></author><author><style face="normal" font="default" size="100%">Olivares-González, Lorena</style></author><author><style face="normal" font="default" size="100%">Rodrigo, Regina</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The mechanistic functional landscape of retinitis pigmentosa: a machine learning-driven approach to therapeutic target discovery.</style></title><secondary-title><style face="normal" font="default" size="100%">J Transl Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">J Transl Med</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Retinitis pigmentosa</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024 Feb 06</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">22</style></volume><pages><style face="normal" font="default" size="100%">139</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Retinitis pigmentosa is the prevailing genetic cause of blindness in developed nations with no effective treatments. In the pursuit of unraveling the intricate dynamics underlying this complex disease, mechanistic models emerge as a tool of proven efficiency rooted in systems biology, to elucidate the interplay between RP genes and their mechanisms. The integration of mechanistic models and drug-target interactions under the umbrella of machine learning methodologies provides a multifaceted approach that can boost the discovery of novel therapeutic targets, facilitating further drug repurposing in RP.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;By mapping Retinitis Pigmentosa-related genes (obtained from Orphanet, OMIM and HPO databases) onto KEGG signaling pathways, a collection of signaling functional circuits encompassing Retinitis Pigmentosa molecular mechanisms was defined. Next, a mechanistic model of the so-defined disease map, where the effects of interventions can be simulated, was built. Then, an explainable multi-output random forest regressor was trained using normal tissue transcriptomic data to learn causal connections between targets of approved drugs from DrugBank and the functional circuits of the mechanistic disease map. Selected target genes involvement were validated on rd10 mice, a murine model of Retinitis Pigmentosa.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;A mechanistic functional map of Retinitis Pigmentosa was constructed resulting in 226 functional circuits belonging to 40 KEGG signaling pathways. The method predicted 109 targets of approved drugs in use with a potential effect over circuits corresponding to nine hallmarks identified. Five of those targets were selected and experimentally validated in rd10 mice: Gabre, Gabra1 (GABARα1 protein), Slc12a5 (KCC2 protein), Grin1 (NR1 protein) and Glr2a. As a result, we provide a resource to evaluate the potential impact of drug target genes in Retinitis Pigmentosa.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;The possibility of building actionable disease models in combination with machine learning algorithms to learn causal drug-disease interactions opens new avenues for boosting drug discovery. Such mechanistically-based hypotheses can guide and accelerate the experimental validations prioritizing drug target candidates. In this work, a mechanistic model describing the functional disease map of Retinitis Pigmentosa was developed, identifying five promising therapeutic candidates targeted by approved drug. Further experimental validation will demonstrate the efficiency of this approach for a systematic application to other rare diseases.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Casimiro-Soriguer, Carlos S</style></author><author><style face="normal" font="default" size="100%">Perez-Florido, Javier</style></author><author><style face="normal" font="default" size="100%">Lara, María</style></author><author><style face="normal" font="default" size="100%">Camacho-Martinez, Pedro</style></author><author><style face="normal" font="default" size="100%">Merino-Diaz, Laura</style></author><author><style face="normal" font="default" size="100%">Pupo-Ledo, Inmaculada</style></author><author><style face="normal" font="default" size="100%">de Salazar, Adolfo</style></author><author><style face="normal" font="default" size="100%">Fuentes, Ana</style></author><author><style face="normal" font="default" size="100%">Viñuela, Laura</style></author><author><style face="normal" font="default" size="100%">Chueca, Natalia</style></author><author><style face="normal" font="default" size="100%">Martinez-Martinez, Luis</style></author><author><style face="normal" font="default" size="100%">Lorusso, Nicola</style></author><author><style face="normal" font="default" size="100%">Lepe, Jose A</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">García, Federico</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Molecular and phylogenetic characterization of the monkeypox outbreak in the South of Spain.</style></title><secondary-title><style face="normal" font="default" size="100%">Health Sci Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Health Sci Rep</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024 Mar</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">7</style></volume><pages><style face="normal" font="default" size="100%">e1965</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND AND AIM: &lt;/b&gt;Until the May 2022 Monkeypox (MPXV) outbreak, which spread rapidly to many non-endemic countries, the virus was considered a viral zoonosis limited to some African countries. The Andalusian circuit of genomic surveillance was rapidly applied to characterize the MPXV outbreak in the South of Spain.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;Whole genome sequencing was used to obtain the genomic profiles of samples collected across the south of Spain, representative of all the provinces of Andalusia. Phylogenetic analysis was used to study the relationship of the isolates and the available sequences of the 2022 outbreak.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Whole genome sequencing of a total of 160 MPXV viruses from the different provinces that reported cases were obtained. Interestingly, we report the sequences of MPXV viruses obtained from two patients who died. While one of the isolates bore no noteworthy mutations that explain a potential heightened virulence, in another patient the second consecutive genome sequence, performed after the administration of tecovirimat, uncovered a mutation within the A0A7H0DN30 gene, known to be a prime target for tecovirimat in its Vaccinia counterpart. In general, a low number of mutations were observed in the sequences reported, which were very similar to the reference of the 2022 outbreak (OX044336), as expected from a DNA virus. The samples likely correspond to several introductions of the circulating MPXV viruses from the last outbreak. The virus sequenced from one of the two patients that died presented a mutation in a gene that bears potential connections to drug resistance. This mutation was absent in the initial sequencing before treatment.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pérez-Gutiérrez, Ana M</style></author><author><style face="normal" font="default" size="100%">Carmona, Rosario</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Cervilla, Jorge A</style></author><author><style face="normal" font="default" size="100%">Gutiérrez, Blanca</style></author><author><style face="normal" font="default" size="100%">Molina, Esther</style></author><author><style face="normal" font="default" size="100%">López-López, Daniel</style></author><author><style face="normal" font="default" size="100%">Perez-Florido, Javier</style></author><author><style face="normal" font="default" size="100%">Zarza-Rebollo, Juan Antonio</style></author><author><style face="normal" font="default" size="100%">López-Isac, Elena</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Martinez-Gonzalez, Luis Javier</style></author><author><style face="normal" font="default" size="100%">Rivera, Margarita</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mutational landscape of risk variants in comorbid depression and obesity: a next-generation sequencing approach.</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Psychiatry</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Mol Psychiatry</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024 May 28</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Major depression (MD) and obesity are complex genetic disorders that are frequently comorbid. However, the study of both diseases concurrently remains poorly addressed and therefore the underlying genetic mechanisms involved in this comorbidity remain largely unknown. Here we examine the contribution of common and rare variants to this comorbidity through a next-generation sequencing (NGS) approach. Specific genomic regions of interest in MD and obesity were sequenced in a group of 654 individuals from the PISMA-ep epidemiological study. We obtained variants across the entire frequency spectrum and assessed their association with comorbid MD and obesity, both at variant and gene levels. We identified 55 independent common variants and a burden of rare variants in 4 genes (PARK2, FGF21, HIST1H3D and RSRC1) associated with the comorbid phenotype. Follow-up analyses revealed significantly enriched gene-sets associated with biological processes and pathways involved in metabolic dysregulation, hormone signaling and cell cycle regulation. Our results suggest that, while risk variants specific to the comorbid phenotype have been identified, the genes functionally impacted by the risk variants share cell biological processes and signaling pathways with MD and obesity phenotypes separately. To the best of our knowledge, this is the first study involving a targeted sequencing approach toward the study of the comorbid MD and obesity. The framework presented here allowed a deep characterization of the genetics of the co-occurring MD and obesity, revealing insights into the mutational and functional profile that underlies this comorbidity and contributing to a better understanding of the relationship between these two disabling disorders.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Baz-Redón, Noelia</style></author><author><style face="normal" font="default" size="100%">Sánchez-Bellver, Laura</style></author><author><style face="normal" font="default" size="100%">Fernández-Cancio, Mónica</style></author><author><style face="normal" font="default" size="100%">Rovira-Amigo, Sandra</style></author><author><style face="normal" font="default" size="100%">Burgoyne, Thomas</style></author><author><style face="normal" font="default" size="100%">Ranjit, Rai</style></author><author><style face="normal" font="default" size="100%">Aquino, Virginia</style></author><author><style face="normal" font="default" size="100%">Toro-Barrios, Noemí</style></author><author><style face="normal" font="default" size="100%">Carmona, Rosario</style></author><author><style face="normal" font="default" size="100%">Polverino, Eva</style></author><author><style face="normal" font="default" size="100%">Cols, Maria</style></author><author><style face="normal" font="default" size="100%">Moreno-Galdó, Antonio</style></author><author><style face="normal" font="default" size="100%">Camats-Tarruella, Núria</style></author><author><style face="normal" font="default" size="100%">Marfany, Gemma</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Primary Ciliary Dyskinesia and Retinitis Pigmentosa: Novel  Variant and Possible Modifier Gene.</style></title><secondary-title><style face="normal" font="default" size="100%">Cells</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cells</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Ciliary Motility Disorders</style></keyword><keyword><style  face="normal" font="default" size="100%">Eye Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Genes, Modifier</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">Retinitis pigmentosa</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2024 Mar 16</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;We report a novel  missense variant co-segregated with a familial X-linked retinitis pigmentosa (XLRP) case. The brothers were hemizygous for this variant, but only the proband presented with primary ciliary dyskinesia (PCD). Thus, we aimed to elucidate the role of the  variant and other modifier genes in the phenotypic variability observed in the family and its impact on motile cilia. The pathogenicity of the variant on the RPGR protein was evaluated by in vitro studies transiently transfecting the mutated  gene, and immunofluorescence analysis on nasal brushing samples. Whole-exome sequencing was conducted to identify potential modifier variants. In vitro studies showed that the mutated RPGR protein could not localise to the cilium and impaired cilium formation. Accordingly, RPGR was abnormally distributed in the siblings' nasal brushing samples. In addition, a missense variant in  was identified. The concurrent  variant influenced ciliary mislocalisation of the protein. We provide a comprehensive characterisation of motile cilia in this XLRP family, with only the proband presenting PCD symptoms. The variant's pathogenicity was confirmed, although it alone does not explain the respiratory symptoms. Finally, the  gene may be a potential modifier for respiratory symptoms in patients with  mutations.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Blasco, Lucia</style></author><author><style face="normal" font="default" size="100%">López-Hernández, Inmaculada</style></author><author><style face="normal" font="default" size="100%">Rodríguez-Fernández, Miguel</style></author><author><style face="normal" font="default" size="100%">Perez-Florido, Javier</style></author><author><style face="normal" font="default" size="100%">Casimiro-Soriguer, Carlos S</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Case report: Analysis of phage therapy failure in a patient with a Pseudomonas aeruginosa prosthetic vascular graft infection</style></title><secondary-title><style face="normal" font="default" size="100%">Front Med (Lausanne)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Front Med (Lausanne)</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235614/</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">10</style></volume><pages><style face="normal" font="default" size="100%">1199657</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Clinical case of a patient with a  multidrug-resistant prosthetic vascular graft infection which was treated with a cocktail of phages (PT07, 14/01, and PNM) in combination with ceftazidime-avibactam (CZA). After the application of the phage treatment and in absence of antimicrobial therapy, a new  bloodstream infection (BSI) with a septic residual limb metastasis occurred, now involving a wild-type strain being susceptible to ß-lactams and quinolones. Clinical strains were analyzed by microbiology and whole genome sequencing techniques. In relation with phage administration, the clinical isolates of  before phage therapy (HE2011471) and post phage therapy (HE2105886) showed a clonal relationship but with important genomic changes which could be involved in the resistance to this therapy. Finally, phenotypic studies showed a decrease in Minimum Inhibitory Concentration (MIC) to ß-lactams and quinolones as well as an increase of the biofilm production and phage resistant mutants in the clinical isolate of  post phage therapy.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>6</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gundogdu, Pelin</style></author><author><style face="normal" font="default" size="100%">Payá-Milans, Miriam</style></author><author><style face="normal" font="default" size="100%">Alamo-Alvarez, Inmaculada</style></author><author><style face="normal" font="default" size="100%">Nepomuceno-Chamorro, Isabel A.</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Cell-Level Pathway Scoring Comparison with a Biologically Constrained Variational Autoencoder</style></title><secondary-title><style face="normal" font="default" size="100%">Lecture Notes in Computer Science. Computational Methods in Systems Biology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://link.springer.com/chapter/10.1007/978-3-031-42697-1_5</style></url></web-urls></urls><publisher><style face="normal" font="default" size="100%">Springer Nature Switzerland</style></publisher><pub-location><style face="normal" font="default" size="100%">Cham</style></pub-location><volume><style face="normal" font="default" size="100%">14137</style></volume><pages><style face="normal" font="default" size="100%">62 - 77</style></pages><isbn><style face="normal" font="default" size="100%">978-3-031-42696-4</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Núñez-Torres, Rocío</style></author><author><style face="normal" font="default" size="100%">Pita, Guillermo</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">López-López, Daniel</style></author><author><style face="normal" font="default" size="100%">Zamora, Jorge</style></author><author><style face="normal" font="default" size="100%">Roldán, Gema</style></author><author><style face="normal" font="default" size="100%">Herráez, Belén</style></author><author><style face="normal" font="default" size="100%">Alvarez, Nuria</style></author><author><style face="normal" font="default" size="100%">Alonso, María Rosario</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">González-Neira, Anna</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A Comprehensive Analysis of 21 Actionable Pharmacogenes in the Spanish Population: From Genetic Characterisation to Clinical Impact.</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmaceutics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Pharmaceutics</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Apr 19</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The implementation of pharmacogenetics (PGx) is a main milestones of precision medicine nowadays in order to achieve safer and more effective therapies. Nevertheless, the implementation of PGx diagnostics is extremely slow and unequal worldwide, in part due to a lack of ethnic PGx information. We analysed genetic data from 3006 Spanish individuals obtained by different high-throughput (HT) techniques. Allele frequencies were determined in our population for the main 21 actionable PGx genes associated with therapeutical changes. We found that 98% of the Spanish population harbours at least one allele associated with a therapeutical change and, thus, there would be a need for a therapeutical change in a mean of 3.31 of the 64 associated drugs. We also identified 326 putative deleterious variants that were not previously related with PGx in 18 out of the 21 main PGx genes evaluated and a total of 7122 putative deleterious variants for the 1045 PGx genes described. Additionally, we performed a comparison of the main HT diagnostic techniques, revealing that after whole genome sequencing, genotyping with the PGx HT array is the most suitable solution for PGx diagnostics. Finally, all this information was integrated in the Collaborative Spanish Variant Server to be available to and updated by the scientific community.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cubuk, Cankut</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Crosstalk between Metabolite Production and Signaling Activity in Breast Cancer.</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Mol Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Int J Mol Sci</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Apr 18</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">24</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The reprogramming of metabolism is a recognized cancer hallmark. It is well known that different signaling pathways regulate and orchestrate this reprogramming that contributes to cancer initiation and development. However, recent evidence is accumulating, suggesting that several metabolites could play a relevant role in regulating signaling pathways. To assess the potential role of metabolites in the regulation of signaling pathways, both metabolic and signaling pathway activities of Breast invasive Carcinoma (BRCA) have been modeled using mechanistic models. Gaussian Processes, powerful machine learning methods, were used in combination with SHapley Additive exPlanations (SHAP), a recent methodology that conveys causality, to obtain potential causal relationships between the production of metabolites and the regulation of signaling pathways. A total of 317 metabolites were found to have a strong impact on signaling circuits. The results presented here point to the existence of a complex crosstalk between signaling and metabolic pathways more complex than previously was thought.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">8</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">López-López, Daniel</style></author><author><style face="normal" font="default" size="100%">Roldán, Gema</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rueda, Jose L</style></author><author><style face="normal" font="default" size="100%">Bostelmann, Gerrit</style></author><author><style face="normal" font="default" size="100%">Carmona, Rosario</style></author><author><style face="normal" font="default" size="100%">Aquino, Virginia</style></author><author><style face="normal" font="default" size="100%">Perez-Florido, Javier</style></author><author><style face="normal" font="default" size="100%">Ortuno, Francisco</style></author><author><style face="normal" font="default" size="100%">Pita, Guillermo</style></author><author><style face="normal" font="default" size="100%">Núñez-Torres, Rocío</style></author><author><style face="normal" font="default" size="100%">González-Neira, Anna</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">CSVS Crowdsourcing Group</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">A crowdsourcing database for the copy-number variation of the Spanish population.</style></title><secondary-title><style face="normal" font="default" size="100%">Hum Genomics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Hum Genomics</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Mar 09</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">20</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Despite being a very common type of genetic variation, the distribution of copy-number variations (CNVs) in the population is still poorly understood. The knowledge of the genetic variability, especially at the level of the local population, is a critical factor for distinguishing pathogenic from non-pathogenic variation in the discovery of new disease variants.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Here, we present the SPAnish Copy Number Alterations Collaborative Server (SPACNACS), which currently contains copy number variation profiles obtained from more than 400 genomes and exomes of unrelated Spanish individuals. By means of a collaborative crowdsourcing effort whole genome and whole exome sequencing data, produced by local genomic projects and for other purposes, is continuously collected. Once checked both, the Spanish ancestry and the lack of kinship with other individuals in the SPACNACS, the CNVs are inferred for these sequences and they are used to populate the database. A web interface allows querying the database with different filters that include ICD10 upper categories. This allows discarding samples from the disease under study and obtaining pseudo-control CNV profiles from the local population. We also show here additional studies on the local impact of CNVs in some phenotypes and on pharmacogenomic variants. SPACNACS can be accessed at: http://csvs.clinbioinfosspa.es/spacnacs/ .&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;SPACNACS facilitates disease gene discovery by providing detailed information of the local variability of the population and exemplifies how to reuse genomic data produced for other purposes to build a local reference database.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pellegrinelli, Vanessa</style></author><author><style face="normal" font="default" size="100%">Figueroa-Juárez, Elizabeth</style></author><author><style face="normal" font="default" size="100%">Samuelson, Isabella</style></author><author><style face="normal" font="default" size="100%">U-Din, Mueez</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Fdez, Sonia</style></author><author><style face="normal" font="default" size="100%">Virtue, Samuel</style></author><author><style face="normal" font="default" size="100%">Leggat, Jennifer</style></author><author><style face="normal" font="default" size="100%">Cubuk, Cankut</style></author><author><style face="normal" font="default" size="100%">Peirce, Vivian J</style></author><author><style face="normal" font="default" size="100%">Niemi, Tarja</style></author><author><style face="normal" font="default" size="100%">Campbell, Mark</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Cuenca, Sergio</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Carobbio, Stefania</style></author><author><style face="normal" font="default" size="100%">Virtanen, Kirsi A</style></author><author><style face="normal" font="default" size="100%">Vidal-Puig, Antonio</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Defective extracellular matrix remodeling in brown adipose tissue is associated with fibro-inflammation and reduced diet-induced thermogenesis.</style></title><secondary-title><style face="normal" font="default" size="100%">Cell Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cell Rep</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Jun 13</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">42</style></volume><pages><style face="normal" font="default" size="100%">112640</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The relevance of extracellular matrix (ECM) remodeling is reported in white adipose tissue (AT) and obesity-related dysfunctions, but little is known about the importance of ECM remodeling in brown AT (BAT) function. Here, we show that a time course of high-fat diet (HFD) feeding progressively impairs diet-induced thermogenesis concomitantly with the development of fibro-inflammation in BAT. Higher markers of fibro-inflammation are associated with lower cold-induced BAT activity in humans. Similarly, when mice are housed at thermoneutrality, inactivated BAT features fibro-inflammation. We validate the pathophysiological relevance of BAT ECM remodeling in response to temperature challenges and HFD using a model of a primary defect in the collagen turnover mediated by partial ablation of the Pepd prolidase. Pepd-heterozygous mice display exacerbated dysfunction and BAT fibro-inflammation at thermoneutrality and in HFD. Our findings show the relevance of ECM remodeling in BAT activation and provide a mechanism for BAT dysfunction in obesity.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perez-Florido, Javier</style></author><author><style face="normal" font="default" size="100%">Casimiro-Soriguer, Carlos S</style></author><author><style face="normal" font="default" size="100%">Ortuno, Francisco</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rueda, Jose L</style></author><author><style face="normal" font="default" size="100%">Aguado, Andrea</style></author><author><style face="normal" font="default" size="100%">Lara, María</style></author><author><style face="normal" font="default" size="100%">Riazzo, Cristina</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Iglesias, Manuel A</style></author><author><style face="normal" font="default" size="100%">Camacho-Martinez, Pedro</style></author><author><style face="normal" font="default" size="100%">Merino-Diaz, Laura</style></author><author><style face="normal" font="default" size="100%">Pupo-Ledo, Inmaculada</style></author><author><style face="normal" font="default" size="100%">de Salazar, Adolfo</style></author><author><style face="normal" font="default" size="100%">Viñuela, Laura</style></author><author><style face="normal" font="default" size="100%">Fuentes, Ana</style></author><author><style face="normal" font="default" size="100%">Chueca, Natalia</style></author><author><style face="normal" font="default" size="100%">García, Federico</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Lepe, Jose A</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Detection of High Level of Co-Infection and the Emergence of Novel SARS CoV-2 Delta-Omicron and Omicron-Omicron Recombinants in the Epidemiological Surveillance of Andalusia.</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Mol Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Int J Mol Sci</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Jan 26</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">24</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Recombination is an evolutionary strategy to quickly acquire new viral properties inherited from the parental lineages. The systematic survey of the SARS-CoV-2 genome sequences of the Andalusian genomic surveillance strategy has allowed the detection of an unexpectedly high number of co-infections, which constitute the ideal scenario for the emergence of new recombinants. Whole genome sequence of SARS-CoV-2 has been carried out as part of the genomic surveillance programme. Sample sources included the main hospitals in the Andalusia region. In addition to the increase of co-infections and known recombinants, three novel SARS-CoV-2 delta-omicron and omicron-omicron recombinant variants with two break points have been detected. Our observations document an epidemiological scenario in which co-infection and recombination are detected more frequently. Finally, we describe a family case in which co-infection is followed by the detection of a recombinant made from the two co-infecting variants. This increased number of recombinants raises the risk of emergence of recombinant variants with increased transmissibility and pathogenicity.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chaves-Blanco, Lucía</style></author><author><style face="normal" font="default" size="100%">de Salazar, Adolfo</style></author><author><style face="normal" font="default" size="100%">Fuentes, Ana</style></author><author><style face="normal" font="default" size="100%">Viñuela, Laura</style></author><author><style face="normal" font="default" size="100%">Perez-Florido, Javier</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">García, Federico</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Evaluation of a combined detection of SARS-CoV-2 and its variants using real-time allele-specific PCR strategy: an advantage for clinical practice.</style></title><secondary-title><style face="normal" font="default" size="100%">Epidemiol Infect</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Epidemiol Infect</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Alleles</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19 Testing</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Real-Time Polymerase Chain Reaction</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Nov 24</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">151</style></volume><pages><style face="normal" font="default" size="100%">e201</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;This study aimed to assess the ability of a real-time reverse transcription polymerase chain reaction (RT-PCR) with multiple targets to detect SARS-CoV-2 and its variants in a single test. Nasopharyngeal specimens were collected from patients in Granada, Spain, between January 2021 and December 2022. Five allele-specific RT-PCR kits were used sequentially, with each kit designed to detect a predominant variant at the time. When the Alpha variant was dominant, the kit included the HV69/70 deletion, E and N genes. When Delta replaced Alpha, the kit incorporated the L452R mutation in addition to E and N genes. When Omicron became dominant, L452R was replaced with the N679K mutation. Before incorporating each variant kit, a comparative analysis was carried out with SARS-CoV-2 whole genome sequencing (WGS). The results demonstrated that RT-PCR with multiple targets can provide rapid and effective detection of SARS-CoV-2 and its variants in a single test. A very high degree of agreement (96.2%) was obtained between the comparison of RT-PCR and WGS. Allele-specific RT-PCR assays make it easier to implement epidemiological surveillance systems for effective public health decision making.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sola-García, Alejandro</style></author><author><style face="normal" font="default" size="100%">Cáliz-Molina, María Ángeles</style></author><author><style face="normal" font="default" size="100%">Espadas, Isabel</style></author><author><style face="normal" font="default" size="100%">Petr, Michael</style></author><author><style face="normal" font="default" size="100%">Panadero-Morón, Concepción</style></author><author><style face="normal" font="default" size="100%">González-Morán, Daniel</style></author><author><style face="normal" font="default" size="100%">Martín-Vázquez, María Eugenia</style></author><author><style face="normal" font="default" size="100%">Narbona-Pérez, Álvaro Jesús</style></author><author><style face="normal" font="default" size="100%">López-Noriega, Livia</style></author><author><style face="normal" font="default" size="100%">Martínez-Corrales, Guillermo</style></author><author><style face="normal" font="default" size="100%">López-Fernández-Sobrino, Raúl</style></author><author><style face="normal" font="default" size="100%">Carmona-Marin, Lina M</style></author><author><style face="normal" font="default" size="100%">Martínez-Force, Enrique</style></author><author><style face="normal" font="default" size="100%">Yanes, Oscar</style></author><author><style face="normal" font="default" size="100%">Vinaixa, Maria</style></author><author><style face="normal" font="default" size="100%">López-López, Daniel</style></author><author><style face="normal" font="default" size="100%">Reyes, José Carlos</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Martín, Franz</style></author><author><style face="normal" font="default" size="100%">Gauthier, Benoit R</style></author><author><style face="normal" font="default" size="100%">Scheibye-Knudsen, Morten</style></author><author><style face="normal" font="default" size="100%">Capilla-González, Vivian</style></author><author><style face="normal" font="default" size="100%">Martín-Montalvo, Alejandro</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Metabolic reprogramming by Acly inhibition using SB-204990 alters glucoregulation and modulates molecular mechanisms associated with aging.</style></title><secondary-title><style face="normal" font="default" size="100%">Commun Biol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Commun Biol</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Mar 08</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">6</style></volume><pages><style face="normal" font="default" size="100%">250</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;ATP-citrate lyase is a central integrator of cellular metabolism in the interface of protein, carbohydrate, and lipid metabolism. The physiological consequences as well as the molecular mechanisms orchestrating the response to long-term pharmacologically induced Acly inhibition are unknown. We report here that the Acly inhibitor SB-204990 improves metabolic health and physical strength in wild-type mice when fed with a high-fat diet, while in mice fed with healthy diet results in metabolic imbalance and moderated insulin resistance. By applying a multiomic approach using untargeted metabolomics, transcriptomics, and proteomics, we determined that, in vivo, SB-204990 plays a role in the regulation of molecular mechanisms associated with aging, such as energy metabolism, mitochondrial function, mTOR signaling, and folate cycle, while global alterations on histone acetylation are absent. Our findings indicate a mechanism for regulating molecular pathways of aging that prevents the development of metabolic abnormalities associated with unhealthy dieting. This strategy might be explored for devising therapeutic approaches to prevent metabolic diseases.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Corrales, Patricia</style></author><author><style face="normal" font="default" size="100%">Martin-Taboada, Marina</style></author><author><style face="normal" font="default" size="100%">Vivas-García, Yurena</style></author><author><style face="normal" font="default" size="100%">Torres, Lucia</style></author><author><style face="normal" font="default" size="100%">Ramirez-Jimenez, Laura</style></author><author><style face="normal" font="default" size="100%">Lopez, Yamila</style></author><author><style face="normal" font="default" size="100%">Horrillo, Daniel</style></author><author><style face="normal" font="default" size="100%">Vila-Bedmar, Rocio</style></author><author><style face="normal" font="default" size="100%">Barber-Cano, Eloisa</style></author><author><style face="normal" font="default" size="100%">Izquierdo-Lahuerta, Adriana</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Martínez, Carmen</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Ros, Manuel</style></author><author><style face="normal" font="default" size="100%">Medina-Gomez, Gema</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">microRNAs-mediated regulation of insulin signaling in white adipose tissue during aging: Role of caloric restriction.</style></title><secondary-title><style face="normal" font="default" size="100%">Aging Cell</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Aging Cell</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Jul 04</style></date></pub-dates></dates><pages><style face="normal" font="default" size="100%">e13919</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Caloric restriction is a non-pharmacological intervention known to ameliorate the metabolic defects associated with aging, including insulin resistance. The levels of miRNA expression may represent a predictive tool for aging-related alterations. In order to investigate the role of miRNAs underlying insulin resistance in adipose tissue during the early stages of aging, 3- and 12-month-old male animals fed ad libitum, and 12-month-old male animals fed with a 20% caloric restricted diet were used. In this work we demonstrate that specific miRNAs may contribute to the impaired insulin-stimulated glucose metabolism specifically in the subcutaneous white adipose tissue, through the regulation of target genes implicated in the insulin signaling cascade. Moreover, the expression of these miRNAs is modified by caloric restriction in middle-aged animals, in accordance with the improvement of the metabolic state. Overall, our work demonstrates that alterations in posttranscriptional gene expression because of miRNAs dysregulation might represent an endogenous mechanism by which insulin response in the subcutaneous fat depot is already affected at middle age. Importantly, caloric restriction could prevent this modulation, demonstrating that certain miRNAs could constitute potential biomarkers of age-related metabolic alterations.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">León, Marian</style></author><author><style face="normal" font="default" size="100%">Prieto, Javier</style></author><author><style face="normal" font="default" size="100%">Molina-Navarro, María Micaela</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Barneo-Muñoz, Manuela</style></author><author><style face="normal" font="default" size="100%">Ponsoda, Xavier</style></author><author><style face="normal" font="default" size="100%">Sáez, Rosana</style></author><author><style face="normal" font="default" size="100%">Palau, Francesc</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Izpisua Belmonte, Juan Carlos</style></author><author><style face="normal" font="default" size="100%">Torres, Josema</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Rapid degeneration of iPSC-derived motor neurons lacking Gdap1 engages a mitochondrial-sustained innate immune response.</style></title><secondary-title><style face="normal" font="default" size="100%">Cell Death Discov</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cell Death Discov</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Jul 01</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">9</style></volume><pages><style face="normal" font="default" size="100%">217</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Charcot-Marie-Tooth disease is a chronic hereditary motor and sensory polyneuropathy targeting Schwann cells and/or motor neurons. Its multifactorial and polygenic origin portrays a complex clinical phenotype of the disease with a wide range of genetic inheritance patterns. The disease-associated gene GDAP1 encodes for a mitochondrial outer membrane protein. Mouse and insect models with mutations in Gdap1 have reproduced several traits of the human disease. However, the precise function in the cell types affected by the disease remains unknown. Here, we use induced-pluripotent stem cells derived from a Gdap1 knockout mouse model to better understand the molecular and cellular phenotypes of the disease caused by the loss-of-function of this gene. Gdap1-null motor neurons display a fragile cell phenotype prone to early degeneration showing (1) altered mitochondrial morphology, with an increase in the fragmentation of these organelles, (2) activation of autophagy and mitophagy, (3) abnormal metabolism, characterized by a downregulation of Hexokinase 2 and ATP5b proteins, (4) increased reactive oxygen species and elevated mitochondrial membrane potential, and (5) increased innate immune response and p38 MAP kinase activation. Our data reveals the existence of an underlying Redox-inflammatory axis fueled by altered mitochondrial metabolism in the absence of Gdap1. As this biochemical axis encompasses a wide variety of druggable targets, our results may have implications for developing therapies using combinatorial pharmacological approaches and improving therefore human welfare. A Redox-immune axis underlying motor neuron degeneration caused by the absence of Gdap1. Our results show that Gdap1 motor neurons have a fragile cellular phenotype that is prone to degeneration. Gdap1 iPSCs differentiated into motor neurons showed an altered metabolic state: decreased glycolysis and increased OXPHOS. These alterations may lead to hyperpolarization of mitochondria and increased ROS levels. Excessive amounts of ROS might be the cause of increased mitophagy, p38 activation and inflammation as a cellular response to oxidative stress. The p38 MAPK pathway and the immune response may, in turn, have feedback mechanisms, leading to the induction of apoptosis and senescence, respectively. CAC, citric acid cycle; ETC, electronic transport chain; Glc, glucose; Lac, lactate; Pyr, pyruvate.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Carmona, Rosario</style></author><author><style face="normal" font="default" size="100%">Esteban-Medina, Marina</style></author><author><style face="normal" font="default" size="100%">Bostelmann, Gerrit</style></author><author><style face="normal" font="default" size="100%">Muñoyerro-Muñiz, Dolores</style></author><author><style face="normal" font="default" size="100%">Villegas, Román</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Real-world evidence with a retrospective cohort of 15,968 COVID-19 hospitalized patients suggests 21 new effective treatments.</style></title><secondary-title><style face="normal" font="default" size="100%">Virol J</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Virol J</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Oct 06</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">20</style></volume><pages><style face="normal" font="default" size="100%">226</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;PURPOSE: &lt;/b&gt;Despite the extensive vaccination campaigns in many countries, COVID-19 is still a major worldwide health problem because of its associated morbidity and mortality. Therefore, finding efficient treatments as fast as possible is a pressing need. Drug repurposing constitutes a convenient alternative when the need for new drugs in an unexpected medical scenario is urgent, as is the case with COVID-19.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;Using data from a central registry of electronic health records (the Andalusian Population Health Database), the effect of prior consumption of drugs for other indications previous to the hospitalization with respect to patient outcomes, including survival and lymphocyte progression, was studied on a retrospective cohort of 15,968 individuals, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Covariate-adjusted hazard ratios and analysis of lymphocyte progression curves support a significant association between consumption of 21 different drugs and better patient survival. Contrarily, one drug, furosemide, displayed a significant increase in patient mortality.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;In this study we have taken advantage of the availability of a regional clinical database to study the effect of drugs, which patients were taking for other indications, on their survival. The large size of the database allowed us to control covariates effectively.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gawron, Piotr</style></author><author><style face="normal" font="default" size="100%">Hoksza, David</style></author><author><style face="normal" font="default" size="100%">Piñero, Janet</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Esteban-Medina, Marina</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rueda, Jose Luis</style></author><author><style face="normal" font="default" size="100%">Colonna, Vincenza</style></author><author><style face="normal" font="default" size="100%">Smula, Ewa</style></author><author><style face="normal" font="default" size="100%">Heirendt, Laurent</style></author><author><style face="normal" font="default" size="100%">Ancien, François</style></author><author><style face="normal" font="default" size="100%">Grouès, Valentin</style></author><author><style face="normal" font="default" size="100%">Satagopam, Venkata P</style></author><author><style face="normal" font="default" size="100%">Schneider, Reinhard</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Furlong, Laura I</style></author><author><style face="normal" font="default" size="100%">Ostaszewski, Marek</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Visualization of automatically combined disease maps and pathway diagrams for rare diseases.</style></title><secondary-title><style face="normal" font="default" size="100%">Front Bioinform</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Front Bioinform</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">3</style></volume><pages><style face="normal" font="default" size="100%">1101505</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt; Investigation of molecular mechanisms of human disorders, especially rare diseases, require exploration of various knowledge repositories for building precise hypotheses and complex data interpretation. Recently, increasingly more resources offer diagrammatic representation of such mechanisms, including disease-dedicated schematics in pathway databases and disease maps. However, collection of knowledge across them is challenging, especially for research projects with limited manpower.  In this article we present an automated workflow for construction of maps of molecular mechanisms for rare diseases. The workflow requires a standardized definition of a disease using Orphanet or HPO identifiers to collect relevant genes and variants, and to assemble a functional, visual repository of related mechanisms, including data overlays. The diagrams composing the final map are unified to a common systems biology format from CellDesigner SBML, GPML and SBML+layout+render. The constructed resource contains disease-relevant genes and variants as data overlays for immediate visual exploration, including embedded genetic variant browser and protein structure viewer.  We demonstrate the functionality of our workflow on two examples of rare diseases: Kawasaki disease and retinitis pigmentosa. Two maps are constructed based on their corresponding identifiers. Moreover, for the retinitis pigmentosa use-case, we include a list of differentially expressed genes to demonstrate how to tailor the workflow using omics datasets.  In summary, our work allows for an ad-hoc construction of molecular diagrams combined from different sources, preserving their layout and graphical style, but integrating them into a single resource. This allows to reduce time consuming tasks of prototyping of a molecular disease map, enabling visual exploration, hypothesis building, data visualization and further refinement. The code of the workflow is open and accessible at https://gitlab.lcsb.uni.lu/minerva/automap/.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Perez-Florido, Javier</style></author><author><style face="normal" font="default" size="100%">Casimiro-Soriguer, Carlos S</style></author><author><style face="normal" font="default" size="100%">Ortuno, Francisco M</style></author><author><style face="normal" font="default" size="100%">Carmona, Rosario</style></author><author><style face="normal" font="default" size="100%">Bostelmann, Gerrit</style></author><author><style face="normal" font="default" size="100%">Martínez-González, L Javier</style></author><author><style face="normal" font="default" size="100%">Muñoyerro-Muñiz, Dolores</style></author><author><style face="normal" font="default" size="100%">Villegas, Román</style></author><author><style face="normal" font="default" size="100%">Rodríguez-Baño, Jesús</style></author><author><style face="normal" font="default" size="100%">Romero-Gómez, Manuel</style></author><author><style face="normal" font="default" size="100%">Lorusso, Nicola</style></author><author><style face="normal" font="default" size="100%">Garcia-León, Javier</style></author><author><style face="normal" font="default" size="100%">Navarro-Marí, Jose M</style></author><author><style face="normal" font="default" size="100%">Camacho-Martinez, Pedro</style></author><author><style face="normal" font="default" size="100%">Merino-Diaz, Laura</style></author><author><style face="normal" font="default" size="100%">Salazar, Adolfo de</style></author><author><style face="normal" font="default" size="100%">Viñuela, Laura</style></author><author><style face="normal" font="default" size="100%">Lepe, Jose A</style></author><author><style face="normal" font="default" size="100%">García, Federico</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Assessing the Impact of SARS-CoV-2 Lineages and Mutations on Patient Survival.</style></title><secondary-title><style face="normal" font="default" size="100%">Viruses</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Viruses</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style  face="normal" font="default" size="100%">Phylogeny</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Aug 27</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;OBJECTIVES: &lt;/b&gt;More than two years into the COVID-19 pandemic, SARS-CoV-2 still remains a global public health problem. Successive waves of infection have produced new SARS-CoV-2 variants with new mutations for which the impact on COVID-19 severity and patient survival is uncertain.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;A total of 764 SARS-CoV-2 genomes, sequenced from COVID-19 patients, hospitalized from 19th February 2020 to 30 April 2021, along with their clinical data, were used for survival analysis.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;A significant association of B.1.1.7, the alpha lineage, with patient mortality (log hazard ratio (LHR) = 0.51, C.I. = [0.14,0.88]) was found upon adjustment by all the covariates known to affect COVID-19 prognosis. Moreover, survival analysis of mutations in the SARS-CoV-2 genome revealed 27 of them were significantly associated with higher mortality of patients. Most of these mutations were located in the genes coding for the S, ORF8, and N proteins.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;This study illustrates how a combination of genomic and clinical data can provide solid evidence for the impact of viral lineage on patient survival.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">9</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Luque, Juan</style></author><author><style face="normal" font="default" size="100%">Mendes, Ingrid</style></author><author><style face="normal" font="default" size="100%">Gómez, Beatriz</style></author><author><style face="normal" font="default" size="100%">Morte, Beatriz</style></author><author><style face="normal" font="default" size="100%">de Heredia, Miguel López</style></author><author><style face="normal" font="default" size="100%">Herreras, Enrique</style></author><author><style face="normal" font="default" size="100%">Corrochano, Virginia</style></author><author><style face="normal" font="default" size="100%">Bueren, Juan</style></author><author><style face="normal" font="default" size="100%">Gallano, Pia</style></author><author><style face="normal" font="default" size="100%">Artuch, Rafael</style></author><author><style face="normal" font="default" size="100%">Fillat, Cristina</style></author><author><style face="normal" font="default" size="100%">Pérez-Jurado, Luis A</style></author><author><style face="normal" font="default" size="100%">Montoliu, Lluis</style></author><author><style face="normal" font="default" size="100%">Carracedo, Ángel</style></author><author><style face="normal" font="default" size="100%">Millán, José M</style></author><author><style face="normal" font="default" size="100%">Webb, Susan M</style></author><author><style face="normal" font="default" size="100%">Palau, Francesc</style></author><author><style face="normal" font="default" size="100%">Lapunzina, Pablo</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">CIBERER Network</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">CIBERER: Spanish National Network for Research on Rare Diseases: a highly productive collaborative initiative.</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Genet</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Clin Genet</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Jan 20</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on Rare Diseases currently consists of 75 research groups belonging to universities, research centers and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical and cellular research of rare diseases. This research is the basis for providing new tools for the diagnosis and therapy of low-prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this paper, we intend to review CIBERER's 15-year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions towards the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to rare disease research. This article is protected by copyright. All rights reserved.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">López-Sánchez, Macarena</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Discovering potential interactions between rare diseases and COVID-19 by combining mechanistic models of viral infection with statistical modeling.</style></title><secondary-title><style face="normal" font="default" size="100%">Hum Mol Genet</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Hum Mol Genet</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Jan 12</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Recent studies have demonstrated a relevant role of the host genetics in the COVID-19 prognosis. Most of the 7000 rare diseases described to date have a genetic component, typically highly penetrant. However, this vast spectrum of genetic variability remains yet unexplored with respect to possible interactions with COVID-19. Here, a mathematical mechanistic model of the COVID-19 molecular disease mechanism has been used to detect potential interactions between rare disease genes and the COVID-19 infection process and downstream consequences. Out of the 2518 disease genes analyzed, causative of 3854 rare diseases, a total of 254 genes have a direct effect on the COVID-19 molecular disease mechanism and 207 have an indirect effect revealed by a significant strong correlation. This remarkable potential of interaction occurs for more than 300 rare diseases. Mechanistic modeling of COVID-19 disease map has allowed a holistic systematic analysis of the potential interactions between the loss of function in known rare disease genes and the pathological consequences of COVID-19 infection. The results identify links between disease genes and COVID-19 hallmarks and demonstrate the usefulness of the proposed approach for future preventive measures in some rare diseases.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Puerto-Camacho, Pilar</style></author><author><style face="normal" font="default" size="100%">Diaz-Martin, Juan</style></author><author><style face="normal" font="default" size="100%">Olmedo-Pelayo, Joaquín</style></author><author><style face="normal" font="default" size="100%">Bolado-Carrancio, Alfonso</style></author><author><style face="normal" font="default" size="100%">Salguero-Aranda, Carmen</style></author><author><style face="normal" font="default" size="100%">Jordán-Pérez, Carmen</style></author><author><style face="normal" font="default" size="100%">Esteban-Medina, Marina</style></author><author><style face="normal" font="default" size="100%">Alamo-Alvarez, Inmaculada</style></author><author><style face="normal" font="default" size="100%">Delgado-Bellido, Daniel</style></author><author><style face="normal" font="default" size="100%">Lobo-Selma, Laura</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Sastre, Ana</style></author><author><style face="normal" font="default" size="100%">Alonso, Javier</style></author><author><style face="normal" font="default" size="100%">Grünewald, Thomas G P</style></author><author><style face="normal" font="default" size="100%">Bernabeu, Carmelo</style></author><author><style face="normal" font="default" size="100%">Byron, Adam</style></author><author><style face="normal" font="default" size="100%">Brunton, Valerie G</style></author><author><style face="normal" font="default" size="100%">Amaral, Ana Teresa</style></author><author><style face="normal" font="default" size="100%">de Alava, Enrique</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Endoglin and MMP14 Contribute to Ewing Sarcoma Spreading by Modulation of Cell-Matrix Interactions.</style></title><secondary-title><style face="normal" font="default" size="100%">Int J Mol Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Int J Mol Sci</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Bone Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Endoglin</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Matrix Metalloproteinase 14</style></keyword><keyword><style  face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Receptors, Growth Factor</style></keyword><keyword><style  face="normal" font="default" size="100%">Sarcoma, Ewing</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Aug 04</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">23</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Endoglin (ENG) is a mesenchymal stem cell (MSC) marker typically expressed by active endothelium. This transmembrane glycoprotein is shed by matrix metalloproteinase 14 (MMP14). Our previous work demonstrated potent preclinical activity of first-in-class anti-ENG antibody-drug conjugates as a nascent strategy to eradicate Ewing sarcoma (ES), a devastating rare bone/soft tissue cancer with a putative MSC origin. We also defined a correlation between ENG and MMP14 expression in ES. Herein, we show that ENG expression is significantly associated with a dismal prognosis in a large cohort of ES patients. Moreover, both ENG/MMP14 are frequently expressed in primary ES tumors and metastasis. To deepen in their functional relevance in ES, we conducted transcriptomic and proteomic profiling of in vitro ES models that unveiled a key role of ENG and MMP14 in cell mechano-transduction. Migration and adhesion assays confirmed that loss of ENG disrupts actin filament assembly and filopodia formation, with a concomitant effect on cell spreading. Furthermore, we observed that ENG regulates cell-matrix interaction through activation of focal adhesion signaling and protein kinase C expression. In turn, loss of MMP14 contributed to a more adhesive phenotype of ES cells by modulating the transcriptional extracellular matrix dynamics. Overall, these results suggest that ENG and MMP14 exert a significant role in mediating correct spreading machinery of ES cells, impacting the aggressiveness of the disease.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">15</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Torrent-Vernetta, Alba</style></author><author><style face="normal" font="default" size="100%">Gaboli, Mirella</style></author><author><style face="normal" font="default" size="100%">Castillo-Corullón, Silvia</style></author><author><style face="normal" font="default" size="100%">Mondéjar-López, Pedro</style></author><author><style face="normal" font="default" size="100%">Sanz Santiago, Verónica</style></author><author><style face="normal" font="default" size="100%">Costa-Colomer, Jordi</style></author><author><style face="normal" font="default" size="100%">Osona, Borja</style></author><author><style face="normal" font="default" size="100%">Torres-Borrego, Javier</style></author><author><style face="normal" font="default" size="100%">de la Serna-Blázquez, Olga</style></author><author><style face="normal" font="default" size="100%">Bellón Alonso, Sara</style></author><author><style face="normal" font="default" size="100%">Caro Aguilera, Pilar</style></author><author><style face="normal" font="default" size="100%">Gimeno-Díaz de Atauri, Álvaro</style></author><author><style face="normal" font="default" size="100%">Valenzuela Soria, Alfredo</style></author><author><style face="normal" font="default" size="100%">Ayats, Roser</style></author><author><style face="normal" font="default" size="100%">Martin de Vicente, Carlos</style></author><author><style face="normal" font="default" size="100%">Velasco González, Valle</style></author><author><style face="normal" font="default" size="100%">Moure González, José Domingo</style></author><author><style face="normal" font="default" size="100%">Canino Calderín, Elisa María</style></author><author><style face="normal" font="default" size="100%">Pastor-Vivero, María Dolores</style></author><author><style face="normal" font="default" size="100%">Villar Álvarez, María Ángeles</style></author><author><style face="normal" font="default" size="100%">Rovira-Amigo, Sandra</style></author><author><style face="normal" font="default" size="100%">Iglesias Serrano, Ignacio</style></author><author><style face="normal" font="default" size="100%">Díez Izquierdo, Ana</style></author><author><style face="normal" font="default" size="100%">de Mir Messa, Inés</style></author><author><style face="normal" font="default" size="100%">Gartner, Silvia</style></author><author><style face="normal" font="default" size="100%">Navarro, Alexandra</style></author><author><style face="normal" font="default" size="100%">Baz-Redón, Noelia</style></author><author><style face="normal" font="default" size="100%">Carmona, Rosario</style></author><author><style face="normal" font="default" size="100%">Camats-Tarruella, Núria</style></author><author><style face="normal" font="default" size="100%">Fernández-Cancio, Mónica</style></author><author><style face="normal" font="default" size="100%">Rapp, Christina</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Griese, Matthias</style></author><author><style face="normal" font="default" size="100%">Moreno-Galdó, Antonio</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">ChILD-Spain Group</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Incidence and Prevalence of Children's Diffuse Lung Disease in Spain.</style></title><secondary-title><style face="normal" font="default" size="100%">Arch Bronconeumol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Arch Bronconeumol</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Jan</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">58</style></volume><pages><style face="normal" font="default" size="100%">22-29</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Children's diffuse lung disease, also known as children's Interstitial Lung Diseases (chILD), are a heterogeneous group of rare diseases with relevant morbidity and mortality, which diagnosis and classification are very complex. Epidemiological data are scarce. The aim of this study was to analyse incidence and prevalence of chILD in Spain.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;Multicentre observational prospective study in patients from 0 to 18 years of age with chILD to analyse its incidence and prevalence in Spain, based on data reported in 2018 and 2019.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;A total of 381 cases with chILD were notified from 51 paediatric pulmonology units all over Spain, covering the 91.7% of the paediatric population. The average incidence of chILD was 8.18 (CI 95% 6.28-10.48) new cases/million of children per year. The average prevalence of chILD was 46.53 (CI 95% 41.81-51.62) cases/million of children. The age group with the highest prevalence were children under 1 year of age. Different types of disorders were seen in children 2-18 years of age compared with children 0-2 years of age. Most frequent cases were: primary pulmonary interstitial glycogenosis in neonates (17/65), neuroendocrine cell hyperplasia of infancy in infants from 1 to 12 months (44/144), idiopathic pulmonary haemosiderosis in children from 1 to 5 years old (13/74), hypersensitivity pneumonitis in children from 5 to 10 years old (9/51), and scleroderma in older than 10 years old (8/47).&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;We found a higher incidence and prevalence of chILD than previously described probably due to greater understanding and increased clinician awareness of these rare diseases.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cruz, Raquel</style></author><author><style face="normal" font="default" size="100%">Almeida, Silvia Diz-de</style></author><author><style face="normal" font="default" size="100%">Heredia, Miguel López</style></author><author><style face="normal" font="default" size="100%">Quintela, Inés</style></author><author><style face="normal" font="default" size="100%">Ceballos, Francisco C</style></author><author><style face="normal" font="default" size="100%">Pita, Guillermo</style></author><author><style face="normal" font="default" size="100%">Lorenzo-Salazar, José M</style></author><author><style face="normal" font="default" size="100%">González-Montelongo, Rafaela</style></author><author><style face="normal" font="default" size="100%">Gago-Domínguez, Manuela</style></author><author><style face="normal" font="default" size="100%">Porras, Marta Sevilla</style></author><author><style face="normal" font="default" size="100%">Castaño, Jair Antonio Tenorio</style></author><author><style face="normal" font="default" size="100%">Nevado, Julián</style></author><author><style face="normal" font="default" size="100%">Aguado, Jose María</style></author><author><style face="normal" font="default" size="100%">Aguilar, Carlos</style></author><author><style face="normal" font="default" size="100%">Aguilera-Albesa, Sergio</style></author><author><style face="normal" font="default" size="100%">Almadana, Virginia</style></author><author><style face="normal" font="default" size="100%">Almoguera, Berta</style></author><author><style face="normal" font="default" size="100%">Alvarez, Nuria</style></author><author><style face="normal" font="default" size="100%">Andreu-Bernabeu, Álvaro</style></author><author><style face="normal" font="default" size="100%">Arana-Arri, Eunate</style></author><author><style face="normal" font="default" size="100%">Arango, Celso</style></author><author><style face="normal" font="default" size="100%">Arranz, María J</style></author><author><style face="normal" font="default" size="100%">Artiga, Maria-Jesus</style></author><author><style face="normal" font="default" size="100%">Baptista-Rosas, Raúl C</style></author><author><style face="normal" font="default" size="100%">Barreda-Sánchez, María</style></author><author><style face="normal" font="default" size="100%">Belhassen-Garcia, Moncef</style></author><author><style face="normal" font="default" size="100%">Bezerra, Joao F</style></author><author><style face="normal" font="default" size="100%">Bezerra, Marcos A C</style></author><author><style face="normal" font="default" size="100%">Boix-Palop, Lucía</style></author><author><style face="normal" font="default" size="100%">Brión, Maria</style></author><author><style face="normal" font="default" size="100%">Brugada, Ramón</style></author><author><style face="normal" font="default" size="100%">Bustos, Matilde</style></author><author><style face="normal" font="default" size="100%">Calderón, Enrique J</style></author><author><style face="normal" font="default" size="100%">Carbonell, Cristina</style></author><author><style face="normal" font="default" size="100%">Castano, Luis</style></author><author><style face="normal" font="default" size="100%">Castelao, Jose E</style></author><author><style face="normal" font="default" size="100%">Conde-Vicente, Rosa</style></author><author><style face="normal" font="default" size="100%">Cordero-Lorenzana, M Lourdes</style></author><author><style face="normal" font="default" size="100%">Cortes-Sanchez, Jose L</style></author><author><style face="normal" font="default" size="100%">Corton, Marta</style></author><author><style face="normal" font="default" size="100%">Darnaude, M Teresa</style></author><author><style face="normal" font="default" size="100%">De Martino-Rodríguez, Alba</style></author><author><style face="normal" font="default" size="100%">Campo-Pérez, Victor</style></author><author><style face="normal" font="default" size="100%">Bustamante, Aranzazu Diaz</style></author><author><style face="normal" font="default" size="100%">Domínguez-Garrido, Elena</style></author><author><style face="normal" font="default" size="100%">Luchessi, André D</style></author><author><style face="normal" font="default" size="100%">Eirós, Rocío</style></author><author><style face="normal" font="default" size="100%">Sanabria, Gladys Mercedes Estigarribia</style></author><author><style face="normal" font="default" size="100%">Fariñas, María Carmen</style></author><author><style face="normal" font="default" size="100%">Fernández-Robelo, Uxía</style></author><author><style face="normal" font="default" size="100%">Fernández-Rodríguez, Amanda</style></author><author><style face="normal" font="default" size="100%">Fernández-Villa, Tania</style></author><author><style face="normal" font="default" size="100%">Gil-Fournier, Belén</style></author><author><style face="normal" font="default" size="100%">Gómez-Arrue, Javier</style></author><author><style face="normal" font="default" size="100%">Álvarez, Beatriz González</style></author><author><style face="normal" font="default" size="100%">Quirós, Fernan Gonzalez Bernaldo</style></author><author><style face="normal" font="default" size="100%">González-Peñas, Javier</style></author><author><style face="normal" font="default" size="100%">Gutiérrez-Bautista, Juan F</style></author><author><style face="normal" font="default" size="100%">Herrero, María José</style></author><author><style face="normal" font="default" size="100%">Herrero-Gonzalez, Antonio</style></author><author><style face="normal" font="default" size="100%">Jimenez-Sousa, María A</style></author><author><style face="normal" font="default" size="100%">Lattig, María Claudia</style></author><author><style face="normal" font="default" size="100%">Borja, Anabel Liger</style></author><author><style face="normal" font="default" size="100%">Lopez-Rodriguez, Rosario</style></author><author><style face="normal" font="default" size="100%">Mancebo, Esther</style></author><author><style face="normal" font="default" size="100%">Martín-López, Caridad</style></author><author><style face="normal" font="default" size="100%">Martín, Vicente</style></author><author><style face="normal" font="default" size="100%">Martinez-Nieto, Oscar</style></author><author><style face="normal" font="default" size="100%">Martinez-Lopez, Iciar</style></author><author><style face="normal" font="default" size="100%">Martinez-Resendez, Michel F</style></author><author><style face="normal" font="default" size="100%">Martinez-Perez, Ángel</style></author><author><style face="normal" font="default" size="100%">Mazzeu, Juliana A</style></author><author><style face="normal" font="default" size="100%">Macías, Eleuterio Merayo</style></author><author><style face="normal" font="default" size="100%">Minguez, Pablo</style></author><author><style face="normal" font="default" size="100%">Cuerda, Victor Moreno</style></author><author><style face="normal" font="default" size="100%">Silbiger, Vivian N</style></author><author><style face="normal" font="default" size="100%">Oliveira, Silviene F</style></author><author><style face="normal" font="default" size="100%">Ortega-Paino, Eva</style></author><author><style face="normal" font="default" size="100%">Parellada, Mara</style></author><author><style face="normal" font="default" size="100%">Paz-Artal, Estela</style></author><author><style face="normal" font="default" size="100%">Santos, Ney P C</style></author><author><style face="normal" font="default" size="100%">Pérez-Matute, Patricia</style></author><author><style face="normal" font="default" size="100%">Perez, Patricia</style></author><author><style face="normal" font="default" size="100%">Pérez-Tomás, M Elena</style></author><author><style face="normal" font="default" size="100%">Perucho, Teresa</style></author><author><style face="normal" font="default" size="100%">Pinsach-Abuin, Mel Lina</style></author><author><style face="normal" font="default" size="100%">Pompa-Mera, Ericka N</style></author><author><style face="normal" font="default" size="100%">Porras-Hurtado, Gloria L</style></author><author><style face="normal" font="default" size="100%">Pujol, Aurora</style></author><author><style face="normal" font="default" size="100%">León, Soraya Ramiro</style></author><author><style face="normal" font="default" size="100%">Resino, Salvador</style></author><author><style face="normal" font="default" size="100%">Fernandes, Marianne R</style></author><author><style face="normal" font="default" size="100%">Rodríguez-Ruiz, Emilio</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Artalejo, Fernando</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Garcia, José A</style></author><author><style face="normal" font="default" size="100%">Ruiz-Cabello, Francisco</style></author><author><style face="normal" font="default" size="100%">Ruiz-Hornillos, Javier</style></author><author><style face="normal" font="default" size="100%">Ryan, Pablo</style></author><author><style face="normal" font="default" size="100%">Soria, José Manuel</style></author><author><style face="normal" font="default" size="100%">Souto, Juan Carlos</style></author><author><style face="normal" font="default" size="100%">Tamayo, Eduardo</style></author><author><style face="normal" font="default" size="100%">Tamayo-Velasco, Alvaro</style></author><author><style face="normal" font="default" size="100%">Taracido-Fernandez, Juan Carlos</style></author><author><style face="normal" font="default" size="100%">Teper, Alejandro</style></author><author><style face="normal" font="default" size="100%">Torres-Tobar, Lilian</style></author><author><style face="normal" font="default" size="100%">Urioste, Miguel</style></author><author><style face="normal" font="default" size="100%">Valencia-Ramos, Juan</style></author><author><style face="normal" font="default" size="100%">Yáñez, Zuleima</style></author><author><style face="normal" font="default" size="100%">Zarate, Ruth</style></author><author><style face="normal" font="default" size="100%">Nakanishi, Tomoko</style></author><author><style face="normal" font="default" size="100%">Pigazzini, Sara</style></author><author><style face="normal" font="default" size="100%">Degenhardt, Frauke</style></author><author><style face="normal" font="default" size="100%">Butler-Laporte, Guillaume</style></author><author><style face="normal" font="default" size="100%">Maya-Miles, Douglas</style></author><author><style face="normal" font="default" size="100%">Bujanda, Luis</style></author><author><style face="normal" font="default" size="100%">Bouysran, Youssef</style></author><author><style face="normal" font="default" size="100%">Palom, Adriana</style></author><author><style face="normal" font="default" size="100%">Ellinghaus, David</style></author><author><style face="normal" font="default" size="100%">Martínez-Bueno, Manuel</style></author><author><style face="normal" font="default" size="100%">Rolker, Selina</style></author><author><style face="normal" font="default" size="100%">Amitrano, Sara</style></author><author><style face="normal" font="default" size="100%">Roade, Luisa</style></author><author><style face="normal" font="default" size="100%">Fava, Francesca</style></author><author><style face="normal" font="default" size="100%">Spinner, Christoph D</style></author><author><style face="normal" font="default" size="100%">Prati, Daniele</style></author><author><style face="normal" font="default" size="100%">Bernardo, David</style></author><author><style face="normal" font="default" size="100%">García, Federico</style></author><author><style face="normal" font="default" size="100%">Darcis, Gilles</style></author><author><style face="normal" font="default" size="100%">Fernández-Cadenas, Israel</style></author><author><style face="normal" font="default" size="100%">Holter, Jan Cato</style></author><author><style face="normal" font="default" size="100%">Banales, Jesus M</style></author><author><style face="normal" font="default" size="100%">Frithiof, Robert</style></author><author><style face="normal" font="default" size="100%">Duga, Stefano</style></author><author><style face="normal" font="default" size="100%">Asselta, Rosanna</style></author><author><style face="normal" font="default" size="100%">Pereira, Alexandre C</style></author><author><style face="normal" font="default" size="100%">Romero-Gómez, Manuel</style></author><author><style face="normal" font="default" size="100%">Nafría-Jiménez, Beatriz</style></author><author><style face="normal" font="default" size="100%">Hov, Johannes R</style></author><author><style face="normal" font="default" size="100%">Migeotte, Isabelle</style></author><author><style face="normal" font="default" size="100%">Renieri, Alessandra</style></author><author><style face="normal" font="default" size="100%">Planas, Anna M</style></author><author><style face="normal" font="default" size="100%">Ludwig, Kerstin U</style></author><author><style face="normal" font="default" size="100%">Buti, Maria</style></author><author><style face="normal" font="default" size="100%">Rahmouni, Souad</style></author><author><style face="normal" font="default" size="100%">Alarcón-Riquelme, Marta E</style></author><author><style face="normal" font="default" size="100%">Schulte, Eva C</style></author><author><style face="normal" font="default" size="100%">Franke, Andre</style></author><author><style face="normal" font="default" size="100%">Karlsen, Tom H</style></author><author><style face="normal" font="default" size="100%">Valenti, Luca</style></author><author><style face="normal" font="default" size="100%">Zeberg, Hugo</style></author><author><style face="normal" font="default" size="100%">Richards, Brent</style></author><author><style face="normal" font="default" size="100%">Ganna, Andrea</style></author><author><style face="normal" font="default" size="100%">Boada, Mercè</style></author><author><style face="normal" font="default" size="100%">Rojas, Itziar</style></author><author><style face="normal" font="default" size="100%">Ruiz, Agustín</style></author><author><style face="normal" font="default" size="100%">Sánchez, Pascual</style></author><author><style face="normal" font="default" size="100%">Real, Luis Miguel</style></author><author><style face="normal" font="default" size="100%">Guillén-Navarro, Encarna</style></author><author><style face="normal" font="default" size="100%">Ayuso, Carmen</style></author><author><style face="normal" font="default" size="100%">González-Neira, Anna</style></author><author><style face="normal" font="default" size="100%">Riancho, José A</style></author><author><style face="normal" font="default" size="100%">Rojas-Martinez, Augusto</style></author><author><style face="normal" font="default" size="100%">Flores, Carlos</style></author><author><style face="normal" font="default" size="100%">Lapunzina, Pablo</style></author><author><style face="normal" font="default" size="100%">Carracedo, Ángel</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">SCOURGE Cohort Group</style></author><author><style face="normal" font="default" size="100%">HOSTAGE Cohort Group</style></author><author><style face="normal" font="default" size="100%">GRA@CE Cohort Group</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Novel genes and sex differences in COVID-19 severity.</style></title><secondary-title><style face="normal" font="default" size="100%">Hum Mol Genet</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Hum Mol Genet</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Jun 16</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Here we describe the results of a genome-wide study conducted in 11 939 COVID-19 positive cases with an extensive clinical information that were recruited from 34 hospitals across Spain (SCOURGE consortium). In sex-disaggregated genome-wide association studies for COVID-19 hospitalization, genome-wide significance (p &lt; 5x10-8) was crossed for variants in 3p21.31 and 21q22.11 loci only among males (p = 1.3x10-22 and p = 8.1x10-12, respectively), and for variants in 9q21.32 near TLE1 only among females (p = 4.4x10-8). In a second phase, results were combined with an independent Spanish cohort (1598 COVID-19 cases and 1068 population controls), revealing in the overall analysis two novel risk loci in 9p13.3 and 19q13.12, with fine-mapping prioritized variants functionally associated with AQP3 (p = 2.7x10-8) and ARHGAP33 (p = 1.3x10-8), respectively. The meta-analysis of both phases with four European studies stratified by sex from the Host Genetics Initiative confirmed the association of the 3p21.31 and 21q22.11 loci predominantly in males and replicated a recently reported variant in 11p13 (ELF5, p = 4.1x10-8). Six of the COVID-19 HGI discovered loci were replicated and an HGI-based genetic risk score predicted the severity strata in SCOURGE. We also found more SNP-heritability and larger heritability differences by age (&lt;60 or ≥ 60 years) among males than among females. Parallel genome-wide screening of inbreeding depression in SCOURGE also showed an effect of homozygosity in COVID-19 hospitalization and severity and this effect was stronger among older males. In summary, new candidate genes for COVID-19 severity and evidence supporting genetic disparities among sexes are provided.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ortiz-Aljaro, Pilar</style></author><author><style face="normal" font="default" size="100%">Montes-Cano, Marco Antonio</style></author><author><style face="normal" font="default" size="100%">García-Lozano, José-Raúl</style></author><author><style face="normal" font="default" size="100%">Aquino, Virginia</style></author><author><style face="normal" font="default" size="100%">Carmona, Rosario</style></author><author><style face="normal" font="default" size="100%">Perez-Florido, Javier</style></author><author><style face="normal" font="default" size="100%">García-Hernández, Francisco José</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">González-Escribano, María Francisca</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Protein and functional isoform levels and genetic variants of the BAFF and APRIL pathway components in systemic lupus erythematosus.</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Sci Rep</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Jul 02</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">11219</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Systemic lupus erythematosus (SLE) is the prototype of an autoimmune disease. Belimumab, a monoclonal antibody targets BAFF, is the only biologic approved for SLE and active lupus nephritis. BAFF is a cytokine with a key-regulatory role in the B cell homeostasis, which acts by binding to three receptors: BAFF-R, TACI and BCMA. TACI and BCMA also bind APRIL. Many studies reported elevated soluble BAFF and APRIL levels in the sera of SLE patients, but other questions about the role of this system in the disease remain open. The study aimed to investigate the utility of the cytokine levels in serum and urine as biomarkers, the role of non-functional isoforms, and the association of gene variants with the disease. This case-control study includes a cohort (women, 18-60 years old) of 100 patients (48% with nephritis) and 100 healthy controls. We used ELISA assays to measure the cytokine concentrations in serum (sBAFF and sAPRIL) and urine (uBAFF and uAPRIL); TaqMan Gene Expression Assays to quantify the relative mRNA expression of ΔBAFF, βAPRIL, and εAPRIL, and next-generation sequencing to genotype the cytokine (TNFSF13 and TNFSF13B) and receptor (TNFRSF13B, TNFRSF17 and TNFRSF13C) genes. The statistical tests used were: Kruskal-Wallis (qualitative variables), the Spearman Rho coefficient (correlations), the Chi-square and SKAT (association of common and rare genetic variants, respectively). As expected, sBAFF and sAPRIL levels were higher in patients than in controls (p ≤ 0.001) but found differences between patient subgroups. sBAFF and sAPRIL significantly correlated only in patients with nephritis (r = 0.67, p ≤ 0.001) and βAPRIL levels were lower in patients with nephritis (p = 0.04), and ΔBAFF levels were lower in patients with dsDNA antibodies (p = 0.04). Rare variants of TNFSF13 and TNFRSF13B and TNFSF13 p.Gly67Arg and TNFRSF13B p.Val220Ala were associated with SLE. Our study supports differences among SLE patient subgroups with diverse clinical features in the BAFF/APRIL pathway. In addition, it suggests the involvement of genetic variants in the susceptibility to the disease.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Olivares-González, Lorena</style></author><author><style face="normal" font="default" size="100%">Velasco, Sheyla</style></author><author><style face="normal" font="default" size="100%">Gallego, Idoia</style></author><author><style face="normal" font="default" size="100%">Esteban-Medina, Marina</style></author><author><style face="normal" font="default" size="100%">Puras, Gustavo</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Martínez-Romero, Alicia</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Pedraz, José Luis</style></author><author><style face="normal" font="default" size="100%">Rodrigo, Regina</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">An SPM-Enriched Marine Oil Supplement Shifted Microglia Polarization toward M2, Ameliorating Retinal Degeneration in  Mice.</style></title><secondary-title><style face="normal" font="default" size="100%">Antioxidants (Basel)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Antioxidants (Basel)</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Dec 30</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Retinitis pigmentosa (RP) is the most common inherited retinal dystrophy causing progressive vision loss. It is accompanied by chronic and sustained inflammation, including M1 microglia activation. This study evaluated the effect of an essential fatty acid (EFA) supplement containing specialized pro-resolving mediators (SPMs), on retinal degeneration and microglia activation in  mice, a model of RP, as well as on LPS-stimulated BV2 cells. The EFA supplement was orally administered to mice from postnatal day (P)9 to P18. At P18, the electrical activity of the retina was examined by electroretinography (ERG) and innate behavior in response to light were measured. Retinal degeneration was studied via histology including the TUNEL assay and microglia immunolabeling. Microglia polarization (M1/M2) was assessed by flow cytometry, qPCR, ELISA and histology. Redox status was analyzed by measuring antioxidant enzymes and markers of oxidative damage. Interestingly, the EFA supplement ameliorated retinal dysfunction and degeneration by improving ERG recording and sensitivity to light, and reducing photoreceptor cell loss. The EFA supplement reduced inflammation and microglia activation attenuating M1 markers as well as inducing a shift to the M2 phenotype in  mouse retinas and LPS-stimulated BV2 cells. It also reduced oxidative stress markers of lipid peroxidation and carbonylation. These findings could open up new therapeutic opportunities based on resolving inflammation with oral supplementation with SPMs such as the EFA supplement.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Casimiro-Soriguer, Carlos S</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Towards a metagenomics machine learning interpretable model for understanding the transition from adenoma to colorectal cancer.</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Sci Rep</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Jan 10</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">450</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Gut microbiome is gaining interest because of its links with several diseases, including colorectal cancer (CRC), as well as the possibility of being used to obtain non-intrusive predictive disease biomarkers. Here we performed a meta-analysis of 1042 fecal metagenomic samples from seven publicly available studies. We used an interpretable machine learning approach based on functional profiles, instead of the conventional taxonomic profiles, to produce a highly accurate predictor of CRC with better precision than those of previous proposals. Moreover, this approach is also able to discriminate samples with adenoma, which makes this approach very promising for CRC prevention by detecting early stages in which intervention is easier and more effective. In addition, interpretable machine learning methods allow extracting features relevant for the classification, which reveals basic molecular mechanisms accounting for the changes undergone by the microbiome functional landscape in the transition from healthy gut to adenoma and CRC conditions. Functional profiles have demonstrated superior accuracy in predicting CRC and adenoma conditions than taxonomic profiles and additionally, in a context of explainable machine learning, provide useful hints on the molecular mechanisms operating in the microbiota behind these conditions.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martorell-Marugán, Jordi</style></author><author><style face="normal" font="default" size="100%">López-Domínguez, Raúl</style></author><author><style face="normal" font="default" size="100%">García-Moreno, Adrián</style></author><author><style face="normal" font="default" size="100%">Toro-Domínguez, Daniel</style></author><author><style face="normal" font="default" size="100%">Villatoro-García, Juan Antonio</style></author><author><style face="normal" font="default" size="100%">Barturen, Guillermo</style></author><author><style face="normal" font="default" size="100%">Martín-Gómez, Adoración</style></author><author><style face="normal" font="default" size="100%">Troule, Kevin</style></author><author><style face="normal" font="default" size="100%">Gómez-López, Gonzalo</style></author><author><style face="normal" font="default" size="100%">Al-Shahrour, Fátima</style></author><author><style face="normal" font="default" size="100%">González-Rumayor, Víctor</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Saez-Rodriguez, Julio</style></author><author><style face="normal" font="default" size="100%">Alarcón-Riquelme, Marta E</style></author><author><style face="normal" font="default" size="100%">Carmona-Sáez, Pedro</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A comprehensive database for integrated analysis of omics data in autoimmune diseases.</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Bioinformatics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">BMC Bioinformatics</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Autoimmune Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Databases, Factual</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Jun 24</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">22</style></volume><pages><style face="normal" font="default" size="100%">343</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Autoimmune diseases are heterogeneous pathologies with difficult diagnosis and few therapeutic options. In the last decade, several omics studies have provided significant insights into the molecular mechanisms of these diseases. Nevertheless, data from different cohorts and pathologies are stored independently in public repositories and a unified resource is imperative to assist researchers in this field.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Here, we present Autoimmune Diseases Explorer ( https://adex.genyo.es ), a database that integrates 82 curated transcriptomics and methylation studies covering 5609 samples for some of the most common autoimmune diseases. The database provides, in an easy-to-use environment, advanced data analysis and statistical methods for exploring omics datasets, including meta-analysis, differential expression or pathway analysis.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;This is the first omics database focused on autoimmune diseases. This resource incorporates homogeneously processed data to facilitate integrative analyses among studies.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34167460?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ostaszewski, Marek</style></author><author><style face="normal" font="default" size="100%">Niarakis, Anna</style></author><author><style face="normal" font="default" size="100%">Mazein, Alexander</style></author><author><style face="normal" font="default" size="100%">Kuperstein, Inna</style></author><author><style face="normal" font="default" size="100%">Phair, Robert</style></author><author><style face="normal" font="default" size="100%">Orta-Resendiz, Aurelio</style></author><author><style face="normal" font="default" size="100%">Singh, Vidisha</style></author><author><style face="normal" font="default" size="100%">Aghamiri, Sara Sadat</style></author><author><style face="normal" font="default" size="100%">Acencio, Marcio Luis</style></author><author><style face="normal" font="default" size="100%">Glaab, Enrico</style></author><author><style face="normal" font="default" size="100%">Ruepp, Andreas</style></author><author><style face="normal" font="default" size="100%">Fobo, Gisela</style></author><author><style face="normal" font="default" size="100%">Montrone, Corinna</style></author><author><style face="normal" font="default" size="100%">Brauner, Barbara</style></author><author><style face="normal" font="default" size="100%">Frishman, Goar</style></author><author><style face="normal" font="default" size="100%">Monraz Gómez, Luis Cristóbal</style></author><author><style face="normal" font="default" size="100%">Somers, Julia</style></author><author><style face="normal" font="default" size="100%">Hoch, Matti</style></author><author><style face="normal" font="default" size="100%">Kumar Gupta, Shailendra</style></author><author><style face="normal" font="default" size="100%">Scheel, Julia</style></author><author><style face="normal" font="default" size="100%">Borlinghaus, Hanna</style></author><author><style face="normal" font="default" size="100%">Czauderna, Tobias</style></author><author><style face="normal" font="default" size="100%">Schreiber, Falk</style></author><author><style face="normal" font="default" size="100%">Montagud, Arnau</style></author><author><style face="normal" font="default" size="100%">Ponce de Leon, Miguel</style></author><author><style face="normal" font="default" size="100%">Funahashi, Akira</style></author><author><style face="normal" font="default" size="100%">Hiki, Yusuke</style></author><author><style face="normal" font="default" size="100%">Hiroi, Noriko</style></author><author><style face="normal" font="default" size="100%">Yamada, Takahiro G</style></author><author><style face="normal" font="default" size="100%">Dräger, Andreas</style></author><author><style face="normal" font="default" size="100%">Renz, Alina</style></author><author><style face="normal" font="default" size="100%">Naveez, Muhammad</style></author><author><style face="normal" font="default" size="100%">Bocskei, Zsolt</style></author><author><style face="normal" font="default" size="100%">Messina, Francesco</style></author><author><style face="normal" font="default" size="100%">Börnigen, Daniela</style></author><author><style face="normal" font="default" size="100%">Fergusson, Liam</style></author><author><style face="normal" font="default" size="100%">Conti, Marta</style></author><author><style face="normal" font="default" size="100%">Rameil, Marius</style></author><author><style face="normal" font="default" size="100%">Nakonecnij, Vanessa</style></author><author><style face="normal" font="default" size="100%">Vanhoefer, Jakob</style></author><author><style face="normal" font="default" size="100%">Schmiester, Leonard</style></author><author><style face="normal" font="default" size="100%">Wang, Muying</style></author><author><style face="normal" font="default" size="100%">Ackerman, Emily E</style></author><author><style face="normal" font="default" size="100%">Shoemaker, Jason E</style></author><author><style face="normal" font="default" size="100%">Zucker, Jeremy</style></author><author><style face="normal" font="default" size="100%">Oxford, Kristie</style></author><author><style face="normal" font="default" size="100%">Teuton, Jeremy</style></author><author><style face="normal" font="default" size="100%">Kocakaya, Ebru</style></author><author><style face="normal" font="default" size="100%">Summak, Gökçe Yağmur</style></author><author><style face="normal" font="default" size="100%">Hanspers, Kristina</style></author><author><style face="normal" font="default" size="100%">Kutmon, Martina</style></author><author><style face="normal" font="default" size="100%">Coort, Susan</style></author><author><style face="normal" font="default" size="100%">Eijssen, Lars</style></author><author><style face="normal" font="default" size="100%">Ehrhart, Friederike</style></author><author><style face="normal" font="default" size="100%">Rex, Devasahayam Arokia Balaya</style></author><author><style face="normal" font="default" size="100%">Slenter, Denise</style></author><author><style face="normal" font="default" size="100%">Martens, Marvin</style></author><author><style face="normal" font="default" size="100%">Pham, Nhung</style></author><author><style face="normal" font="default" size="100%">Haw, Robin</style></author><author><style face="normal" font="default" size="100%">Jassal, Bijay</style></author><author><style face="normal" font="default" size="100%">Matthews, Lisa</style></author><author><style face="normal" font="default" size="100%">Orlic-Milacic, Marija</style></author><author><style face="normal" font="default" size="100%">Senff Ribeiro, Andrea</style></author><author><style face="normal" font="default" size="100%">Rothfels, Karen</style></author><author><style face="normal" font="default" size="100%">Shamovsky, Veronica</style></author><author><style face="normal" font="default" size="100%">Stephan, Ralf</style></author><author><style face="normal" font="default" size="100%">Sevilla, Cristoffer</style></author><author><style face="normal" font="default" size="100%">Varusai, Thawfeek</style></author><author><style face="normal" font="default" size="100%">Ravel, Jean-Marie</style></author><author><style face="normal" font="default" size="100%">Fraser, Rupsha</style></author><author><style face="normal" font="default" size="100%">Ortseifen, Vera</style></author><author><style face="normal" font="default" size="100%">Marchesi, Silvia</style></author><author><style face="normal" font="default" size="100%">Gawron, Piotr</style></author><author><style face="normal" font="default" size="100%">Smula, Ewa</style></author><author><style face="normal" font="default" size="100%">Heirendt, Laurent</style></author><author><style face="normal" font="default" size="100%">Satagopam, Venkata</style></author><author><style face="normal" font="default" size="100%">Wu, Guanming</style></author><author><style face="normal" font="default" size="100%">Riutta, Anders</style></author><author><style face="normal" font="default" size="100%">Golebiewski, Martin</style></author><author><style face="normal" font="default" size="100%">Owen, Stuart</style></author><author><style face="normal" font="default" size="100%">Goble, Carole</style></author><author><style face="normal" font="default" size="100%">Hu, Xiaoming</style></author><author><style face="normal" font="default" size="100%">Overall, Rupert W</style></author><author><style face="normal" font="default" size="100%">Maier, Dieter</style></author><author><style face="normal" font="default" size="100%">Bauch, Angela</style></author><author><style face="normal" font="default" size="100%">Gyori, Benjamin M</style></author><author><style face="normal" font="default" size="100%">Bachman, John A</style></author><author><style face="normal" font="default" size="100%">Vega, Carlos</style></author><author><style face="normal" font="default" size="100%">Grouès, Valentin</style></author><author><style face="normal" font="default" size="100%">Vazquez, Miguel</style></author><author><style face="normal" font="default" size="100%">Porras, Pablo</style></author><author><style face="normal" font="default" size="100%">Licata, Luana</style></author><author><style face="normal" font="default" size="100%">Iannuccelli, Marta</style></author><author><style face="normal" font="default" size="100%">Sacco, Francesca</style></author><author><style face="normal" font="default" size="100%">Nesterova, Anastasia</style></author><author><style face="normal" font="default" size="100%">Yuryev, Anton</style></author><author><style face="normal" font="default" size="100%">de Waard, Anita</style></author><author><style face="normal" font="default" size="100%">Turei, Denes</style></author><author><style face="normal" font="default" size="100%">Luna, Augustin</style></author><author><style face="normal" font="default" size="100%">Babur, Ozgun</style></author><author><style face="normal" font="default" size="100%">Soliman, Sylvain</style></author><author><style face="normal" font="default" size="100%">Valdeolivas, Alberto</style></author><author><style face="normal" font="default" size="100%">Esteban-Medina, Marina</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Rian, Kinza</style></author><author><style face="normal" font="default" size="100%">Helikar, Tomáš</style></author><author><style face="normal" font="default" size="100%">Puniya, Bhanwar Lal</style></author><author><style face="normal" font="default" size="100%">Modos, Dezso</style></author><author><style face="normal" font="default" size="100%">Treveil, Agatha</style></author><author><style face="normal" font="default" size="100%">Olbei, Marton</style></author><author><style face="normal" font="default" size="100%">De Meulder, Bertrand</style></author><author><style face="normal" font="default" size="100%">Ballereau, Stephane</style></author><author><style face="normal" font="default" size="100%">Dugourd, Aurélien</style></author><author><style face="normal" font="default" size="100%">Naldi, Aurélien</style></author><author><style face="normal" font="default" size="100%">Noël, Vincent</style></author><author><style face="normal" font="default" size="100%">Calzone, Laurence</style></author><author><style face="normal" font="default" size="100%">Sander, Chris</style></author><author><style face="normal" font="default" size="100%">Demir, Emek</style></author><author><style face="normal" font="default" size="100%">Korcsmaros, Tamas</style></author><author><style face="normal" font="default" size="100%">Freeman, Tom C</style></author><author><style face="normal" font="default" size="100%">Augé, Franck</style></author><author><style face="normal" font="default" size="100%">Beckmann, Jacques S</style></author><author><style face="normal" font="default" size="100%">Hasenauer, Jan</style></author><author><style face="normal" font="default" size="100%">Wolkenhauer, Olaf</style></author><author><style face="normal" font="default" size="100%">Wilighagen, Egon L</style></author><author><style face="normal" font="default" size="100%">Pico, Alexander R</style></author><author><style face="normal" font="default" size="100%">Evelo, Chris T</style></author><author><style face="normal" font="default" size="100%">Gillespie, Marc E</style></author><author><style face="normal" font="default" size="100%">Stein, Lincoln D</style></author><author><style face="normal" font="default" size="100%">Hermjakob, Henning</style></author><author><style face="normal" font="default" size="100%">D'Eustachio, Peter</style></author><author><style face="normal" font="default" size="100%">Saez-Rodriguez, Julio</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Valencia, Alfonso</style></author><author><style face="normal" font="default" size="100%">Kitano, Hiroaki</style></author><author><style face="normal" font="default" size="100%">Barillot, Emmanuel</style></author><author><style face="normal" font="default" size="100%">Auffray, Charles</style></author><author><style face="normal" font="default" size="100%">Balling, Rudi</style></author><author><style face="normal" font="default" size="100%">Schneider, Reinhard</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">COVID-19 Disease Map Community</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">COVID19 Disease Map, a computational knowledge repository of virus-host interaction mechanisms.</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Syst Biol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Mol Syst Biol</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antiviral Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Computer Graphics</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style  face="normal" font="default" size="100%">Data Mining</style></keyword><keyword><style  face="normal" font="default" size="100%">Databases, Factual</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Host Microbial Interactions</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunity, Cellular</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunity, Humoral</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style  face="normal" font="default" size="100%">Lymphocytes</style></keyword><keyword><style  face="normal" font="default" size="100%">Metabolic Networks and Pathways</style></keyword><keyword><style  face="normal" font="default" size="100%">Myeloid Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Interaction Mapping</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style  face="normal" font="default" size="100%">Software</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcription Factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Viral Proteins</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 10</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">e10387</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;We need to effectively combine the knowledge from surging literature with complex datasets to propose mechanistic models of SARS-CoV-2 infection, improving data interpretation and predicting key targets of intervention. Here, we describe a large-scale community effort to build an open access, interoperable and computable repository of COVID-19 molecular mechanisms. The COVID-19 Disease Map (C19DMap) is a graphical, interactive representation of disease-relevant molecular mechanisms linking many knowledge sources. Notably, it is a computational resource for graph-based analyses and disease modelling. To this end, we established a framework of tools, platforms and guidelines necessary for a multifaceted community of biocurators, domain experts, bioinformaticians and computational biologists. The diagrams of the C19DMap, curated from the literature, are integrated with relevant interaction and text mining databases. We demonstrate the application of network analysis and modelling approaches by concrete examples to highlight new testable hypotheses. This framework helps to find signatures of SARS-CoV-2 predisposition, treatment response or prioritisation of drug candidates. Such an approach may help deal with new waves of COVID-19 or similar pandemics in the long-term perspective.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34664389?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Roldán, Gema</style></author><author><style face="normal" font="default" size="100%">Perez-Florido, Javier</style></author><author><style face="normal" font="default" size="100%">Ortuno, Francisco M</style></author><author><style face="normal" font="default" size="100%">Carmona, Rosario</style></author><author><style face="normal" font="default" size="100%">Aquino, Virginia</style></author><author><style face="normal" font="default" size="100%">López-López, Daniel</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rueda, Jose L</style></author><author><style face="normal" font="default" size="100%">Gallego, Asunción</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">González-Neira, Anna</style></author><author><style face="normal" font="default" size="100%">Pita, Guillermo</style></author><author><style face="normal" font="default" size="100%">Núñez-Torres, Rocío</style></author><author><style face="normal" font="default" size="100%">Santoyo-López, Javier</style></author><author><style face="normal" font="default" size="100%">Ayuso, Carmen</style></author><author><style face="normal" font="default" size="100%">Minguez, Pablo</style></author><author><style face="normal" font="default" size="100%">Avila-Fernandez, Almudena</style></author><author><style face="normal" font="default" size="100%">Corton, Marta</style></author><author><style face="normal" font="default" size="100%">Moreno-Pelayo, Miguel Ángel</style></author><author><style face="normal" font="default" size="100%">Morin, Matías</style></author><author><style face="normal" font="default" size="100%">Gallego-Martinez, Alvaro</style></author><author><style face="normal" font="default" size="100%">Lopez-Escamez, Jose A</style></author><author><style face="normal" font="default" size="100%">Borrego, Salud</style></author><author><style face="normal" font="default" size="100%">Antiňolo, Guillermo</style></author><author><style face="normal" font="default" size="100%">Amigo, Jorge</style></author><author><style face="normal" font="default" size="100%">Salgado-Garrido, Josefa</style></author><author><style face="normal" font="default" size="100%">Pasalodos-Sanchez, Sara</style></author><author><style face="normal" font="default" size="100%">Morte, Beatriz</style></author><author><style face="normal" font="default" size="100%">Carracedo, Ángel</style></author><author><style face="normal" font="default" size="100%">Alonso, Ángel</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">Spanish Exome Crowdsourcing Consortium</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">CSVS, a crowdsourcing database of the Spanish population genetic variability.</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Alleles</style></keyword><keyword><style  face="normal" font="default" size="100%">Chromosome Mapping</style></keyword><keyword><style  face="normal" font="default" size="100%">Crowdsourcing</style></keyword><keyword><style  face="normal" font="default" size="100%">Databases, Genetic</style></keyword><keyword><style  face="normal" font="default" size="100%">Exome</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Frequency</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Variation</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetics, Population</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome, Human</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Internet</style></keyword><keyword><style  face="normal" font="default" size="100%">Precision Medicine</style></keyword><keyword><style  face="normal" font="default" size="100%">Software</style></keyword><keyword><style  face="normal" font="default" size="100%">Spain</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 01 08</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">49</style></volume><pages><style face="normal" font="default" size="100%">D1130-D1137</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The knowledge of the genetic variability of the local population is of utmost importance in personalized medicine and has been revealed as a critical factor for the discovery of new disease variants. Here, we present the Collaborative Spanish Variability Server (CSVS), which currently contains more than 2000 genomes and exomes of unrelated Spanish individuals. This database has been generated in a collaborative crowdsourcing effort collecting sequencing data produced by local genomic projects and for other purposes. Sequences have been grouped by ICD10 upper categories. A web interface allows querying the database removing one or more ICD10 categories. In this way, aggregated counts of allele frequencies of the pseudo-control Spanish population can be obtained for diseases belonging to the category removed. Interestingly, in addition to pseudo-control studies, some population studies can be made, as, for example, prevalence of pharmacogenomic variants, etc. In addition, this genomic data has been used to define the first Spanish Genome Reference Panel (SGRP1.0) for imputation. This is the first local repository of variability entirely produced by a crowdsourcing effort and constitutes an example for future initiatives to characterize local variability worldwide. CSVS is also part of the GA4GH Beacon network. CSVS can be accessed at: http://csvs.babelomics.org/.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">D1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32990755?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martinez-Delgado, Beatriz</style></author><author><style face="normal" font="default" size="100%">Lopez-Martin, Estrella</style></author><author><style face="normal" font="default" size="100%">Lara-Herguedas, Julián</style></author><author><style face="normal" font="default" size="100%">Monzon, Sara</style></author><author><style face="normal" font="default" size="100%">Cuesta, Isabel</style></author><author><style face="normal" font="default" size="100%">Juliá, Miguel</style></author><author><style face="normal" font="default" size="100%">Aquino, Virginia</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Martin, Carlos</style></author><author><style face="normal" font="default" size="100%">Damian, Alejandra</style></author><author><style face="normal" font="default" size="100%">Gonzalo, Irene</style></author><author><style face="normal" font="default" size="100%">Gomez-Mariano, Gema</style></author><author><style face="normal" font="default" size="100%">Baladron, Beatriz</style></author><author><style face="normal" font="default" size="100%">Cazorla, Rosario</style></author><author><style face="normal" font="default" size="100%">Iglesias, Gema</style></author><author><style face="normal" font="default" size="100%">Roman, Enriqueta</style></author><author><style face="normal" font="default" size="100%">Ros, Purificacion</style></author><author><style face="normal" font="default" size="100%">Tutor, Pablo</style></author><author><style face="normal" font="default" size="100%">Mellor, Susana</style></author><author><style face="normal" font="default" size="100%">Jimenez, Carlos</style></author><author><style face="normal" font="default" size="100%">Cabrejas, Maria Jose</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Vioque, Emiliano</style></author><author><style face="normal" font="default" size="100%">Alonso, Javier</style></author><author><style face="normal" font="default" size="100%">Bermejo-Sánchez, Eva</style></author><author><style face="normal" font="default" size="100%">Posada, Manuel</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">De novo small deletion affecting transcription start site of short isoform of AUTS2 gene in a patient with syndromic neurodevelopmental defects.</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Med Genet A</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Am J Med Genet A</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style  face="normal" font="default" size="100%">Cytoskeletal Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Dwarfism</style></keyword><keyword><style  face="normal" font="default" size="100%">Exons</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Association Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Neurodevelopmental Disorders</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Isoforms</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style  face="normal" font="default" size="100%">Sequence Deletion</style></keyword><keyword><style  face="normal" font="default" size="100%">Syndrome</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcription Factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcription Initiation Site</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcription, Genetic</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 03</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">185</style></volume><pages><style face="normal" font="default" size="100%">877-883</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Disruption of the autism susceptibility candidate 2 (AUTS2) gene through genomic rearrangements, copy number variations (CNVs), and intragenic deletions and mutations, has been recurrently involved in syndromic forms of developmental delay and intellectual disability, known as AUTS2 syndrome. The AUTS2 gene plays an important role in regulation of neuronal migration, and when altered, associates with a variable phenotype from severely to mildly affected patients. The more severe phenotypes significantly correlate with the presence of defects affecting the C-terminus part of the gene. This article reports a new patient with a syndromic neurodevelopmental disorder, who presents a deletion of 30 nucleotides in the exon 9 of the AUTS2 gene. Importantly, this deletion includes the transcription start site for the AUTS2 short transcript isoform, which has an important role in brain development. Gene expression analysis of AUTS2 full-length and short isoforms revealed that the deletion found in this patient causes a remarkable reduction in the expression level, not only of the short isoform, but also of the full AUTS2 transcripts. This report adds more evidence for the role of mutated AUTS2 short transcripts in the development of a severe phenotype in the AUTS2 syndrome.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moura, David S</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Cordero Varela, Juan Antonio</style></author><author><style face="normal" font="default" size="100%">Alvarez-Alegret, Ramiro</style></author><author><style face="normal" font="default" size="100%">Agra-Pujol, Carolina</style></author><author><style face="normal" font="default" size="100%">Izquierdo, Francisco</style></author><author><style face="normal" font="default" size="100%">Ramos, Rafael</style></author><author><style face="normal" font="default" size="100%">Ortega-Medina, Luis</style></author><author><style face="normal" font="default" size="100%">Martin-Davila, Francisco</style></author><author><style face="normal" font="default" size="100%">Castilla-Ramirez, Carolina</style></author><author><style face="normal" font="default" size="100%">Hernandez-Leon, Carmen Nieves</style></author><author><style face="normal" font="default" size="100%">Romagosa, Cleofe</style></author><author><style face="normal" font="default" size="100%">Vaz Salgado, Maria Angeles</style></author><author><style face="normal" font="default" size="100%">Lavernia, Javier</style></author><author><style face="normal" font="default" size="100%">Bagué, Silvia</style></author><author><style face="normal" font="default" size="100%">Mayodormo-Aranda, Empar</style></author><author><style face="normal" font="default" size="100%">Vicioso, Luis</style></author><author><style face="normal" font="default" size="100%">Hernández Barceló, Jose Emilio</style></author><author><style face="normal" font="default" size="100%">Rubio-Casadevall, Jordi</style></author><author><style face="normal" font="default" size="100%">de Juan, Ana</style></author><author><style face="normal" font="default" size="100%">Fiaño-Valverde, Maria Concepcion</style></author><author><style face="normal" font="default" size="100%">Hindi, Nadia</style></author><author><style face="normal" font="default" size="100%">Lopez-Alvarez, Maria</style></author><author><style face="normal" font="default" size="100%">Lacerenza, Serena</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Gutierrez, Antonio</style></author><author><style face="normal" font="default" size="100%">Alvarez, Rosa</style></author><author><style face="normal" font="default" size="100%">Valverde, Claudia</style></author><author><style face="normal" font="default" size="100%">Martinez-Trufero, Javier</style></author><author><style face="normal" font="default" size="100%">Martin-Broto, Javier</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin.</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Oncol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Mol Oncol</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 12</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">3691-3705</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Predictive biomarkers of trabectedin represent an unmet need in advanced soft-tissue sarcomas (STS). DNA damage repair (DDR) genes, involved in homologous recombination or nucleotide excision repair, had been previously described as biomarkers of trabectedin resistance or sensitivity, respectively. The majority of these studies only focused on specific factors (ERCC1, ERCC5, and BRCA1) and did not evaluate several other DDR-related genes that could have a relevant role for trabectedin efficacy. In this retrospective translational study, 118 genes involved in DDR were evaluated to determine, by transcriptomics, a predictive gene signature of trabectedin efficacy. A six-gene predictive signature of trabectedin efficacy was built in a series of 139 tumor samples from patients with advanced STS. Patients in the high-risk gene signature group showed a significantly worse progression-free survival compared with patients in the low-risk group (2.1 vs 6.0 months, respectively). Differential gene expression analysis defined new potential predictive biomarkers of trabectedin sensitivity (PARP3 and CCNH) or resistance (DNAJB11 and PARP1). Our study identified a new gene signature that significantly predicts patients with higher probability to respond to treatment with trabectedin. Targeting some genes of this signature emerges as a potential strategy to enhance trabectedin efficacy.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33983674?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Walsh, Ian</style></author><author><style face="normal" font="default" size="100%">Fishman, Dmytro</style></author><author><style face="normal" font="default" size="100%">Garcia-Gasulla, Dario</style></author><author><style face="normal" font="default" size="100%">Titma, Tiina</style></author><author><style face="normal" font="default" size="100%">Pollastri, Gianluca</style></author><author><style face="normal" font="default" size="100%">Harrow, Jennifer</style></author><author><style face="normal" font="default" size="100%">Psomopoulos, Fotis E</style></author><author><style face="normal" font="default" size="100%">Tosatto, Silvio C E</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">ELIXIR Machine Learning Focus Group</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">DOME: recommendations for supervised machine learning validation in biology.</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Methods</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nat Methods</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Guidelines as Topic</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Models, Biological</style></keyword><keyword><style  face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style  face="normal" font="default" size="100%">Supervised Machine Learning</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 10</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">18</style></volume><pages><style face="normal" font="default" size="100%">1122-1127</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">10</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34316068?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rian, Kinza</style></author><author><style face="normal" font="default" size="100%">Hidalgo, Marta R.</style></author><author><style face="normal" font="default" size="100%">Cubuk, Cankut</style></author><author><style face="normal" font="default" size="100%">Falco, Matias M.</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Esteban-Medina, Marina</style></author><author><style face="normal" font="default" size="100%">Alamo-Alvarez, Inmaculada</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Genome-scale mechanistic modeling of signaling pathways made easy: A bioconductor/cytoscape/web server framework for the analysis of omic data</style></title><secondary-title><style face="normal" font="default" size="100%">Computational and Structural Biotechnology Journal</style></secondary-title><short-title><style face="normal" font="default" size="100%">Computational and Structural Biotechnology Journal</style></short-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan-01-2021</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://linkinghub.elsevier.com/retrieve/pii/S2001037021002038</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">19</style></volume><pages><style face="normal" font="default" size="100%">2968 - 2978</style></pages><language><style face="normal" font="default" size="100%">eng</style></language></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ortuno, Francisco M</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Casimiro-Soriguer, Carlos S</style></author><author><style face="normal" font="default" size="100%">Lepe, Jose A</style></author><author><style face="normal" font="default" size="100%">Camacho Martinez, Pedro</style></author><author><style face="normal" font="default" size="100%">Merino Diaz, Laura</style></author><author><style face="normal" font="default" size="100%">de Salazar, Adolfo</style></author><author><style face="normal" font="default" size="100%">Chueca, Natalia</style></author><author><style face="normal" font="default" size="100%">García, Federico</style></author><author><style face="normal" font="default" size="100%">Perez-Florido, Javier</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Highly accurate whole-genome imputation of SARS-CoV-2 from partial or low-quality sequences.</style></title><secondary-title><style face="normal" font="default" size="100%">Gigascience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Gigascience</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Genome, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">Phylogeny</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Whole Genome Sequencing</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 12 02</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">10</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;The current SARS-CoV-2 pandemic has emphasized the utility of viral whole-genome sequencing in the surveillance and control of the pathogen. An unprecedented ongoing global initiative is producing hundreds of thousands of sequences worldwide. However, the complex circumstances in which viruses are sequenced, along with the demand of urgent results, causes a high rate of incomplete and, therefore, useless sequences. Viral sequences evolve in the context of a complex phylogeny and different positions along the genome are in linkage disequilibrium. Therefore, an imputation method would be able to predict missing positions from the available sequencing data.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;We have developed the impuSARS application, which takes advantage of the enormous number of SARS-CoV-2 genomes available, using a reference panel containing 239,301 sequences, to produce missing data imputation in viral genomes. ImpuSARS was tested in a wide range of conditions (continuous fragments, amplicons or sparse individual positions missing), showing great fidelity when reconstructing the original sequences, recovering the lineage with a 100% precision for almost all the lineages, even in very poorly covered genomes (&lt;20%).&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;Imputation can improve the pace of SARS-CoV-2 sequencing production by recovering many incomplete or low-quality sequences that would be otherwise discarded. ImpuSARS can be incorporated in any primary data processing pipeline for SARS-CoV-2 whole-genome sequencing.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34865008?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Brozos-Vázquez, Elena María</style></author><author><style face="normal" font="default" size="100%">Díaz-Peña, Roberto</style></author><author><style face="normal" font="default" size="100%">García-González, Jorge</style></author><author><style face="normal" font="default" size="100%">León-Mateos, Luis</style></author><author><style face="normal" font="default" size="100%">Mondelo-Macía, Patricia</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">López-López, Rafael</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Immunol Immunother</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cancer Immunol Immunother</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Biomarkers, Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Carcinoma, Non-Small-Cell Lung</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell-Free Nucleic Acids</style></keyword><keyword><style  face="normal" font="default" size="100%">Exosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Liquid Biopsy</style></keyword><keyword><style  face="normal" font="default" size="100%">Lung Neoplasms</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 May</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">70</style></volume><pages><style face="normal" font="default" size="100%">1177-1188</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Immunotherapy has been one of the great advances in the recent years for the treatment of advanced tumors, with nonsmall-cell lung cancer (NSCLC) being one of the cancers that has benefited most from this approach. Currently, the only validated companion diagnostic test for first-line immunotherapy in metastatic NSCLC patients is testing for programmed death ligand 1 (PD-L1) expression in tumor tissues. However, not all patients experience an effective response with the established selection criteria and immune checkpoint inhibitors (ICIs). Liquid biopsy offers a noninvasive opportunity to monitor disease in patients with cancer and identify those who would benefit the most from immunotherapy. This review focuses on the use of liquid biopsy in immunotherapy treatment of NSCLC patients. Circulating tumor cells (CTCs), cell-free DNA (cfDNA) and exosomes are promising tools for developing new biomarkers. We discuss the current application and future implementation of these parameters to improve therapeutic decision-making and identify the patients who will benefit most from immunotherapy.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Maya-Miles, Douglas</style></author><author><style face="normal" font="default" size="100%">García, Federico</style></author><author><style face="normal" font="default" size="100%">Lorusso, Nicola</style></author><author><style face="normal" font="default" size="100%">Calleja, Miguel Ángel</style></author><author><style face="normal" font="default" size="100%">Pareja, María Jesús</style></author><author><style face="normal" font="default" size="100%">López-Miranda, José</style></author><author><style face="normal" font="default" size="100%">Rodríguez-Baño, Jesús</style></author><author><style face="normal" font="default" size="100%">Padillo, Javier</style></author><author><style face="normal" font="default" size="100%">Túnez, Isaac</style></author><author><style face="normal" font="default" size="100%">Romero-Gómez, Manuel</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Implementing Personalized Medicine in COVID-19 in Andalusia: An Opportunity to Transform the Healthcare System.</style></title><secondary-title><style face="normal" font="default" size="100%">J Pers Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">J Pers Med</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 May 26</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">11</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The COVID-19 pandemic represents an unprecedented opportunity to exploit the advantages of personalized medicine for the prevention, diagnosis, treatment, surveillance and management of a new challenge in public health. COVID-19 infection is highly variable, ranging from asymptomatic infections to severe, life-threatening manifestations. Personalized medicine can play a key role in elucidating individual susceptibility to the infection as well as inter-individual variability in clinical course, prognosis and response to treatment. Integrating personalized medicine into clinical practice can also transform health care by enabling the design of preventive and therapeutic strategies tailored to individual profiles, improving the detection of outbreaks or defining transmission patterns at an increasingly local level. SARS-CoV2 genome sequencing, together with the assessment of specific patient genetic variants, will support clinical decision-makers and ultimately better ways to fight this disease. Additionally, it would facilitate a better stratification and selection of patients for clinical trials, thus increasing the likelihood of obtaining positive results. Lastly, defining a national strategy to implement in clinical practice all available tools of personalized medicine in COVID-19 could be challenging but linked to a positive transformation of the health care system. In this review, we provide an update of the achievements, promises, and challenges of personalized medicine in the fight against COVID-19 from susceptibility to natural history and response to therapy, as well as from surveillance to control measures and vaccination. We also discuss strategies to facilitate the adoption of this new paradigm for medical and public health measures during and after the pandemic in health care systems.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34073493?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rian, Kinza</style></author><author><style face="normal" font="default" size="100%">Esteban-Medina, Marina</style></author><author><style face="normal" font="default" size="100%">Hidalgo, Marta R</style></author><author><style face="normal" font="default" size="100%">Cubuk, Cankut</style></author><author><style face="normal" font="default" size="100%">Falco, Matias M</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Gunyel, Devrim</style></author><author><style face="normal" font="default" size="100%">Ostaszewski, Marek</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mechanistic modeling of the SARS-CoV-2 disease map.</style></title><secondary-title><style face="normal" font="default" size="100%">BioData Min</style></secondary-title><alt-title><style face="normal" font="default" size="100%">BioData Min</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Jan 21</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">5</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Here we present a web interface that implements a comprehensive mechanistic model of the SARS-CoV-2 disease map. In this framework, the detailed activity of the human signaling circuits related to the viral infection, covering from the entry and replication mechanisms to the downstream consequences as inflammation and antigenic response, can be inferred from gene expression experiments. Moreover, the effect of potential interventions, such as knock-downs, or drug effects (currently the system models the effect of more than 8000 DrugBank drugs) can be studied. This freely available tool not only provides an unprecedentedly detailed view of the mechanisms of viral invasion and the consequences in the cell but has also the potential of becoming an invaluable asset in the search for efficient antiviral treatments.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33478554?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Millán-Esteban, David</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">García-Casado, Zaida</style></author><author><style face="normal" font="default" size="100%">Manrique-Silva, Esperanza</style></author><author><style face="normal" font="default" size="100%">Requena, Celia</style></author><author><style face="normal" font="default" size="100%">Bañuls, José</style></author><author><style face="normal" font="default" size="100%">Lopez-Guerrero, Jose Antonio</style></author><author><style face="normal" font="default" size="100%">Rodríguez-Hernández, Aranzazu</style></author><author><style face="normal" font="default" size="100%">Traves, Víctor</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Virós, Amaya</style></author><author><style face="normal" font="default" size="100%">Kumar, Rajiv</style></author><author><style face="normal" font="default" size="100%">Nagore, Eduardo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mutational Characterization of Cutaneous Melanoma Supports Divergent Pathways Model for Melanoma Development.</style></title><secondary-title><style face="normal" font="default" size="100%">Cancers (Basel)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cancers (Basel)</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 Oct 18</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;According to the divergent pathway model, cutaneous melanoma comprises a nevogenic group with a propensity to melanocyte proliferation and another one associated with cumulative solar damage (CSD). While characterized clinically and epidemiologically, the differences in the molecular profiles between the groups have remained primarily uninvestigated. This study has used a custom gene panel and bioinformatics tools to investigate the potential molecular differences in a thoroughly characterized cohort of 119 melanoma patients belonging to nevogenic and CSD groups. We found that the nevogenic melanomas had a restricted set of mutations, with the prominently mutated gene being . The CSD melanomas, in contrast, showed mutations in a diverse group of genes that included , , , and . We thus provide evidence that nevogenic and CSD melanomas constitute different biological entities and highlight the need to explore new targeted therapies.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">20</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Heath, Allison P.</style></author><author><style face="normal" font="default" size="100%">Ferretti, Vincent</style></author><author><style face="normal" font="default" size="100%">Agrawal, Stuti</style></author><author><style face="normal" font="default" size="100%">An, Maksim</style></author><author><style face="normal" font="default" size="100%">Angelakos, James C.</style></author><author><style face="normal" font="default" size="100%">Arya, Renuka</style></author><author><style face="normal" font="default" size="100%">Bajari, Rosita</style></author><author><style face="normal" font="default" size="100%">Baqar, Bilal</style></author><author><style face="normal" font="default" size="100%">Barnowski, Justin H. B.</style></author><author><style face="normal" font="default" size="100%">Burt, Jeffrey</style></author><author><style face="normal" font="default" size="100%">Catton, Ann</style></author><author><style face="normal" font="default" size="100%">Chan, Brandon F.</style></author><author><style face="normal" font="default" size="100%">Chu, Fay</style></author><author><style face="normal" font="default" size="100%">Cullion, Kim</style></author><author><style face="normal" font="default" size="100%">Davidsen, Tanja</style></author><author><style face="normal" font="default" size="100%">Do, Phuong-My</style></author><author><style face="normal" font="default" size="100%">Dompierre, Christian</style></author><author><style face="normal" font="default" size="100%">Ferguson, Martin L.</style></author><author><style face="normal" font="default" size="100%">Fitzsimons, Michael S.</style></author><author><style face="normal" font="default" size="100%">Ford, Michael</style></author><author><style face="normal" font="default" size="100%">Fukuma, Miyuki</style></author><author><style face="normal" font="default" size="100%">Gaheen, Sharon</style></author><author><style face="normal" font="default" size="100%">Ganji, Gajanan L.</style></author><author><style face="normal" font="default" size="100%">Garcia, Tzintzuni I.</style></author><author><style face="normal" font="default" size="100%">George, Sameera S.</style></author><author><style face="normal" font="default" size="100%">Gerhard, Daniela S.</style></author><author><style face="normal" font="default" size="100%">Gerthoffert, Francois</style></author><author><style face="normal" font="default" size="100%">Gomez, Fauzi</style></author><author><style face="normal" font="default" size="100%">Han, Kang</style></author><author><style face="normal" font="default" size="100%">Hernandez, Kyle M.</style></author><author><style face="normal" font="default" size="100%">Issac, Biju</style></author><author><style face="normal" font="default" size="100%">Jackson, Richard</style></author><author><style face="normal" font="default" size="100%">Jensen, Mark A.</style></author><author><style face="normal" font="default" size="100%">Joshi, Sid</style></author><author><style face="normal" font="default" size="100%">Kadam, Ajinkya</style></author><author><style face="normal" font="default" size="100%">Khurana, Aishmit</style></author><author><style face="normal" font="default" size="100%">Kim, Kyle M. J.</style></author><author><style face="normal" font="default" size="100%">Kraft, Victoria E.</style></author><author><style face="normal" font="default" size="100%">Li, Shenglai</style></author><author><style face="normal" font="default" size="100%">Lichtenberg, Tara M.</style></author><author><style face="normal" font="default" size="100%">Lodato, Janice</style></author><author><style face="normal" font="default" size="100%">Lolla, Laxmi</style></author><author><style face="normal" font="default" size="100%">Martinov, Plamen</style></author><author><style face="normal" font="default" size="100%">Mazzone, Jeffrey A.</style></author><author><style face="normal" font="default" size="100%">Miller, Daniel P.</style></author><author><style face="normal" font="default" size="100%">Miller, Ian</style></author><author><style face="normal" font="default" size="100%">Miller, Joshua S.</style></author><author><style face="normal" font="default" size="100%">Miyauchi, Koji</style></author><author><style face="normal" font="default" size="100%">Murphy, Mark W.</style></author><author><style face="normal" font="default" size="100%">Nullet, Thomas</style></author><author><style face="normal" font="default" size="100%">Ogwara, Rowland O.</style></author><author><style face="normal" font="default" size="100%">Ortuño, Francisco M.</style></author><author><style face="normal" font="default" size="100%">Pedrosa, Jesús</style></author><author><style face="normal" font="default" size="100%">Pham, Phuong L.</style></author><author><style face="normal" font="default" size="100%">Popov, Maxim Y.</style></author><author><style face="normal" font="default" size="100%">Porter, James J.</style></author><author><style face="normal" font="default" size="100%">Powell, Raymond</style></author><author><style face="normal" font="default" size="100%">Rademacher, Karl</style></author><author><style face="normal" font="default" size="100%">Reid, Colin P.</style></author><author><style face="normal" font="default" size="100%">Rich, Samantha</style></author><author><style face="normal" font="default" size="100%">Rogel, Bessie</style></author><author><style face="normal" font="default" size="100%">Sahni, Himanso</style></author><author><style face="normal" font="default" size="100%">Savage, Jeremiah H.</style></author><author><style face="normal" font="default" size="100%">Schmitt, Kyle A.</style></author><author><style face="normal" font="default" size="100%">Simmons, Trevar J.</style></author><author><style face="normal" font="default" size="100%">Sislow, Joseph</style></author><author><style face="normal" font="default" size="100%">Spring, Jonathan</style></author><author><style face="normal" font="default" size="100%">Stein, Lincoln</style></author><author><style face="normal" font="default" size="100%">Sullivan, Sean</style></author><author><style face="normal" font="default" size="100%">Tang, Yajing</style></author><author><style face="normal" font="default" size="100%">Thiagarajan, Mathangi</style></author><author><style face="normal" font="default" size="100%">Troyer, Heather D.</style></author><author><style face="normal" font="default" size="100%">Wang, Chang</style></author><author><style face="normal" font="default" size="100%">Wang, Zhining</style></author><author><style face="normal" font="default" size="100%">West, Bedford L.</style></author><author><style face="normal" font="default" size="100%">Wilmer, Alex</style></author><author><style face="normal" font="default" size="100%">Wilson, Shane</style></author><author><style face="normal" font="default" size="100%">Wu, Kaman</style></author><author><style face="normal" font="default" size="100%">Wysocki, William P.</style></author><author><style face="normal" font="default" size="100%">Xiang, Linda</style></author><author><style face="normal" font="default" size="100%">Yamada, Joseph T.</style></author><author><style face="normal" font="default" size="100%">Yang, Liming</style></author><author><style face="normal" font="default" size="100%">Yu, Christine</style></author><author><style face="normal" font="default" size="100%">Yung, Christina K.</style></author><author><style face="normal" font="default" size="100%">Zenklusen, Jean Claude</style></author><author><style face="normal" font="default" size="100%">Zhang, Junjun</style></author><author><style face="normal" font="default" size="100%">Zhang, Zhenyu</style></author><author><style face="normal" font="default" size="100%">Zhao, Yuanheng</style></author><author><style face="normal" font="default" size="100%">Zubair, Ariz</style></author><author><style face="normal" font="default" size="100%">Staudt, Louis M.</style></author><author><style face="normal" font="default" size="100%">Grossman, Robert L.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The NCI Genomic Data Commons</style></title><secondary-title><style face="normal" font="default" size="100%">Nature Genetics</style></secondary-title><short-title><style face="normal" font="default" size="100%">Nat Genet</style></short-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Oct-02-2022</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.nature.com/articles/s41588-021-00791-5</style></url></web-urls></urls><language><style face="normal" font="default" size="100%">eng</style></language></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Casimiro-Soriguer, Carlos S.</style></author><author><style face="normal" font="default" size="100%">Perez-Florido, Javier</style></author><author><style face="normal" font="default" size="100%">Fernandez-Rueda, Jose L.</style></author><author><style face="normal" font="default" size="100%">Pedrosa-Corral, Irene</style></author><author><style face="normal" font="default" size="100%">Guillot-Sulay, Vicente</style></author><author><style face="normal" font="default" size="100%">Lorusso, Nicola</style></author><author><style face="normal" font="default" size="100%">Martinez-Gonzalez, Luis Javier</style></author><author><style face="normal" font="default" size="100%">Navarro-Marí, Jose M.</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Sanbonmatsu-Gámez, Sara</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Phylogenetic Analysis of the 2020 West Nile Virus (WNV) Outbreak in Andalusia (Spain)</style></title><secondary-title><style face="normal" font="default" size="100%">Viruses</style></secondary-title><short-title><style face="normal" font="default" size="100%">Viruses</style></short-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan-05-2021</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.mdpi.com/1999-4915/13/5/836 </style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">13</style></volume><pages><style face="normal" font="default" size="100%">836</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">5</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vázquez-Costa, Juan Francisco</style></author><author><style face="normal" font="default" size="100%">Payá-Montes, María</style></author><author><style face="normal" font="default" size="100%">Martínez-Molina, Marina</style></author><author><style face="normal" font="default" size="100%">Jaijo, Teresa</style></author><author><style face="normal" font="default" size="100%">Szymanski, Jazek</style></author><author><style face="normal" font="default" size="100%">Mazón, Miguel</style></author><author><style face="normal" font="default" size="100%">Sopena-Novales, Pablo</style></author><author><style face="normal" font="default" size="100%">Pérez-Tur, Jordi</style></author><author><style face="normal" font="default" size="100%">Sevilla, Teresa</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">ENoD Consortium</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Presenilin-1 Mutations Are a Cause of Primary Lateral Sclerosis-Like Syndrome.</style></title><secondary-title><style face="normal" font="default" size="100%">Front Mol Neurosci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Front Mol Neurosci</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">721047</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;Background and Purpose: &lt;/b&gt;Primary lateral sclerosis (PLS) is a progressive upper motor neuron (UMN) disorder. It is debated whether PLS is part of the amyotrophic lateral sclerosis (ALS) spectrum, or a syndrome encompassing different neurodegenerative diseases. Recently, new diagnostic criteria for PLS have been proposed. We describe four patients of two pedigrees, meeting definite PLS criteria and harboring two different mutations in presenilin 1 ().&lt;/p&gt;&lt;p&gt;&lt;b&gt;Methods: &lt;/b&gt;Patients underwent neurological and neuropsychological examination, MRI, 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), amyloid-related biomarkers, and next-generation sequencing (NGS) testing.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results: &lt;/b&gt;Four patients, aged 25-45 years old, presented with a progressive UMN syndrome meeting clinical criteria of definite PLS. Cognitive symptoms and signs were mild or absent during the first year of the disease but appeared or progressed later in the disease course. Brain MRI showed microbleeds in two siblings, but iron-related hypointensities in the motor cortex were absent. Brain FDG-PET showed variable areas of hypometabolism, including the motor cortex and frontotemporal lobes. Amyloid deposition was confirmed with either cerebrospinal fluid (CSF) or imaging biomarkers. Two heterozygous likely pathogenic mutations in  (p.Pro88Leu and p.Leu166Pro) were found in the NGS testing.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Conclusion: &lt;/b&gt;Clinically defined PLS is a syndrome encompassing different neurodegenerative diseases. The NGS testing should be part of the diagnostic workup in patients with PLS, at least in those with red flags, such as early-onset, cognitive impairment, and/or family history of neurodegenerative diseases.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Esteban-Medina, Marina</style></author><author><style face="normal" font="default" size="100%">Muñoyerro-Muñiz, Dolores</style></author><author><style face="normal" font="default" size="100%">Villegas, Román</style></author><author><style face="normal" font="default" size="100%">López-Miranda, José</style></author><author><style face="normal" font="default" size="100%">Rodríguez-Baño, Jesús</style></author><author><style face="normal" font="default" size="100%">Túnez, Isaac</style></author><author><style face="normal" font="default" size="100%">Bouillon, Roger</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Quesada Gomez, Jose Manuel</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients.</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Sci Rep</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Calcifediol</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Kaplan-Meier Estimate</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Retrospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Spain</style></keyword><keyword><style  face="normal" font="default" size="100%">Survival Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Vitamin D</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 12 03</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">11</style></volume><pages><style face="normal" font="default" size="100%">23380</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;COVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19. We present a survival study on a retrospective cohort of 15,968 patients, comprising all COVID-19 patients hospitalized in Andalusia between January and November 2020. Based on a central registry of electronic health records (the Andalusian Population Health Database, BPS), prescription of vitamin D or its metabolites within 15-30 days before hospitalization were recorded. The effect of prescription of vitamin D (metabolites) for other indication previous to the hospitalization was studied with respect to patient survival. Kaplan-Meier survival curves and hazard ratios support an association between prescription of these metabolites and patient survival. Such association was stronger for calcifediol (Hazard Ratio, HR = 0.67, with 95% confidence interval, CI, of [0.50-0.91]) than for cholecalciferol (HR = 0.75, with 95% CI of [0.61-0.91]), when prescribed 15 days prior hospitalization. Although the relation is maintained, there is a general decrease of this effect when a longer period of 30 days prior hospitalization is considered (calcifediol HR = 0.73, with 95% CI [0.57-0.95] and cholecalciferol HR = 0.88, with 95% CI [0.75, 1.03]), suggesting that association was stronger when the prescription was closer to the hospitalization.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mirzayi, Chloe</style></author><author><style face="normal" font="default" size="100%">Renson, Audrey</style></author><author><style face="normal" font="default" size="100%">Zohra, Fatima</style></author><author><style face="normal" font="default" size="100%">Elsafoury, Shaimaa</style></author><author><style face="normal" font="default" size="100%">Geistlinger, Ludwig</style></author><author><style face="normal" font="default" size="100%">Kasselman, Lora J</style></author><author><style face="normal" font="default" size="100%">Eckenrode, Kelly</style></author><author><style face="normal" font="default" size="100%">van de Wijgert, Janneke</style></author><author><style face="normal" font="default" size="100%">Loughman, Amy</style></author><author><style face="normal" font="default" size="100%">Marques, Francine Z</style></author><author><style face="normal" font="default" size="100%">MacIntyre, David A</style></author><author><style face="normal" font="default" size="100%">Arumugam, Manimozhiyan</style></author><author><style face="normal" font="default" size="100%">Azhar, Rimsha</style></author><author><style face="normal" font="default" size="100%">Beghini, Francesco</style></author><author><style face="normal" font="default" size="100%">Bergstrom, Kirk</style></author><author><style face="normal" font="default" size="100%">Bhatt, Ami</style></author><author><style face="normal" font="default" size="100%">Bisanz, Jordan E</style></author><author><style face="normal" font="default" size="100%">Braun, Jonathan</style></author><author><style face="normal" font="default" size="100%">Bravo, Hector Corrada</style></author><author><style face="normal" font="default" size="100%">Buck, Gregory A</style></author><author><style face="normal" font="default" size="100%">Bushman, Frederic</style></author><author><style face="normal" font="default" size="100%">Casero, David</style></author><author><style face="normal" font="default" size="100%">Clarke, Gerard</style></author><author><style face="normal" font="default" size="100%">Collado, Maria Carmen</style></author><author><style face="normal" font="default" size="100%">Cotter, Paul D</style></author><author><style face="normal" font="default" size="100%">Cryan, John F</style></author><author><style face="normal" font="default" size="100%">Demmer, Ryan T</style></author><author><style face="normal" font="default" size="100%">Devkota, Suzanne</style></author><author><style face="normal" font="default" size="100%">Elinav, Eran</style></author><author><style face="normal" font="default" size="100%">Escobar, Juan S</style></author><author><style face="normal" font="default" size="100%">Fettweis, Jennifer</style></author><author><style face="normal" font="default" size="100%">Finn, Robert D</style></author><author><style face="normal" font="default" size="100%">Fodor, Anthony A</style></author><author><style face="normal" font="default" size="100%">Forslund, Sofia</style></author><author><style face="normal" font="default" size="100%">Franke, Andre</style></author><author><style face="normal" font="default" size="100%">Furlanello, Cesare</style></author><author><style face="normal" font="default" size="100%">Gilbert, Jack</style></author><author><style face="normal" font="default" size="100%">Grice, Elizabeth</style></author><author><style face="normal" font="default" size="100%">Haibe-Kains, Benjamin</style></author><author><style face="normal" font="default" size="100%">Handley, Scott</style></author><author><style face="normal" font="default" size="100%">Herd, Pamela</style></author><author><style face="normal" font="default" size="100%">Holmes, Susan</style></author><author><style face="normal" font="default" size="100%">Jacobs, Jonathan P</style></author><author><style face="normal" font="default" size="100%">Karstens, Lisa</style></author><author><style face="normal" font="default" size="100%">Knight, Rob</style></author><author><style face="normal" font="default" size="100%">Knights, Dan</style></author><author><style face="normal" font="default" size="100%">Koren, Omry</style></author><author><style face="normal" font="default" size="100%">Kwon, Douglas S</style></author><author><style face="normal" font="default" size="100%">Langille, Morgan</style></author><author><style face="normal" font="default" size="100%">Lindsay, Brianna</style></author><author><style face="normal" font="default" size="100%">McGovern, Dermot</style></author><author><style face="normal" font="default" size="100%">McHardy, Alice C</style></author><author><style face="normal" font="default" size="100%">McWeeney, Shannon</style></author><author><style face="normal" font="default" size="100%">Mueller, Noel T</style></author><author><style face="normal" font="default" size="100%">Nezi, Luigi</style></author><author><style face="normal" font="default" size="100%">Olm, Matthew</style></author><author><style face="normal" font="default" size="100%">Palm, Noah</style></author><author><style face="normal" font="default" size="100%">Pasolli, Edoardo</style></author><author><style face="normal" font="default" size="100%">Raes, Jeroen</style></author><author><style face="normal" font="default" size="100%">Redinbo, Matthew R</style></author><author><style face="normal" font="default" size="100%">Rühlemann, Malte</style></author><author><style face="normal" font="default" size="100%">Balfour Sartor, R</style></author><author><style face="normal" font="default" size="100%">Schloss, Patrick D</style></author><author><style face="normal" font="default" size="100%">Schriml, Lynn</style></author><author><style face="normal" font="default" size="100%">Segal, Eran</style></author><author><style face="normal" font="default" size="100%">Shardell, Michelle</style></author><author><style face="normal" font="default" size="100%">Sharpton, Thomas</style></author><author><style face="normal" font="default" size="100%">Smirnova, Ekaterina</style></author><author><style face="normal" font="default" size="100%">Sokol, Harry</style></author><author><style face="normal" font="default" size="100%">Sonnenburg, Justin L</style></author><author><style face="normal" font="default" size="100%">Srinivasan, Sujatha</style></author><author><style face="normal" font="default" size="100%">Thingholm, Louise B</style></author><author><style face="normal" font="default" size="100%">Turnbaugh, Peter J</style></author><author><style face="normal" font="default" size="100%">Upadhyay, Vaibhav</style></author><author><style face="normal" font="default" size="100%">Walls, Ramona L</style></author><author><style face="normal" font="default" size="100%">Wilmes, Paul</style></author><author><style face="normal" font="default" size="100%">Yamada, Takuji</style></author><author><style face="normal" font="default" size="100%">Zeller, Georg</style></author><author><style face="normal" font="default" size="100%">Zhang, Mingyu</style></author><author><style face="normal" font="default" size="100%">Zhao, Ni</style></author><author><style face="normal" font="default" size="100%">Zhao, Liping</style></author><author><style face="normal" font="default" size="100%">Bao, Wenjun</style></author><author><style face="normal" font="default" size="100%">Culhane, Aedin</style></author><author><style face="normal" font="default" size="100%">Devanarayan, Viswanath</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Fan, Xiaohui</style></author><author><style face="normal" font="default" size="100%">Fischer, Matthias</style></author><author><style face="normal" font="default" size="100%">Jones, Wendell</style></author><author><style face="normal" font="default" size="100%">Kusko, Rebecca</style></author><author><style face="normal" font="default" size="100%">Mason, Christopher E</style></author><author><style face="normal" font="default" size="100%">Mercer, Tim R</style></author><author><style face="normal" font="default" size="100%">Sansone, Susanna-Assunta</style></author><author><style face="normal" font="default" size="100%">Scherer, Andreas</style></author><author><style face="normal" font="default" size="100%">Shi, Leming</style></author><author><style face="normal" font="default" size="100%">Thakkar, Shraddha</style></author><author><style face="normal" font="default" size="100%">Tong, Weida</style></author><author><style face="normal" font="default" size="100%">Wolfinger, Russ</style></author><author><style face="normal" font="default" size="100%">Hunter, Christopher</style></author><author><style face="normal" font="default" size="100%">Segata, Nicola</style></author><author><style face="normal" font="default" size="100%">Huttenhower, Curtis</style></author><author><style face="normal" font="default" size="100%">Dowd, Jennifer B</style></author><author><style face="normal" font="default" size="100%">Jones, Heidi E</style></author><author><style face="normal" font="default" size="100%">Waldron, Levi</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">Genomic Standards Consortium</style></author><author><style face="normal" font="default" size="100%">Massive Analysis and Quality Control Society</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Reporting guidelines for human microbiome research: the STORMS checklist.</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nat Med</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Dysbiosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Microbiota</style></keyword><keyword><style  face="normal" font="default" size="100%">Observational Studies as Topic</style></keyword><keyword><style  face="normal" font="default" size="100%">Research Design</style></keyword><keyword><style  face="normal" font="default" size="100%">Translational Science, Biomedical</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 11</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">27</style></volume><pages><style face="normal" font="default" size="100%">1885-1892</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The particularly interdisciplinary nature of human microbiome research makes the organization and reporting of results spanning epidemiology, biology, bioinformatics, translational medicine and statistics a challenge. Commonly used reporting guidelines for observational or genetic epidemiology studies lack key features specific to microbiome studies. Therefore, a multidisciplinary group of microbiome epidemiology researchers adapted guidelines for observational and genetic studies to culture-independent human microbiome studies, and also developed new reporting elements for laboratory, bioinformatics and statistical analyses tailored to microbiome studies. The resulting tool, called 'Strengthening The Organization and Reporting of Microbiome Studies' (STORMS), is composed of a 17-item checklist organized into six sections that correspond to the typical sections of a scientific publication, presented as an editable table for inclusion in supplementary materials. The STORMS checklist provides guidance for concise and complete reporting of microbiome studies that will facilitate manuscript preparation, peer review, and reader comprehension of publications and comparative analysis of published results.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">11</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34789871?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tenorio-Castaño, Jair</style></author><author><style face="normal" font="default" size="100%">Morte, Beatriz</style></author><author><style face="normal" font="default" size="100%">Nevado, Julián</style></author><author><style face="normal" font="default" size="100%">Martínez-Glez, Víctor</style></author><author><style face="normal" font="default" size="100%">Santos-Simarro, Fernando</style></author><author><style face="normal" font="default" size="100%">García-Miñaur, Sixto</style></author><author><style face="normal" font="default" size="100%">Palomares-Bralo, María</style></author><author><style face="normal" font="default" size="100%">Pacio-Míguez, Marta</style></author><author><style face="normal" font="default" size="100%">Gómez, Beatriz</style></author><author><style face="normal" font="default" size="100%">Arias, Pedro</style></author><author><style face="normal" font="default" size="100%">Alcochea, Alba</style></author><author><style face="normal" font="default" size="100%">Carrión, Juan</style></author><author><style face="normal" font="default" size="100%">Arias, Patricia</style></author><author><style face="normal" font="default" size="100%">Almoguera, Berta</style></author><author><style face="normal" font="default" size="100%">López-Grondona, Fermina</style></author><author><style face="normal" font="default" size="100%">Lorda-Sanchez, Isabel</style></author><author><style face="normal" font="default" size="100%">Galán-Gómez, Enrique</style></author><author><style face="normal" font="default" size="100%">Valenzuela, Irene</style></author><author><style face="normal" font="default" size="100%">Méndez Perez, María</style></author><author><style face="normal" font="default" size="100%">Cuscó, Ivón</style></author><author><style face="normal" font="default" size="100%">Barros, Francisco</style></author><author><style face="normal" font="default" size="100%">Pié, Juan</style></author><author><style face="normal" font="default" size="100%">Ramos, Sergio</style></author><author><style face="normal" font="default" size="100%">Ramos, Feliciano</style></author><author><style face="normal" font="default" size="100%">Kuechler, Alma</style></author><author><style face="normal" font="default" size="100%">Tizzano, Eduardo</style></author><author><style face="normal" font="default" size="100%">Ayuso, Carmen</style></author><author><style face="normal" font="default" size="100%">Kaiser, Frank</style></author><author><style face="normal" font="default" size="100%">Pérez-Jurado, Luis</style></author><author><style face="normal" font="default" size="100%">Carracedo, Ángel</style></author><author><style face="normal" font="default" size="100%">Lapunzina, Pablo</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">The ENoD-CIBERER Consortium</style></author><author><style face="normal" font="default" size="100%">The SIDE Consortium</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Schuurs–Hoeijmakers Syndrome (PACS1 Neurodevelopmental Disorder): Seven Novel Patients and a Review</style></title><secondary-title><style face="normal" font="default" size="100%">Genes</style></secondary-title><short-title><style face="normal" font="default" size="100%">Genes</style></short-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan-05-2021</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.mdpi.com/2073-4425/12/5/738https://www.mdpi.com/2073-4425/12/5/738/pdf</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">738</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">5</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Méndez-Salazar, Eder Orlando</style></author><author><style face="normal" font="default" size="100%">Vázquez-Mellado, Janitzia</style></author><author><style face="normal" font="default" size="100%">Casimiro-Soriguer, Carlos S</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Cubuk, Cankut</style></author><author><style face="normal" font="default" size="100%">Zamudio-Cuevas, Yessica</style></author><author><style face="normal" font="default" size="100%">Francisco-Balderas, Adriana</style></author><author><style face="normal" font="default" size="100%">Martínez-Flores, Karina</style></author><author><style face="normal" font="default" size="100%">Fernández-Torres, Javier</style></author><author><style face="normal" font="default" size="100%">Lozada-Pérez, Carlos</style></author><author><style face="normal" font="default" size="100%">Pineda, Carlos</style></author><author><style face="normal" font="default" size="100%">Sánchez-González, Austreberto</style></author><author><style face="normal" font="default" size="100%">Silveira, Luis H</style></author><author><style face="normal" font="default" size="100%">Burguete-García, Ana I</style></author><author><style face="normal" font="default" size="100%">Orbe-Orihuela, Citlalli</style></author><author><style face="normal" font="default" size="100%">Lagunas-Martínez, Alfredo</style></author><author><style face="normal" font="default" size="100%">Vazquez-Gomez, Alonso</style></author><author><style face="normal" font="default" size="100%">López-Reyes, Alberto</style></author><author><style face="normal" font="default" size="100%">Palacios-González, Berenice</style></author><author><style face="normal" font="default" size="100%">Martínez-Nava, Gabriela Angélica</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Taxonomic variations in the gut microbiome of gout patients with and without tophi might have a functional impact on urate metabolism.</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Mol Med</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Biodiversity</style></keyword><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Dysbiosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Gastrointestinal Microbiome</style></keyword><keyword><style  face="normal" font="default" size="100%">Gout</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Metagenome</style></keyword><keyword><style  face="normal" font="default" size="100%">metagenomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Interaction Mapping</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Interaction Maps</style></keyword><keyword><style  face="normal" font="default" size="100%">Uric Acid</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 05 24</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">27</style></volume><pages><style face="normal" font="default" size="100%">50</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;OBJECTIVE: &lt;/b&gt;To evaluate the taxonomic composition of the gut microbiome in gout patients with and without tophi formation, and predict bacterial functions that might have an impact on urate metabolism.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;Hypervariable V3-V4 regions of the bacterial 16S rRNA gene from fecal samples of gout patients with and without tophi (n = 33 and n = 25, respectively) were sequenced and compared to fecal samples from 53 healthy controls. We explored predictive functional profiles using bioinformatics in order to identify differences in taxonomy and metabolic pathways.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;We identified a microbiome characterized by the lowest richness and a higher abundance of Phascolarctobacterium, Bacteroides, Akkermansia, and Ruminococcus_gnavus_group genera in patients with gout without tophi when compared to controls. The Proteobacteria phylum and the Escherichia-Shigella genus were more abundant in patients with tophaceous gout than in controls. Fold change analysis detected nine genera enriched in healthy controls compared to gout groups (Bifidobacterium, Butyricicoccus, Oscillobacter, Ruminococcaceae_UCG_010, Lachnospiraceae_ND2007_group, Haemophilus, Ruminococcus_1, Clostridium_sensu_stricto_1, and Ruminococcaceae_UGC_013). We found that the core microbiota of both gout groups shared Bacteroides caccae, Bacteroides stercoris ATCC 43183, and Bacteroides coprocola DSM 17136. These bacteria might perform functions linked to one-carbon metabolism, nucleotide binding, amino acid biosynthesis, and purine biosynthesis. Finally, we observed differences in key bacterial enzymes involved in urate synthesis, degradation, and elimination.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;Our findings revealed that taxonomic variations in the gut microbiome of gout patients with and without tophi might have a functional impact on urate metabolism.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34030623?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Garrido-Rodriguez, Martín</style></author><author><style face="normal" font="default" size="100%">López-López, Daniel</style></author><author><style face="normal" font="default" size="100%">Ortuno, Francisco M</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Muñoz, Eduardo</style></author><author><style face="normal" font="default" size="100%">Calzado, Marco A</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A versatile workflow to integrate RNA-seq genomic and transcriptomic data into mechanistic models of signaling pathways.</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS Comput Biol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PLoS Comput Biol</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Line, Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Databases, Factual</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">High-Throughput Nucleotide Sequencing</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Models, Theoretical</style></keyword><keyword><style  face="normal" font="default" size="100%">mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA-seq</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style  face="normal" font="default" size="100%">Software</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style  face="normal" font="default" size="100%">whole exome sequencing</style></keyword><keyword><style  face="normal" font="default" size="100%">Workflow</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 02</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">e1008748</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;MIGNON is a workflow for the analysis of RNA-Seq experiments, which not only efficiently manages the estimation of gene expression levels from raw sequencing reads, but also calls genomic variants present in the transcripts analyzed. Moreover, this is the first workflow that provides a framework for the integration of transcriptomic and genomic data based on a mechanistic model of signaling pathway activities that allows a detailed biological interpretation of the results, including a comprehensive functional profiling of cell activity. MIGNON covers the whole process, from reads to signaling circuit activity estimations, using state-of-the-art tools, it is easy to use and it is deployable in different computational environments, allowing an optimized use of the resources available.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33571195?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Díez-Fuertes, F</style></author><author><style face="normal" font="default" size="100%">De La Torre-Tarazona, H E</style></author><author><style face="normal" font="default" size="100%">Calonge, E</style></author><author><style face="normal" font="default" size="100%">Pernas, M</style></author><author><style face="normal" font="default" size="100%">Bermejo, M</style></author><author><style face="normal" font="default" size="100%">García-Pérez, J</style></author><author><style face="normal" font="default" size="100%">Álvarez, A</style></author><author><style face="normal" font="default" size="100%">Capa, L</style></author><author><style face="normal" font="default" size="100%">García-García, F</style></author><author><style face="normal" font="default" size="100%">Saumoy, M</style></author><author><style face="normal" font="default" size="100%">Riera, M</style></author><author><style face="normal" font="default" size="100%">Boland-Auge, A</style></author><author><style face="normal" font="default" size="100%">López-Galíndez, C</style></author><author><style face="normal" font="default" size="100%">Lathrop, M</style></author><author><style face="normal" font="default" size="100%">Dopazo, J</style></author><author><style face="normal" font="default" size="100%">Sakuntabhai, A</style></author><author><style face="normal" font="default" size="100%">Alcamí, J</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Association of a single nucleotide polymorphism in the ubxn6 gene with long-term non-progression phenotype in HIV-positive individuals.</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Microbiol Infect</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Clin Microbiol Infect</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adaptor Proteins, Vesicular Transport</style></keyword><keyword><style  face="normal" font="default" size="100%">Autophagy-Related Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Caveolin 1</style></keyword><keyword><style  face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Dendritic Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Frequency</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Association Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">HeLa Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">HIV Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">HIV Long-Term Survivors</style></keyword><keyword><style  face="normal" font="default" size="100%">HIV-1</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Macrophages</style></keyword><keyword><style  face="normal" font="default" size="100%">Oligonucleotide Array Sequence Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style  face="normal" font="default" size="100%">whole exome sequencing</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 Jan</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">26</style></volume><pages><style face="normal" font="default" size="100%">107-114</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;OBJECTIVES: &lt;/b&gt;The long-term non-progressors (LTNPs) are a heterogeneous group of HIV-positive individuals characterized by their ability to maintain high CD4 T-cell counts and partially control viral replication for years in the absence of antiretroviral therapy. The present study aims to identify host single nucleotide polymorphisms (SNPs) associated with non-progression in a cohort of 352 individuals.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;DNA microarrays and exome sequencing were used for genotyping about 240 000 functional polymorphisms throughout more than 20 000 human genes. The allele frequencies of 85 LTNPs were compared with a control population. SNPs associated with LTNPs were confirmed in a population of typical progressors. Functional analyses in the affected gene were carried out through knockdown experiments in HeLa-P4, macrophages and dendritic cells.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Several SNPs located within the major histocompatibility complex region previously related to LTNPs were confirmed in this new cohort. The SNP rs1127888 (UBXN6) surpassed the statistical significance of these markers after Bonferroni correction (q = 2.11 × 10). An uncommon allelic frequency of rs1127888 among LTNPs was confirmed by comparison with typical progressors and other publicly available populations. UBXN6 knockdown experiments caused an increase in CAV1 expression and its accumulation in the plasma membrane. In vitro infection of different cell types with HIV-1 replication-competent recombinant viruses caused a reduction of the viral replication capacity compared with their corresponding wild-type cells expressing UBXN6.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;A higher prevalence of Ala31Thr in UBXN6 was found among LTNPs within its N-terminal region, which is crucial for UBXN6/VCP protein complex formation. UBXN6 knockdown affected CAV1 turnover and HIV-1 replication capacity.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31158522?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yang, Mi</style></author><author><style face="normal" font="default" size="100%">Petralia, Francesca</style></author><author><style face="normal" font="default" size="100%">Li, Zhi</style></author><author><style face="normal" font="default" size="100%">Li, Hongyang</style></author><author><style face="normal" font="default" size="100%">Ma, Weiping</style></author><author><style face="normal" font="default" size="100%">Song, Xiaoyu</style></author><author><style face="normal" font="default" size="100%">Kim, Sunkyu</style></author><author><style face="normal" font="default" size="100%">Lee, Heewon</style></author><author><style face="normal" font="default" size="100%">Yu, Han</style></author><author><style face="normal" font="default" size="100%">Lee, Bora</style></author><author><style face="normal" font="default" size="100%">Bae, Seohui</style></author><author><style face="normal" font="default" size="100%">Heo, Eunji</style></author><author><style face="normal" font="default" size="100%">Kaczmarczyk, Jan</style></author><author><style face="normal" font="default" size="100%">Stępniak, Piotr</style></author><author><style face="normal" font="default" size="100%">Warchoł, Michał</style></author><author><style face="normal" font="default" size="100%">Yu, Thomas</style></author><author><style face="normal" font="default" size="100%">Calinawan, Anna P</style></author><author><style face="normal" font="default" size="100%">Boutros, Paul C</style></author><author><style face="normal" font="default" size="100%">Payne, Samuel H</style></author><author><style face="normal" font="default" size="100%">Reva, Boris</style></author><author><style face="normal" font="default" size="100%">Boja, Emily</style></author><author><style face="normal" font="default" size="100%">Rodriguez, Henry</style></author><author><style face="normal" font="default" size="100%">Stolovitzky, Gustavo</style></author><author><style face="normal" font="default" size="100%">Guan, Yuanfang</style></author><author><style face="normal" font="default" size="100%">Kang, Jaewoo</style></author><author><style face="normal" font="default" size="100%">Wang, Pei</style></author><author><style face="normal" font="default" size="100%">Fenyö, David</style></author><author><style face="normal" font="default" size="100%">Saez-Rodriguez, Julio</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">NCI-CPTAC-DREAM Consortium</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Community Assessment of the Predictability of Cancer Protein and Phosphoprotein Levels from Genomics and Transcriptomics.</style></title><secondary-title><style face="normal" font="default" size="100%">Cell Syst</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cell Syst</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Crowdsourcing</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Machine Learning</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Phosphoproteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Proteomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcriptome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 08 26</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">11</style></volume><pages><style face="normal" font="default" size="100%">186-195.e9</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Cancer is driven by genomic alterations, but the processes causing this disease are largely performed by proteins. However, proteins are harder and more expensive to measure than genes and transcripts. To catalyze developments of methods to infer protein levels from other omics measurements, we leveraged crowdsourcing via the NCI-CPTAC DREAM proteogenomic challenge. We asked for methods to predict protein and phosphorylation levels from genomic and transcriptomic data in cancer patients. The best performance was achieved by an ensemble of models, including as predictors transcript level of the corresponding genes, interaction between genes, conservation across tumor types, and phosphosite proximity for phosphorylation prediction. Proteins from metabolic pathways and complexes were the best and worst predicted, respectively. The performance of even the best-performing model was modest, suggesting that many proteins are strongly regulated through translational control and degradation. Our results set a reference for the limitations of computational inference in proteogenomics. A record of this paper's transparent peer review process is included in the Supplemental Information.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32710834?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ostaszewski, Marek</style></author><author><style face="normal" font="default" size="100%">Mazein, Alexander</style></author><author><style face="normal" font="default" size="100%">Gillespie, Marc E</style></author><author><style face="normal" font="default" size="100%">Kuperstein, Inna</style></author><author><style face="normal" font="default" size="100%">Niarakis, Anna</style></author><author><style face="normal" font="default" size="100%">Hermjakob, Henning</style></author><author><style face="normal" font="default" size="100%">Pico, Alexander R</style></author><author><style face="normal" font="default" size="100%">Willighagen, Egon L</style></author><author><style face="normal" font="default" size="100%">Evelo, Chris T</style></author><author><style face="normal" font="default" size="100%">Hasenauer, Jan</style></author><author><style face="normal" font="default" size="100%">Schreiber, Falk</style></author><author><style face="normal" font="default" size="100%">Dräger, Andreas</style></author><author><style face="normal" font="default" size="100%">Demir, Emek</style></author><author><style face="normal" font="default" size="100%">Wolkenhauer, Olaf</style></author><author><style face="normal" font="default" size="100%">Furlong, Laura I</style></author><author><style face="normal" font="default" size="100%">Barillot, Emmanuel</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Orta-Resendiz, Aurelio</style></author><author><style face="normal" font="default" size="100%">Messina, Francesco</style></author><author><style face="normal" font="default" size="100%">Valencia, Alfonso</style></author><author><style face="normal" font="default" size="100%">Funahashi, Akira</style></author><author><style face="normal" font="default" size="100%">Kitano, Hiroaki</style></author><author><style face="normal" font="default" size="100%">Auffray, Charles</style></author><author><style face="normal" font="default" size="100%">Balling, Rudi</style></author><author><style face="normal" font="default" size="100%">Schneider, Reinhard</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">COVID-19 Disease Map, building a computational repository of SARS-CoV-2 virus-host interaction mechanisms.</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Data</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Sci Data</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Betacoronavirus</style></keyword><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Coronavirus Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Databases, Factual</style></keyword><keyword><style  face="normal" font="default" size="100%">Host Microbial Interactions</style></keyword><keyword><style  face="normal" font="default" size="100%">Host-Pathogen Interactions</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">International Cooperation</style></keyword><keyword><style  face="normal" font="default" size="100%">Models, Biological</style></keyword><keyword><style  face="normal" font="default" size="100%">Pandemics</style></keyword><keyword><style  face="normal" font="default" size="100%">Pneumonia, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 05 05</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">7</style></volume><pages><style face="normal" font="default" size="100%">136</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32371892?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Esteban-Medina, Marina</style></author><author><style face="normal" font="default" size="100%">Rian, Kinza</style></author><author><style face="normal" font="default" size="100%">Falco, Matias M</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Drug repurposing for COVID-19 using machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection.</style></title><secondary-title><style face="normal" font="default" size="100%">Signal Transduct Target Ther</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Signal Transduct Target Ther</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Computational Chemistry</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">drug repositioning</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Machine Learning</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Docking Simulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Targeted Therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 12 11</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">5</style></volume><pages><style face="normal" font="default" size="100%">290</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33311438?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Salgado, David</style></author><author><style face="normal" font="default" size="100%">Armean, Irina M</style></author><author><style face="normal" font="default" size="100%">Baudis, Michael</style></author><author><style face="normal" font="default" size="100%">Beltran, Sergi</style></author><author><style face="normal" font="default" size="100%">Capella-Gutíerrez, Salvador</style></author><author><style face="normal" font="default" size="100%">Carvalho-Silva, Denise</style></author><author><style face="normal" font="default" size="100%">Dominguez Del Angel, Victoria</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Furlong, Laura I</style></author><author><style face="normal" font="default" size="100%">Gao, Bo</style></author><author><style face="normal" font="default" size="100%">Garcia, Leyla</style></author><author><style face="normal" font="default" size="100%">Gerloff, Dietlind</style></author><author><style face="normal" font="default" size="100%">Gut, Ivo</style></author><author><style face="normal" font="default" size="100%">Gyenesei, Attila</style></author><author><style face="normal" font="default" size="100%">Habermann, Nina</style></author><author><style face="normal" font="default" size="100%">Hancock, John M</style></author><author><style face="normal" font="default" size="100%">Hanauer, Marc</style></author><author><style face="normal" font="default" size="100%">Hovig, Eivind</style></author><author><style face="normal" font="default" size="100%">Johansson, Lennart F</style></author><author><style face="normal" font="default" size="100%">Keane, Thomas</style></author><author><style face="normal" font="default" size="100%">Korbel, Jan</style></author><author><style face="normal" font="default" size="100%">Lauer, Katharina B</style></author><author><style face="normal" font="default" size="100%">Laurie, Steve</style></author><author><style face="normal" font="default" size="100%">Leskošek, Brane</style></author><author><style face="normal" font="default" size="100%">Lloyd, David</style></author><author><style face="normal" font="default" size="100%">Marqués-Bonet, Tomás</style></author><author><style face="normal" font="default" size="100%">Mei, Hailiang</style></author><author><style face="normal" font="default" size="100%">Monostory, Katalin</style></author><author><style face="normal" font="default" size="100%">Piñero, Janet</style></author><author><style face="normal" font="default" size="100%">Poterlowicz, Krzysztof</style></author><author><style face="normal" font="default" size="100%">Rath, Ana</style></author><author><style face="normal" font="default" size="100%">Samarakoon, Pubudu</style></author><author><style face="normal" font="default" size="100%">Sanz, Ferran</style></author><author><style face="normal" font="default" size="100%">Saunders, Gary</style></author><author><style face="normal" font="default" size="100%">Sie, Daoud</style></author><author><style face="normal" font="default" size="100%">Swertz, Morris A</style></author><author><style face="normal" font="default" size="100%">Tsukanov, Kirill</style></author><author><style face="normal" font="default" size="100%">Valencia, Alfonso</style></author><author><style face="normal" font="default" size="100%">Vidak, Marko</style></author><author><style face="normal" font="default" size="100%">Yenyxe González, Cristina</style></author><author><style face="normal" font="default" size="100%">Ylstra, Bauke</style></author><author><style face="normal" font="default" size="100%">Béroud, Christophe</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The ELIXIR Human Copy Number Variations Community: building bioinformatics infrastructure for research.</style></title><secondary-title><style face="normal" font="default" size="100%">F1000Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">F1000Res</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA Copy Number Variations</style></keyword><keyword><style  face="normal" font="default" size="100%">High-Throughput Nucleotide Sequencing</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">9</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Copy number variations (CNVs) are major causative contributors both in the genesis of genetic diseases and human neoplasias. While &quot;High-Throughput&quot; sequencing technologies are increasingly becoming the primary choice for genomic screening analysis, their ability to efficiently detect CNVs is still heterogeneous and remains to be developed. The aim of this white paper is to provide a guiding framework for the future contributions of ELIXIR's recently established   with implications beyond human disease diagnostics and population genomics. This white paper is the direct result of a strategy meeting that took place in September 2018 in Hinxton (UK) and involved representatives of 11 ELIXIR Nodes. The meeting led to the definition of priority objectives and tasks, to address a wide range of CNV-related challenges ranging from detection and interpretation to sharing and training. Here, we provide suggestions on how to align these tasks within the ELIXIR Platforms strategy, and on how to frame the activities of this new ELIXIR Community in the international context.&lt;/p&gt;</style></abstract><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/34367618?dopt=Abstract</style></custom1><section><style face="normal" font="default" size="100%">1229</style></section></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palomero, Luis</style></author><author><style face="normal" font="default" size="100%">Galván-Femenía, Ivan</style></author><author><style face="normal" font="default" size="100%">de Cid, Rafael</style></author><author><style face="normal" font="default" size="100%">Espín, Roderic</style></author><author><style face="normal" font="default" size="100%">Barnes, Daniel R</style></author><author><style face="normal" font="default" size="100%">Blommaert, Eline</style></author><author><style face="normal" font="default" size="100%">Gil-Gil, Miguel</style></author><author><style face="normal" font="default" size="100%">Falo, Catalina</style></author><author><style face="normal" font="default" size="100%">Stradella, Agostina</style></author><author><style face="normal" font="default" size="100%">Ouchi, Dan</style></author><author><style face="normal" font="default" size="100%">Roso-Llorach, Albert</style></author><author><style face="normal" font="default" size="100%">Violan, Concepció</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Extremera, Ana Isabel</style></author><author><style face="normal" font="default" size="100%">García-Valero, Mar</style></author><author><style face="normal" font="default" size="100%">Herranz, Carmen</style></author><author><style face="normal" font="default" size="100%">Mateo, Francesca</style></author><author><style face="normal" font="default" size="100%">Mereu, Elisabetta</style></author><author><style face="normal" font="default" size="100%">Beesley, Jonathan</style></author><author><style face="normal" font="default" size="100%">Chenevix-Trench, Georgia</style></author><author><style face="normal" font="default" size="100%">Roux, Cecilia</style></author><author><style face="normal" font="default" size="100%">Mak, Tak</style></author><author><style face="normal" font="default" size="100%">Brunet, Joan</style></author><author><style face="normal" font="default" size="100%">Hakem, Razq</style></author><author><style face="normal" font="default" size="100%">Gorrini, Chiara</style></author><author><style face="normal" font="default" size="100%">Antoniou, Antonis C</style></author><author><style face="normal" font="default" size="100%">Lázaro, Conxi</style></author><author><style face="normal" font="default" size="100%">Pujana, Miquel Angel</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Immune Cell Associations with Cancer Risk.</style></title><secondary-title><style face="normal" font="default" size="100%">iScience</style></secondary-title><alt-title><style face="normal" font="default" size="100%">iScience</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 Jul 24</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">23</style></volume><pages><style face="normal" font="default" size="100%">101296</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Proper immune system function hinders cancer development, but little is known about whether genetic variants linked to cancer risk alter immune cells. Here, we report 57 cancer risk loci associated with differences in immune and/or stromal cell contents in the corresponding tissue. Predicted target genes show expression and regulatory associations with immune features. Polygenic risk scores also reveal associations with immune and/or stromal cell contents, and breast cancer scores show consistent results in normal and tumor tissue. SH2B3 links peripheral alterations of several immune cell types to the risk of this malignancy. Pleiotropic SH2B3 variants are associated with breast cancer risk in BRCA1/2 mutation carriers. A retrospective case-cohort study indicates a positive association between blood counts of basophils, leukocytes, and monocytes and age at breast cancer diagnosis. These findings broaden our knowledge of the role of the immune system in cancer and highlight promising prevention strategies for individuals at high risk.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32622267?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Falco, Matias M</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Hidalgo, Marta R</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mechanistic models of signaling pathways deconvolute the glioblastoma single-cell functional landscapeAbstract</style></title><secondary-title><style face="normal" font="default" size="100%">NAR Cancer</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan-06-2020</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://academic.oup.com/narcancer/article/doi/10.1093/narcan/zcaa011/5862620http://academic.oup.com/narcancer/article-pdf/2/2/zcaa011/33428092/zcaa011.pdfhttp://academic.oup.com/narcancer/article-pdf/2/2/zcaa011/33428092/zcaa011.pdf</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">2</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">2</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cubuk, Cankut</style></author><author><style face="normal" font="default" size="100%">Can, Fatma E</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mechanistic Models of Signaling Pathways Reveal the Drug Action Mechanisms behind Gender-Specific Gene Expression for Cancer Treatments.</style></title><secondary-title><style face="normal" font="default" size="100%">Cells</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cells</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation, Neoplastic</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 06 29</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">9</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Despite the existence of differences in gene expression across numerous genes between males and females having been known for a long time, these have been mostly ignored in many studies, including drug development and its therapeutic use. In fact, the consequences of such differences over the disease mechanisms or the drug action mechanisms are completely unknown. Here we applied mechanistic mathematical models of signaling activity to reveal the ultimate functional consequences that gender-specific gene expression activities have over cell functionality and fate. Moreover, we also used the mechanistic modeling framework to simulate the drug interventions and unravel how drug action mechanisms are affected by gender-specific differential gene expression. Interestingly, some cancers have many biological processes significantly affected by these gender-specific differences (e.g., bladder or head and neck carcinomas), while others (e.g., glioblastoma or rectum cancer) are almost insensitive to them. We found that many of these gender-specific differences affect cancer-specific pathways or in physiological signaling pathways, also involved in cancer origin and development. Finally, mechanistic models have the potential to be used for finding alternative therapeutic interventions on the pathways targeted by the drug, which lead to similar results compensating the downstream consequences of gender-specific differences in gene expression.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32610626?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martin-Broto, Javier</style></author><author><style face="normal" font="default" size="100%">Hindi, Nadia</style></author><author><style face="normal" font="default" size="100%">Grignani, Giovanni</style></author><author><style face="normal" font="default" size="100%">Martinez-Trufero, Javier</style></author><author><style face="normal" font="default" size="100%">Redondo, Andres</style></author><author><style face="normal" font="default" size="100%">Valverde, Claudia</style></author><author><style face="normal" font="default" size="100%">Stacchiotti, Silvia</style></author><author><style face="normal" font="default" size="100%">Lopez-Pousa, Antonio</style></author><author><style face="normal" font="default" size="100%">D'Ambrosio, Lorenzo</style></author><author><style face="normal" font="default" size="100%">Gutierrez, Antonio</style></author><author><style face="normal" font="default" size="100%">Perez-Vega, Herminia</style></author><author><style face="normal" font="default" size="100%">Encinas-Tobajas, Victor</style></author><author><style face="normal" font="default" size="100%">de Alava, Enrique</style></author><author><style face="normal" font="default" size="100%">Collini, Paola</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Carrasco-Garcia, Irene</style></author><author><style face="normal" font="default" size="100%">Lopez-Alvarez, Maria</style></author><author><style face="normal" font="default" size="100%">Moura, David S</style></author><author><style face="normal" font="default" size="100%">Lopez-Martin, Jose A</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.</style></title><secondary-title><style face="normal" font="default" size="100%">J Immunother Cancer</style></secondary-title><alt-title><style face="normal" font="default" size="100%">J Immunother Cancer</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Antineoplastic Agents, Immunological</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Nivolumab</style></keyword><keyword><style  face="normal" font="default" size="100%">Sarcoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Sunitinib</style></keyword><keyword><style  face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 11</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">8</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. As tumor angiogenesis promotes immunosuppression, we designed a phase Ib/II trial to test the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab).&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;This single-arm, phase Ib/II trial enrolled adult patients with selected subtypes of sarcoma. Phase Ib established two dose levels: level 0 with sunitinib 37.5 mg daily from day 1, plus nivolumab 3 mg/kg intravenously on day 15, and then every 2 weeks; and level -1 with sunitinib 37.5 mg on the first 14 days (induction) and then 25 mg per day plus nivolumab on the same schedule. The primary endpoint was to determine the recommended dose for phase II (phase I) and the 6-month progression-free survival rate, according to Response Evaluation Criteria in Solid Tumors 1.1 (phase II).&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;From May 2017 to April 2019, 68 patients were enrolled: 16 in phase Ib and 52 in phase II. The recommended dose of sunitinib for phase II was 37.5 mg as induction and then 25 mg in combination with nivolumab. After a median follow-up of 17 months (4-26), the 6-month progression-free survival rate was 48% (95% CI 41% to 55%). The most common grade 3-4 adverse events included transaminitis (17.3%) and neutropenia (11.5%).&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;Sunitinib plus nivolumab is an active scheme with manageable toxicity in the treatment of selected patients with advanced soft tissue sarcoma, with almost half of patients free of progression at 6 months. NCT03277924.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33203665?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bogliolo, Massimo</style></author><author><style face="normal" font="default" size="100%">Pujol, Roser</style></author><author><style face="normal" font="default" size="100%">Aza-Carmona, Miriam</style></author><author><style face="normal" font="default" size="100%">Muñoz-Subirana, Núria</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Santiago, Benjamin</style></author><author><style face="normal" font="default" size="100%">Casado, José Antonio</style></author><author><style face="normal" font="default" size="100%">Rio, Paula</style></author><author><style face="normal" font="default" size="100%">Bauser, Christopher</style></author><author><style face="normal" font="default" size="100%">Reina-Castillón, Judith</style></author><author><style face="normal" font="default" size="100%">Lopez-Sanchez, Marcos</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Quereda, Lidia</style></author><author><style face="normal" font="default" size="100%">Gallano, Pia</style></author><author><style face="normal" font="default" size="100%">Catalá, Albert</style></author><author><style face="normal" font="default" size="100%">Ruiz-Llobet, Ana</style></author><author><style face="normal" font="default" size="100%">Badell, Isabel</style></author><author><style face="normal" font="default" size="100%">Diaz-Heredia, Cristina</style></author><author><style face="normal" font="default" size="100%">Hladun, Raquel</style></author><author><style face="normal" font="default" size="100%">Senent, Leonort</style></author><author><style face="normal" font="default" size="100%">Argiles, Bienvenida</style></author><author><style face="normal" font="default" size="100%">Bergua Burgues, Juan Miguel</style></author><author><style face="normal" font="default" size="100%">Bañez, Fatima</style></author><author><style face="normal" font="default" size="100%">Arrizabalaga, Beatriz</style></author><author><style face="normal" font="default" size="100%">López Almaraz, Ricardo</style></author><author><style face="normal" font="default" size="100%">Lopez, Monica</style></author><author><style face="normal" font="default" size="100%">Figuera, Ángela</style></author><author><style face="normal" font="default" size="100%">Molinés, Antonio</style></author><author><style face="normal" font="default" size="100%">Pérez de Soto, Inmaculada</style></author><author><style face="normal" font="default" size="100%">Hernando, Inés</style></author><author><style face="normal" font="default" size="100%">Muñoz, Juan Antonio</style></author><author><style face="normal" font="default" size="100%">Del Rosario Marin, Maria</style></author><author><style face="normal" font="default" size="100%">Balmaña, Judith</style></author><author><style face="normal" font="default" size="100%">Stjepanovic, Neda</style></author><author><style face="normal" font="default" size="100%">Carrasco, Estela</style></author><author><style face="normal" font="default" size="100%">Cuesta, Isabel</style></author><author><style face="normal" font="default" size="100%">Cosuelo, José Miguel</style></author><author><style face="normal" font="default" size="100%">Regueiro, Alexandra</style></author><author><style face="normal" font="default" size="100%">Moraleda Jimenez, José</style></author><author><style face="normal" font="default" size="100%">Galera-Miñarro, Ana Maria</style></author><author><style face="normal" font="default" size="100%">Rosiñol, Laura</style></author><author><style face="normal" font="default" size="100%">Carrió, Anna</style></author><author><style face="normal" font="default" size="100%">Beléndez-Bieler, Cristina</style></author><author><style face="normal" font="default" size="100%">Escudero Soto, Antonio</style></author><author><style face="normal" font="default" size="100%">Cela, Elena</style></author><author><style face="normal" font="default" size="100%">de la Mata, Gregorio</style></author><author><style face="normal" font="default" size="100%">Fernández-Delgado, Rafael</style></author><author><style face="normal" font="default" size="100%">Garcia-Pardos, Maria Carmen</style></author><author><style face="normal" font="default" size="100%">Sáez-Villaverde, Raquel</style></author><author><style face="normal" font="default" size="100%">Barragaño, Marta</style></author><author><style face="normal" font="default" size="100%">Portugal, Raquel</style></author><author><style face="normal" font="default" size="100%">Lendinez, Francisco</style></author><author><style face="normal" font="default" size="100%">Hernadez, Ines</style></author><author><style face="normal" font="default" size="100%">Vagace, José Manue</style></author><author><style face="normal" font="default" size="100%">Tapia, Maria</style></author><author><style face="normal" font="default" size="100%">Nieto, José</style></author><author><style face="normal" font="default" size="100%">Garcia, Marta</style></author><author><style face="normal" font="default" size="100%">Gonzalez, Macarena</style></author><author><style face="normal" font="default" size="100%">Vicho, Cristina</style></author><author><style face="normal" font="default" size="100%">Galvez, Eva</style></author><author><style face="normal" font="default" size="100%">Valiente, Alberto</style></author><author><style face="normal" font="default" size="100%">Antelo, Maria Luisa</style></author><author><style face="normal" font="default" size="100%">Ancliff, Phil</style></author><author><style face="normal" font="default" size="100%">García, Francisco</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Sevilla, Julian</style></author><author><style face="normal" font="default" size="100%">Paprotka, Tobias</style></author><author><style face="normal" font="default" size="100%">Pérez-Jurado, Luis Alberto</style></author><author><style face="normal" font="default" size="100%">Bueren, Juan</style></author><author><style face="normal" font="default" size="100%">Surralles, Jordi</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies.</style></title><secondary-title><style face="normal" font="default" size="100%">J Med Genet</style></secondary-title><alt-title><style face="normal" font="default" size="100%">J Med Genet</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA Copy Number Variations</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA Repair</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA-Binding Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Fanconi Anemia</style></keyword><keyword><style  face="normal" font="default" size="100%">Fanconi Anemia Complementation Group A Protein</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Knockout Techniques</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Mutation, Missense</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style  face="normal" font="default" size="100%">whole exome sequencing</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 04</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">57</style></volume><pages><style face="normal" font="default" size="100%">258-268</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;PURPOSE: &lt;/b&gt;Patients with Fanconi anaemia (FA), a rare DNA repair genetic disease, exhibit chromosome fragility, bone marrow failure, malformations and cancer susceptibility. FA molecular diagnosis is challenging since FA is caused by point mutations and large deletions in 22 genes following three heritability patterns. To optimise FA patients' characterisation, we developed a simplified but effective methodology based on whole exome sequencing (WES) and functional studies.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;68 patients with FA were analysed by commercial WES services. Copy number variations were evaluated by sequencing data analysis with RStudio. To test  missense variants, wt FANCA cDNA was cloned and variants were introduced by site-directed mutagenesis. Vectors were then tested for their ability to complement DNA repair defects of a FANCA-KO human cell line generated by TALEN technologies.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;We identified 93.3% of mutated alleles including large deletions. We determined the pathogenicity of three FANCA missense variants and demonstrated that two  variants reported in mutations databases as 'affecting functions' are SNPs. Deep analysis of sequencing data revealed patients' true mutations, highlighting the importance of functional analysis. In one patient, no pathogenic variant could be identified in any of the 22 known FA genes, and in seven patients, only one deleterious variant could be identified (three patients each with FANCA and FANCD2 and one patient with FANCE mutations) CONCLUSION: WES and proper bioinformatics analysis are sufficient to effectively characterise patients with FA regardless of the rarity of their complementation group, type of mutations, mosaic condition and DNA source.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31586946?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martin-Broto, Javier</style></author><author><style face="normal" font="default" size="100%">Cruz, Josefina</style></author><author><style face="normal" font="default" size="100%">Penel, Nicolas</style></author><author><style face="normal" font="default" size="100%">Le Cesne, Axel</style></author><author><style face="normal" font="default" size="100%">Hindi, Nadia</style></author><author><style face="normal" font="default" size="100%">Luna, Pablo</style></author><author><style face="normal" font="default" size="100%">Moura, David S</style></author><author><style face="normal" font="default" size="100%">Bernabeu, Daniel</style></author><author><style face="normal" font="default" size="100%">de Alava, Enrique</style></author><author><style face="normal" font="default" size="100%">Lopez-Guerrero, Jose Antonio</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Gutierrez, Antonio</style></author><author><style face="normal" font="default" size="100%">Collini, Paola</style></author><author><style face="normal" font="default" size="100%">Karanian, Marie</style></author><author><style face="normal" font="default" size="100%">Redondo, Andres</style></author><author><style face="normal" font="default" size="100%">Lopez-Pousa, Antonio</style></author><author><style face="normal" font="default" size="100%">Grignani, Giovanni</style></author><author><style face="normal" font="default" size="100%">Diaz-Martin, Juan</style></author><author><style face="normal" font="default" size="100%">Marcilla, David</style></author><author><style face="normal" font="default" size="100%">Fernandez-Serra, Antonio</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Aguilera, Cristina</style></author><author><style face="normal" font="default" size="100%">Casali, Paolo G</style></author><author><style face="normal" font="default" size="100%">Blay, Jean-Yves</style></author><author><style face="normal" font="default" size="100%">Stacchiotti, Silvia</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial.</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet Oncol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Lancet Oncol</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Follow-Up Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Indazoles</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm Metastasis</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Kinase Inhibitors</style></keyword><keyword><style  face="normal" font="default" size="100%">Pyrimidines</style></keyword><keyword><style  face="normal" font="default" size="100%">Response Evaluation Criteria in Solid Tumors</style></keyword><keyword><style  face="normal" font="default" size="100%">Solitary Fibrous Tumors</style></keyword><keyword><style  face="normal" font="default" size="100%">Sulfonamides</style></keyword><keyword><style  face="normal" font="default" size="100%">Survival Rate</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 03</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">21</style></volume><pages><style face="normal" font="default" size="100%">456-466</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Solitary fibrous tumour is an ultra-rare sarcoma, which encompasses different clinicopathological subgroups. The dedifferentiated subgroup shows an aggressive course with resistance to pazopanib, whereas in the malignant subgroup, pazopanib shows higher activity than in previous studies with chemotherapy. We designed a trial to test pazopanib activity in two different cohorts of solitary fibrous tumour: the malignant-dedifferentiated cohort, which was previously published, and the typical cohort, which is presented here.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;In this single-arm, phase 2 trial, adult patients (aged ≥18 years) diagnosed with confirmed metastatic or unresectable typical solitary fibrous tumour of any location, who had progressed in the previous 6 months (by Choi criteria or Response Evaluation Criteria in Solid Tumors [RECIST]) and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 were enrolled at 11 tertiary hospitals in Italy, France, and Spain. Patients received pazopanib 800 mg once daily, taken orally, until progression, unacceptable toxicity, withdrawal of consent, non-compliance, or a delay in pazopanib administration of longer than 3 weeks. The primary endpoint was proportion of patients achieving an overall response measured by Choi criteria in patients who received at least 1 month of treatment with at least one radiological assessment. All patients who received at least one dose of the study drug were included in the safety analyses. This study is registered in ClinicalTrials.gov, NCT02066285, and with the European Clinical Trials Database, EudraCT 2013-005456-15.&lt;/p&gt;&lt;p&gt;&lt;b&gt;FINDINGS: &lt;/b&gt;From June 26, 2014, to Dec 13, 2018, of 40 patients who were assessed, 34 patients were enrolled and 31 patients were included in the response analysis. Median follow-up was 18 months (IQR 14-34), and 18 (58%) of 31 patients had a partial response, 12 (39%) had stable disease, and one (3%) showed progressive disease according to Choi criteria and central review. The proportion of overall response based on Choi criteria was 58% (95% CI 34-69). There were no deaths caused by toxicity, and the most frequent adverse events were diarrhoea (18 [53%] of 34 patients), fatigue (17 [50%]), and hypertension (17 [50%]).&lt;/p&gt;&lt;p&gt;&lt;b&gt;INTERPRETATION: &lt;/b&gt;To our knowledge, this is the first prospective trial of pazopanib for advanced typical solitary fibrous tumour. The manageable toxicity and activity shown by pazopanib in this cohort suggest that this drug could be considered as first-line treatment for advanced typical solitary fibrous tumour.&lt;/p&gt;&lt;p&gt;&lt;b&gt;FUNDING: &lt;/b&gt;Spanish Group for Research on Sarcomas (GEIS), Italian Sarcoma Group (ISG), French Sarcoma Group (FSG), GlaxoSmithKline, and Novartis.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32066540?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">López-López, Daniel</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Carmona, Rosario</style></author><author><style face="normal" font="default" size="100%">Aquino, Virginia</style></author><author><style face="normal" font="default" size="100%">Salgado, Josefa</style></author><author><style face="normal" font="default" size="100%">Pasalodos, Sara</style></author><author><style face="normal" font="default" size="100%">Miranda, María</style></author><author><style face="normal" font="default" size="100%">Alonso, Ángel</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">SMN1 copy-number and sequence variant analysis from next-generation sequencing data.</style></title><secondary-title><style face="normal" font="default" size="100%">Hum Mutat</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Hum Mutat</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Base Sequence</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA Copy Number Variations</style></keyword><keyword><style  face="normal" font="default" size="100%">High-Throughput Nucleotide Sequencing</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style  face="normal" font="default" size="100%">Software</style></keyword><keyword><style  face="normal" font="default" size="100%">Survival of Motor Neuron 1 Protein</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 12</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">41</style></volume><pages><style face="normal" font="default" size="100%">2073-2077</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Spinal muscular atrophy (SMA) is a severe neuromuscular autosomal recessive disorder affecting 1/10,000 live births. Most SMA patients present homozygous deletion of SMN1, while the vast majority of SMA carriers present only a single SMN1 copy. The sequence similarity between SMN1 and SMN2, and the complexity of the SMN locus makes the estimation of the SMN1 copy-number by next-generation sequencing (NGS) very difficult. Here, we present SMAca, the first python tool to detect SMA carriers and estimate the absolute SMN1 copy-number using NGS data. Moreover, SMAca takes advantage of the knowledge of certain variants specific to SMN1 duplication to also identify silent carriers. This tool has been validated with a cohort of 326 samples from the Navarra 1000 Genomes Project (NAGEN1000). SMAca was developed with a focus on execution speed and easy installation. This combination makes it especially suitable to be integrated into production NGS pipelines. Source code and documentation are available at https://www.github.com/babelomics/SMAca.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33058415?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Galvez, Juan M</style></author><author><style face="normal" font="default" size="100%">Castillo-Secilla, Daniel</style></author><author><style face="normal" font="default" size="100%">Herrera, Luis J</style></author><author><style face="normal" font="default" size="100%">Valenzuela, Olga</style></author><author><style face="normal" font="default" size="100%">Caba, Octavio</style></author><author><style face="normal" font="default" size="100%">Prados, Jose C</style></author><author><style face="normal" font="default" size="100%">Ortuno, Francisco M</style></author><author><style face="normal" font="default" size="100%">Rojas, Ignacio</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Towards Improving Skin Cancer Diagnosis by Integrating Microarray and RNA-Seq Datasets.</style></title><secondary-title><style face="normal" font="default" size="100%">IEEE J Biomed Health Inform</style></secondary-title><alt-title><style face="normal" font="default" size="100%">IEEE J Biomed Health Inform</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Biomarkers, Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Diagnosis, Computer-Assisted</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Machine Learning</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA-seq</style></keyword><keyword><style  face="normal" font="default" size="100%">Skin Neoplasms</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 07</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">24</style></volume><pages><style face="normal" font="default" size="100%">2119-2130</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Many clinical studies have revealed the high biological similarities existing among different skin pathological states. These similarities create difficulties in the efficient diagnosis of skin cancer, and encourage to study and design new intelligent clinical decision support systems. In this sense, gene expression analysis can help find differentially expressed genes (DEGs) simultaneously discerning multiple skin pathological states in a single test. The integration of multiple heterogeneous transcriptomic datasets requires different pipeline stages to be properly designed: from suitable batch merging and efficient biomarker selection to automated classification assessment. This article presents a novel approach addressing all these technical issues, with the intention of providing new sights about skin cancer diagnosis. Although new future efforts will have to be made in the search for better biomarkers recognizing specific skin pathological states, our study found a panel of 8 highly relevant multiclass DEGs for discerning up to 10 skin pathological states: 2 healthy skin conditions a priori, 2 cataloged precancerous skin diseases and 6 cancerous skin states. Their power of diagnosis over new samples was widely tested by previously well-trained classification models. Robust performance metrics such as overall and mean multiclass F1-score outperformed recognition rates of 94% and 80%, respectively. Clinicians should give special attention to highlighted multiclass DEGs that have high gene expression changes present among them, and understand their biological relationship to different skin pathological states.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31871000?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Haibe-Kains, Benjamin</style></author><author><style face="normal" font="default" size="100%">Adam, George Alexandru</style></author><author><style face="normal" font="default" size="100%">Hosny, Ahmed</style></author><author><style face="normal" font="default" size="100%">Khodakarami, Farnoosh</style></author><author><style face="normal" font="default" size="100%">Waldron, Levi</style></author><author><style face="normal" font="default" size="100%">Wang, Bo</style></author><author><style face="normal" font="default" size="100%">McIntosh, Chris</style></author><author><style face="normal" font="default" size="100%">Goldenberg, Anna</style></author><author><style face="normal" font="default" size="100%">Kundaje, Anshul</style></author><author><style face="normal" font="default" size="100%">Greene, Casey S</style></author><author><style face="normal" font="default" size="100%">Broderick, Tamara</style></author><author><style face="normal" font="default" size="100%">Hoffman, Michael M</style></author><author><style face="normal" font="default" size="100%">Leek, Jeffrey T</style></author><author><style face="normal" font="default" size="100%">Korthauer, Keegan</style></author><author><style face="normal" font="default" size="100%">Huber, Wolfgang</style></author><author><style face="normal" font="default" size="100%">Brazma, Alvis</style></author><author><style face="normal" font="default" size="100%">Pineau, Joelle</style></author><author><style face="normal" font="default" size="100%">Tibshirani, Robert</style></author><author><style face="normal" font="default" size="100%">Hastie, Trevor</style></author><author><style face="normal" font="default" size="100%">Ioannidis, John P A</style></author><author><style face="normal" font="default" size="100%">Quackenbush, John</style></author><author><style face="normal" font="default" size="100%">Aerts, Hugo J W L</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">Massive Analysis Quality Control (MAQC) Society Board of Directors</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Transparency and reproducibility in artificial intelligence.</style></title><secondary-title><style face="normal" font="default" size="100%">Nature</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nature</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style  face="normal" font="default" size="100%">Artificial Intelligence</style></keyword><keyword><style  face="normal" font="default" size="100%">Reproducibility of Results</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 10</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">586</style></volume><pages><style face="normal" font="default" size="100%">E14-E16</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">7829</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/33057217?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Casimiro-Soriguer, C S</style></author><author><style face="normal" font="default" size="100%">Rigual, M M</style></author><author><style face="normal" font="default" size="100%">Brokate-Llanos, A M</style></author><author><style face="normal" font="default" size="100%">Muñoz, M J</style></author><author><style face="normal" font="default" size="100%">Garzón, A</style></author><author><style face="normal" font="default" size="100%">Pérez-Pulido, A J</style></author><author><style face="normal" font="default" size="100%">Jimenez, J</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Using AnABlast for intergenic sORF prediction in the Caenorhabditis elegans genome.</style></title><secondary-title><style face="normal" font="default" size="100%">Bioinformatics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Bioinformatics</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Caenorhabditis elegans</style></keyword><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome</style></keyword><keyword><style  face="normal" font="default" size="100%">Open Reading Frames</style></keyword><keyword><style  face="normal" font="default" size="100%">Software</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020 12 08</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">36</style></volume><pages><style face="normal" font="default" size="100%">4827-4832</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;MOTIVATION: &lt;/b&gt;Short bioactive peptides encoded by small open reading frames (sORFs) play important roles in eukaryotes. Bioinformatics prediction of ORFs is an early step in a genome sequence analysis, but sORFs encoding short peptides, often using non-AUG initiation codons, are not easily discriminated from false ORFs occurring by chance.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;AnABlast is a computational tool designed to highlight putative protein-coding regions in genomic DNA sequences. This protein-coding finder is independent of ORF length and reading frame shifts, thus making of AnABlast a potentially useful tool to predict sORFs. Using this algorithm, here, we report the identification of 82 putative new intergenic sORFs in the Caenorhabditis elegans genome. Sequence similarity, motif presence, expression data and RNA interference experiments support that the underlined sORFs likely encode functional peptides, encouraging the use of AnABlast as a new approach for the accurate prediction of intergenic sORFs in annotated eukaryotic genomes.&lt;/p&gt;&lt;p&gt;&lt;b&gt;AVAILABILITY AND IMPLEMENTATION: &lt;/b&gt;AnABlast is freely available at http://www.bioinfocabd.upo.es/ab/. The C.elegans genome browser with AnABlast results, annotated genes and all data used in this study is available at http://www.bioinfocabd.upo.es/celegans.&lt;/p&gt;&lt;p&gt;&lt;b&gt;SUPPLEMENTARY INFORMATION: &lt;/b&gt;Supplementary data are available at Bioinformatics online.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">19</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/32614398?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cubuk, Cankut</style></author><author><style face="normal" font="default" size="100%">Hidalgo, Marta R</style></author><author><style face="normal" font="default" size="100%">Amadoz, Alicia</style></author><author><style face="normal" font="default" size="100%">Rian, Kinza</style></author><author><style face="normal" font="default" size="100%">Salavert, Francisco</style></author><author><style face="normal" font="default" size="100%">Pujana, Miguel A</style></author><author><style face="normal" font="default" size="100%">Mateo, Francesca</style></author><author><style face="normal" font="default" size="100%">Herranz, Carmen</style></author><author><style face="normal" font="default" size="100%">Carbonell-Caballero, José</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Differential metabolic activity and discovery of therapeutic targets using summarized metabolic pathway models.</style></title><secondary-title><style face="normal" font="default" size="100%">NPJ Syst Biol Appl</style></secondary-title><alt-title><style face="normal" font="default" size="100%">NPJ Syst Biol Appl</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Computer Simulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug discovery</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Regulatory Networks</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Internet</style></keyword><keyword><style  face="normal" font="default" size="100%">Metabolic Networks and Pathways</style></keyword><keyword><style  face="normal" font="default" size="100%">Models, Biological</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style  face="normal" font="default" size="100%">Software</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcriptome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">5</style></volume><pages><style face="normal" font="default" size="100%">7</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;In spite of the increasing availability of genomic and transcriptomic data, there is still a gap between the detection of perturbations in gene expression and the understanding of their contribution to the molecular mechanisms that ultimately account for the phenotype studied. Alterations in the metabolism are behind the initiation and progression of many diseases, including cancer. The wealth of available knowledge on metabolic processes can therefore be used to derive mechanistic models that link gene expression perturbations to changes in metabolic activity that provide relevant clues on molecular mechanisms of disease and drug modes of action (MoA). In particular, pathway modules, which recapitulate the main aspects of metabolism, are especially suitable for this type of modeling. We present Metabolizer, a web-based application that offers an intuitive, easy-to-use interactive interface to analyze differences in pathway metabolic module activities that can also be used for class prediction and in silico prediction of knock-out (KO) effects. Moreover, Metabolizer can automatically predict the optimal KO intervention for restoring a diseased phenotype. We provide different types of validations of some of the predictions made by Metabolizer. Metabolizer is a web tool that allows understanding molecular mechanisms of disease or the MoA of drugs within the context of the metabolism by using gene expression measurements. In addition, this tool automatically suggests potential therapeutic targets for individualized therapeutic interventions.&lt;/p&gt;</style></abstract><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30854222?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Esteban-Medina, Marina</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Exploring the druggable space around the Fanconi anemia pathway using machine learning and mechanistic models.</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Bioinformatics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">BMC Bioinformatics</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Databases, Factual</style></keyword><keyword><style  face="normal" font="default" size="100%">Fanconi Anemia</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Machine Learning</style></keyword><keyword><style  face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style  face="normal" font="default" size="100%">Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019 Jul 02</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">20</style></volume><pages><style face="normal" font="default" size="100%">370</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;In spite of the abundance of genomic data, predictive models that describe phenotypes as a function of gene expression or mutations are difficult to obtain because they are affected by the curse of dimensionality, given the disbalance between samples and candidate genes. And this is especially dramatic in scenarios in which the availability of samples is difficult, such as the case of rare diseases.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;The application of multi-output regression machine learning methodologies to predict the potential effect of external proteins over the signaling circuits that trigger Fanconi anemia related cell functionalities, inferred with a mechanistic model, allowed us to detect over 20 potential therapeutic targets.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;The use of artificial intelligence methods for the prediction of potentially causal relationships between proteins of interest and cell activities related with disease-related phenotypes opens promising avenues for the systematic search of new targets in rare diseases.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/31266445?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chacón-Solano, E</style></author><author><style face="normal" font="default" size="100%">León, C</style></author><author><style face="normal" font="default" size="100%">Díaz, F</style></author><author><style face="normal" font="default" size="100%">García-García, F</style></author><author><style face="normal" font="default" size="100%">García, M</style></author><author><style face="normal" font="default" size="100%">Escámez, M J</style></author><author><style face="normal" font="default" size="100%">Guerrero-Aspizua, S</style></author><author><style face="normal" font="default" size="100%">Conti, C J</style></author><author><style face="normal" font="default" size="100%">Mencía, Á</style></author><author><style face="normal" font="default" size="100%">Martínez-Santamaría, L</style></author><author><style face="normal" font="default" size="100%">Llames, S</style></author><author><style face="normal" font="default" size="100%">Pévida, M</style></author><author><style face="normal" font="default" size="100%">Carbonell-Caballero, J</style></author><author><style face="normal" font="default" size="100%">Puig-Butillé, J A</style></author><author><style face="normal" font="default" size="100%">Maseda, R</style></author><author><style face="normal" font="default" size="100%">Puig, S</style></author><author><style face="normal" font="default" size="100%">de Lucas, R</style></author><author><style face="normal" font="default" size="100%">Baselga, E</style></author><author><style face="normal" font="default" size="100%">Larcher, F</style></author><author><style face="normal" font="default" size="100%">Dopazo, J</style></author><author><style face="normal" font="default" size="100%">Del Rio, M</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses.</style></title><secondary-title><style face="normal" font="default" size="100%">Br J Dermatol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Br J Dermatol</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Biopsy</style></keyword><keyword><style  face="normal" font="default" size="100%">Blister</style></keyword><keyword><style  face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style  face="normal" font="default" size="100%">Child</style></keyword><keyword><style  face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style  face="normal" font="default" size="100%">Epidermolysis Bullosa</style></keyword><keyword><style  face="normal" font="default" size="100%">Epidermolysis Bullosa Dystrophica</style></keyword><keyword><style  face="normal" font="default" size="100%">Extracellular Matrix</style></keyword><keyword><style  face="normal" font="default" size="100%">Extracellular Matrix Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Fibroblasts</style></keyword><keyword><style  face="normal" font="default" size="100%">Fibrosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Healthy Volunteers</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Infant</style></keyword><keyword><style  face="normal" font="default" size="100%">Infant, Newborn</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">Periodontal Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Photosensitivity Disorders</style></keyword><keyword><style  face="normal" font="default" size="100%">Primary Cell Culture</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA-seq</style></keyword><keyword><style  face="normal" font="default" size="100%">Skin</style></keyword><keyword><style  face="normal" font="default" size="100%">Xeroderma Pigmentosum</style></keyword><keyword><style  face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019 09</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">181</style></volume><pages><style face="normal" font="default" size="100%">512-522</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Recessive dystrophic epidermolysis bullosa (RDEB), Kindler syndrome (KS) and xeroderma pigmentosum complementation group C (XPC) are three cancer-prone genodermatoses whose causal genetic mutations cannot fully explain, on their own, the array of associated phenotypic manifestations. Recent evidence highlights the role of the stromal microenvironment in the pathology of these disorders.&lt;/p&gt;&lt;p&gt;&lt;b&gt;OBJECTIVES: &lt;/b&gt;To investigate, by means of comparative gene expression analysis, the role played by dermal fibroblasts in the pathogenesis of RDEB, KS and XPC.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;We conducted RNA-Seq analysis, which included a thorough examination of the differentially expressed genes, a functional enrichment analysis and a description of affected signalling circuits. Transcriptomic data were validated at the protein level in cell cultures, serum samples and skin biopsies.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Interdisease comparisons against control fibroblasts revealed a unifying signature of 186 differentially expressed genes and four signalling pathways in the three genodermatoses. Remarkably, some of the uncovered expression changes suggest a synthetic fibroblast phenotype characterized by the aberrant expression of extracellular matrix (ECM) proteins. Western blot and immunofluorescence in situ analyses validated the RNA-Seq data. In addition, enzyme-linked immunosorbent assay revealed increased circulating levels of periostin in patients with RDEB.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;Our results suggest that the different causal genetic defects converge into common changes in gene expression, possibly due to injury-sensitive events. These, in turn, trigger a cascade of reactions involving abnormal ECM deposition and underexpression of antioxidant enzymes. The elucidated expression signature provides new potential biomarkers and common therapeutic targets in RDEB, XPC and KS. What's already known about this topic? Recessive dystrophic epidermolysis bullosa (RDEB), Kindler syndrome (KS) and xeroderma pigmentosum complementation group C (XPC) are three genodermatoses with high predisposition to cancer development. Although their causal genetic mutations mainly affect epithelia, the dermal microenvironment likely contributes to the physiopathology of these disorders. What does this study add? We disclose a large overlapping transcription profile between XPC, KS and RDEB fibroblasts that points towards an activated phenotype with high matrix-synthetic capacity. This common signature seems to be independent of the primary causal deficiency, but reflects an underlying derangement of the extracellular matrix via transforming growth factor-β signalling activation and oxidative state imbalance. What is the translational message? This study broadens the current knowledge about the pathology of these diseases and highlights new targets and biomarkers for effective therapeutic intervention. It is suggested that high levels of circulating periostin could represent a potential biomarker in RDEB.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30693469?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Martin-Broto, Javier</style></author><author><style face="normal" font="default" size="100%">Stacchiotti, Silvia</style></author><author><style face="normal" font="default" size="100%">Lopez-Pousa, Antonio</style></author><author><style face="normal" font="default" size="100%">Redondo, Andres</style></author><author><style face="normal" font="default" size="100%">Bernabeu, Daniel</style></author><author><style face="normal" font="default" size="100%">de Alava, Enrique</style></author><author><style face="normal" font="default" size="100%">Casali, Paolo G</style></author><author><style face="normal" font="default" size="100%">Italiano, Antoine</style></author><author><style face="normal" font="default" size="100%">Gutierrez, Antonio</style></author><author><style face="normal" font="default" size="100%">Moura, David S</style></author><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Diaz-Martin, Juan</style></author><author><style face="normal" font="default" size="100%">Biscuola, Michele</style></author><author><style face="normal" font="default" size="100%">Taron, Miguel</style></author><author><style face="normal" font="default" size="100%">Collini, Paola</style></author><author><style face="normal" font="default" size="100%">Ranchere-Vince, Dominique</style></author><author><style face="normal" font="default" size="100%">Garcia Del Muro, Xavier</style></author><author><style face="normal" font="default" size="100%">Grignani, Giovanni</style></author><author><style face="normal" font="default" size="100%">Dumont, Sarah</style></author><author><style face="normal" font="default" size="100%">Martinez-Trufero, Javier</style></author><author><style face="normal" font="default" size="100%">Palmerini, Emanuela</style></author><author><style face="normal" font="default" size="100%">Hindi, Nadia</style></author><author><style face="normal" font="default" size="100%">Sebio, Ana</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Dei Tos, Angelo Paolo</style></author><author><style face="normal" font="default" size="100%">LeCesne, Axel</style></author><author><style face="normal" font="default" size="100%">Blay, Jean-Yves</style></author><author><style face="normal" font="default" size="100%">Cruz, Josefina</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.</style></title><secondary-title><style face="normal" font="default" size="100%">Lancet Oncol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Lancet Oncol</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Angiogenesis Inhibitors</style></keyword><keyword><style  face="normal" font="default" size="100%">Antineoplastic Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Indazoles</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Multivariate Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Pyrimidines</style></keyword><keyword><style  face="normal" font="default" size="100%">Response Evaluation Criteria in Solid Tumors</style></keyword><keyword><style  face="normal" font="default" size="100%">Soft Tissue Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Solitary Fibrous Tumors</style></keyword><keyword><style  face="normal" font="default" size="100%">Sulfonamides</style></keyword><keyword><style  face="normal" font="default" size="100%">Survival Analysis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019 Jan</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">20</style></volume><pages><style face="normal" font="default" size="100%">134-144</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;A solitary fibrous tumour is a rare soft-tissue tumour with three clinicopathological variants: typical, malignant, and dedifferentiated. Preclinical experiments and retrospective studies have shown different sensitivities of solitary fibrous tumour to chemotherapy and antiangiogenics. We therefore designed a trial to assess the activity of pazopanib in a cohort of patients with malignant or dedifferentiated solitary fibrous tumour. The clinical and translational results are presented here.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;In this single-arm, phase 2 trial, adult patients (aged ≥ 18 years) with histologically confirmed metastatic or unresectable malignant or dedifferentiated solitary fibrous tumour at any location, who had progressed (by RECIST and Choi criteria) in the previous 6 months and had an ECOG performance status of 0-2, were enrolled at 16 third-level hospitals with expertise in sarcoma care in Spain, Italy, and France. Patients received pazopanib 800 mg once daily, taken orally without food, at least 1 h before or 2 h after a meal, until progression or intolerance. The primary endpoint of the study was overall response measured by Choi criteria in the subset of the intention-to-treat population (patients who received at least 1 month of treatment with at least one radiological assessment). All patients who received at least one dose of the study drug were included in the safety analyses. This study is registered with ClinicalTrials.gov, number NCT02066285, and with the European Clinical Trials Database, EudraCT number 2013-005456-15.&lt;/p&gt;&lt;p&gt;&lt;b&gt;FINDINGS: &lt;/b&gt;From June 26, 2014, to Nov 24, 2016, of 40 patients assessed, 36 were enrolled (34 with malignant solitary fibrous tumour and two with dedifferentiated solitary fibrous tumour). Median follow-up was 27 months (IQR 16-31). Based on central radiology review, 18 (51%) of 35 evaluable patients had partial responses, nine (26%) had stable disease, and eight (23%) had progressive disease according to Choi criteria. Further enrolment of patients with dedifferentiated solitary fibrous tumour was stopped after detection of early and fast progressions in a planned interim analysis. 51% (95% CI 34-69) of 35 patients achieved an overall response according to Choi criteria. Ten (29%) of 35 patients died. There were no deaths related to adverse events and the most frequent grade 3 or higher adverse events were hypertension (11 [31%] of 36 patients), neutropenia (four [11%]), increased concentrations of alanine aminotransferase (four [11%]), and increased concentrations of bilirubin (three [8%]).&lt;/p&gt;&lt;p&gt;&lt;b&gt;INTERPRETATION: &lt;/b&gt;To our knowledge, this is the first trial of pazopanib for treatment of malignant solitary fibrous tumour showing activity in this patient group. The manageable toxicity profile and the activity shown by pazopanib suggests that this drug could be an option for systemic treatment of advanced malignant solitary fibrous tumour, and provides a benchmark for future trials.&lt;/p&gt;&lt;p&gt;&lt;b&gt;FUNDING: &lt;/b&gt;Spanish Group for Research on Sarcomas (GEIS), Italian Sarcoma Group (ISG), French Sarcoma Group (FSG), GlaxoSmithKline, and Novartis.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30578023?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Perez-Gil, Daniel</style></author><author><style face="normal" font="default" size="100%">Lopez, Francisco J</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Marin-Garcia, Pablo</style></author><author><style face="normal" font="default" size="100%">Rendon, Augusto</style></author><author><style face="normal" font="default" size="100%">Medina, Ignacio</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">PyCellBase, an efficient python package for easy retrieval of biological data from heterogeneous sources.</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Bioinformatics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">BMC Bioinformatics</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Databases, Factual</style></keyword><keyword><style  face="normal" font="default" size="100%">Software</style></keyword><keyword><style  face="normal" font="default" size="100%">User-Computer Interface</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2019 Mar 28</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">20</style></volume><pages><style face="normal" font="default" size="100%">159</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Biological databases and repositories are incrementing in diversity and complexity over the years. This rapid expansion of current and new sources of biological knowledge raises serious problems of data accessibility and integration. To handle the growing necessity of unification, CellBase was created as an integrative solution. CellBase provides a centralized NoSQL database containing biological information from different and heterogeneous sources. Access to this information is done through a RESTful web service API, which provides an efficient interface to the data.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;In this work we present PyCellBase, a Python package that provides programmatic access to the rich RESTful web service API offered by CellBase. This package offers a fast and user-friendly access to biological information without the need of installing any local database. In addition, a series of command-line tools are provided to perform common bioinformatic tasks, such as variant annotation. CellBase data is always available by a high-availability cluster and queries have been tuned to ensure a real-time performance.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;PyCellBase is an open-source Python package that provides an efficient access to heterogeneous biological information. It allows to perform tasks that require a comprehensive set of knowledge resources, as for example variant annotation. Queries can be easily fine-tuned to retrieve the desired information of particular biological features. PyCellBase offers the convenience of an object-oriented scripting language and provides the ability to integrate the obtained results into other Python applications and pipelines.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30922213?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Peña-Chilet, Maria</style></author><author><style face="normal" font="default" size="100%">Esteban-Medina, Marina</style></author><author><style face="normal" font="default" size="100%">Falco, Matias M.</style></author><author><style face="normal" font="default" size="100%">Rian, Kinza</style></author><author><style face="normal" font="default" size="100%">Hidalgo, Marta R.</style></author><author><style face="normal" font="default" size="100%">Loucera, Carlos</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Using mechanistic models for the clinical interpretation of complex genomic variation</style></title><secondary-title><style face="normal" font="default" size="100%">Scientific Reports</style></secondary-title><short-title><style face="normal" font="default" size="100%">Sci Rep</style></short-title></titles><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan-12-2019</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.nature.com/articles/s41598-019-55454-7http://www.nature.com/articles/s41598-019-55454-7.pdfhttp://www.nature.com/articles/s41598-019-55454-7.pdfhttp://www.nature.com/articles/s41598-019-55454-7</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">9</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fourati, Slim</style></author><author><style face="normal" font="default" size="100%">Talla, Aarthi</style></author><author><style face="normal" font="default" size="100%">Mahmoudian, Mehrad</style></author><author><style face="normal" font="default" size="100%">Burkhart, Joshua G.</style></author><author><style face="normal" font="default" size="100%">Klén, Riku</style></author><author><style face="normal" font="default" size="100%">Henao, Ricardo</style></author><author><style face="normal" font="default" size="100%">Yu, Thomas</style></author><author><style face="normal" font="default" size="100%">Aydın, Zafer</style></author><author><style face="normal" font="default" size="100%">Yeung, Ka Yee</style></author><author><style face="normal" font="default" size="100%">Ahsen, Mehmet Eren</style></author><author><style face="normal" font="default" size="100%">Almugbel, Reem</style></author><author><style face="normal" font="default" size="100%">Jahandideh, Samad</style></author><author><style face="normal" font="default" size="100%">Liang, Xiao</style></author><author><style face="normal" font="default" size="100%">Nordling, Torbjörn E. M.</style></author><author><style face="normal" font="default" size="100%">Shiga, Motoki</style></author><author><style face="normal" font="default" size="100%">Stanescu, Ana</style></author><author><style face="normal" font="default" size="100%">Vogel, Robert</style></author><author><style face="normal" font="default" size="100%">Pandey, Gaurav</style></author><author><style face="normal" font="default" size="100%">Chiu, Christopher</style></author><author><style face="normal" font="default" size="100%">McClain, Micah T.</style></author><author><style face="normal" font="default" size="100%">Woods, Christopher W.</style></author><author><style face="normal" font="default" size="100%">Ginsburg, Geoffrey S.</style></author><author><style face="normal" font="default" size="100%">Elo, Laura L.</style></author><author><style face="normal" font="default" size="100%">Tsalik, Ephraim L.</style></author><author><style face="normal" font="default" size="100%">Mangravite, Lara M.</style></author><author><style face="normal" font="default" size="100%">Sieberts, Solveig K.</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">The Respiratory Viral DREAM Challenge Consortium</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">A crowdsourced analysis to identify ab initio molecular signatures predictive of susceptibility to viral infection</style></title><secondary-title><style face="normal" font="default" size="100%">Nature Communications</style></secondary-title><short-title><style face="normal" font="default" size="100%">Nat Commun</style></short-title></titles><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan-12-2018</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.nature.com/articles/s41467-018-06735-8http://www.nature.com/articles/s41467-018-06735-8.pdfhttp://www.nature.com/articles/s41467-018-06735-8.pdfhttp://www.nature.com/articles/s41467-018-06735-8</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">9</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ferreira, Pedro G</style></author><author><style face="normal" font="default" size="100%">Muñoz-Aguirre, Manuel</style></author><author><style face="normal" font="default" size="100%">Reverter, Ferran</style></author><author><style face="normal" font="default" size="100%">Sá Godinho, Caio P</style></author><author><style face="normal" font="default" size="100%">Sousa, Abel</style></author><author><style face="normal" font="default" size="100%">Amadoz, Alicia</style></author><author><style face="normal" font="default" size="100%">Sodaei, Reza</style></author><author><style face="normal" font="default" size="100%">Hidalgo, Marta R</style></author><author><style face="normal" font="default" size="100%">Pervouchine, Dmitri</style></author><author><style face="normal" font="default" size="100%">Carbonell-Caballero, José</style></author><author><style face="normal" font="default" size="100%">Nurtdinov, Ramil</style></author><author><style face="normal" font="default" size="100%">Breschi, Alessandra</style></author><author><style face="normal" font="default" size="100%">Amador, Raziel</style></author><author><style face="normal" font="default" size="100%">Oliveira, Patrícia</style></author><author><style face="normal" font="default" size="100%">Cubuk, Cankut</style></author><author><style face="normal" font="default" size="100%">Curado, João</style></author><author><style face="normal" font="default" size="100%">Aguet, François</style></author><author><style face="normal" font="default" size="100%">Oliveira, Carla</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Sammeth, Michael</style></author><author><style face="normal" font="default" size="100%">Ardlie, Kristin G</style></author><author><style face="normal" font="default" size="100%">Guigó, Roderic</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The effects of death and post-mortem cold ischemia on human tissue transcriptomes.</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Commun</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nat Commun</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Blood</style></keyword><keyword><style  face="normal" font="default" size="100%">Cold Ischemia</style></keyword><keyword><style  face="normal" font="default" size="100%">Death</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Models, Biological</style></keyword><keyword><style  face="normal" font="default" size="100%">Postmortem Changes</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style  face="normal" font="default" size="100%">Stochastic Processes</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcriptome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2018 Feb 13</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">9</style></volume><pages><style face="normal" font="default" size="100%">490</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Post-mortem tissues samples are a key resource for investigating patterns of gene expression. However, the processes triggered by death and the post-mortem interval (PMI) can significantly alter physiologically normal RNA levels. We investigate the impact of PMI on gene expression using data from multiple tissues of post-mortem donors obtained from the GTEx project. We find that many genes change expression over relatively short PMIs in a tissue-specific manner, but this potentially confounding effect in a biological analysis can be minimized by taking into account appropriate covariates. By comparing ante- and post-mortem blood samples, we identify the cascade of transcriptional events triggered by death of the organism. These events do not appear to simply reflect stochastic variation resulting from mRNA degradation, but active and ongoing regulation of transcription. Finally, we develop a model to predict the time since death from the analysis of the transcriptome of a few readily accessible tissues.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/29440659?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">López, M</style></author><author><style face="normal" font="default" size="100%">Rueda, A</style></author><author><style face="normal" font="default" size="100%">Florido, J P</style></author><author><style face="normal" font="default" size="100%">Blasco, L</style></author><author><style face="normal" font="default" size="100%">Fernández-García, L</style></author><author><style face="normal" font="default" size="100%">Trastoy, R</style></author><author><style face="normal" font="default" size="100%">Fernández-Cuenca, F</style></author><author><style face="normal" font="default" size="100%">Martínez-Martínez, L</style></author><author><style face="normal" font="default" size="100%">Vila, J</style></author><author><style face="normal" font="default" size="100%">Pascual, A</style></author><author><style face="normal" font="default" size="100%">Bou, G</style></author><author><style face="normal" font="default" size="100%">Tomas, M</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Evolution of the Quorum network and the mobilome (plasmids and bacteriophages) in clinical strains of Acinetobacter baumannii during a decade.</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Sci Rep</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Acinetobacter baumannii</style></keyword><keyword><style  face="normal" font="default" size="100%">Acinetobacter Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">Bacteriophages</style></keyword><keyword><style  face="normal" font="default" size="100%">Cross Infection</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Plasmids</style></keyword><keyword><style  face="normal" font="default" size="100%">Quorum Sensing</style></keyword><keyword><style  face="normal" font="default" size="100%">Retrospective Studies</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2018 Feb 06</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">8</style></volume><pages><style face="normal" font="default" size="100%">2523</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;In this study, we compared eighteen clinical strains of A. baumannii belonging to the ST-2 clone and isolated from patients in the same intensive care unit (ICU) in 2000 (9 strains referred to collectively as Ab_GEIH-2000) and 2010 (9 strains referred to collectively as Ab_GEIH-2010), during the GEIH-REIPI project (Umbrella BioProject PRJNA422585). We observed two main molecular differences between the Ab_GEIH-2010 and the Ab_GEIH-2000 collections, acquired over the course of the decade long sampling interval and involving the mobilome: i) a plasmid harbouring genes for bla ß-lactamase and abKA/abkB proteins of a toxin-antitoxin system; and ii) two temperate bacteriophages, Ab105-1ϕ (63 proteins) and Ab105-2ϕ (93 proteins), containing important viral defence proteins. Moreover, all Ab_GEIH-2010 strains contained a Quorum functional network of Quorum Sensing (QS) and Quorum Quenching (QQ) mechanisms, including a new QQ enzyme, AidA, which acts as a bacterial defence mechanism against the exogenous 3-oxo-C12-HSL. Interestingly, the infective capacity of the bacteriophages isolated in this study (Ab105-1ϕ and Ab105-2ϕ) was higher in the Ab_GEIH-2010 strains (carrying a functional Quorum network) than in the Ab_GEIH-2000 strains (carrying a deficient Quorum network), in which the bacteriophages showed little or no infectivity. This is the first study about the evolution of the Quorum network and the mobilome in clinical strains of Acinetobacter baumannii during a decade.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/29410443?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rodríguez Hernáez, Javier</style></author><author><style face="normal" font="default" size="100%">Cerón Cucchi, Maria Esperanza</style></author><author><style face="normal" font="default" size="100%">Cravero, Silvio</style></author><author><style face="normal" font="default" size="100%">Martinez, Maria Carolina</style></author><author><style face="normal" font="default" size="100%">Gonzalez, Sergio</style></author><author><style face="normal" font="default" size="100%">Puebla, Andrea</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Farber, Marisa</style></author><author><style face="normal" font="default" size="100%">Paniego, Norma</style></author><author><style face="normal" font="default" size="100%">Rivarola, Máximo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The first complete genomic structure of Butyrivibrio fibrisolvens and its chromid.</style></title><secondary-title><style face="normal" font="default" size="100%">Microb Genom</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Microb Genom</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Butyrivibrio fibrisolvens</style></keyword><keyword><style  face="normal" font="default" size="100%">Cattle</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome, Bacterial</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Milk</style></keyword><keyword><style  face="normal" font="default" size="100%">Rumen</style></keyword><keyword><style  face="normal" font="default" size="100%">Sequence Analysis, DNA</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2018 Oct</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">4</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Butyrivibrio fibrisolvens forms part of the gastrointestinal microbiome of ruminants and other mammals, including humans. Indeed, it is one of the most common bacteria found in the rumen and plays an important role in ruminal fermentation of polysaccharides, yet, to date, there is no closed reference genome published for this species in any ruminant animal. We successfully assembled the nearly complete genome sequence of B. fibrisolvens strain INBov1 isolated from cow rumen using Illumina paired-end reads, 454 Roche single-end and mate pair sequencing technology. Additionally, we constructed an optical restriction map of this strain to aid in scaffold ordering and positioning, and completed the first genomic structure of this species. Moreover, we identified and assembled the first chromid of this species (pINBov266). The INBov1 genome encodes a large set of genes involved in the cellulolytic process but lacks key genes. This seems to indicate that B. fibrisolvens plays an important role in ruminal cellulolytic processes, but does not have autonomous cellulolytic capacity. When searching for genes involved in the biohydrogenation of unsaturated fatty acids, no linoleate isomerase gene was found in this strain. INBov1 does encode oleate hydratase genes known to participate in the hydrogenation of oleic acids. Furthermore, INBov1 contains an enolase gene, which has been recently determined to participate in the synthesis of conjugated linoleic acids. This work confirms the presence of a novel chromid in B. fibrisolvens and provides a new potential reference genome sequence for this species, providing new insight into its role in biohydrogenation and carbohydrate degradation.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30216146?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cubuk, Cankut</style></author><author><style face="normal" font="default" size="100%">Hidalgo, Marta R</style></author><author><style face="normal" font="default" size="100%">Amadoz, Alicia</style></author><author><style face="normal" font="default" size="100%">Pujana, Miguel A</style></author><author><style face="normal" font="default" size="100%">Mateo, Francesca</style></author><author><style face="normal" font="default" size="100%">Herranz, Carmen</style></author><author><style face="normal" font="default" size="100%">Carbonell-Caballero, José</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Gene Expression Integration into Pathway Modules Reveals a Pan-Cancer Metabolic Landscape.</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cancer Res</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cell Line, Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Cluster Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation, Neoplastic</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Regulatory Networks</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Kaplan-Meier Estimate</style></keyword><keyword><style  face="normal" font="default" size="100%">Metabolome</style></keyword><keyword><style  face="normal" font="default" size="100%">mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Oncogenes</style></keyword><keyword><style  face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style  face="normal" font="default" size="100%">Prognosis</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style  face="normal" font="default" size="100%">Sequence Analysis, RNA</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment Outcome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2018 Nov 01</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">78</style></volume><pages><style face="normal" font="default" size="100%">6059-6072</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Metabolic reprogramming plays an important role in cancer development and progression and is a well-established hallmark of cancer. Despite its inherent complexity, cellular metabolism can be decomposed into functional modules that represent fundamental metabolic processes. Here, we performed a pan-cancer study involving 9,428 samples from 25 cancer types to reveal metabolic modules whose individual or coordinated activity predict cancer type and outcome, in turn highlighting novel therapeutic opportunities. Integration of gene expression levels into metabolic modules suggests that the activity of specific modules differs between cancers and the corresponding tissues of origin. Some modules may cooperate, as indicated by the positive correlation of their activity across a range of tumors. The activity of many metabolic modules was significantly associated with prognosis at a stronger magnitude than any of their constituent genes. Thus, modules may be classified as tumor suppressors and oncomodules according to their potential impact on cancer progression. Using this modeling framework, we also propose novel potential therapeutic targets that constitute alternative ways of treating cancer by inhibiting their reprogrammed metabolism. Collectively, this study provides an extensive resource of predicted cancer metabolic profiles and dependencies. Combining gene expression with metabolic modules identifies molecular mechanisms of cancer undetected on an individual gene level and allows discovery of new potential therapeutic targets. .&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">21</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/30135189?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wu, Guohong Albert</style></author><author><style face="normal" font="default" size="100%">Terol, Javier</style></author><author><style face="normal" font="default" size="100%">Ibañez, Victoria</style></author><author><style face="normal" font="default" size="100%">López-García, Antonio</style></author><author><style face="normal" font="default" size="100%">Pérez-Román, Estela</style></author><author><style face="normal" font="default" size="100%">Borredá, Carles</style></author><author><style face="normal" font="default" size="100%">Domingo, Concha</style></author><author><style face="normal" font="default" size="100%">Tadeo, Francisco R</style></author><author><style face="normal" font="default" size="100%">Carbonell-Caballero, José</style></author><author><style face="normal" font="default" size="100%">Alonso, Roberto</style></author><author><style face="normal" font="default" size="100%">Curk, Franck</style></author><author><style face="normal" font="default" size="100%">Du, Dongliang</style></author><author><style face="normal" font="default" size="100%">Ollitrault, Patrick</style></author><author><style face="normal" font="default" size="100%">Roose, Mikeal L</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Gmitter, Frederick G</style></author><author><style face="normal" font="default" size="100%">Rokhsar, Daniel S</style></author><author><style face="normal" font="default" size="100%">Talon, Manuel</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Genomics of the origin and evolution of Citrus.</style></title><secondary-title><style face="normal" font="default" size="100%">Nature</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nature</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Asia, Southeastern</style></keyword><keyword><style  face="normal" font="default" size="100%">Biodiversity</style></keyword><keyword><style  face="normal" font="default" size="100%">citrus</style></keyword><keyword><style  face="normal" font="default" size="100%">Crop Production</style></keyword><keyword><style  face="normal" font="default" size="100%">Evolution, Molecular</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Speciation</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome, Plant</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Haplotypes</style></keyword><keyword><style  face="normal" font="default" size="100%">Heterozygote</style></keyword><keyword><style  face="normal" font="default" size="100%">History, Ancient</style></keyword><keyword><style  face="normal" font="default" size="100%">Human Migration</style></keyword><keyword><style  face="normal" font="default" size="100%">Hybridization, Genetic</style></keyword><keyword><style  face="normal" font="default" size="100%">Phylogeny</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2018 Feb 15</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">554</style></volume><pages><style face="normal" font="default" size="100%">311-316</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The genus Citrus, comprising some of the most widely cultivated fruit crops worldwide, includes an uncertain number of species. Here we describe ten natural citrus species, using genomic, phylogenetic and biogeographic analyses of 60 accessions representing diverse citrus germ plasms, and propose that citrus diversified during the late Miocene epoch through a rapid southeast Asian radiation that correlates with a marked weakening of the monsoons. A second radiation enabled by migration across the Wallace line gave rise to the Australian limes in the early Pliocene epoch. Further identification and analyses of hybrids and admixed genomes provides insights into the genealogy of major commercial cultivars of citrus. Among mandarins and sweet orange, we find an extensive network of relatedness that illuminates the domestication of these groups. Widespread pummelo admixture among these mandarins and its correlation with fruit size and acidity suggests a plausible role of pummelo introgression in the selection of palatable mandarins. This work provides a new evolutionary framework for the genus Citrus.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">7692</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/29414943?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cobo-Vuilleumier, Nadia</style></author><author><style face="normal" font="default" size="100%">Lorenzo, Petra I</style></author><author><style face="normal" font="default" size="100%">Rodríguez, Noelia García</style></author><author><style face="normal" font="default" size="100%">Herrera Gómez, Irene de Gracia</style></author><author><style face="normal" font="default" size="100%">Fuente-Martin, Esther</style></author><author><style face="normal" font="default" size="100%">López-Noriega, Livia</style></author><author><style face="normal" font="default" size="100%">Mellado-Gil, José Manuel</style></author><author><style face="normal" font="default" size="100%">Romero-Zerbo, Silvana-Yanina</style></author><author><style face="normal" font="default" size="100%">Baquié, Mathurin</style></author><author><style face="normal" font="default" size="100%">Lachaud, Christian Claude</style></author><author><style face="normal" font="default" size="100%">Stifter, Katja</style></author><author><style face="normal" font="default" size="100%">Perdomo, German</style></author><author><style face="normal" font="default" size="100%">Bugliani, Marco</style></author><author><style face="normal" font="default" size="100%">De Tata, Vincenzo</style></author><author><style face="normal" font="default" size="100%">Bosco, Domenico</style></author><author><style face="normal" font="default" size="100%">Parnaud, Geraldine</style></author><author><style face="normal" font="default" size="100%">Pozo, David</style></author><author><style face="normal" font="default" size="100%">Hmadcha, Abdelkrim</style></author><author><style face="normal" font="default" size="100%">Florido, Javier P</style></author><author><style face="normal" font="default" size="100%">Toscano, Miguel G</style></author><author><style face="normal" font="default" size="100%">de Haan, Peter</style></author><author><style face="normal" font="default" size="100%">Schoonjans, Kristina</style></author><author><style face="normal" font="default" size="100%">Sánchez Palazón, Luis</style></author><author><style face="normal" font="default" size="100%">Marchetti, Piero</style></author><author><style face="normal" font="default" size="100%">Schirmbeck, Reinhold</style></author><author><style face="normal" font="default" size="100%">Martín-Montalvo, Alejandro</style></author><author><style face="normal" font="default" size="100%">Meda, Paolo</style></author><author><style face="normal" font="default" size="100%">Soria, Bernat</style></author><author><style face="normal" font="default" size="100%">Bermúdez-Silva, Francisco-Javier</style></author><author><style face="normal" font="default" size="100%">St-Onge, Luc</style></author><author><style face="normal" font="default" size="100%">Gauthier, Benoit R</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus.</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Commun</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nat Commun</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Communication</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Survival</style></keyword><keyword><style  face="normal" font="default" size="100%">Diabetes Mellitus, Experimental</style></keyword><keyword><style  face="normal" font="default" size="100%">Diabetes Mellitus, Type 2</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Hypoglycemic Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Immunity, Innate</style></keyword><keyword><style  face="normal" font="default" size="100%">insulin</style></keyword><keyword><style  face="normal" font="default" size="100%">Insulin-Secreting Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Islets of Langerhans</style></keyword><keyword><style  face="normal" font="default" size="100%">Islets of Langerhans Transplantation</style></keyword><keyword><style  face="normal" font="default" size="100%">Macrophages</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice, Inbred C57BL</style></keyword><keyword><style  face="normal" font="default" size="100%">Phenalenes</style></keyword><keyword><style  face="normal" font="default" size="100%">Receptors, Cytoplasmic and Nuclear</style></keyword><keyword><style  face="normal" font="default" size="100%">Streptozocin</style></keyword><keyword><style  face="normal" font="default" size="100%">T-Lymphocytes, Regulatory</style></keyword><keyword><style  face="normal" font="default" size="100%">Transplantation, Heterologous</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2018 Apr 16</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">9</style></volume><pages><style face="normal" font="default" size="100%">1488</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Type 1 diabetes mellitus (T1DM) is due to the selective destruction of islet beta cells by immune cells. Current therapies focused on repressing the immune attack or stimulating beta cell regeneration still have limited clinical efficacy. Therefore, it is timely to identify innovative targets to dampen the immune process, while promoting beta cell survival and function. Liver receptor homologue-1 (LRH-1) is a nuclear receptor that represses inflammation in digestive organs, and protects pancreatic islets against apoptosis. Here, we show that BL001, a small LRH-1 agonist, impedes hyperglycemia progression and the immune-dependent inflammation of pancreas in murine models of T1DM, and beta cell apoptosis in islets of type 2 diabetic patients, while increasing beta cell mass and insulin secretion. Thus, we suggest that LRH-1 agonism favors a dialogue between immune and islet cells, which could be druggable to protect against diabetes mellitus.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/29662071?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gonzalez, Sergio</style></author><author><style face="normal" font="default" size="100%">Clavijo, Bernardo</style></author><author><style face="normal" font="default" size="100%">Rivarola, Máximo</style></author><author><style face="normal" font="default" size="100%">Moreno, Patricio</style></author><author><style face="normal" font="default" size="100%">Fernandez, Paula</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Paniego, Norma</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">ATGC transcriptomics: a web-based application to integrate, explore and analyze de novo transcriptomic data.</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Bioinformatics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">BMC Bioinformatics</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Databases, Genetic</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">High-Throughput Nucleotide Sequencing</style></keyword><keyword><style  face="normal" font="default" size="100%">Internet</style></keyword><keyword><style  face="normal" font="default" size="100%">Sequence Analysis, RNA</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style  face="normal" font="default" size="100%">User-Computer Interface</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017 Feb 22</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">18</style></volume><pages><style face="normal" font="default" size="100%">121</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;In the last years, applications based on massively parallelized RNA sequencing (RNA-seq) have become valuable approaches for studying non-model species, e.g., without a fully sequenced genome. RNA-seq is a useful tool for detecting novel transcripts and genetic variations and for evaluating differential gene expression by digital measurements. The large and complex datasets resulting from functional genomic experiments represent a challenge in data processing, management, and analysis. This problem is especially significant for small research groups working with non-model species.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;We developed a web-based application, called ATGC transcriptomics, with a flexible and adaptable interface that allows users to work with new generation sequencing (NGS) transcriptomic analysis results using an ontology-driven database. This new application simplifies data exploration, visualization, and integration for a better comprehension of the results.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;ATGC transcriptomics provides access to non-expert computer users and small research groups to a scalable storage option and simple data integration, including database administration and management. The software is freely available under the terms of GNU public license at http://atgcinta.sourceforge.net .&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/28222698?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Puig-Butille, Joan Anton</style></author><author><style face="normal" font="default" size="100%">Gimenez-Xavier, Pol</style></author><author><style face="normal" font="default" size="100%">Visconti, Alessia</style></author><author><style face="normal" font="default" size="100%">Nsengimana, Jérémie</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Tell-Marti, Gemma</style></author><author><style face="normal" font="default" size="100%">Escamez, Maria José</style></author><author><style face="normal" font="default" size="100%">Newton-Bishop, Julia</style></author><author><style face="normal" font="default" size="100%">Bataille, Veronique</style></author><author><style face="normal" font="default" size="100%">Del Rio, Marcela</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Falchi, Mario</style></author><author><style face="normal" font="default" size="100%">Puig, Susana</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Genomic expression differences between cutaneous cells from red hair color individuals and black hair color individuals based on bioinformatic analysis.</style></title><secondary-title><style face="normal" font="default" size="100%">Oncotarget</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Oncotarget</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Coculture Techniques</style></keyword><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Hair Color</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Keratinocytes</style></keyword><keyword><style  face="normal" font="default" size="100%">Melanocytes</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style  face="normal" font="default" size="100%">Receptor, Melanocortin, Type 1</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017 Feb 14</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&amp;page=article&amp;op=view&amp;path%5B%5D=14140&amp;path%5B%5D=45094</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">8</style></volume><pages><style face="normal" font="default" size="100%">11589-11599</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The MC1R gene plays a crucial role in pigmentation synthesis. Loss-of-function MC1R variants, which impair protein function, are associated with red hair color (RHC) phenotype and increased skin cancer risk. Cultured cutaneous cells bearing loss-of-function MC1R variants show a distinct gene expression profile compared to wild-type MC1R cultured cutaneous cells. We analysed the gene signature associated with RHC co-cultured melanocytes and keratinocytes by Protein-Protein interaction (PPI) network analysis to identify genes related with non-functional MC1R variants. From two detected networks, we selected 23 nodes as hub genes based on topological parameters. Differential expression of hub genes was then evaluated in healthy skin biopsies from RHC and black hair color (BHC) individuals. We also compared gene expression in melanoma tumors from individuals with RHC versus BHC. Gene expression in normal skin from RHC cutaneous cells showed dysregulation in 8 out of 23 hub genes (CLN3, ATG10, WIPI2, SNX2, GABARAPL2, YWHA, PCNA and GBAS). Hub genes did not differ between melanoma tumors in RHC versus BHC individuals. The study suggests that healthy skin cells from RHC individuals present a constitutive genomic deregulation associated with the red hair phenotype and identify novel genes involved in melanocyte biology.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/28030792?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Roca-Ayats, Neus</style></author><author><style face="normal" font="default" size="100%">Balcells, Susana</style></author><author><style face="normal" font="default" size="100%">Garcia-Giralt, Natàlia</style></author><author><style face="normal" font="default" size="100%">Falcó-Mascaró, Maite</style></author><author><style face="normal" font="default" size="100%">Martínez-Gil, Núria</style></author><author><style face="normal" font="default" size="100%">Abril, Josep F</style></author><author><style face="normal" font="default" size="100%">Urreizti, Roser</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Quesada-Gómez, José M</style></author><author><style face="normal" font="default" size="100%">Nogués, Xavier</style></author><author><style face="normal" font="default" size="100%">Mellibovsky, Leonardo</style></author><author><style face="normal" font="default" size="100%">Prieto-Alhambra, Daniel</style></author><author><style face="normal" font="default" size="100%">Dunford, James E</style></author><author><style face="normal" font="default" size="100%">Javaid, Muhammad K</style></author><author><style face="normal" font="default" size="100%">Russell, R Graham</style></author><author><style face="normal" font="default" size="100%">Grinberg, Daniel</style></author><author><style face="normal" font="default" size="100%">Díez-Pérez, Adolfo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">GGPS1 Mutation and Atypical Femoral Fractures with Bisphosphonates.</style></title><secondary-title><style face="normal" font="default" size="100%">N Engl J Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">N Engl J Med</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Amino Acid Sequence</style></keyword><keyword><style  face="normal" font="default" size="100%">Bone Density Conservation Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Dimethylallyltranstransferase</style></keyword><keyword><style  face="normal" font="default" size="100%">Diphosphonates</style></keyword><keyword><style  face="normal" font="default" size="100%">Exome</style></keyword><keyword><style  face="normal" font="default" size="100%">Farnesyltranstransferase</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Femoral Fractures</style></keyword><keyword><style  face="normal" font="default" size="100%">Geranyltranstransferase</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">mutation</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017 May 04</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.nejm.org/doi/full/10.1056/NEJMc1612804</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">376</style></volume><pages><style face="normal" font="default" size="100%">1794-1795</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">18</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/28467865?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moschen, Sebastián</style></author><author><style face="normal" font="default" size="100%">Di Rienzo, Julio A</style></author><author><style face="normal" font="default" size="100%">Higgins, Janet</style></author><author><style face="normal" font="default" size="100%">Tohge, Takayuki</style></author><author><style face="normal" font="default" size="100%">Watanabe, Mutsumi</style></author><author><style face="normal" font="default" size="100%">Gonzalez, Sergio</style></author><author><style face="normal" font="default" size="100%">Rivarola, Máximo</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Hopp, H Esteban</style></author><author><style face="normal" font="default" size="100%">Hoefgen, Rainer</style></author><author><style face="normal" font="default" size="100%">Fernie, Alisdair R</style></author><author><style face="normal" font="default" size="100%">Paniego, Norma</style></author><author><style face="normal" font="default" size="100%">Fernandez, Paula</style></author><author><style face="normal" font="default" size="100%">Heinz, Ruth A</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Integration of transcriptomic and metabolic data reveals hub transcription factors involved in drought stress response in sunflower (Helianthus annuus L.).</style></title><secondary-title><style face="normal" font="default" size="100%">Plant Mol Biol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Plant Mol Biol</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Chlorophyll</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation, Plant</style></keyword><keyword><style  face="normal" font="default" size="100%">Helianthus</style></keyword><keyword><style  face="normal" font="default" size="100%">Plant Leaves</style></keyword><keyword><style  face="normal" font="default" size="100%">Plant Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Array Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Plant</style></keyword><keyword><style  face="normal" font="default" size="100%">Stress, Physiological</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcription Factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Water</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017 Jul</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">94</style></volume><pages><style face="normal" font="default" size="100%">549-564</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;By integration of transcriptional and metabolic profiles we identified pathways and hubs transcription factors regulated during drought conditions in sunflower, useful for applications in molecular and/or biotechnological breeding. Drought is one of the most important environmental stresses that effects crop productivity in many agricultural regions. Sunflower is tolerant to drought conditions but the mechanisms involved in this tolerance remain unclear at the molecular level. The aim of this study was to characterize and integrate transcriptional and metabolic pathways related to drought stress in sunflower plants, by using a system biology approach. Our results showed a delay in plant senescence with an increase in the expression level of photosynthesis related genes as well as higher levels of sugars, osmoprotectant amino acids and ionic nutrients under drought conditions. In addition, we identified transcription factors that were upregulated during drought conditions and that may act as hubs in the transcriptional network. Many of these transcription factors belong to families implicated in the drought response in model species. The integration of transcriptomic and metabolomic data in this study, together with physiological measurements, has improved our understanding of the biological responses during droughts and contributes to elucidate the molecular mechanisms involved under this environmental condition. These findings will provide useful biotechnological tools to improve stress tolerance while maintaining crop yield under restricted water availability.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">4-5</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/28639116?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Olanda, Ricardo</style></author><author><style face="normal" font="default" size="100%">Pérez, Mariano</style></author><author><style face="normal" font="default" size="100%">Orduña, Juan M</style></author><author><style face="normal" font="default" size="100%">Tárraga, Joaquín</style></author><author><style face="normal" font="default" size="100%">Joaquín Dopazo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A new parallel pipeline for DNA methylation analysis of long reads datasets.</style></title><secondary-title><style face="normal" font="default" size="100%">BMC bioinformatics</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Methyl-Seq</style></keyword><keyword><style  face="normal" font="default" size="100%">NGS</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017 Mar 09</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-017-1574-3</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">18</style></volume><pages><style face="normal" font="default" size="100%">161</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: DNA methylation is an important mechanism of epigenetic regulation in development and disease. New generation sequencers allow genome-wide measurements of the methylation status by reading short stretches of the DNA sequence (Methyl-seq). Several software tools for methylation analysis have been proposed over recent years. However, the current trend is that the new sequencers and the ones expected for an upcoming future yield sequences of increasing length, making these software tools inefficient and obsolete. RESULTS: In this paper, we propose a new software based on a strategy for methylation analysis of Methyl-seq sequencing data that requires much shorter execution times while yielding a better level of sensitivity, particularly for datasets composed of long reads. This strategy can be exported to other methylation, DNA and RNA analysis tools. CONCLUSIONS: The developed software tool achieves execution times one order of magnitude shorter than the existing tools, while yielding equal sensitivity for short reads and even better sensitivity for long reads.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gui, Hongsheng</style></author><author><style face="normal" font="default" size="100%">Schriemer, Duco</style></author><author><style face="normal" font="default" size="100%">Cheng, William W</style></author><author><style face="normal" font="default" size="100%">Chauhan, Rajendra K</style></author><author><style face="normal" font="default" size="100%">Antiňolo, Guillermo</style></author><author><style face="normal" font="default" size="100%">Berrios, Courtney</style></author><author><style face="normal" font="default" size="100%">Bleda, Marta</style></author><author><style face="normal" font="default" size="100%">Brooks, Alice S</style></author><author><style face="normal" font="default" size="100%">Brouwer, Rutger W W</style></author><author><style face="normal" font="default" size="100%">Burns, Alan J</style></author><author><style face="normal" font="default" size="100%">Cherny, Stacey S</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Eggen, Bart J L</style></author><author><style face="normal" font="default" size="100%">Griseri, Paola</style></author><author><style face="normal" font="default" size="100%">Jalloh, Binta</style></author><author><style face="normal" font="default" size="100%">Le, Thuy-Linh</style></author><author><style face="normal" font="default" size="100%">Lui, Vincent C H</style></author><author><style face="normal" font="default" size="100%">Luzón-Toro, Berta</style></author><author><style face="normal" font="default" size="100%">Matera, Ivana</style></author><author><style face="normal" font="default" size="100%">Ngan, Elly S W</style></author><author><style face="normal" font="default" size="100%">Pelet, Anna</style></author><author><style face="normal" font="default" size="100%">Ruiz-Ferrer, Macarena</style></author><author><style face="normal" font="default" size="100%">Sham, Pak C</style></author><author><style face="normal" font="default" size="100%">Shepherd, Iain T</style></author><author><style face="normal" font="default" size="100%">So, Man-Ting</style></author><author><style face="normal" font="default" size="100%">Sribudiani, Yunia</style></author><author><style face="normal" font="default" size="100%">Tang, Clara S M</style></author><author><style face="normal" font="default" size="100%">van den Hout, Mirjam C G N</style></author><author><style face="normal" font="default" size="100%">van der Linde, Herma C</style></author><author><style face="normal" font="default" size="100%">van Ham, Tjakko J</style></author><author><style face="normal" font="default" size="100%">van IJcken, Wilfred F J</style></author><author><style face="normal" font="default" size="100%">Verheij, Joke B G M</style></author><author><style face="normal" font="default" size="100%">Amiel, Jeanne</style></author><author><style face="normal" font="default" size="100%">Borrego, Salud</style></author><author><style face="normal" font="default" size="100%">Ceccherini, Isabella</style></author><author><style face="normal" font="default" size="100%">Chakravarti, Aravinda</style></author><author><style face="normal" font="default" size="100%">Lyonnet, Stanislas</style></author><author><style face="normal" font="default" size="100%">Tam, Paul K H</style></author><author><style face="normal" font="default" size="100%">Garcia-Barceló, Maria-Mercè</style></author><author><style face="normal" font="default" size="100%">Hofstra, Robert Mw</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Whole exome sequencing coupled with unbiased functional analysis reveals new Hirschsprung disease genes.</style></title><secondary-title><style face="normal" font="default" size="100%">Genome biology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Hirschprung</style></keyword><keyword><style  face="normal" font="default" size="100%">Rare Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">WES</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017 Mar 08</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://genomebiology.biomedcentral.com/articles/10.1186/s13059-017-1174-6</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">18</style></volume><pages><style face="normal" font="default" size="100%">48</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: Hirschsprung disease (HSCR), which is congenital obstruction of the bowel, results from a failure of enteric nervous system (ENS) progenitors to migrate, proliferate, differentiate, or survive within the distal intestine. Previous studies that have searched for genes underlying HSCR have focused on ENS-related pathways and genes not fitting the current knowledge have thus often been ignored. We identify and validate novel HSCR genes using whole exome sequencing (WES), burden tests, in silico prediction, unbiased in vivo analyses of the mutated genes in zebrafish, and expression analyses in zebrafish, mouse, and human. RESULTS: We performed de novo mutation (DNM) screening on 24 HSCR trios. We identify 28 DNMs in 21 different genes. Eight of the DNMs we identified occur in RET, the main HSCR gene, and the remaining 20 DNMs reside in genes not reported in the ENS. Knockdown of all 12 genes with missense or loss-of-function DNMs showed that the orthologs of four genes (DENND3, NCLN, NUP98, and TBATA) are indispensable for ENS development in zebrafish, and these results were confirmed by CRISPR knockout. These genes are also expressed in human and mouse gut and/or ENS progenitors. Importantly, the encoded proteins are linked to neuronal processes shared by the central nervous system and the ENS. CONCLUSIONS: Our data open new fields of investigation into HSCR pathology and provide novel insights into the development of the ENS. Moreover, the study demonstrates that functional analyses of genes carrying DNMs are warranted to delineate the full genetic architecture of rare complex diseases.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gui, Hongsheng</style></author><author><style face="normal" font="default" size="100%">Schriemer, Duco</style></author><author><style face="normal" font="default" size="100%">Cheng, William W.</style></author><author><style face="normal" font="default" size="100%">Chauhan, Rajendra K.</style></author><author><style face="normal" font="default" size="100%">Antiňolo, Guillermo</style></author><author><style face="normal" font="default" size="100%">Berrios, Courtney</style></author><author><style face="normal" font="default" size="100%">Bleda, Marta</style></author><author><style face="normal" font="default" size="100%">Brooks, Alice S.</style></author><author><style face="normal" font="default" size="100%">Brouwer, Rutger W. W.</style></author><author><style face="normal" font="default" size="100%">Burns, Alan J.</style></author><author><style face="normal" font="default" size="100%">Cherny, Stacey S.</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Eggen, Bart J. L.</style></author><author><style face="normal" font="default" size="100%">Griseri, Paola</style></author><author><style face="normal" font="default" size="100%">Jalloh, Binta</style></author><author><style face="normal" font="default" size="100%">Le, Thuy-Linh</style></author><author><style face="normal" font="default" size="100%">Lui, Vincent C. H.</style></author><author><style face="normal" font="default" size="100%">Luzón-Toro, Berta</style></author><author><style face="normal" font="default" size="100%">Matera, Ivana</style></author><author><style face="normal" font="default" size="100%">Ngan, Elly S. W.</style></author><author><style face="normal" font="default" size="100%">Pelet, Anna</style></author><author><style face="normal" font="default" size="100%">Ruiz-Ferrer, Macarena</style></author><author><style face="normal" font="default" size="100%">Sham, Pak C.</style></author><author><style face="normal" font="default" size="100%">Shepherd, Iain T.</style></author><author><style face="normal" font="default" size="100%">So, Man-Ting</style></author><author><style face="normal" font="default" size="100%">Sribudiani, Yunia</style></author><author><style face="normal" font="default" size="100%">Tang, Clara S. M.</style></author><author><style face="normal" font="default" size="100%">van den Hout, Mirjam C. G. N.</style></author><author><style face="normal" font="default" size="100%">van der Linde, Herma C.</style></author><author><style face="normal" font="default" size="100%">van Ham, Tjakko J.</style></author><author><style face="normal" font="default" size="100%">van IJcken, Wilfred F. J.</style></author><author><style face="normal" font="default" size="100%">Verheij, Joke B. G. M.</style></author><author><style face="normal" font="default" size="100%">Amiel, Jeanne</style></author><author><style face="normal" font="default" size="100%">Borrego, Salud</style></author><author><style face="normal" font="default" size="100%">Ceccherini, Isabella</style></author><author><style face="normal" font="default" size="100%">Chakravarti, Aravinda</style></author><author><style face="normal" font="default" size="100%">Lyonnet, Stanislas</style></author><author><style face="normal" font="default" size="100%">Tam, Paul K. H.</style></author><author><style face="normal" font="default" size="100%">Garcia-Barceló, Maria-Mercè</style></author><author><style face="normal" font="default" size="100%">Hofstra, Robert M. W.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Whole exome sequencing coupled with unbiased functional analysis reveals new Hirschsprung disease genes</style></title><secondary-title><style face="normal" font="default" size="100%">Genome Biology</style></secondary-title><short-title><style face="normal" font="default" size="100%">Genome Biol</style></short-title></titles><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan-12-2017</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://genomebiology.biomedcentral.com/articles/10.1186/s13059-017-1174-6http://link.springer.com/content/pdf/10.1186/s13059-017-1174-6.pdf</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">18</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">1</style></issue></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lupo, Vincenzo</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Sancho, Paula</style></author><author><style face="normal" font="default" size="100%">Tello, Cristina</style></author><author><style face="normal" font="default" size="100%">García-Romero, Mar</style></author><author><style face="normal" font="default" size="100%">Villarreal, Liliana</style></author><author><style face="normal" font="default" size="100%">Alberti, Antonia</style></author><author><style face="normal" font="default" size="100%">Sivera, Rafael</style></author><author><style face="normal" font="default" size="100%">Joaquín Dopazo</style></author><author><style face="normal" font="default" size="100%">Pascual-Pascual, Samuel I</style></author><author><style face="normal" font="default" size="100%">Márquez-Infante, Celedonio</style></author><author><style face="normal" font="default" size="100%">Casasnovas, Carlos</style></author><author><style face="normal" font="default" size="100%">Sevilla, Teresa</style></author><author><style face="normal" font="default" size="100%">Espinós, Carmen</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Assessment of Targeted Next-Generation Sequencing as a Tool for the Diagnosis of Charcot-Marie-Tooth Disease and Hereditary Motor Neuropathy.</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of molecular diagnostics : JMD</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Charcot-Marie-Tooth</style></keyword><keyword><style  face="normal" font="default" size="100%">CMT</style></keyword><keyword><style  face="normal" font="default" size="100%">Diagnostic</style></keyword><keyword><style  face="normal" font="default" size="100%">NGS</style></keyword><keyword><style  face="normal" font="default" size="100%">Panels</style></keyword><keyword><style  face="normal" font="default" size="100%">rare diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Targeted resequencing</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016 Jan 2</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.sciencedirect.com/science/article/pii/S1525157815002615</style></url></web-urls></urls><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Charcot-Marie-Tooth disease is characterized by broad genetic heterogeneity with &gt;50 known disease-associated genes. Mutations in some of these genes can cause a pure motor form of hereditary motor neuropathy, the genetics of which are poorly characterized. We designed a panel comprising 56 genes associated with Charcot-Marie-Tooth disease/hereditary motor neuropathy. We validated this diagnostic tool by first testing 11 patients with pathological mutations. A cohort of 33 affected subjects was selected for this study. The DNAJB2 c.352+1G&gt;A mutation was detected in two cases; novel changes and/or variants with low frequency (&lt;1%) were found in 12 cases. There were no candidate variants in 18 cases, and amplification failed for one sample. The DNAJB2 c.352+1G&gt;A mutation was also detected in three additional families. On haplotype analysis, all of the patients from these five families shared the same haplotype; therefore, the DNAJB2 c.352+1G&gt;A mutation may be a founder event. Our gene panel allowed us to perform a very rapid and cost-effective screening of genes involved in Charcot-Marie-Tooth disease/hereditary motor neuropathy. Our diagnostic strategy was robust in terms of both coverage and read depth for all of the genes and patient samples. These findings demonstrate the difficulty in achieving a definitive molecular diagnosis because of the complexity of interpreting new variants and the genetic heterogeneity that is associated with these neuropathies.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prieto, Javier</style></author><author><style face="normal" font="default" size="100%">León, Marian</style></author><author><style face="normal" font="default" size="100%">Ponsoda, Xavier</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Bort, Roque</style></author><author><style face="normal" font="default" size="100%">Serna, Eva</style></author><author><style face="normal" font="default" size="100%">Barneo-Muñoz, Manuela</style></author><author><style face="normal" font="default" size="100%">Palau, Francesc</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">López-García, Carlos</style></author><author><style face="normal" font="default" size="100%">Torres, Josema</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Dysfunctional mitochondrial fission impairs cell reprogramming.</style></title><secondary-title><style face="normal" font="default" size="100%">Cell Cycle</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Cell Cycle</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Cycle Checkpoints</style></keyword><keyword><style  face="normal" font="default" size="100%">Cellular Reprogramming</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA Damage</style></keyword><keyword><style  face="normal" font="default" size="100%">G2 Phase</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Mitochondrial Dynamics</style></keyword><keyword><style  face="normal" font="default" size="100%">Mitosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Nerve Tissue Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Pluripotent Stem Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcription Factors</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016 Dec</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">3240-3250</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;We have recently shown that mitochondrial fission is induced early in reprogramming in a Drp1-dependent manner; however, the identity of the factors controlling Drp1 recruitment to mitochondria was unexplored. To investigate this, we used a panel of RNAi targeting factors involved in the regulation of mitochondrial dynamics and we observed that MiD51, Gdap1 and, to a lesser extent, Mff were found to play key roles in this process. Cells derived from Gdap1-null mice were used to further explore the role of this factor in cell reprogramming. Microarray data revealed a prominent down-regulation of cell cycle pathways in Gdap1-null cells early in reprogramming and cell cycle profiling uncovered a G2/M growth arrest in Gdap1-null cells undergoing reprogramming. High-Content analysis showed that this growth arrest was DNA damage-independent. We propose that lack of efficient mitochondrial fission impairs cell reprogramming by interfering with cell cycle progression in a DNA damage-independent manner.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">23</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/27753531?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Medina, I</style></author><author><style face="normal" font="default" size="100%">Tárraga, J</style></author><author><style face="normal" font="default" size="100%">Martínez, H</style></author><author><style face="normal" font="default" size="100%">Barrachina, S</style></author><author><style face="normal" font="default" size="100%">Castillo, M I</style></author><author><style face="normal" font="default" size="100%">Paschall, J</style></author><author><style face="normal" font="default" size="100%">Salavert-Torres, J</style></author><author><style face="normal" font="default" size="100%">Blanquer-Espert, I</style></author><author><style face="normal" font="default" size="100%">Hernández-García, V</style></author><author><style face="normal" font="default" size="100%">Quintana-Ortí, E S</style></author><author><style face="normal" font="default" size="100%">Dopazo, J</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Highly sensitive and ultrafast read mapping for RNA-seq analysis.</style></title><secondary-title><style face="normal" font="default" size="100%">DNA Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">DNA Res</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">High-Throughput Nucleotide Sequencing</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Sensitivity and Specificity</style></keyword><keyword><style  face="normal" font="default" size="100%">Sequence Analysis, RNA</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcriptome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016 Apr</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">23</style></volume><pages><style face="normal" font="default" size="100%">93-100</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;As sequencing technologies progress, the amount of data produced grows exponentially, shifting the bottleneck of discovery towards the data analysis phase. In particular, currently available mapping solutions for RNA-seq leave room for improvement in terms of sensitivity and performance, hindering an efficient analysis of transcriptomes by massive sequencing. Here, we present an innovative approach that combines re-engineering, optimization and parallelization. This solution results in a significant increase of mapping sensitivity over a wide range of read lengths and substantial shorter runtimes when compared with current RNA-seq mapping methods available.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/26740642?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sanchez-Mut, J V</style></author><author><style face="normal" font="default" size="100%">Heyn, H</style></author><author><style face="normal" font="default" size="100%">Vidal, E</style></author><author><style face="normal" font="default" size="100%">Moran, S</style></author><author><style face="normal" font="default" size="100%">Sayols, S</style></author><author><style face="normal" font="default" size="100%">Delgado-Morales, R</style></author><author><style face="normal" font="default" size="100%">Schultz, M D</style></author><author><style face="normal" font="default" size="100%">Ansoleaga, B</style></author><author><style face="normal" font="default" size="100%">Garcia-Esparcia, P</style></author><author><style face="normal" font="default" size="100%">Pons-Espinal, M</style></author><author><style face="normal" font="default" size="100%">de Lagran, M M</style></author><author><style face="normal" font="default" size="100%">Dopazo, J</style></author><author><style face="normal" font="default" size="100%">Rabano, A</style></author><author><style face="normal" font="default" size="100%">Avila, J</style></author><author><style face="normal" font="default" size="100%">Dierssen, M</style></author><author><style face="normal" font="default" size="100%">Lott, I</style></author><author><style face="normal" font="default" size="100%">Ferrer, I</style></author><author><style face="normal" font="default" size="100%">Ecker, J R</style></author><author><style face="normal" font="default" size="100%">Esteller, M</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Human DNA methylomes of neurodegenerative diseases show common epigenomic patterns.</style></title><secondary-title><style face="normal" font="default" size="100%">Transl Psychiatry</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Transl Psychiatry</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA Methylation</style></keyword><keyword><style  face="normal" font="default" size="100%">Epigenomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">neurodegenerative diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Prefrontal Cortex</style></keyword><keyword><style  face="normal" font="default" size="100%">Tissue Array Analysis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016 Jan 19</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">6</style></volume><pages><style face="normal" font="default" size="100%">e718</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Different neurodegenerative disorders often show similar lesions, such as the presence of amyloid plaques, TAU-neurotangles and synuclein inclusions. The genetically inherited forms are rare, so we wondered whether shared epigenetic aberrations, such as those affecting DNA methylation, might also exist. The studied samples were gray matter samples from the prefrontal cortex of control and neurodegenerative disease-associated cases. We performed the DNA methylation analyses of Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease and Alzheimer-like neurodegenerative profile associated with Down's syndrome samples. The DNA methylation landscapes obtained show that neurodegenerative diseases share similar aberrant CpG methylation shifts targeting a defined gene set. Our findings suggest that neurodegenerative disorders might have similar pathogenetic mechanisms that subsequently evolve into different clinical entities. The identified aberrant DNA methylation changes can be used as biomarkers of the disorders and as potential new targets for the development of new therapies. &lt;/p&gt;</style></abstract><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/26784972?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Corton, M</style></author><author><style face="normal" font="default" size="100%">Avila-Fernández, A</style></author><author><style face="normal" font="default" size="100%">Campello, L</style></author><author><style face="normal" font="default" size="100%">Sánchez, M</style></author><author><style face="normal" font="default" size="100%">Benavides, B</style></author><author><style face="normal" font="default" size="100%">López-Molina, M I</style></author><author><style face="normal" font="default" size="100%">Fernández-Sánchez, L</style></author><author><style face="normal" font="default" size="100%">Sánchez-Alcudia, R</style></author><author><style face="normal" font="default" size="100%">da Silva, L R J</style></author><author><style face="normal" font="default" size="100%">Reyes, N</style></author><author><style face="normal" font="default" size="100%">Martín-Garrido, E</style></author><author><style face="normal" font="default" size="100%">Zurita, O</style></author><author><style face="normal" font="default" size="100%">Fernández-San José, P</style></author><author><style face="normal" font="default" size="100%">Pérez-Carro, R</style></author><author><style face="normal" font="default" size="100%">García-García, F</style></author><author><style face="normal" font="default" size="100%">Dopazo, J</style></author><author><style face="normal" font="default" size="100%">García-Sandoval, B</style></author><author><style face="normal" font="default" size="100%">Cuenca, N</style></author><author><style face="normal" font="default" size="100%">Ayuso, C</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Identification of the Photoreceptor Transcriptional Co-Repressor SAMD11 as Novel Cause of Autosomal Recessive Retinitis Pigmentosa.</style></title><secondary-title><style face="normal" font="default" size="100%">Sci Rep</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Sci Rep</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Co-Repressor Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Codon, Nonsense</style></keyword><keyword><style  face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Comparative Genomic Hybridization</style></keyword><keyword><style  face="normal" font="default" size="100%">Consanguinity</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA Mutational Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Exome</style></keyword><keyword><style  face="normal" font="default" size="100%">Eye Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Genes, Recessive</style></keyword><keyword><style  face="normal" font="default" size="100%">Homeodomain Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Homozygote</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Interaction Mapping</style></keyword><keyword><style  face="normal" font="default" size="100%">Retina</style></keyword><keyword><style  face="normal" font="default" size="100%">Retinal Dystrophies</style></keyword><keyword><style  face="normal" font="default" size="100%">Retinal Rod Photoreceptor Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Retinitis pigmentosa</style></keyword><keyword><style  face="normal" font="default" size="100%">Spain</style></keyword><keyword><style  face="normal" font="default" size="100%">Trans-Activators</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcription Factors</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016 Oct 13</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">6</style></volume><pages><style face="normal" font="default" size="100%">35370</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Retinitis pigmentosa (RP), the most frequent form of inherited retinal dystrophy is characterized by progressive photoreceptor degeneration. Many genes have been implicated in RP development, but several others remain to be identified. Using a combination of homozygosity mapping, whole-exome and targeted next-generation sequencing, we found a novel homozygous nonsense mutation in SAMD11 in five individuals diagnosed with adult-onset RP from two unrelated consanguineous Spanish families. SAMD11 is ortholog to the mouse major retinal SAM domain (mr-s) protein that is implicated in CRX-mediated transcriptional regulation in the retina. Accordingly, protein-protein network analysis revealed a significant interaction of SAMD11 with CRX. Immunoblotting analysis confirmed strong expression of SAMD11 in human retina. Immunolocalization studies revealed SAMD11 was detected in the three nuclear layers of the human retina and interestingly differential expression between cone and rod photoreceptors was observed. Our study strongly implicates SAMD11 as novel cause of RP playing an important role in the pathogenesis of human degeneration of photoreceptors.&lt;/p&gt;</style></abstract><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/27734943?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Panadero, Joaquin</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Integrated gene set analysis for microRNA studies.</style></title><secondary-title><style face="normal" font="default" size="100%">Bioinformatics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Bioinformatics</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene ontology</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Regulatory Networks</style></keyword><keyword><style  face="normal" font="default" size="100%">High-Throughput Nucleotide Sequencing</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">MicroRNAs</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Reproducibility of Results</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016 Sep 15</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">32</style></volume><pages><style face="normal" font="default" size="100%">2809-16</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;MOTIVATION: &lt;/b&gt;Functional interpretation of miRNA expression data is currently done in a three step procedure: select differentially expressed miRNAs, find their target genes, and carry out gene set overrepresentation analysis Nevertheless, major limitations of this approach have already been described at the gene level, while some newer arise in the miRNA scenario.Here, we propose an enhanced methodology that builds on the well-established gene set analysis paradigm. Evidence for differential expression at the miRNA level is transferred to a gene differential inhibition score which is easily interpretable in terms of gene sets or pathways. Such transferred indexes account for the additive effect of several miRNAs targeting the same gene, and also incorporate cancellation effects between cases and controls. Together, these two desirable characteristics allow for more accurate modeling of regulatory processes.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;We analyze high-throughput sequencing data from 20 different cancer types and provide exhaustive reports of gene and Gene Ontology-term deregulation by miRNA action.&lt;/p&gt;&lt;p&gt;&lt;b&gt;AVAILABILITY AND IMPLEMENTATION: &lt;/b&gt;The proposed methodology was implemented in the Bioconductor library mdgsa http://bioconductor.org/packages/mdgsa For the purpose of reproducibility all of the scripts are available at https://github.com/dmontaner-papers/gsa4mirna&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONTACT: &lt;/b&gt;: david.montaner@gmail.com&lt;/p&gt;&lt;p&gt;&lt;b&gt;SUPPLEMENTARY INFORMATION: &lt;/b&gt;Supplementary data are available at Bioinformatics online.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">18</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/27324197?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Moschen, Sebastián</style></author><author><style face="normal" font="default" size="100%">Bengoa Luoni, Sofía</style></author><author><style face="normal" font="default" size="100%">Di Rienzo, Julio A</style></author><author><style face="normal" font="default" size="100%">Caro, María Del Pilar</style></author><author><style face="normal" font="default" size="100%">Tohge, Takayuki</style></author><author><style face="normal" font="default" size="100%">Watanabe, Mutsumi</style></author><author><style face="normal" font="default" size="100%">Hollmann, Julien</style></author><author><style face="normal" font="default" size="100%">Gonzalez, Sergio</style></author><author><style face="normal" font="default" size="100%">Rivarola, Máximo</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Hopp, Horacio Esteban</style></author><author><style face="normal" font="default" size="100%">Hoefgen, Rainer</style></author><author><style face="normal" font="default" size="100%">Fernie, Alisdair R</style></author><author><style face="normal" font="default" size="100%">Paniego, Norma</style></author><author><style face="normal" font="default" size="100%">Fernandez, Paula</style></author><author><style face="normal" font="default" size="100%">Heinz, Ruth A</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Integrating transcriptomic and metabolomic analysis to understand natural leaf senescence in sunflower.</style></title><secondary-title><style face="normal" font="default" size="100%">Plant Biotechnol J</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Plant Biotechnol J</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Gas Chromatography-Mass Spectrometry</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation, Plant</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene ontology</style></keyword><keyword><style  face="normal" font="default" size="100%">Genes, Plant</style></keyword><keyword><style  face="normal" font="default" size="100%">Helianthus</style></keyword><keyword><style  face="normal" font="default" size="100%">Ions</style></keyword><keyword><style  face="normal" font="default" size="100%">metabolomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Oligonucleotide Array Sequence Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Plant Leaves</style></keyword><keyword><style  face="normal" font="default" size="100%">Principal Component Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcription Factors</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016 Feb</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">719-34</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Leaf senescence is a complex process, which has dramatic consequences on crop yield. In sunflower, gap between potential and actual yields reveals the economic impact of senescence. Indeed, sunflower plants are incapable of maintaining their green leaf area over sustained periods. This study characterizes the leaf senescence process in sunflower through a systems biology approach integrating transcriptomic and metabolomic analyses: plants being grown under both glasshouse and field conditions. Our results revealed a correspondence between profile changes detected at the molecular, biochemical and physiological level throughout the progression of leaf senescence measured at different plant developmental stages. Early metabolic changes were detected prior to anthesis and before the onset of the first senescence symptoms, with more pronounced changes observed when physiological and molecular variables were assessed under field conditions. During leaf development, photosynthetic activity and cell growth processes decreased, whereas sucrose, fatty acid, nucleotide and amino acid metabolisms increased. Pathways related to nutrient recycling processes were also up-regulated. Members of the NAC, AP2-EREBP, HB, bZIP and MYB transcription factor families showed high expression levels, and their expression level was highly correlated, suggesting their involvement in sunflower senescence. The results of this study thus contribute to the elucidation of the molecular mechanisms involved in the onset and progression of leaf senescence in sunflower leaves as well as to the identification of candidate genes involved in this process. &lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/26132509?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sevilla, Teresa</style></author><author><style face="normal" font="default" size="100%">Lupo, Vincenzo</style></author><author><style face="normal" font="default" size="100%">Martínez-Rubio, Dolores</style></author><author><style face="normal" font="default" size="100%">Sancho, Paula</style></author><author><style face="normal" font="default" size="100%">Sivera, Rafael</style></author><author><style face="normal" font="default" size="100%">Chumillas, María J</style></author><author><style face="normal" font="default" size="100%">García-Romero, Mar</style></author><author><style face="normal" font="default" size="100%">Pascual-Pascual, Samuel I</style></author><author><style face="normal" font="default" size="100%">Muelas, Nuria</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Vílchez, Juan J</style></author><author><style face="normal" font="default" size="100%">Palau, Francesc</style></author><author><style face="normal" font="default" size="100%">Espinós, Carmen</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mutations in the MORC2 gene cause axonal Charcot-Marie-Tooth disease.</style></title><secondary-title><style face="normal" font="default" size="100%">Brain</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brain</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Axons</style></keyword><keyword><style  face="normal" font="default" size="100%">Charcot-Marie-Tooth Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Infant</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">Pedigree</style></keyword><keyword><style  face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style  face="normal" font="default" size="100%">Sciatic Nerve</style></keyword><keyword><style  face="normal" font="default" size="100%">Sural Nerve</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcription Factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016 Jan</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">139</style></volume><pages><style face="normal" font="default" size="100%">62-72</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Charcot-Marie-Tooth disease (CMT) is a complex disorder with wide genetic heterogeneity. Here we present a new axonal Charcot-Marie-Tooth disease form, associated with the gene microrchidia family CW-type zinc finger 2 (MORC2). Whole-exome sequencing in a family with autosomal dominant segregation identified the novel MORC2 p.R190W change in four patients. Further mutational screening in our axonal Charcot-Marie-Tooth disease clinical series detected two additional sporadic cases, one patient who also carried the same MORC2 p.R190W mutation and another patient that harboured a MORC2 p.S25L mutation. Genetic and in silico studies strongly supported the pathogenicity of these sequence variants. The phenotype was variable and included patients with congenital or infantile onset, as well as others whose symptoms started in the second decade. The patients with early onset developed a spinal muscular atrophy-like picture, whereas in the later onset cases, the initial symptoms were cramps, distal weakness and sensory impairment. Weakness and atrophy progressed in a random and asymmetric fashion and involved limb girdle muscles, leading to a severe incapacity in adulthood. Sensory loss was always prominent and proportional to disease severity. Electrophysiological studies were consistent with an asymmetric axonal motor and sensory neuropathy, while fasciculations and myokymia were recorded rather frequently by needle electromyography. Sural nerve biopsy revealed pronounced multifocal depletion of myelinated fibres with some regenerative clusters and occasional small onion bulbs. Morc2 is expressed in both axons and Schwann cells of mouse peripheral nerve. Different roles in biological processes have been described for MORC2. As the silencing of Charcot-Marie-Tooth disease genes have been associated with DNA damage response, it is tempting to speculate that a deregulation of this pathway may be linked to the axonal degeneration observed in MORC2 neuropathy, thus adding a new pathogenic mechanism to the long list of causes of Charcot-Marie-Tooth disease. &lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">Pt 1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/26497905?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maroñas, Olalla</style></author><author><style face="normal" font="default" size="100%">Latorre, Ana</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Pirmohamed, Munir</style></author><author><style face="normal" font="default" size="100%">Rodríguez-Antona, Cristina</style></author><author><style face="normal" font="default" size="100%">Siest, Gérard</style></author><author><style face="normal" font="default" size="100%">Carracedo, Ángel</style></author><author><style face="normal" font="default" size="100%">LLerena, Adrián</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Progress in pharmacogenetics: consortiums and new strategies.</style></title><secondary-title><style face="normal" font="default" size="100%">Drug Metab Pers Ther</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Drug Metab Pers Ther</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cooperative Behavior</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome-Wide Association Study</style></keyword><keyword><style  face="normal" font="default" size="100%">High-Throughput Screening Assays</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Patient Care Team</style></keyword><keyword><style  face="normal" font="default" size="100%">pharmacogenetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style  face="normal" font="default" size="100%">Precision Medicine</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016 Mar</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">31</style></volume><pages><style face="normal" font="default" size="100%">17-23</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Pharmacogenetics (PGx), as a field dedicated to achieving the goal of personalized medicine (PM), is devoted to the study of genes involved in inter-individual response to drugs. Due to its nature, PGx requires access to large samples; therefore, in order to progress, the formation of collaborative consortia seems to be crucial. Some examples of this collective effort are the European Society of Pharmacogenomics and personalized Therapy and the Ibero-American network of Pharmacogenetics. As an emerging field, one of the major challenges that PGx faces is translating their discoveries from research bench to bedside. The development of genomic high-throughput technologies is generating a revolution and offers the possibility of producing vast amounts of genome-wide single nucleotide polymorphisms for each patient. Moreover, there is a need of identifying and replicating associations of new biomarkers, and, in addition, a greater effort must be invested in developing regulatory organizations to accomplish a correct standardization. In this review, we outline the current progress in PGx using examples to highlight both the importance of polymorphisms and the research strategies for their detection. These concepts need to be applied together with a proper dissemination of knowledge to improve clinician and patient understanding, in a multidisciplinary team-based approach. &lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/26913460?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Puchades-Carrasco, Leonor</style></author><author><style face="normal" font="default" size="100%">Jantus-Lewintre, Eloisa</style></author><author><style face="normal" font="default" size="100%">Pérez-Rambla, Clara</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Lucas, Rut</style></author><author><style face="normal" font="default" size="100%">Calabuig, Silvia</style></author><author><style face="normal" font="default" size="100%">Blasco, Ana</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Camps, Carlos</style></author><author><style face="normal" font="default" size="100%">Pineda-Lucena, Antonio</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer.</style></title><secondary-title><style face="normal" font="default" size="100%">Oncotarget</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Oncotarget</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Biomarkers, Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Carcinoma, Non-Small-Cell Lung</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Lung Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">metabolomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Proton Magnetic Resonance Spectroscopy</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016 Mar 15</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">7</style></volume><pages><style face="normal" font="default" size="100%">12904-16</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Lung cancer (LC) is responsible for most cancer deaths. One of the main factors contributing to the lethality of this disease is the fact that a large proportion of patients are diagnosed at advanced stages when a clinical intervention is unlikely to succeed. In this study, we evaluated the potential of metabolomics by 1H-NMR to facilitate the identification of accurate and reliable biomarkers to support the early diagnosis and prognosis of non-small cell lung cancer (NSCLC).We found that the metabolic profile of NSCLC patients, compared with healthy individuals, is characterized by statistically significant changes in the concentration of 18 metabolites representing different amino acids, organic acids and alcohols, as well as different lipids and molecules involved in lipid metabolism. Furthermore, the analysis of the differences between the metabolic profiles of NSCLC patients at different stages of the disease revealed the existence of 17 metabolites involved in metabolic changes associated with disease progression.Our results underscore the potential of metabolomics profiling to uncover pathophysiological mechanisms that could be useful to objectively discriminate NSCLC patients from healthy individuals, as well as between different stages of the disease. &lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">11</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/26883203?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lucariello, Mario</style></author><author><style face="normal" font="default" size="100%">Vidal, Enrique</style></author><author><style face="normal" font="default" size="100%">Vidal, Silvia</style></author><author><style face="normal" font="default" size="100%">Saez, Mauricio</style></author><author><style face="normal" font="default" size="100%">Roa, Laura</style></author><author><style face="normal" font="default" size="100%">Huertas, Dori</style></author><author><style face="normal" font="default" size="100%">Pineda, Mercè</style></author><author><style face="normal" font="default" size="100%">Dalfó, Esther</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Jurado, Paola</style></author><author><style face="normal" font="default" size="100%">Armstrong, Judith</style></author><author><style face="normal" font="default" size="100%">Esteller, Manel</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Whole exome sequencing of Rett syndrome-like patients reveals the mutational diversity of the clinical phenotype.</style></title><secondary-title><style face="normal" font="default" size="100%">Hum Genet</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Hum Genet</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Caenorhabditis elegans</style></keyword><keyword><style  face="normal" font="default" size="100%">Carrier Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Cycle Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Child</style></keyword><keyword><style  face="normal" font="default" size="100%">Child, Preschool</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA Mutational Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Exome</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Forkhead Transcription Factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Variation</style></keyword><keyword><style  face="normal" font="default" size="100%">High-Throughput Nucleotide Sequencing</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Methyl-CpG-Binding Protein 2</style></keyword><keyword><style  face="normal" font="default" size="100%">mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">Nerve Tissue Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Serine-Threonine Kinases</style></keyword><keyword><style  face="normal" font="default" size="100%">Receptors, Nicotinic</style></keyword><keyword><style  face="normal" font="default" size="100%">Rett Syndrome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016 12</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">135</style></volume><pages><style face="normal" font="default" size="100%">1343-1354</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Classical Rett syndrome (RTT) is a neurodevelopmental disorder where most of cases carry MECP2 mutations. Atypical RTT variants involve mutations in CDKL5 and FOXG1. However, a subset of RTT patients remains that do not carry any mutation in the described genes. Whole exome sequencing was carried out in a cohort of 21 female probands with clinical features overlapping with those of RTT, but without mutations in the customarily studied genes. Candidates were functionally validated by assessing the appearance of a neurological phenotype in Caenorhabditis elegans upon disruption of the corresponding ortholog gene. We detected pathogenic variants that accounted for the RTT-like phenotype in 14 (66.6 %) patients. Five patients were carriers of mutations in genes already known to be associated with other syndromic neurodevelopmental disorders. We determined that the other patients harbored mutations in genes that have not previously been linked to RTT or other neurodevelopmental syndromes, such as the ankyrin repeat containing protein ANKRD31 or the neuronal acetylcholine receptor subunit alpha-5 (CHRNA5). Furthermore, worm assays demonstrated that mutations in the studied candidate genes caused locomotion defects. Our findings indicate that mutations in a variety of genes contribute to the development of RTT-like phenotypes.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/27541642?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alonso, Roberto</style></author><author><style face="normal" font="default" size="100%">Salavert, Francisco</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Carbonell-Caballero, José</style></author><author><style face="normal" font="default" size="100%">Bleda, Marta</style></author><author><style face="normal" font="default" size="100%">García-Alonso, Luz</style></author><author><style face="normal" font="default" size="100%">Sanchis-Juan, Alba</style></author><author><style face="normal" font="default" size="100%">Perez-Gil, Daniel</style></author><author><style face="normal" font="default" size="100%">Marin-Garcia, Pablo</style></author><author><style face="normal" font="default" size="100%">Sánchez, Rubén</style></author><author><style face="normal" font="default" size="100%">Cubuk, Cankut</style></author><author><style face="normal" font="default" size="100%">Hidalgo, Marta R</style></author><author><style face="normal" font="default" size="100%">Amadoz, Alicia</style></author><author><style face="normal" font="default" size="100%">Hernansaiz-Ballesteros, Rosa D</style></author><author><style face="normal" font="default" size="100%">Alemán, Alejandro</style></author><author><style face="normal" font="default" size="100%">Tárraga, Joaquín</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Medina, Ignacio</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Babelomics 5.0: functional interpretation for new generations of genomic data.</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic acids research</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">babelomics</style></keyword><keyword><style  face="normal" font="default" size="100%">data integration</style></keyword><keyword><style  face="normal" font="default" size="100%">gene set analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">interactome</style></keyword><keyword><style  face="normal" font="default" size="100%">network analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">NGS</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA-seq</style></keyword><keyword><style  face="normal" font="default" size="100%">Systems biology</style></keyword><keyword><style  face="normal" font="default" size="100%">transcriptomics</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015 Apr 20</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://nar.oxfordjournals.org/content/43/W1/W117</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">W1</style></number><volume><style face="normal" font="default" size="100%">43</style></volume><pages><style face="normal" font="default" size="100%">W117-W121</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Babelomics has been running for more than one decade offering a user-friendly interface for the functional analysis of gene expression and genomic data. Here we present its fifth release, which includes support for Next Generation Sequencing data including gene expression (RNA-seq), exome or genome resequencing. Babelomics has simplified its interface, being now more intuitive. Improved visualization options, such as a genome viewer as well as an interactive network viewer, have been implemented. New technical enhancements at both, client and server sides, makes the user experience faster and more dynamic. Babelomics offers user-friendly access to a full range of methods that cover: (i) primary data analysis, (ii) a variety of tests for different experimental designs and (iii) different enrichment and network analysis algorithms for the interpretation of the results of such tests in the proper functional context. In addition to the public server, local copies of Babelomics can be downloaded and installed. Babelomics is freely available at: http://www.babelomics.org.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ewing, Adam D</style></author><author><style face="normal" font="default" size="100%">Houlahan, Kathleen E</style></author><author><style face="normal" font="default" size="100%">Hu, Yin</style></author><author><style face="normal" font="default" size="100%">Ellrott, Kyle</style></author><author><style face="normal" font="default" size="100%">Caloian, Cristian</style></author><author><style face="normal" font="default" size="100%">Yamaguchi, Takafumi N</style></author><author><style face="normal" font="default" size="100%">Bare, J Christopher</style></author><author><style face="normal" font="default" size="100%">P’ng, Christine</style></author><author><style face="normal" font="default" size="100%">Waggott, Daryl</style></author><author><style face="normal" font="default" size="100%">Sabelnykova, Veronica Y</style></author><author><style face="normal" font="default" size="100%">Kellen, Michael R</style></author><author><style face="normal" font="default" size="100%">Norman, Thea C</style></author><author><style face="normal" font="default" size="100%">Haussler, David</style></author><author><style face="normal" font="default" size="100%">Friend, Stephen H</style></author><author><style face="normal" font="default" size="100%">Stolovitzky, Gustavo</style></author><author><style face="normal" font="default" size="100%">Margolin, Adam A</style></author><author><style face="normal" font="default" size="100%">Stuart, Joshua M</style></author><author><style face="normal" font="default" size="100%">Boutros, Paul C</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">ICGC-TCGA DREAM Somatic Mutation Calling Challenge participants</style></author><author><style face="normal" font="default" size="100%">Liu Xi</style></author><author><style face="normal" font="default" size="100%">Ninad Dewal</style></author><author><style face="normal" font="default" size="100%">Yu Fan</style></author><author><style face="normal" font="default" size="100%">Wenyi Wang</style></author><author><style face="normal" font="default" size="100%">David Wheeler</style></author><author><style face="normal" font="default" size="100%">Andreas Wilm</style></author><author><style face="normal" font="default" size="100%">Grace Hui Ting</style></author><author><style face="normal" font="default" size="100%">Chenhao Li</style></author><author><style face="normal" font="default" size="100%">Denis Bertrand</style></author><author><style face="normal" font="default" size="100%">Niranjan Nagarajan</style></author><author><style face="normal" font="default" size="100%">Qing-Rong Chen</style></author><author><style face="normal" font="default" size="100%">Chih-Hao Hsu</style></author><author><style face="normal" font="default" size="100%">Ying Hu</style></author><author><style face="normal" font="default" size="100%">Chunhua Yan</style></author><author><style face="normal" font="default" size="100%">Warren Kibbe</style></author><author><style face="normal" font="default" size="100%">Daoud Meerzaman</style></author><author><style face="normal" font="default" size="100%">Kristian Cibulskis</style></author><author><style face="normal" font="default" size="100%">Mara Rosenberg</style></author><author><style face="normal" font="default" size="100%">Louis Bergelson</style></author><author><style face="normal" font="default" size="100%">Adam Kiezun</style></author><author><style face="normal" font="default" size="100%">Amie Radenbaugh</style></author><author><style face="normal" font="default" size="100%">Anne-Sophie Sertier</style></author><author><style face="normal" font="default" size="100%">Anthony Ferrari</style></author><author><style face="normal" font="default" size="100%">Laurie Tonton</style></author><author><style face="normal" font="default" size="100%">Kunal Bhutani</style></author><author><style face="normal" font="default" size="100%">Nancy F Hansen</style></author><author><style face="normal" font="default" size="100%">Difei Wang</style></author><author><style face="normal" font="default" size="100%">Lei Song</style></author><author><style face="normal" font="default" size="100%">Zhongwu Lai</style></author><author><style face="normal" font="default" size="100%">Liao, Yang</style></author><author><style face="normal" font="default" size="100%">Shi, Wei</style></author><author><style face="normal" font="default" size="100%">Carbonell-Caballero, José</style></author><author><style face="normal" font="default" size="100%">Joaquín Dopazo</style></author><author><style face="normal" font="default" size="100%">Cheryl C K Lau</style></author><author><style face="normal" font="default" size="100%">Justin Guinney</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection.</style></title><secondary-title><style face="normal" font="default" size="100%">Nature methods</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">NGS</style></keyword><keyword><style  face="normal" font="default" size="100%">variant calling</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015 May 18</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.nature.com/nmeth/journal/vaop/ncurrent/full/nmeth.3407.html</style></url></web-urls></urls><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The detection of somatic mutations from cancer genome sequences is key to understanding the genetic basis of disease progression, patient survival and response to therapy. Benchmarking is needed for tool assessment and improvement but is complicated by a lack of gold standards, by extensive resource requirements and by difficulties in sharing personal genomic information. To resolve these issues, we launched the ICGC-TCGA DREAM Somatic Mutation Calling Challenge, a crowdsourced benchmark of somatic mutation detection algorithms. Here we report the BAMSurgeon tool for simulating cancer genomes and the results of 248 analyses of three in silico tumors created with it. Different algorithms exhibit characteristic error profiles, and, intriguingly, false positives show a trinucleotide profile very similar to one found in human tumors. Although the three simulated tumors differ in sequence contamination (deviation from normal cell sequence) and in subclonality, an ensemble of pipelines outperforms the best individual pipeline in all cases. BAMSurgeon is available at https://github.com/adamewing/bamsurgeon/.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sevilla, T</style></author><author><style face="normal" font="default" size="100%">Sivera, R</style></author><author><style face="normal" font="default" size="100%">Martínez-Rubio, D</style></author><author><style face="normal" font="default" size="100%">Lupo, V</style></author><author><style face="normal" font="default" size="100%">Chumillas, M J</style></author><author><style face="normal" font="default" size="100%">Calpena, E</style></author><author><style face="normal" font="default" size="100%">Dopazo, J</style></author><author><style face="normal" font="default" size="100%">Vílchez, J J</style></author><author><style face="normal" font="default" size="100%">Palau, F</style></author><author><style face="normal" font="default" size="100%">Espinós, C</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The EGR2 gene is involved in axonal Charcot-Marie-Tooth disease.</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Neurol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Eur J Neurol</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style  face="normal" font="default" size="100%">Axons</style></keyword><keyword><style  face="normal" font="default" size="100%">Charcot-Marie-Tooth Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Early Growth Response Protein 2</style></keyword><keyword><style  face="normal" font="default" size="100%">Exome</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">Pedigree</style></keyword><keyword><style  face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style  face="normal" font="default" size="100%">Severity of Illness Index</style></keyword><keyword><style  face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015 Dec</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">22</style></volume><pages><style face="normal" font="default" size="100%">1548-55</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND AND PURPOSE: &lt;/b&gt;A three-generation family affected by axonal Charcot-Marie-Tooth disease (CMT) was investigated with the aim of discovering genetic defects and to further characterize the phenotype.&lt;/p&gt;&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;The clinical, nerve conduction studies and muscle magnetic resonance images of the patients were reviewed. A whole exome sequencing was performed and the changes were investigated by genetic studies, in silico analysis and luciferase reporter assays.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;A novel c.1226G&gt;A change (p.R409Q) in the EGR2 gene was identified. Patients presented with a typical, late-onset axonal CMT phenotype with variable severity that was confirmed in the ancillary tests. The in silico studies showed that the residue R409 is an evolutionary conserved amino acid. The p.R409Q mutation, which is predicted as probably damaging, would alter the conformation of the protein slightly and would cause a decrease of gene expression.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;This is the first report of an EGR2 mutation presenting as an axonal CMT phenotype with variable severity. This study broadens the phenotype of the EGR2-related neuropathies and suggests that the genetic testing of patients suffering from axonal CMT should include the EGR2 gene.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/26204789?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fonseca, Renata F</style></author><author><style face="normal" font="default" size="100%">de Carvalho, Flávia M</style></author><author><style face="normal" font="default" size="100%">Poletta, Fernando A</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Mereb, Juan C</style></author><author><style face="normal" font="default" size="100%">Moreira, Miguel A M</style></author><author><style face="normal" font="default" size="100%">Seuanez, Hector N</style></author><author><style face="normal" font="default" size="100%">Vieira, Alexandre R</style></author><author><style face="normal" font="default" size="100%">Castilla, Eduardo E</style></author><author><style face="normal" font="default" size="100%">Orioli, Iêda M</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Family-based genome-wide association study in Patagonia confirms the association of the DMD locus and cleft lip and palate.</style></title><secondary-title><style face="normal" font="default" size="100%">Eur J Oral Sci</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Eur J Oral Sci</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015 Oct</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">123</style></volume><pages><style face="normal" font="default" size="100%">381-384</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The etiology of cleft lip with or without cleft palate (CL±P) is complex and heterogeneous, and multiple genetic and environmental factors are involved. Some candidate genes reported to be associated with oral clefts are located on the X chromosome. At least three genes causing X-linked syndromes [midline 1 (MID1), oral-facial-digital syndrome 1 (OFD1), and dystrophin (DMD)] were previously found to be associated with isolated CL±P. We attempted to confirm the role of X-linked genes in the etiology of isolated CL±P in a South American population through a family-based genome-wide scan. We studied 27 affected children and their mothers, from 26 families, in a Patagonian population with a high prevalence of CL±P. We conducted an exploratory analysis of the X chromosome to identify candidate regions associated with CL±P. Four genomic segments were identified, two of which showed a statistically significant association with CL±P. One is an 11-kb region of Xp21.1 containing the DMD gene, and the other is an intergenic region (8.7 kb; Xp11.4). Our results are consistent with recent data on the involvement of the DMD gene in the etiology of CL±P. The MID1 and OFD1 genes were not included in the four potential CL±P-associated X-chromosome genomic segments.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/26331285?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Porta-Pardo, Eduard</style></author><author><style face="normal" font="default" size="100%">García-Alonso, Luz</style></author><author><style face="normal" font="default" size="100%">Hrabe, Thomas</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Godzik, Adam</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces.</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS Comput Biol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PLoS Comput Biol</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Base Sequence</style></keyword><keyword><style  face="normal" font="default" size="100%">Biomarkers, Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Catalogs as Topic</style></keyword><keyword><style  face="normal" font="default" size="100%">Chromosome Mapping</style></keyword><keyword><style  face="normal" font="default" size="100%">Computer Simulation</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA Mutational Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Models, Genetic</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Sequence Data</style></keyword><keyword><style  face="normal" font="default" size="100%">mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Interaction Mapping</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015 Oct</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">11</style></volume><pages><style face="normal" font="default" size="100%">e1004518</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Despite their importance in maintaining the integrity of all cellular pathways, the role of mutations on protein-protein interaction (PPI) interfaces as cancer drivers has not been systematically studied. Here we analyzed the mutation patterns of the PPI interfaces from 10,028 proteins in a pan-cancer cohort of 5,989 tumors from 23 projects of The Cancer Genome Atlas (TCGA) to find interfaces enriched in somatic missense mutations. To that end we use e-Driver, an algorithm to analyze the mutation distribution of specific protein functional regions. We identified 103 PPI interfaces enriched in somatic cancer mutations. 32 of these interfaces are found in proteins coded by known cancer driver genes. The remaining 71 interfaces are found in proteins that have not been previously identified as cancer drivers even that, in most cases, there is an extensive literature suggesting they play an important role in cancer. Finally, we integrate these findings with clinical information to show how tumors apparently driven by the same gene have different behaviors, including patient outcomes, depending on which specific interfaces are mutated. &lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/26485003?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tárraga, Joaquín</style></author><author><style face="normal" font="default" size="100%">Pérez, Mariano</style></author><author><style face="normal" font="default" size="100%">Orduña, Juan M</style></author><author><style face="normal" font="default" size="100%">Duato, José</style></author><author><style face="normal" font="default" size="100%">Medina, Ignacio</style></author><author><style face="normal" font="default" size="100%">Joaquín Dopazo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A Parallel and Sensitive Software Tool for Methylation Analysis on Multicore Platforms.</style></title><secondary-title><style face="normal" font="default" size="100%">Bioinformatics (Oxford, England)</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">BS-seq</style></keyword><keyword><style  face="normal" font="default" size="100%">HPC</style></keyword><keyword><style  face="normal" font="default" size="100%">methylation</style></keyword><keyword><style  face="normal" font="default" size="100%">NGS</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015 Jun 10</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://bioinformatics.oxfordjournals.org/content/31/19/3130.long</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">19</style></number><volume><style face="normal" font="default" size="100%">31</style></volume><pages><style face="normal" font="default" size="100%">3130-3138</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">MOTIVATION: DNA methylation analysis suffers from very long processing time, since the advent of Next-Generation Sequencers (NGS) has shifted the bottleneck of genomic studies from the sequencers that obtain the DNA samples to the software that performs the analysis of these samples. The existing software for methylation analysis does not seem to scale efficiently neither with the size of the dataset nor with the length of the reads to be analyzed. Since it is expected that the sequencers will provide longer and longer reads in the near future, efficient and scalable methylation software should be developed. RESULTS: We present a new software tool, called HPG-Methyl, which efficiently maps bisulfite sequencing reads on DNA, analyzing DNA methylation. The strategy used by this software consists of leveraging the speed of the Burrows-Wheeler Transform to map a large number of DNA fragments (reads) rapidly, as well as the accuracy of the Smith-Waterman algorithm, which is exclusively employed to deal with the most ambiguous and shortest reads. Experimental results on platforms with Intel multicore processors show that HPGMethyl significantly outperforms in both execution time and sensitivity state-of-the-art software such as Bismark, BS-Seeker or BSMAP, particularly for long bisulfite reads. AVAILABILITY: Software in the form of C libraries and functions, together with instructions to compile and execute this software. Available by sftp to anonymous@clariano.uv.es (password &quot;anonymous&quot;). CONTACT: Juan.Orduna@uv.es.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Minguez, Pablo</style></author><author><style face="normal" font="default" size="100%">Letunic, Ivica</style></author><author><style face="normal" font="default" size="100%">Parca, Luca</style></author><author><style face="normal" font="default" size="100%">García-Alonso, Luz</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Huerta-Cepas, Jaime</style></author><author><style face="normal" font="default" size="100%">Bork, Peer</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">PTMcode v2: a resource for functional associations of post-translational modifications within and between proteins.</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Databases, Protein</style></keyword><keyword><style  face="normal" font="default" size="100%">Internet</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Interaction Mapping</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Processing, Post-Translational</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015 Jan</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">43</style></volume><pages><style face="normal" font="default" size="100%">D494-502</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The post-translational regulation of proteins is mainly driven by two molecular events, their modification by several types of moieties and their interaction with other proteins. These two processes are interdependent and together are responsible for the function of the protein in a particular cell state. Several databases focus on the prediction and compilation of protein-protein interactions (PPIs) and no less on the collection and analysis of protein post-translational modifications (PTMs), however, there are no resources that concentrate on describing the regulatory role of PTMs in PPIs. We developed several methods based on residue co-evolution and proximity to predict the functional associations of pairs of PTMs that we apply to modifications in the same protein and between two interacting proteins. In order to make data available for understudied organisms, PTMcode v2 (http://ptmcode.embl.de) includes a new strategy to propagate PTMs from validated modified sites through orthologous proteins. The second release of PTMcode covers 19 eukaryotic species from which we collected more than 300,000 experimentally verified PTMs (&gt;1,300,000 propagated) of 69 types extracting the post-translational regulation of &gt;100,000 proteins and &gt;100,000 interactions. In total, we report 8 million associations of PTMs regulating single proteins and over 9.4 million interplays tuning PPIs.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">Database issue</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/25361965?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Avila-Fernandez, Almudena</style></author><author><style face="normal" font="default" size="100%">Perez-Carro, Raquel</style></author><author><style face="normal" font="default" size="100%">Corton, Marta</style></author><author><style face="normal" font="default" size="100%">Lopez-Molina, Maria Isabel</style></author><author><style face="normal" font="default" size="100%">Campello, Laura</style></author><author><style face="normal" font="default" size="100%">Garanto, Alex</style></author><author><style face="normal" font="default" size="100%">Fernadez-Sanchez, Laura</style></author><author><style face="normal" font="default" size="100%">Duijkers, Lonneke</style></author><author><style face="normal" font="default" size="100%">Lopez-Martinez, Miguel Angel</style></author><author><style face="normal" font="default" size="100%">Riveiro-Alvarez, Rosa</style></author><author><style face="normal" font="default" size="100%">da Silva, Luciana Rodrigues Jacy</style></author><author><style face="normal" font="default" size="100%">Sanchez-Alcudia, Rocío</style></author><author><style face="normal" font="default" size="100%">Martin-Garrido, Esther</style></author><author><style face="normal" font="default" size="100%">Reyes, Noelia</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Garcia-Sandoval, Blanca</style></author><author><style face="normal" font="default" size="100%">Collin, Rob W</style></author><author><style face="normal" font="default" size="100%">Cuenca, Nicolas</style></author><author><style face="normal" font="default" size="100%">Ayuso, Carmen</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Whole Exome Sequencing Reveals ZNF408 as a New Gene Associated With Autosomal Recessive Retinitis Pigmentosa with Vitreal Alterations.</style></title><secondary-title><style face="normal" font="default" size="100%">Human molecular genetics</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015 Apr 16</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://hmg.oxfordjournals.org/content/early/2015/04/16/hmg.ddv140.abstract</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">24</style></volume><pages><style face="normal" font="default" size="100%">4037-4048</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Retinitis Pigmentosa (RP) is a group of progressive inherited retinal dystrophies that cause visual impairment as a result of photoreceptor cell death. RP is heterogeneous, both clinically and genetically making difficult to establish precise genotype-phenotype correlations. In a Spanish family with autosomal recessive RP (arRP), homozygosity mapping and whole exome sequencing led to the identification of a homozygous mutation (c.358_359delGT; p.Ala122Leufs*2) in the ZNF408 gene. A screening performed in 217 additional unrelated families revealed another homozygous mutation (c.1621C&gt;T; p.Arg541Cys) in an isolated RP case. ZNF408 encodes a transcription factor that harbors ten predicted C2H2-type fingers thought to be implicated in DNA binding. To elucidate the ZNF408 role in the retina and the pathogenesis of these mutations we have performed different functional studies. By immunohistochemical analysis in healthy human retina, we identified that ZNF408 is expressed in both cone and rod photoreceptors, in a specific type of amacrine and ganglion cells, and in retinal blood vessels. ZNF408 revealed a cytoplasmic localization and a nuclear distribution in areas corresponding with the euchromatin fraction. Immunolocalization studies showed a partial mislocalization of the p.Arg541Cys mutant protein retaining part of the WT protein in the cytoplasm. Our study demonstrates that ZNF408, previously associated with Familial Exudative Vitreoretinopathy (FEVR), is a new gene causing arRP with vitreous condensations supporting the evidence that this protein plays additional functions into the human retina.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Avila-Fernandez, Almudena</style></author><author><style face="normal" font="default" size="100%">Perez-Carro, Raquel</style></author><author><style face="normal" font="default" size="100%">Corton, Marta</style></author><author><style face="normal" font="default" size="100%">Lopez-Molina, Maria Isabel</style></author><author><style face="normal" font="default" size="100%">Campello, Laura</style></author><author><style face="normal" font="default" size="100%">Garanto, Alejandro</style></author><author><style face="normal" font="default" size="100%">Fernandez-Sanchez, Laura</style></author><author><style face="normal" font="default" size="100%">Duijkers, Lonneke</style></author><author><style face="normal" font="default" size="100%">Lopez-Martinez, Miguel Angel</style></author><author><style face="normal" font="default" size="100%">Riveiro-Alvarez, Rosa</style></author><author><style face="normal" font="default" size="100%">da Silva, Luciana Rodrigues Jacy</style></author><author><style face="normal" font="default" size="100%">Sanchez-Alcudia, Rocío</style></author><author><style face="normal" font="default" size="100%">Martin-Garrido, Esther</style></author><author><style face="normal" font="default" size="100%">Reyes, Noelia</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Garcia-Sandoval, Blanca</style></author><author><style face="normal" font="default" size="100%">Collin, Rob W J</style></author><author><style face="normal" font="default" size="100%">Cuenca, Nicolas</style></author><author><style face="normal" font="default" size="100%">Ayuso, Carmen</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Whole-exome sequencing reveals ZNF408 as a new gene associated with autosomal recessive retinitis pigmentosa with vitreal alterations.</style></title><secondary-title><style face="normal" font="default" size="100%">Hum Mol Genet</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Hum Mol Genet</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Amino Acid Sequence</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Chlorocebus aethiops</style></keyword><keyword><style  face="normal" font="default" size="100%">Chromosome Mapping</style></keyword><keyword><style  face="normal" font="default" size="100%">COS Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA-Binding Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Exome</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome-Wide Association Study</style></keyword><keyword><style  face="normal" font="default" size="100%">High-Throughput Nucleotide Sequencing</style></keyword><keyword><style  face="normal" font="default" size="100%">Homozygote</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Sequence Data</style></keyword><keyword><style  face="normal" font="default" size="100%">Mutant Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Pedigree</style></keyword><keyword><style  face="normal" font="default" size="100%">Retina</style></keyword><keyword><style  face="normal" font="default" size="100%">Retinal Cone Photoreceptor Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Retinal Rod Photoreceptor Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Retinitis pigmentosa</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcription Factors</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015 Jul 15</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">24</style></volume><pages><style face="normal" font="default" size="100%">4037-48</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Retinitis pigmentosa (RP) is a group of progressive inherited retinal dystrophies that cause visual impairment as a result of photoreceptor cell death. RP is heterogeneous, both clinically and genetically making difficult to establish precise genotype-phenotype correlations. In a Spanish family with autosomal recessive RP (arRP), homozygosity mapping and whole-exome sequencing led to the identification of a homozygous mutation (c.358_359delGT; p.Ala122Leufs*2) in the ZNF408 gene. A screening performed in 217 additional unrelated families revealed another homozygous mutation (c.1621C&gt;T; p.Arg541Cys) in an isolated RP case. ZNF408 encodes a transcription factor that harbors 10 predicted C2H2-type fingers thought to be implicated in DNA binding. To elucidate the ZNF408 role in the retina and the pathogenesis of these mutations we have performed different functional studies. By immunohistochemical analysis in healthy human retina, we identified that ZNF408 is expressed in both cone and rod photoreceptors, in a specific type of amacrine and ganglion cells, and in retinal blood vessels. ZNF408 revealed a cytoplasmic localization and a nuclear distribution in areas corresponding with the euchromatin fraction. Immunolocalization studies showed a partial mislocalization of the p.Arg541Cys mutant protein retaining part of the WT protein in the cytoplasm. Our study demonstrates that ZNF408, previously associated with Familial Exudative Vitreoretinopathy (FEVR), is a new gene causing arRP with vitreous condensations supporting the evidence that this protein plays additional functions into the human retina. &lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">14</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/25882705?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Iglesias, Juan Manuel</style></author><author><style face="normal" font="default" size="100%">Leis, Olatz</style></author><author><style face="normal" font="default" size="100%">Pérez Ruiz, Estíbaliz</style></author><author><style face="normal" font="default" size="100%">Gumuzio Barrie, Juan</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Aduriz, Ariane</style></author><author><style face="normal" font="default" size="100%">Beloqui, Izaskun</style></author><author><style face="normal" font="default" size="100%">Hernandez-Garcia, Susana</style></author><author><style face="normal" font="default" size="100%">Lopez-Mato, Maria Paz</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Pandiella, Atanasio</style></author><author><style face="normal" font="default" size="100%">Menendez, Javier A</style></author><author><style face="normal" font="default" size="100%">Martin, Angel Garcia</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorigenic Potential.</style></title><secondary-title><style face="normal" font="default" size="100%">Front Oncol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Front Oncol</style></alt-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">4</style></volume><pages><style face="normal" font="default" size="100%">308</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The striking similarity displayed at the mechanistic level between tumorigenesis and the generation of induced pluripotent stem cells and the fact that genes and pathways relevant for embryonic development are reactivated during tumor progression highlights the link between pluripotency and cancer. Based on these observations, we tested whether it is possible to use a pluripotency-associated transcriptional reporter, whose activation is driven by the SRR2 enhancer from the Sox2 gene promoter (named S4+ reporter), to isolate cancer stem cells (CSCs) from breast cancer cell lines. The S4+ pluripotency transcriptional reporter allows the isolation of cells with enhanced tumorigenic potential and its activation was switched on and off in the cell lines studied, reflecting a plastic cellular process. Microarray analysis comparing the populations in which the reporter construct is active versus inactive showed that positive cells expressed higher mRNA levels of cytokines (IL-8, IL-6, TNF) and genes (such as ATF3, SNAI2, and KLF6) previously related with the CSC phenotype in breast cancer. &lt;/p&gt;</style></abstract><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/25414831?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Munro, Sarah A</style></author><author><style face="normal" font="default" size="100%">Lund, Steven P</style></author><author><style face="normal" font="default" size="100%">Pine, P Scott</style></author><author><style face="normal" font="default" size="100%">Binder, Hans</style></author><author><style face="normal" font="default" size="100%">Clevert, Djork-Arné</style></author><author><style face="normal" font="default" size="100%">Ana Conesa</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Fasold, Mario</style></author><author><style face="normal" font="default" size="100%">Hochreiter, Sepp</style></author><author><style face="normal" font="default" size="100%">Hong, Huixiao</style></author><author><style face="normal" font="default" size="100%">Jafari, Nadereh</style></author><author><style face="normal" font="default" size="100%">Kreil, David P</style></author><author><style face="normal" font="default" size="100%">Labaj, Paweł P</style></author><author><style face="normal" font="default" size="100%">Li, Sheng</style></author><author><style face="normal" font="default" size="100%">Liao, Yang</style></author><author><style face="normal" font="default" size="100%">Lin, Simon M</style></author><author><style face="normal" font="default" size="100%">Meehan, Joseph</style></author><author><style face="normal" font="default" size="100%">Mason, Christopher E</style></author><author><style face="normal" font="default" size="100%">Santoyo-López, Javier</style></author><author><style face="normal" font="default" size="100%">Setterquist, Robert A</style></author><author><style face="normal" font="default" size="100%">Shi, Leming</style></author><author><style face="normal" font="default" size="100%">Shi, Wei</style></author><author><style face="normal" font="default" size="100%">Smyth, Gordon K</style></author><author><style face="normal" font="default" size="100%">Stralis-Pavese, Nancy</style></author><author><style face="normal" font="default" size="100%">Su, Zhenqiang</style></author><author><style face="normal" font="default" size="100%">Tong, Weida</style></author><author><style face="normal" font="default" size="100%">Wang, Charles</style></author><author><style face="normal" font="default" size="100%">Wang, Jian</style></author><author><style face="normal" font="default" size="100%">Xu, Joshua</style></author><author><style face="normal" font="default" size="100%">Ye, Zhan</style></author><author><style face="normal" font="default" size="100%">Yang, Yong</style></author><author><style face="normal" font="default" size="100%">Yu, Ying</style></author><author><style face="normal" font="default" size="100%">Salit, Marc</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Assessing technical performance in differential gene expression experiments with external spike-in RNA control ratio mixtures.</style></title><secondary-title><style face="normal" font="default" size="100%">Nature communications</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">RNA-seq</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.nature.com/ncomms/2014/140925/ncomms6125/full/ncomms6125.html</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">5</style></volume><pages><style face="normal" font="default" size="100%">5125</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">There is a critical need for standard approaches to assess, report and compare the technical performance of genome-scale differential gene expression experiments. Here we assess technical performance with a proposed standard ’dashboard’ of metrics derived from analysis of external spike-in RNA control ratio mixtures. These control ratio mixtures with defined abundance ratios enable assessment of diagnostic performance of differentially expressed transcript lists, limit of detection of ratio (LODR) estimates and expression ratio variability and measurement bias. The performance metrics suite is applicable to analysis of a typical experiment, and here we also apply these metrics to evaluate technical performance among laboratories. An interlaboratory study using identical samples shared among 12 laboratories with three different measurement processes demonstrates generally consistent diagnostic power across 11 laboratories. Ratio measurement variability and bias are also comparable among laboratories for the same measurement process. We observe different biases for measurement processes using different mRNA-enrichment protocols.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">de Castro-Miró, Marta</style></author><author><style face="normal" font="default" size="100%">Pomares, Esther</style></author><author><style face="normal" font="default" size="100%">Lorés-Motta, Laura</style></author><author><style face="normal" font="default" size="100%">Tonda, Raul</style></author><author><style face="normal" font="default" size="100%">Joaquín Dopazo</style></author><author><style face="normal" font="default" size="100%">Marfany, Gemma</style></author><author><style face="normal" font="default" size="100%">Gonzàlez-Duarte, Roser</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Combined genetic and high-throughput strategies for molecular diagnosis of inherited retinal dystrophies.</style></title><secondary-title><style face="normal" font="default" size="100%">PloS one</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://dx.plos.org/10.1371/journal.pone.0088410</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">9</style></volume><pages><style face="normal" font="default" size="100%">e88410</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Most diagnostic laboratories are confronted with the increasing demand for molecular diagnosis from patients and families and the ever-increasing genetic heterogeneity of visual disorders. Concerning Retinal Dystrophies (RD), almost 200 causative genes have been reported to date, and most families carry private mutations. We aimed to approach RD genetic diagnosis using all the available genetic information to prioritize candidates for mutational screening, and then restrict the number of cases to be analyzed by massive sequencing. We constructed and optimized a comprehensive cosegregation RD-chip based on SNP genotyping and haplotype analysis. The RD-chip allows to genotype 768 selected SNPs (closely linked to 100 RD causative genes) in a single cost-, time-effective step. Full diagnosis was attained in 17/36 Spanish pedigrees, yielding 12 new and 12 previously reported mutations in 9 RD genes. The most frequently mutated genes were USH2A and CRB1. Notably, RD3-up to now only associated to Leber Congenital Amaurosis- was identified as causative of Retinitis Pigmentosa. The main assets of the RD-chip are: i) the robustness of the genetic information that underscores the most probable candidates, ii) the invaluable clues in cases of shared haplotypes, which are indicative of a common founder effect, and iii) the detection of extended haplotypes over closely mapping genes, which substantiates cosegregation, although the assumptions in which the genetic analysis is based could exceptionally lead astray. The combination of the genetic approach with whole exome sequencing (WES) greatly increases the diagnosis efficiency, and revealed novel mutations in USH2A and GUCY2D. Overall, the RD-chip diagnosis efficiency ranges from 16% in dominant, to 80% in consanguineous recessive pedigrees, with an average of 47%, well within the upper range of massive sequencing approaches, highlighting the validity of this time- and cost-effective approach whilst high-throughput methodologies become amenable for routine diagnosis in medium sized labs.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tenorio, Jair</style></author><author><style face="normal" font="default" size="100%">Mansilla, Alicia</style></author><author><style face="normal" font="default" size="100%">Valencia, María</style></author><author><style face="normal" font="default" size="100%">Martínez-Glez, Víctor</style></author><author><style face="normal" font="default" size="100%">Romanelli, Valeria</style></author><author><style face="normal" font="default" size="100%">Arias, Pedro</style></author><author><style face="normal" font="default" size="100%">Castrejón, Nerea</style></author><author><style face="normal" font="default" size="100%">Poletta, Fernando</style></author><author><style face="normal" font="default" size="100%">Guillén-Navarro, Encarna</style></author><author><style face="normal" font="default" size="100%">Gordo, Gema</style></author><author><style face="normal" font="default" size="100%">Mansilla, Elena</style></author><author><style face="normal" font="default" size="100%">García-Santiago, Fé</style></author><author><style face="normal" font="default" size="100%">González-Casado, Isabel</style></author><author><style face="normal" font="default" size="100%">Vallespín, Elena</style></author><author><style face="normal" font="default" size="100%">Palomares, María</style></author><author><style face="normal" font="default" size="100%">Mori, María A</style></author><author><style face="normal" font="default" size="100%">Santos-Simarro, Fernando</style></author><author><style face="normal" font="default" size="100%">García-Miñaur, Sixto</style></author><author><style face="normal" font="default" size="100%">Fernández, Luis</style></author><author><style face="normal" font="default" size="100%">Mena, Rocío</style></author><author><style face="normal" font="default" size="100%">Benito-Sanz, Sara</style></author><author><style face="normal" font="default" size="100%">Del Pozo, Angela</style></author><author><style face="normal" font="default" size="100%">Silla, Juan Carlos</style></author><author><style face="normal" font="default" size="100%">Ibañez, Kristina</style></author><author><style face="normal" font="default" size="100%">López-Granados, Eduardo</style></author><author><style face="normal" font="default" size="100%">Martín-Trujillo, Alex</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Heath, Karen E</style></author><author><style face="normal" font="default" size="100%">Campos-Barros, Angel</style></author><author><style face="normal" font="default" size="100%">Joaquín Dopazo</style></author><author><style face="normal" font="default" size="100%">Nevado, Julián</style></author><author><style face="normal" font="default" size="100%">Monk, David</style></author><author><style face="normal" font="default" size="100%">Ruiz-Pérez, Víctor L</style></author><author><style face="normal" font="default" size="100%">Lapunzina, Pablo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A New Overgrowth Syndrome is Due to Mutations in RNF125.</style></title><secondary-title><style face="normal" font="default" size="100%">Human mutation</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">NGS</style></keyword><keyword><style  face="normal" font="default" size="100%">prioritization</style></keyword><keyword><style  face="normal" font="default" size="100%">Rare Disease</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014 Sep 5</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/humu.22689/abstract</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">35</style></volume><pages><style face="normal" font="default" size="100%">1436–1441</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Overgrowth syndromes (OGS) are a group of disorders in which all parameters of growth and physical development are above the mean for age and sex. We evaluated a series of 270 families from the Spanish Overgrowth Syndrome Registry with no known overgrowth syndrome. We identified one de novo deletion and three missense mutations in RNF125 in six patients from 4 families with overgrowth, macrocephaly, intellectual disability, mild hydrocephaly, hypoglycaemia and inflammatory diseases resembling Sjögren syndrome. RNF125 encodes an E3 ubiquitin ligase and is a novel gene of OGS. Our studies of the RNF125 pathway point to upregulation of RIG-I-IPS1-MDA5 and/or disruption of the PI3K-AKT and interferon signaling pathways as the putative final effectors. This article is protected by copyright. All rights reserved.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Calpena, E</style></author><author><style face="normal" font="default" size="100%">Martínez-Rubio, D</style></author><author><style face="normal" font="default" size="100%">Arpa, J</style></author><author><style face="normal" font="default" size="100%">García-Peñas, J J</style></author><author><style face="normal" font="default" size="100%">Montaner, D.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Palau, F</style></author><author><style face="normal" font="default" size="100%">Espinós, C</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A novel locus for a hereditary recurrent neuropathy on chromosome 21q21.</style></title><secondary-title><style face="normal" font="default" size="100%">Neuromuscular disorders : NMD</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014 May 9</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.sciencedirect.com/science/article/pii/S0960896614001060#</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">24</style></volume><pages><style face="normal" font="default" size="100%">660-5</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Hereditary recurrent neuropathies are uncommon. Disorders with a known molecular basis falling within this group include hereditary neuropathy with liability to pressure palsies (HNPP) due to the deletion of the PMP22 gene or to mutations in this same gene, and hereditary neuralgic amyotrophy (HNA) caused by mutations in the SEPT9 gene. We report a three-generation family presenting a hereditary recurrent neuropathy without pathological changes in either PMP22 or SEPT9 genes. We performed a genome-wide mapping, which yielded a locus of 12.4Mb on chromosome 21q21. The constructed haplotype fully segregated with the disease and we found significant evidence of linkage. After mutational screening of genes located within this locus, encoding for proteins and microRNAs, as well as analysis of large deletions/insertions, we identified 71 benign polymorphisms. Our findings suggest a novel genetic locus for a recurrent hereditary neuropathy of which the molecular defect remains elusive. Our results further underscore the clinical and genetic heterogeneity of this group of neuropathies.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ponzoni, Ignacio</style></author><author><style face="normal" font="default" size="100%">Nueda, María</style></author><author><style face="normal" font="default" size="100%">Tarazona, Sonia</style></author><author><style face="normal" font="default" size="100%">Götz, Stefan</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Dussaut, Julieta</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Conesa, Ana</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Pathway network inference from gene expression data.</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Syst Biol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">BMC Syst Biol</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Alzheimer Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Cycle</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA Replication</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Regulatory Networks</style></keyword><keyword><style  face="normal" font="default" size="100%">Gluconeogenesis</style></keyword><keyword><style  face="normal" font="default" size="100%">Glycolysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Oxidative Phosphorylation</style></keyword><keyword><style  face="normal" font="default" size="100%">Proteolysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Purines</style></keyword><keyword><style  face="normal" font="default" size="100%">Saccharomyces cerevisiae</style></keyword><keyword><style  face="normal" font="default" size="100%">Systems biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Ubiquitin</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">8 Suppl 2</style></volume><pages><style face="normal" font="default" size="100%">S7</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;The development of high-throughput omics technologies enabled genome-wide measurements of the activity of cellular elements and provides the analytical resources for the progress of the Systems Biology discipline. Analysis and interpretation of gene expression data has evolved from the gene to the pathway and interaction level, i.e. from the detection of differentially expressed genes, to the establishment of gene interaction networks and the identification of enriched functional categories. Still, the understanding of biological systems requires a further level of analysis that addresses the characterization of the interaction between functional modules.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;We present a novel computational methodology to study the functional interconnections among the molecular elements of a biological system. The PANA approach uses high-throughput genomics measurements and a functional annotation scheme to extract an activity profile from each functional block -or pathway- followed by machine-learning methods to infer the relationships between these functional profiles. The result is a global, interconnected network of pathways that represents the functional cross-talk within the molecular system. We have applied this approach to describe the functional transcriptional connections during the yeast cell cycle and to identify pathways that change their connectivity in a disease condition using an Alzheimer example.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSIONS: &lt;/b&gt;PANA is a useful tool to deepen in our understanding of the functional interdependences that operate within complex biological systems. We show the approach is algorithmically consistent and the inferred network is well supported by the available functional data. The method allows the dissection of the molecular basis of the functional connections and we describe the different regulatory mechanisms that explain the network's topology obtained for the yeast cell cycle data.&lt;/p&gt;</style></abstract><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/25032889?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">García-Cazorla, Angels</style></author><author><style face="normal" font="default" size="100%">Oyarzabal, Alfonso</style></author><author><style face="normal" font="default" size="100%">Fort, Joana</style></author><author><style face="normal" font="default" size="100%">Robles, Concepción</style></author><author><style face="normal" font="default" size="100%">Castejón, Esperanza</style></author><author><style face="normal" font="default" size="100%">Ruiz-Sala, Pedro</style></author><author><style face="normal" font="default" size="100%">Bodoy, Susanna</style></author><author><style face="normal" font="default" size="100%">Merinero, Begoña</style></author><author><style face="normal" font="default" size="100%">Lopez-Sala, Anna</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Nunes, Virginia</style></author><author><style face="normal" font="default" size="100%">Ugarte, Magdalena</style></author><author><style face="normal" font="default" size="100%">Artuch, Rafael</style></author><author><style face="normal" font="default" size="100%">Palacín, Manuel</style></author><author><style face="normal" font="default" size="100%">Rodríguez-Pombo, Pilar</style></author><author><style face="normal" font="default" size="100%">Alcaide, Patricia</style></author><author><style face="normal" font="default" size="100%">Navarrete, Rosa</style></author><author><style face="normal" font="default" size="100%">Sanz, Paloma</style></author><author><style face="normal" font="default" size="100%">Font-Llitjós, Mariona</style></author><author><style face="normal" font="default" size="100%">Vilaseca, Ma Antonia</style></author><author><style face="normal" font="default" size="100%">Ormaizabal, Aida</style></author><author><style face="normal" font="default" size="100%">Pristoupilova, Anna</style></author><author><style face="normal" font="default" size="100%">Agulló, Sergi Beltran</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Two novel mutations in the BCKDK (branched-chain keto-acid dehydrogenase kinase) gene are responsible for a neurobehavioral deficit in two pediatric unrelated patients.</style></title><secondary-title><style face="normal" font="default" size="100%">Hum Mutat</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Hum Mutat</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Amino Acids, Branched-Chain</style></keyword><keyword><style  face="normal" font="default" size="100%">Developmental Disabilities</style></keyword><keyword><style  face="normal" font="default" size="100%">Fibroblasts</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Mutation, Missense</style></keyword><keyword><style  face="normal" font="default" size="100%">Nervous System Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Pediatrics</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Kinases</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014 Apr</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">35</style></volume><pages><style face="normal" font="default" size="100%">470-7</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Inactivating mutations in the BCKDK gene, which codes for the kinase responsible for the negative regulation of the branched-chain α-keto acid dehydrogenase complex (BCKD), have recently been associated with a form of autism in three families. In this work, two novel exonic BCKDK mutations, c.520C&gt;G/p.R174G and c.1166T&gt;C/p.L389P, were identified at the homozygous state in two unrelated children with persistently reduced body fluid levels of branched-chain amino acids (BCAAs), developmental delay, microcephaly, and neurobehavioral abnormalities. Functional analysis of the mutations confirmed the missense character of the c.1166T&gt;C change and showed a splicing defect r.[520c&gt;g;521_543del]/p.R174Gfs1*, for c.520C&gt;G due to the presence of a new donor splice site. Mutation p.L389P showed total loss of kinase activity. Moreover, patient-derived fibroblasts showed undetectable (p.R174Gfs1*) or barely detectable (p.L389P) levels of BCKDK protein and its phosphorylated substrate (phospho-E1α), resulting in increased BCKD activity and the very rapid BCAA catabolism manifested by the patients' clinical phenotype. Based on these results, a protein-rich diet plus oral BCAA supplementation was implemented in the patient homozygous for p.R174Gfs1*. This treatment normalized plasma BCAA levels and improved growth, developmental and behavioral variables. Our results demonstrate that BCKDK mutations can result in neurobehavioral deficits in humans and support the rationale for dietary intervention. &lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/24449431?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">García-Cazorla, Angels</style></author><author><style face="normal" font="default" size="100%">Oyarzabal, Alfonso</style></author><author><style face="normal" font="default" size="100%">Fort, Joana</style></author><author><style face="normal" font="default" size="100%">Robles, Concepción</style></author><author><style face="normal" font="default" size="100%">Castejón, Esperanza</style></author><author><style face="normal" font="default" size="100%">Ruiz-Sala, Pedro</style></author><author><style face="normal" font="default" size="100%">Bodoy, Susanna</style></author><author><style face="normal" font="default" size="100%">Merinero, Begoña</style></author><author><style face="normal" font="default" size="100%">Lopez-Sala, Anna</style></author><author><style face="normal" font="default" size="100%">Joaquín Dopazo</style></author><author><style face="normal" font="default" size="100%">Nunes, Virginia</style></author><author><style face="normal" font="default" size="100%">Ugarte, Magdalena</style></author><author><style face="normal" font="default" size="100%">Artuch, Rafael</style></author><author><style face="normal" font="default" size="100%">Palacín, Manuel</style></author><author><style face="normal" font="default" size="100%">Rodríguez-Pombo, Pilar</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Two Novel Mutations in the BCKDK Gene (Branched-Chain Keto-Acid Dehydrogenase Kinase) are Responsible of a Neurobehavioral Deficit in two Pediatric Unrelated Patients.</style></title><secondary-title><style face="normal" font="default" size="100%">Human mutation</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014 Jan 21</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://onlinelibrary.wiley.com/doi/10.1002/humu.22513/abstract</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">35</style></volume><pages><style face="normal" font="default" size="100%">470-7</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Inactivating mutations in the BCKDK gene, which codes for the kinase responsible for the negative regulation of the branched-chain keto-acid dehydrogenase complex (BCKD), have recently been associated with a form of autism in three families. In this work, two novel exonic BCKDK mutations, c.520C&gt;G/p.R174G and c.1166T&gt;C/p.L389P, were identified at the homozygous state in two unrelated children with persistently reduced body fluid levels of branched-chain amino acids (BCAAs), developmental delay, microcephaly and neurobehavioral abnormalities. Functional analysis of the mutations confirmed the missense character of the c.1166T&gt;C change and showed a splicing defect r.[520c&gt;g;521_543del]/p.R174Gfs1*, for c.520C&gt;G due to the presence of a new donor splice site. Mutation p.L389P showed total loss of kinase activity. Moreover, patient-derived fibroblasts showed undetectable (p.R174Gfs1*) or barely detectable (p.L389P) levels of BCKDK protein and its phosphorylated substrate (phospho-E1α), resulting in increased BCKD activity and the very rapid BCAA catabolism manifested by the patients’ clinical phenotype. Based on these results, a protein-rich diet plus oral BCAA supplementation was implemented in the patient homozygous for p.R174Gfs1*. This treatment normalized plasma BCAA levels and improved growth, developmental and behavioral variables. Our results demonstrate that BCKDK mutations can result in neurobehavioral deficits in humans and support the rationale for dietary intervention. This article is protected by copyright. All rights reserved.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ariño, Joaquín</style></author><author><style face="normal" font="default" size="100%">Casamayor, Antonio</style></author><author><style face="normal" font="default" size="100%">Pérez, Julián Perez</style></author><author><style face="normal" font="default" size="100%">Pedrola, Laia</style></author><author><style face="normal" font="default" size="100%">Alvarez-Tejado, Miguel</style></author><author><style face="normal" font="default" size="100%">Marbà, Martina</style></author><author><style face="normal" font="default" size="100%">Santoyo, Javier</style></author><author><style face="normal" font="default" size="100%">Joaquín Dopazo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Assessing Differential Expression Measurements by Highly Parallel Pyrosequencing and DNA Microarrays: A Comparative Study.</style></title><secondary-title><style face="normal" font="default" size="100%">Omics : a journal of integrative biology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011 Sep 15</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3545353/</style></url></web-urls></urls><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Abstract To explore the feasibility of pyrosequencing for quantitative differential gene expression analysis we have performed a comparative study of the results of the sequencing experiments to those obtained by a conventional DNA microarray platform. A conclusion from our analysis is that, over a threshold of 35 normalized reads per gene, the measurements of gene expression display a good correlation with the references. The observed concordance between pyrosequencing and DNA microarray platforms beyond the threshold was of 0.8, measured as a Pearson’s correlation coefficient. In differential gene expression the initial aim is the quantification the differences among transcripts when comparing experimental conditions. Thus, even in a scenario of low coverage the concordance in the measurements is quite acceptable. On the other hand, the comparatively longer read size obtained by pyrosequencing allows detecting unconventional splicing forms.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Puig-Butille, Joan Anton</style></author><author><style face="normal" font="default" size="100%">Escamez, Maria José</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Tell-Marti, Gemma</style></author><author><style face="normal" font="default" size="100%">Fabra, Angels</style></author><author><style face="normal" font="default" size="100%">Martínez-Santamaría, Lucía</style></author><author><style face="normal" font="default" size="100%">Badenas, Celia</style></author><author><style face="normal" font="default" size="100%">Aguilera, Paula</style></author><author><style face="normal" font="default" size="100%">Pevida, Marta</style></author><author><style face="normal" font="default" size="100%">Joaquín Dopazo</style></author><author><style face="normal" font="default" size="100%">Del Rio, Marcela</style></author><author><style face="normal" font="default" size="100%">Puig, Susana</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer.</style></title><secondary-title><style face="normal" font="default" size="100%">Oncotarget</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013 Dec 16</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&amp;page=article&amp;op=view&amp;path%5B%5D=1444&amp;path%5B%5D=1824</style></url></web-urls></urls><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Germline mutations in CDKN2A and/or red hair color variants in MC1R genes are associated with an increased susceptibility to develop cutaneous melanoma or non melanoma skin cancer. We studied the impact of the CDKN2A germinal mutation p.G101W and MC1R variants on gene expression and transcription profiles associated with skin cancer. To this end we set-up primary skin cell co-cultures from siblings of melanoma prone-families that were later analyzed using the expression array approach. As a result, we found that 1535 transcripts were deregulated in CDKN2A mutated cells, with over-expression of immunity-related genes (HLA-DPB1, CLEC2B, IFI44, IFI44L, IFI27, IFIT1, IFIT2, SP110 and IFNK) and down-regulation of genes playing a role in the Notch signaling pathway. 3570 transcripts were deregulated in MC1R variant carriers. In particular, genes related to oxidative stress and DNA damage pathways were up-regulated as well as genes associated with neurodegenerative diseases such as Parkinson’s, Alzheimer and Huntington. Finally, we observed that the expression signatures indentified in phenotypically normal cells carrying CDKN2A mutations or MC1R variants are maintained in skin cancer tumors (melanoma and squamous cell carcinoma). These results indicate that transcriptome deregulation represents an early event critical for skin cancer development.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Galan, Amparo</style></author><author><style face="normal" font="default" size="100%">Diaz-Gimeno, Patricia</style></author><author><style face="normal" font="default" size="100%">Poo, Maria Eugenia</style></author><author><style face="normal" font="default" size="100%">Valbuena, Diana</style></author><author><style face="normal" font="default" size="100%">Sanchez, Eva</style></author><author><style face="normal" font="default" size="100%">Ruiz, Veronica</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Conesa, Ana</style></author><author><style face="normal" font="default" size="100%">Simon, Carlos</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Defining the genomic signature of totipotency and pluripotency during early human development.</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PLoS One</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Blastocyst Inner Cell Mass</style></keyword><keyword><style  face="normal" font="default" size="100%">Blastomeres</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style  face="normal" font="default" size="100%">Embryonic Development</style></keyword><keyword><style  face="normal" font="default" size="100%">Embryonic Stem Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Regulatory Networks</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome, Human</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Sequence Annotation</style></keyword><keyword><style  face="normal" font="default" size="100%">Pluripotent Stem Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Totipotent Stem Cells</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">8</style></volume><pages><style face="normal" font="default" size="100%">e62135</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The genetic mechanisms governing human pre-implantation embryo development and the in vitro counterparts, human embryonic stem cells (hESCs), still remain incomplete. Previous global genome studies demonstrated that totipotent blastomeres from day-3 human embryos and pluripotent inner cell masses (ICMs) from blastocysts, display unique and differing transcriptomes. Nevertheless, comparative gene expression analysis has revealed that no significant differences exist between hESCs derived from blastomeres versus those obtained from ICMs, suggesting that pluripotent hESCs involve a new developmental progression. To understand early human stages evolution, we developed an undifferentiation network signature (UNS) and applied it to a differential gene expression profile between single blastomeres from day-3 embryos, ICMs and hESCs. This allowed us to establish a unique signature composed of highly interconnected genes characteristic of totipotency (61 genes), in vivo pluripotency (20 genes), and in vitro pluripotency (107 genes), and which are also proprietary according to functional analysis. This systems biology approach has led to an improved understanding of the molecular and signaling processes governing human pre-implantation embryo development, as well as enabling us to comprehend how hESCs might adapt to in vitro culture conditions.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/23614026?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Manuel Iglesias, Juan</style></author><author><style face="normal" font="default" size="100%">Beloqui, Izaskun</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Leis, Olatz</style></author><author><style face="normal" font="default" size="100%">Vazquez-Martin, Alejandro</style></author><author><style face="normal" font="default" size="100%">Eguiara, Arrate</style></author><author><style face="normal" font="default" size="100%">Cufi, Silvia</style></author><author><style face="normal" font="default" size="100%">Pavon, Andres</style></author><author><style face="normal" font="default" size="100%">Menendez, Javier A.</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Martin, Angel G.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mammosphere Formation in Breast Carcinoma Cell Lines Depends upon Expression of E-cadherin</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS ONE</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013/10/04</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://dx.doi.org/10.1371%2Fjournal.pone.0077281</style></url></web-urls></urls><publisher><style face="normal" font="default" size="100%">Public Library of Science</style></publisher><volume><style face="normal" font="default" size="100%">8</style></volume><pages><style face="normal" font="default" size="100%">e77281 -</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Tumors are heterogeneous at the cellular level where the ability to maintain tumor growth resides in discrete cell populations. Floating sphere-forming assays are broadly used to test stem cell activity in tissues, tumors and cell lines. Spheroids are originated from a small population of cells with stem cell features able to grow in suspension culture and behaving as tumorigenic in mice. We tested the ability of eleven common breast cancer cell lines representing the major breast cancer subtypes to grow as mammospheres, measuring the ability to maintain cell viability upon serial non-adherent passage. Only MCF7, T47D, BT474, MDA-MB-436 and JIMT1 were successfully propagated as long-term mammosphere cultures, measured as the increase in the number of viable cells upon serial non-adherent passages. Other cell lines tested (SKBR3, MDA-MB-231, MDA-MB-468 and MDA-MB-435) formed cell clumps that can be disaggregated mechanically, but cell viability drops dramatically on their second passage. HCC1937 and HCC1569 cells formed typical mammospheres, although they could not be propagated as long-term mammosphere cultures. All the sphere forming lines but MDA-MB-436 express E-cadherin on their surface. Knock down of E-cadherin expression in MCF-7 cells abrogated its ability to grow as mammospheres, while re-expression of E-cadherin in SKBR3 cells allow them to form mammospheres. Therefore, the mammosphere assay is suitable to reveal stem like features in breast cancer cell lines that express E-cadherin.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Manuel Iglesias, Juan</style></author><author><style face="normal" font="default" size="100%">Beloqui, Izaskun</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Leis, Olatz</style></author><author><style face="normal" font="default" size="100%">Vazquez-Martin, Alejandro</style></author><author><style face="normal" font="default" size="100%">Eguiara, Arrate</style></author><author><style face="normal" font="default" size="100%">Cufi, Silvia</style></author><author><style face="normal" font="default" size="100%">Pavon, Andres</style></author><author><style face="normal" font="default" size="100%">Menendez, Javier A</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Martin, Angel G</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mammosphere formation in breast carcinoma cell lines depends upon expression of E-cadherin.</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PLoS One</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Breast Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Cadherins</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Line, Tumor</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Proliferation</style></keyword><keyword><style  face="normal" font="default" size="100%">Cluster Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation, Neoplastic</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Knockdown Techniques</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">MCF-7 Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplastic Stem Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Spheroids, Cellular</style></keyword><keyword><style  face="normal" font="default" size="100%">Tumor Cells, Cultured</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">8</style></volume><pages><style face="normal" font="default" size="100%">e77281</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Tumors are heterogeneous at the cellular level where the ability to maintain tumor growth resides in discrete cell populations. Floating sphere-forming assays are broadly used to test stem cell activity in tissues, tumors and cell lines. Spheroids are originated from a small population of cells with stem cell features able to grow in suspension culture and behaving as tumorigenic in mice. We tested the ability of eleven common breast cancer cell lines representing the major breast cancer subtypes to grow as mammospheres, measuring the ability to maintain cell viability upon serial non-adherent passage. Only MCF7, T47D, BT474, MDA-MB-436 and JIMT1 were successfully propagated as long-term mammosphere cultures, measured as the increase in the number of viable cells upon serial non-adherent passages. Other cell lines tested (SKBR3, MDA-MB-231, MDA-MB-468 and MDA-MB-435) formed cell clumps that can be disaggregated mechanically, but cell viability drops dramatically on their second passage. HCC1937 and HCC1569 cells formed typical mammospheres, although they could not be propagated as long-term mammosphere cultures. All the sphere forming lines but MDA-MB-436 express E-cadherin on their surface. Knock down of E-cadherin expression in MCF-7 cells abrogated its ability to grow as mammospheres, while re-expression of E-cadherin in SKBR3 cells allow them to form mammospheres. Therefore, the mammosphere assay is suitable to reveal stem like features in breast cancer cell lines that express E-cadherin.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/24124614?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Puig-Butille, Joan Anton</style></author><author><style face="normal" font="default" size="100%">Malvehy, Josep</style></author><author><style face="normal" font="default" size="100%">Potrony, Miriam</style></author><author><style face="normal" font="default" size="100%">Trullas, Carles</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Puig, Susana</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Role of CPI-17 in restoring skin homoeostasis in cutaneous field of cancerization: effects of topical application of a film-forming medical device containing photolyase and UV filters.</style></title><secondary-title><style face="normal" font="default" size="100%">Exp Dermatol</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Exp Dermatol</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Administration, Topical</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Aged, 80 and over</style></keyword><keyword><style  face="normal" font="default" size="100%">Biopsy</style></keyword><keyword><style  face="normal" font="default" size="100%">Deoxyribodipyrimidine Photo-Lyase</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation, Enzymologic</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation, Neoplastic</style></keyword><keyword><style  face="normal" font="default" size="100%">Homeostasis</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style  face="normal" font="default" size="100%">Intracellular Signaling Peptides and Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Liposomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Muscle Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Phenotype</style></keyword><keyword><style  face="normal" font="default" size="100%">Phosphoprotein Phosphatases</style></keyword><keyword><style  face="normal" font="default" size="100%">Reactive Oxygen Species</style></keyword><keyword><style  face="normal" font="default" size="100%">Skin</style></keyword><keyword><style  face="normal" font="default" size="100%">Skin Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Ultraviolet Rays</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013 Jul</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">22</style></volume><pages><style face="normal" font="default" size="100%">494-6</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Cutaneous field of cancerization (CFC) is caused in part by the carcinogenic effect of the cyclobutane pyrimidine dimers CPD and 6-4 photoproducts (6-4PPs). Photoreactivation is carried out by photolyases which specifically recognize and repair both photoproducts. The study evaluates the molecular effects of topical application of a film-forming medical device containing photolyase and UV filters on the precancerous field in AK from seven patients. Skin improvement after treatment was confirmed in all patients by histopathological and molecular assessment. A gene set analysis showed that skin recovery was associated with biological processes involved in tissue homoeostasis and cell maintenance. The CFC response was associated with over-expression of the CPI-17 gene, and a dependence on the initial expression level was observed (P = 0.001). Low CPI-17 levels were directly associated with pro-inflammatory genes such as TNF (P = 0.012) and IL-1B (P = 0.07). Our results suggest a role for CPI-17 in restoring skin homoeostasis in CFC lesions. &lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/23800065?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fernandez, Paula</style></author><author><style face="normal" font="default" size="100%">Soria, Marcelo</style></author><author><style face="normal" font="default" size="100%">Blesa, David</style></author><author><style face="normal" font="default" size="100%">Dirienzo, Julio</style></author><author><style face="normal" font="default" size="100%">Moschen, Sebastián</style></author><author><style face="normal" font="default" size="100%">Rivarola, Máximo</style></author><author><style face="normal" font="default" size="100%">Clavijo, Bernardo Jose</style></author><author><style face="normal" font="default" size="100%">Gonzalez, Sergio</style></author><author><style face="normal" font="default" size="100%">Peluffo, Lucila</style></author><author><style face="normal" font="default" size="100%">Príncipi, Dario</style></author><author><style face="normal" font="default" size="100%">Dosio, Guillermo</style></author><author><style face="normal" font="default" size="100%">Aguirrezabal, Luis</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Ana Conesa</style></author><author><style face="normal" font="default" size="100%">Hopp, Esteban</style></author><author><style face="normal" font="default" size="100%">Joaquín Dopazo</style></author><author><style face="normal" font="default" size="100%">Heinz, Ruth Amelia</style></author><author><style face="normal" font="default" size="100%">Paniego, Norma</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Development, Characterization and Experimental Validation of a Cultivated Sunflower (Helianthus annuus L.) Gene Expression Oligonucleotide Microarray.</style></title><secondary-title><style face="normal" font="default" size="100%">PloS one</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0045899</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">7</style></volume><pages><style face="normal" font="default" size="100%">e45899</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Oligonucleotide-based microarrays with accurate gene coverage represent a key strategy for transcriptional studies in orphan species such as sunflower, H. annuus L., which lacks full genome sequences. The goal of this study was the development and functional annotation of a comprehensive sunflower unigene collection and the design and validation of a custom sunflower oligonucleotide-based microarray. A large scale EST (&gt;130,000 ESTs) curation, assembly and sequence annotation was performed using Blast2GO (www.blast2go.de). The EST assembly comprises 41,013 putative transcripts (12,924 contigs and 28,089 singletons). The resulting Sunflower Unigen Resource (SUR version 1.0) was used to design an oligonucleotide-based Agilent microarray for cultivated sunflower. This microarray includes a total of 42,326 features: 1,417 Agilent controls, 74 control probes for sunflower replicated 10 times (740 controls) and 40,169 different non-control probes. Microarray performance was validated using a model experiment examining the induction of senescence by water deficit. Pre-processing and differential expression analysis of Agilent microarrays was performed using the Bioconductor limma package. The analyses based on p-values calculated by eBayes (p&lt;0.01) allowed the detection of 558 differentially expressed genes between water stress and control conditions; from these, ten genes were further validated by qPCR. Over-represented ontologies were identified using FatiScan in the Babelomics suite. This work generated a curated and trustable sunflower unigene collection, and a custom, validated sunflower oligonucleotide-based microarray using Agilent technology. Both the curated unigene collection and the validated oligonucleotide microarray provide key resources for sunflower genome analysis, transcriptional studies, and molecular breeding for crop improvement.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Conesa-Zamora, Pablo</style></author><author><style face="normal" font="default" size="100%">García-Solano, José</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Del Carmen Turpin, María</style></author><author><style face="normal" font="default" size="100%">Trujillo-Santos, Javier</style></author><author><style face="normal" font="default" size="100%">Torres-Moreno, Daniel</style></author><author><style face="normal" font="default" size="100%">Oviedo-Ramírez, Isabel</style></author><author><style face="normal" font="default" size="100%">Carbonell-Muñoz, Rosa</style></author><author><style face="normal" font="default" size="100%">Muñoz-Delgado, Encarnación</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Braun, Edith</style></author><author><style face="normal" font="default" size="100%">Ana Conesa</style></author><author><style face="normal" font="default" size="100%">Pérez-Guillermo, Miguel</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Expression profiling shows differential molecular pathways and provides potential new diagnostic biomarkers for colorectal serrated adenocarcinoma.</style></title><secondary-title><style face="normal" font="default" size="100%">International journal of cancer. Journal international du cancer</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012 Jun 14</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Serrated adenocarcinoma (SAC) is a recently recognized colorectal cancer (CRC) subtype accounting for 7.5-8.7% of CRCs. It has been shown that SAC has a poorer prognosis and has different molecular and immunohistochemical features compared to conventional carcinoma (CC) but, to date, only one previous study has analysed its mRNA expression profile by microarray. Using a different microarray platform, we have studied the molecular signature of 11 SACs and compared it with that of 15 matched CC with the aim of discerning the functions which characterize SAC biology and validating, at the mRNA and protein level, the most differentially expressed genes which were also tested using a validation set of 70 SACs and 70 CCs to assess their diagnostic and prognostic values. Microarray data showed a higher representation of morphogenesis-, hypoxia-, cytoskeleton- and vesicle transport-related functions and also an over-expression of fascin1 (actin-bundling protein associated with invasion) and the antiapoptotic gene hippocalcin in SAC all of which were validated both by qPCR and immunohistochemistry. Fascin1 expression was statistically associated with KRAS mutation with 88.6% sensitivity and 85.7% specificity for SAC diagnosis and the positivity of fascin1 or hippocalcin was highly suggestive of SAC diagnosis (sensitivity=100%). Evaluation of these markers in CRCs showing histological and molecular characteristics of high-level microsatellite instability (MSI-H) also helped to distinguish SACs from MSI-H CRCs. Molecular profiling demonstrates that SAC shows activation of distinct signalling pathways and that immunohistochemical fascin1 and hippocalcin expression can be reliably used for its differentiation from other CRC subtypes. © 2012 Wiley Periodicals, Inc.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jaime, María D L A</style></author><author><style face="normal" font="default" size="100%">Lopez-Llorca, Luis Vicente</style></author><author><style face="normal" font="default" size="100%">Ana Conesa</style></author><author><style face="normal" font="default" size="100%">Lee, Anna Y</style></author><author><style face="normal" font="default" size="100%">Proctor, Michael</style></author><author><style face="normal" font="default" size="100%">Heisler, Lawrence E</style></author><author><style face="normal" font="default" size="100%">Gebbia, Marinella</style></author><author><style face="normal" font="default" size="100%">Giaever, Guri</style></author><author><style face="normal" font="default" size="100%">Westwood, J Timothy</style></author><author><style face="normal" font="default" size="100%">Nislow, Corey</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Identification of yeast genes that confer resistance to chitosan oligosaccharide (COS) using chemogenomics.</style></title><secondary-title><style face="normal" font="default" size="100%">BMC genomics</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><pages><style face="normal" font="default" size="100%">267</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: Chitosan oligosaccharide (COS), a deacetylated derivative of chitin, is an abundant, and renewable natural polymer. COS has higher antimicrobial properties than chitosan and is presumed to act by disrupting/permeabilizing the cell membranes of bacteria, yeast and fungi. COS is relatively non-toxic to mammals. By identifying the molecular and genetic targets of COS, we hope to gain a better understanding of the antifungal mode of action of COS. RESULTS: Three different chemogenomic fitness assays, haploinsufficiency (HIP), homozygous deletion (HOP), and multicopy suppression (MSP) profiling were combined with a transcriptomic analysis to gain insight in to the mode of action and mechanisms of resistance to chitosan oligosaccharides. The fitness assays identified 39 yeast deletion strains sensitive to COS and 21 suppressors of COS sensitivity. The genes identified are involved in processes such as RNA biology (transcription, translation and regulatory mechanisms), membrane functions (e.g. signalling, transport and targeting), membrane structural components, cell division, and proteasome processes. The transcriptomes of control wild type and 5 suppressor strains overexpressing ARL1, BCK2, ERG24, MSG5, or RBA50, were analyzed in the presence and absence of COS. Some of the up-regulated transcripts in the suppressor overexpressing strains exposed to COS included genes involved in transcription, cell cycle, stress response and the Ras signal transduction pathway. Down-regulated transcripts included those encoding protein folding components and respiratory chain proteins. The COS-induced transcriptional response is distinct from previously described environmental stress responses (i.e. thermal, salt, osmotic and oxidative stress) and pre-treatment with these well characterized environmental stressors provided little or any resistance to COS. CONCLUSIONS: Overexpression of the ARL1 gene, a member of the Ras superfamily that regulates membrane trafficking, provides protection against COS-induced cell membrane permeability and damage. We found that the ARL1 COS-resistant over-expression strain was as sensitive to Amphotericin B, Fluconazole and Terbinafine as the wild type cells and that when COS and Fluconazole are used in combination they act in a synergistic fashion. The gene targets of COS identified in this study indicate that COS’s mechanism of action is different from other commonly studied fungicides that target membranes, suggesting that COS may be an effective fungicide for drug-resistant fungal pathogens.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koziol, Agnieszka</style></author><author><style face="normal" font="default" size="100%">Gonzalo, Pilar</style></author><author><style face="normal" font="default" size="100%">Mota, Alba</style></author><author><style face="normal" font="default" size="100%">Pollán, Angela</style></author><author><style face="normal" font="default" size="100%">Lorenzo, Cristina</style></author><author><style face="normal" font="default" size="100%">Colomé, Nuria</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Arribas, Joaquín</style></author><author><style face="normal" font="default" size="100%">Canals, Francesc</style></author><author><style face="normal" font="default" size="100%">Arroyo, Alicia G</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The protease MT1-MMP drives a combinatorial proteolytic program in activated endothelial cells.</style></title><secondary-title><style face="normal" font="default" size="100%">FASEB J</style></secondary-title><alt-title><style face="normal" font="default" size="100%">FASEB J</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Blotting, Western</style></keyword><keyword><style  face="normal" font="default" size="100%">Combinatorial Chemistry Techniques</style></keyword><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Endothelial Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation, Enzymologic</style></keyword><keyword><style  face="normal" font="default" size="100%">Inflammation</style></keyword><keyword><style  face="normal" font="default" size="100%">Matrix Metalloproteinase 14</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Array Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA Interference</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Small Interfering</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcriptome</style></keyword><keyword><style  face="normal" font="default" size="100%">Tumor Necrosis Factor-alpha</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012 Nov</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">26</style></volume><pages><style face="normal" font="default" size="100%">4481-94</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The mechanism by which proteolytic events translate into biological responses is not well understood. To explore the link of pericellular proteolysis to events relevant to capillary sprouting within the inflammatory context, we aimed at the identification of the collection of substrates of the protease MT1-MMP in endothelial tip cells induced by inflammatory stimuli. We applied quantitative proteomics to endothelial cells (ECs) derived from wild-type and MT1-MMP-null mice to identify the substrate repertoire of this protease in TNF-α-activated ECs. Bioinformatics analysis revealed a combinatorial MT1-MMP proteolytic program, in which combined rather than single substrate processing would determine biological decisions by activated ECs, including chemotaxis, cell motility and adhesion, and vasculature development. MT1-MMP-deficient ECs inefficiently processed several of these substrates (TSP1, CYR61, NID1, and SEM3C), validating the model. This novel concept of MT1-MMP-driven combinatorial proteolysis in angiogenesis might be extendable to proteolytic actions in other cellular contexts.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">11</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/22859368?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lorente-Galdos, Belén</style></author><author><style face="normal" font="default" size="100%">Medina, Ignacio</style></author><author><style face="normal" font="default" size="100%">Morcillo-Suarez, Carlos</style></author><author><style face="normal" font="default" size="100%">Heredia, Txema</style></author><author><style face="normal" font="default" size="100%">Carreño-Torres, Angel</style></author><author><style face="normal" font="default" size="100%">Sangrós, Ricardo</style></author><author><style face="normal" font="default" size="100%">Alegre, Josep</style></author><author><style face="normal" font="default" size="100%">Pita, Guillermo</style></author><author><style face="normal" font="default" size="100%">Vellalta, Gemma</style></author><author><style face="normal" font="default" size="100%">Malats, Nuria</style></author><author><style face="normal" font="default" size="100%">Pisano, David G</style></author><author><style face="normal" font="default" size="100%">Joaquín Dopazo</style></author><author><style face="normal" font="default" size="100%">Navarro, Arcadi</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Select your SNPs (SYSNPs): a web tool for automatic and massive selection of SNPs.</style></title><secondary-title><style face="normal" font="default" size="100%">International journal of data mining and bioinformatics</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://inderscience.metapress.com/content/f76740x8071u513n/</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">6</style></volume><pages><style face="normal" font="default" size="100%">324-34</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Association studies are the choice approach in the discovery of the genomic basis of complex traits. To carry out such analysis, researchers frequently need to (1) select optimally informative sets of Single Nucleotide Polymorphisms (SNPs) in candidate regions and (2) annotate the results of associations found by means of genome-wide SNP arrays. These are complex tasks, since many criteria have to be considered, including the SNPs’ functional properties, technological information and haplotype frequencies in given populations. SYSNPs implements algorithms that allow for efficient and simultaneous consideration of all the relevant criteria to obtain sets of SNPs that properly cover arbitrarily large lists of genes or genomic regions. Complementarily, SYSNPs allows for comprehensive functional annotation of SNPs linked to any given marker SNP. SYSNPs dramatically reduces the effort needed for SNP selection from days of searching various databases to a few minutes using a simple browser.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Carcel-Trullols, Jaime</style></author><author><style face="normal" font="default" size="100%">Aguilar-Gallardo, Cristóbal</style></author><author><style face="normal" font="default" size="100%">García-Alcalde, Fernando</style></author><author><style face="normal" font="default" size="100%">Pardo-Cea, Miguel Angel</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Ana Conesa</style></author><author><style face="normal" font="default" size="100%">Simon, Carlos</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Transdifferentiation of MALME-3M and MCF-7 Cells toward Adipocyte-like Cells is Dependent on Clathrin-mediated Endocytosis.</style></title><secondary-title><style face="normal" font="default" size="100%">SpringerPlus</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3725915/</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">1</style></volume><pages><style face="normal" font="default" size="100%">44</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">ABSTRACT: Enforced cell transdifferentiation of human cancer cells is a promising alternative to conventional chemotherapy. We previously identified albumin-associated lipid- and, more specifically, saturated fatty acid-induced transdifferentiation programs in human cancer cells (HCCLs). In this study, we further characterized the adipocyte-like cells, resulting from the transdifferentiation of human cancer cell lines MCF-7 and MALME-3M, and proposed a common mechanistic approach for these transdifferentiating programs. We showed the loss of pigmentation in MALME-3M cells treated with albumin-associated lipids, based on electron microscopic analysis, and the overexpression of perilipin 2 (PLIN2) by western blotting in MALME-3M and MCF-7 cells treated with unsaturated fatty acids. Comparing the gene expression profiles of naive melanoma MALME-3M cells and albumin-associated lipid-treated cells, based on RNA sequencing, we confirmed the transcriptional upregulation of some key adipogenic gene markers and also an alternative splicing of the adipogenic master regulator PPARG, that is probably related to the reported up regulated expression of the protein. Most importantly, these results also showed the upregulation of genes responsible for Clathrin (CLTC) and other adaptor-related proteins. An increase in CLTC expression in the transdifferentiated cells was confirmed by western blotting. Inactivation of CLTC by chlorpromazine (CHP), an inhibitor of CTLC mediated endocytosis (CME), and gene silencing by siRNAs, partially reversed the accumulation of neutral lipids observed in the transdifferentiated cells. These findings give a deeper insight into the phenotypic changes observed in HCCL to adipocyte-like transdifferentiation and point towards CME as a key pathway in distinct transdifferentiation programs. DISCLOSURES: Simon C and Aguilar-Gallardo C are co-inventors of the International Patent Application No. PCT/EP2011/004941 entitled &quot;Methods for tumor treatment and adipogenesis differentiation&quot;.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prieur, Xavier</style></author><author><style face="normal" font="default" size="100%">Mok, Crystal Y L</style></author><author><style face="normal" font="default" size="100%">Velagapudi, Vidya R</style></author><author><style face="normal" font="default" size="100%">Núñez, Vanessa</style></author><author><style face="normal" font="default" size="100%">Fuentes, Lucía</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Ishikawa, Ko</style></author><author><style face="normal" font="default" size="100%">Camacho, Alberto</style></author><author><style face="normal" font="default" size="100%">Barbarroja, Nuria</style></author><author><style face="normal" font="default" size="100%">O’Rahilly, Stephen</style></author><author><style face="normal" font="default" size="100%">Sethi, Jaswinder</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Oresic, Matej</style></author><author><style face="normal" font="default" size="100%">Ricote, Mercedes</style></author><author><style face="normal" font="default" size="100%">Vidal-Puig, Antonio</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Differential Lipid Partitioning Between Adipocytes and Tissue Macrophages Modulates Macrophage Lipotoxicity and M2/M1 Polarization in Obese Mice.</style></title><secondary-title><style face="normal" font="default" size="100%">Diabetes</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011 Jan 24</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">60</style></volume><pages><style face="normal" font="default" size="100%">797-809</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;OBJECTIVE Obesity-associated insulin resistance is characterized by a state of chronic, low-grade inflammation that is associated with the accumulation of M1 proinflammatory macrophages in adipose tissue. Although different evidence explains the mechanisms linking the expansion of adipose tissue and adipose tissue macrophage (ATM) polarization, in the current study we investigated the concept of lipid-induced toxicity as the pathogenic link that could explain the trigger of this response. RESEARCH DESIGN AND METHODS We addressed this question using isolated ATMs and adipocytes from genetic and diet-induced murine models of obesity. Through transcriptomic and lipidomic analysis, we created a model integrating transcript and lipid species networks simultaneously occurring in adipocytes and ATMs and their reversibility by thiazolidinedione treatment. RESULTS We show that polarization of ATMs is associated with lipid accumulation and the consequent formation of foam cell-like cells in adipose tissue. Our study reveals that early stages of adipose tissue expansion are characterized by M2-polarized ATMs and that progressive lipid accumulation within ATMs heralds the M1 polarization, a macrophage phenotype associated with severe obesity and insulin resistance. Furthermore, rosiglitazone treatment, which promotes redistribution of lipids toward adipocytes and extends the M2 ATM polarization state, prevents the lipid alterations associated with M1 ATM polarization. CONCLUSIONS Our data indicate that the M1 ATM polarization in obesity might be a macrophage-specific manifestation of a more general lipotoxic pathogenic mechanism. This indicates that strategies to optimize fat deposition and repartitioning toward adipocytes might improve insulin sensitivity by preventing ATM lipotoxicity and M1 polarization.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Negredo, Ana</style></author><author><style face="normal" font="default" size="100%">Palacios, Gustavo</style></author><author><style face="normal" font="default" size="100%">Vázquez-Morón, Sonia</style></author><author><style face="normal" font="default" size="100%">González, Félix</style></author><author><style face="normal" font="default" size="100%">Dopazo, Hernán</style></author><author><style face="normal" font="default" size="100%">Molero, Francisca</style></author><author><style face="normal" font="default" size="100%">Juste, Javier</style></author><author><style face="normal" font="default" size="100%">Quetglas, Juan</style></author><author><style face="normal" font="default" size="100%">Savji, Nazir</style></author><author><style face="normal" font="default" size="100%">de la Cruz Martínez, Maria</style></author><author><style face="normal" font="default" size="100%">Herrera, Jesus Enrique</style></author><author><style face="normal" font="default" size="100%">Pizarro, Manuel</style></author><author><style face="normal" font="default" size="100%">Hutchison, Stephen K</style></author><author><style face="normal" font="default" size="100%">Echevarría, Juan E</style></author><author><style face="normal" font="default" size="100%">Lipkin, W Ian</style></author><author><style face="normal" font="default" size="100%">Tenorio, Antonio</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Discovery of an ebolavirus-like filovirus in europe.</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS pathogens</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011 Oct</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">7</style></volume><pages><style face="normal" font="default" size="100%">e1002304</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Filoviruses, amongst the most lethal of primate pathogens, have only been reported as natural infections in sub-Saharan Africa and the Philippines. Infections of bats with the ebolaviruses and marburgviruses do not appear to be associated with disease. Here we report identification in dead insectivorous bats of a genetically distinct filovirus, provisionally named Lloviu virus, after the site of detection, Cueva del Lloviu, in Spain.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arbiza, Leonardo</style></author><author><style face="normal" font="default" size="100%">Patricio, Mateus</style></author><author><style face="normal" font="default" size="100%">Dopazo, Hernán</style></author><author><style face="normal" font="default" size="100%">Posada, David</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Genome-wide heterogeneity of nucleotide substitution model fit.</style></title><secondary-title><style face="normal" font="default" size="100%">Genome biology and evolution</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">3</style></volume><pages><style face="normal" font="default" size="100%">896-908</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;At a genomic scale, the patterns that have shaped molecular evolution are believed to be largely heterogeneous. Consequently, comparative analyses should use appropriate probabilistic substitution models that capture the main features under which different genomic regions have evolved. While efforts have concentrated in the development and understanding of model selection techniques, no descriptions of overall relative substitution model fit at the genome level have been reported. Here, we provide a characterization of best-fit substitution models across three genomic data sets including coding regions from mammals, vertebrates, and Drosophila (24,000 alignments). According to the Akaike Information Criterion (AIC), 82 of 88 models considered were selected as best-fit models at least in one occasion, although with very different frequencies. Most parameter estimates also varied broadly among genes. Patterns found for vertebrates and Drosophila were quite similar and often more complex than those found in mammals. Phylogenetic trees derived from models in the 95% confidence interval set showed much less variance and were significantly closer to the tree estimated under the best-fit model than trees derived from models outside this interval. Although alternative criteria selected simpler models than the AIC, they suggested similar patterns. All together our results show that at a genomic scale, different gene alignments for the same set of taxa are best explained by a large variety of different substitution models and that model choice has implications on different parameter estimates including the inferred phylogenetic trees. After taking into account the differences related to sample size, our results suggest a noticeable diversity in the underlying evolutionary process. All together, we conclude that the use of model selection techniques is important to obtain consistent phylogenetic estimates from real data at a genomic scale.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yung, Sun</style></author><author><style face="normal" font="default" size="100%">Ledran, Maria</style></author><author><style face="normal" font="default" size="100%">Moreno-Gimeno, Inmaculada</style></author><author><style face="normal" font="default" size="100%">Conesa, Ana</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Dimmick, Ian</style></author><author><style face="normal" font="default" size="100%">Slater, Nicholas J</style></author><author><style face="normal" font="default" size="100%">Marenah, Lamin</style></author><author><style face="normal" font="default" size="100%">Real, Pedro J</style></author><author><style face="normal" font="default" size="100%">Paraskevopoulou, Iliana</style></author><author><style face="normal" font="default" size="100%">Bisbal, Viviana</style></author><author><style face="normal" font="default" size="100%">Burks, Deborah</style></author><author><style face="normal" font="default" size="100%">Santibanez-Koref, Mauro</style></author><author><style face="normal" font="default" size="100%">Moreno, Ruben</style></author><author><style face="normal" font="default" size="100%">Mountford, Joanne</style></author><author><style face="normal" font="default" size="100%">Menendez, Pablo</style></author><author><style face="normal" font="default" size="100%">Armstrong, Lyle</style></author><author><style face="normal" font="default" size="100%">Lako, Majlinda</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Large-scale transcriptional profiling and functional assays reveal important roles for Rho-GTPase signalling and SCL during haematopoietic differentiation of human embryonic stem cells.</style></title><secondary-title><style face="normal" font="default" size="100%">Hum Mol Genet</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Hum Mol Genet</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Acute Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Anemia, Hemolytic</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Basic Helix-Loop-Helix Transcription Factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Lineage</style></keyword><keyword><style  face="normal" font="default" size="100%">Cluster Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Embryonic Stem Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Erythroid Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Flow Cytometry</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Hematopoietic Stem Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Myeloid Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Paracrine Communication</style></keyword><keyword><style  face="normal" font="default" size="100%">Proto-Oncogene Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style  face="normal" font="default" size="100%">rho GTP-Binding Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style  face="normal" font="default" size="100%">Stem Cell Transplantation</style></keyword><keyword><style  face="normal" font="default" size="100%">T-Cell Acute Lymphocytic Leukemia Protein 1</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcriptome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011 Dec 15</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">20</style></volume><pages><style face="normal" font="default" size="100%">4932-46</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Understanding the transcriptional cues that direct differentiation of human embryonic stem cells (hESCs) and human-induced pluripotent stem cells to defined and functional cell types is essential for future clinical applications. In this study, we have compared transcriptional profiles of haematopoietic progenitors derived from hESCs at various developmental stages of a feeder- and serum-free differentiation method and show that the largest transcriptional changes occur during the first 4 days of differentiation. Data mining on the basis of molecular function revealed Rho-GTPase signalling as a key regulator of differentiation. Inhibition of this pathway resulted in a significant reduction in the numbers of emerging haematopoietic progenitors throughout the differentiation window, thereby uncovering a previously unappreciated role for Rho-GTPase signalling during human haematopoietic development. Our analysis indicated that SCL was the 11th most upregulated transcript during the first 4 days of the hESC differentiation process. Overexpression of SCL in hESCs promoted differentiation to meso-endodermal lineages, the emergence of haematopoietic and erythro-megakaryocytic progenitors and accelerated erythroid differentiation. Importantly, intrasplenic transplantation of SCL-overexpressing hESC-derived haematopoietic cells enhanced recovery from induced acute anaemia without significant cell engraftment, suggesting a paracrine-mediated effect.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">24</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/21937587?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Garrido-Gomez, Tamara</style></author><author><style face="normal" font="default" size="100%">Dominguez, Francisco</style></author><author><style face="normal" font="default" size="100%">Lopez, Juan Antonio</style></author><author><style face="normal" font="default" size="100%">Camafeita, Emilio</style></author><author><style face="normal" font="default" size="100%">Quiñonero, Alicia</style></author><author><style face="normal" font="default" size="100%">Martinez-Conejero, Jose Antonio</style></author><author><style face="normal" font="default" size="100%">Pellicer, Antonio</style></author><author><style face="normal" font="default" size="100%">Ana Conesa</style></author><author><style face="normal" font="default" size="100%">Simon, Carlos</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Modeling human endometrial decidualization from the interaction between proteome and secretome.</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of clinical endocrinology and metabolism</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011 Mar</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">96</style></volume><pages><style face="normal" font="default" size="100%">706-16</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Decidualization of the human endometrium, which involves morphological and biochemical modifications of the endometrial stromal cells (ESCs), is a prerequisite for adequate trophoblast invasion and placenta formation.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">González-del Pozo, María</style></author><author><style face="normal" font="default" size="100%">Borrego, Salud</style></author><author><style face="normal" font="default" size="100%">Barragán, Isabel</style></author><author><style face="normal" font="default" size="100%">Pieras, Juan I</style></author><author><style face="normal" font="default" size="100%">Santoyo, Javier</style></author><author><style face="normal" font="default" size="100%">Matamala, Nerea</style></author><author><style face="normal" font="default" size="100%">Naranjo, Belén</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Antiňolo, Guillermo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mutation screening of multiple genes in Spanish patients with autosomal recessive retinitis pigmentosa by targeted resequencing.</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PLoS One</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Alleles</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA Mutational Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Exons</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Variation</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome</style></keyword><keyword><style  face="normal" font="default" size="100%">Hispanic or Latino</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Introns</style></keyword><keyword><style  face="normal" font="default" size="100%">Language</style></keyword><keyword><style  face="normal" font="default" size="100%">mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">Mutation, Missense</style></keyword><keyword><style  face="normal" font="default" size="100%">Oligonucleotide Array Sequence Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymerase Chain Reaction</style></keyword><keyword><style  face="normal" font="default" size="100%">Reproducibility of Results</style></keyword><keyword><style  face="normal" font="default" size="100%">Retinitis pigmentosa</style></keyword><keyword><style  face="normal" font="default" size="100%">United States</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">6</style></volume><pages><style face="normal" font="default" size="100%">e27894</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Retinitis Pigmentosa (RP) is a heterogeneous group of inherited retinal dystrophies characterised ultimately by the loss of photoreceptor cells. RP is the leading cause of visual loss in individuals younger than 60 years, with a prevalence of about 1 in 4000. The molecular genetic diagnosis of autosomal recessive RP (arRP) is challenging due to the large genetic and clinical heterogeneity. Traditional methods for sequencing arRP genes are often laborious and not easily available and a screening technique that enables the rapid detection of the genetic cause would be very helpful in the clinical practice. The goal of this study was to develop and apply microarray-based resequencing technology capable of detecting both known and novel mutations on a single high-throughput platform. Hence, the coding regions and exon/intron boundaries of 16 arRP genes were resequenced using microarrays in 102 Spanish patients with clinical diagnosis of arRP. All the detected variations were confirmed by direct sequencing and potential pathogenicity was assessed by functional predictions and frequency in controls. For validation purposes 4 positive controls for variants consisting of previously identified changes were hybridized on the array. As a result of the screening, we detected 44 variants, of which 15 are very likely pathogenic detected in 14 arRP families (14%). Finally, the design of this array can easily be transformed in an equivalent diagnostic system based on targeted enrichment followed by next generation sequencing.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">12</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/22164218?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sánchez, Rubén</style></author><author><style face="normal" font="default" size="100%">Serra, François</style></author><author><style face="normal" font="default" size="100%">Tárraga, Joaquín</style></author><author><style face="normal" font="default" size="100%">Medina, Ignacio</style></author><author><style face="normal" font="default" size="100%">Carbonell, José</style></author><author><style face="normal" font="default" size="100%">Pulido, Luis</style></author><author><style face="normal" font="default" size="100%">De Maria, Alejandro</style></author><author><style face="normal" font="default" size="100%">Capella-Gutíerrez, Salvador</style></author><author><style face="normal" font="default" size="100%">Huerta-Cepas, Jaime</style></author><author><style face="normal" font="default" size="100%">Gabaldón, Toni</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Dopazo, Hernán</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Phylemon 2.0: a suite of web-tools for molecular evolution, phylogenetics, phylogenomics and hypotheses testing.</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Evolution, Molecular</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Internet</style></keyword><keyword><style  face="normal" font="default" size="100%">Phylogeny</style></keyword><keyword><style  face="normal" font="default" size="100%">Sequence Alignment</style></keyword><keyword><style  face="normal" font="default" size="100%">Software</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011 Jul</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">39</style></volume><pages><style face="normal" font="default" size="100%">W470-4</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Phylemon 2.0 is a new release of the suite of web tools for molecular evolution, phylogenetics, phylogenomics and hypotheses testing. It has been designed as a response to the increasing demand of molecular sequence analyses for experts and non-expert users. Phylemon 2.0 has several unique features that differentiates it from other similar web resources: (i) it offers an integrated environment that enables evolutionary analyses, format conversion, file storage and edition of results; (ii) it suggests further analyses, thereby guiding the users through the web server; and (iii) it allows users to design and save phylogenetic pipelines to be used over multiple genes (phylogenomics). Altogether, Phylemon 2.0 integrates a suite of 30 tools covering sequence alignment reconstruction and trimming; tree reconstruction, visualization and manipulation; and evolutionary hypotheses testing.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">Web Server issue</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/21646336?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cardona, Fernando</style></author><author><style face="normal" font="default" size="100%">Sánchez-Mut, Jose Vicente</style></author><author><style face="normal" font="default" size="100%">Dopazo, Hernán</style></author><author><style face="normal" font="default" size="100%">Pérez-Tur, Jordi</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Phylogenetic and in silico structural analysis of the Parkinson disease-related kinase PINK1.</style></title><secondary-title><style face="normal" font="default" size="100%">Human mutation</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011 Apr</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">32</style></volume><pages><style face="normal" font="default" size="100%">369-78</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Parkinson disease (PD) is the second most common neurodegenerative disorder and is characterized by the loss of dopaminergic neurons in the substantia nigra. Mutations in PINK1 were shown to cause recessive familial PD, and today are proposed to be associated with the disease via mitochondrial dysfunction and oxidative damage. The PINK1 gene comprises eight exons, which encode a ubiquitously expressed 581 amino acid protein that contains an N-terminal mitochondrial targeting domain and a serine/threonine protein kinase. To better understand the relationship between PINK1 and PD we have first analyzed the evolutionary history of the gene showing its late emergence in evolution. In addition, we have modeled the three-dimensional structure of PINK1 and found some evidences that help to explain the effect of some PD-related mutations in this protein’s function.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cuenca-Bono, Bernardo</style></author><author><style face="normal" font="default" size="100%">García-Molinero, Varinia</style></author><author><style face="normal" font="default" size="100%">Pascual-García, Pau</style></author><author><style face="normal" font="default" size="100%">Dopazo, Hernán</style></author><author><style face="normal" font="default" size="100%">Llopis, Ana</style></author><author><style face="normal" font="default" size="100%">Vilardell, Josep</style></author><author><style face="normal" font="default" size="100%">Rodríguez-Navarro, Susana</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">SUS1 introns are required for efficient mRNA nuclear export in yeast.</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic acids research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011 Oct 1</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">39</style></volume><pages><style face="normal" font="default" size="100%">8599-611</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Efficient coupling between mRNA synthesis and export is essential for gene expression. Sus1/ENY2, a component of the SAGA and TREX-2 complexes, is involved in both transcription and mRNA export. While most yeast genes lack introns, we previously reported that yeast SUS1 bears two. Here we show that this feature is evolutionarily conserved and critical for Sus1 function. We determine that while SUS1 splicing is inefficient, it responds to cellular conditions, and intronic mutations either promoting or blocking splicing lead to defects in mRNA export and cell growth. Consistent with this, we find that an intron-less SUS1 only partially rescues sus1&amp;Delta; phenotypes. Remarkably, splicing of each SUS1 intron is also affected by the presence of the other and by SUS1 exonic sequences. Moreover, by following SUS1 RNA and protein levels we establish that nonsense-mediated decay (NMD) pathway and the splicing factor Mud2 both play a role in SUS1 expression. Our data (and those of the accompanying work by Hossain et al.) provide evidence of the involvement of splicing, translation, and decay in the regulation of early events in mRNP biogenesis; and imply the additional requirement for a balance in splicing isoforms from a single gene.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Medina, Ignacio</style></author><author><style face="normal" font="default" size="100%">Carbonell, José</style></author><author><style face="normal" font="default" size="100%">Pulido, Luis</style></author><author><style face="normal" font="default" size="100%">Madeira, Sara C</style></author><author><style face="normal" font="default" size="100%">Goetz, Stefan</style></author><author><style face="normal" font="default" size="100%">Ana Conesa</style></author><author><style face="normal" font="default" size="100%">Tárraga, Joaquín</style></author><author><style face="normal" font="default" size="100%">Pascual-Montano, Alberto</style></author><author><style face="normal" font="default" size="100%">Nogales-Cadenas, Ruben</style></author><author><style face="normal" font="default" size="100%">Santoyo, Javier</style></author><author><style face="normal" font="default" size="100%">García, Francisco</style></author><author><style face="normal" font="default" size="100%">Marbà, Martina</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Joaquín Dopazo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Babelomics: an integrative platform for the analysis of transcriptomics, proteomics and genomic data with advanced functional profiling.</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic Acids Research</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">babelomics</style></keyword><keyword><style  face="normal" font="default" size="100%">gene expression</style></keyword><keyword><style  face="normal" font="default" size="100%">genotyping</style></keyword><keyword><style  face="normal" font="default" size="100%">gepas</style></keyword><keyword><style  face="normal" font="default" size="100%">GSA</style></keyword><keyword><style  face="normal" font="default" size="100%">GWAS</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010 May 16</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://nar.oxfordjournals.org/content/38/suppl_2/W210.full</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">38</style></volume><pages><style face="normal" font="default" size="100%">W210-W213. Featured in NAR</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Babelomics is a response to the growing necessity of integrating and analyzing different types of genomic data in an environment that allows an easy functional interpretation of the results. Babelomics includes a complete suite of methods for the analysis of gene expression data that include normalization (covering most commercial platforms), pre-processing, differential gene expression (case-controls, multiclass, survival or continuous values), predictors, clustering; large-scale genotyping assays (case controls and TDTs, and allows population stratification analysis and correction). All these genomic data analysis facilities are integrated and connected to multiple options for the functional interpretation of the experiments. Different methods of functional enrichment or gene set enrichment can be used to understand the functional basis of the experiment analyzed. Many sources of biological information, which include functional (GO, KEGG, Biocarta, Reactome, etc.), regulatory (Transfac, Jaspar, ORegAnno, miRNAs, etc.), text-mining or protein-protein interaction modules can be used for this purpose. Finally a tool for the de novo functional annotation of sequences has been included in the system. This provides support for the functional analysis of non-model species. Mirrors of Babelomics or command line execution of their individual components are now possible. Babelomics is available at http://www.babelomics.org.&lt;/p&gt;</style></abstract><section><style face="normal" font="default" size="100%">Featured in NAR</style></section></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Javierre, Biola M</style></author><author><style face="normal" font="default" size="100%">Fernandez, Agustin F</style></author><author><style face="normal" font="default" size="100%">Richter, Julia</style></author><author><style face="normal" font="default" size="100%">Fatima Al-Shahrour</style></author><author><style face="normal" font="default" size="100%">Martin-Subero, J Ignacio</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Ubreva, Javier</style></author><author><style face="normal" font="default" size="100%">Berdasco, Maria</style></author><author><style face="normal" font="default" size="100%">Fraga, Mario F</style></author><author><style face="normal" font="default" size="100%">O’Hanlon, Terrance P</style></author><author><style face="normal" font="default" size="100%">Rider, Lisa G</style></author><author><style face="normal" font="default" size="100%">Jacinto, Filipe V</style></author><author><style face="normal" font="default" size="100%">Lopez-Longo, F Javier</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Forn, Marta</style></author><author><style face="normal" font="default" size="100%">Peinado, Miguel A</style></author><author><style face="normal" font="default" size="100%">Carreño, Luis</style></author><author><style face="normal" font="default" size="100%">Sawalha, Amr H</style></author><author><style face="normal" font="default" size="100%">Harley, John B</style></author><author><style face="normal" font="default" size="100%">Siebert, Reiner</style></author><author><style face="normal" font="default" size="100%">Esteller, Manel</style></author><author><style face="normal" font="default" size="100%">Miller, Frederick W</style></author><author><style face="normal" font="default" size="100%">Ballestar, Esteban</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus.</style></title><secondary-title><style face="normal" font="default" size="100%">Genome research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010 Feb</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">20</style></volume><pages><style face="normal" font="default" size="100%">170-9</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Monozygotic (MZ) twins are partially concordant for most complex diseases, including autoimmune disorders. Whereas phenotypic concordance can be used to study heritability, discordance suggests the role of non-genetic factors. In autoimmune diseases, environmentally driven epigenetic changes are thought to contribute to their etiology. Here we report the first high-throughput and candidate sequence analyses of DNA methylation to investigate discordance for autoimmune disease in twins. We used a cohort of MZ twins discordant for three diseases whose clinical signs often overlap: systemic lupus erythematosus (SLE), rheumatoid arthritis, and dermatomyositis. Only MZ twins discordant for SLE featured widespread changes in the DNA methylation status of a significant number of genes. Gene ontology analysis revealed enrichment in categories associated with immune function. Individual analysis confirmed the existence of DNA methylation and expression changes in genes relevant to SLE pathogenesis. These changes occurred in parallel with a global decrease in the 5-methylcytosine content that was concomitantly accompanied with changes in DNA methylation and expression levels of ribosomal RNA genes, although no changes in repetitive sequences were found. Our findings not only identify potentially relevant DNA methylation markers for the clinical characterization of SLE patients but also support the notion that epigenetic changes may be critical in the clinical manifestations of autoimmune disease.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bonifaci, Núria</style></author><author><style face="normal" font="default" size="100%">Górski, Bohdan</style></author><author><style face="normal" font="default" size="100%">Masojć, Bartlomiej</style></author><author><style face="normal" font="default" size="100%">Wokołorczyk, Dominika</style></author><author><style face="normal" font="default" size="100%">Jakubowska, Anna</style></author><author><style face="normal" font="default" size="100%">Dębniak, Tadeusz</style></author><author><style face="normal" font="default" size="100%">Berenguer, Antoni</style></author><author><style face="normal" font="default" size="100%">Serra Musach, Jordi</style></author><author><style face="normal" font="default" size="100%">Brunet, Joan</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Narod, Steven A</style></author><author><style face="normal" font="default" size="100%">Lubiński, Jan</style></author><author><style face="normal" font="default" size="100%">Lázaro, Conxi</style></author><author><style face="normal" font="default" size="100%">Cybulski, Cezary</style></author><author><style face="normal" font="default" size="100%">Pujana, Miguel Angel</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Exploring the link between germline and somatic genetic alterations in breast carcinogenesis.</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PLoS One</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Bone Morphogenetic Protein Receptors, Type I</style></keyword><keyword><style  face="normal" font="default" size="100%">Breast</style></keyword><keyword><style  face="normal" font="default" size="100%">Breast Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Calcium-Calmodulin-Dependent Protein Kinases</style></keyword><keyword><style  face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Cyclin-Dependent Kinases</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Progression</style></keyword><keyword><style  face="normal" font="default" size="100%">Estrogen Receptor alpha</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Frequency</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Predisposition to Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome-Wide Association Study</style></keyword><keyword><style  face="normal" font="default" size="100%">Genotype</style></keyword><keyword><style  face="normal" font="default" size="100%">Germ-Line Mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Odds Ratio</style></keyword><keyword><style  face="normal" font="default" size="100%">Poland</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Serine-Threonine Kinases</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein-Tyrosine Kinases</style></keyword><keyword><style  face="normal" font="default" size="100%">Receptor Protein-Tyrosine Kinases</style></keyword><keyword><style  face="normal" font="default" size="100%">Receptor, EphA3</style></keyword><keyword><style  face="normal" font="default" size="100%">Receptor, EphA7</style></keyword><keyword><style  face="normal" font="default" size="100%">Receptor, EphB1</style></keyword><keyword><style  face="normal" font="default" size="100%">Risk Factors</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010 Nov 22</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">5</style></volume><pages><style face="normal" font="default" size="100%">e14078</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Recent genome-wide association studies (GWASs) have identified candidate genes contributing to cancer risk through low-penetrance mutations. Many of these genes were unexpected and, intriguingly, included well-known players in carcinogenesis at the somatic level. To assess the hypothesis of a germline-somatic link in carcinogenesis, we evaluated the distribution of somatic gene labels within the ordered results of a breast cancer risk GWAS. This analysis suggested frequent influence on risk of genetic variation in loci encoding for &quot;driver kinases&quot; (i.e., kinases encoded by genes that showed higher somatic mutation rates than expected by chance and, therefore, whose deregulation may contribute to cancer development and/or progression). Assessment of these predictions using a population-based case-control study in Poland replicated the association for rs3732568 in EPHB1 (odds ratio (OR) = 0.79; 95% confidence interval (CI): 0.63-0.98; P(trend) = 0.031). Analyses by early age at diagnosis and by estrogen receptor α (ERα) tumor status indicated potential associations for rs6852678 in CDKL2 (OR = 0.32, 95% CI: 0.10-1.00; P(recessive) = 0.044) and rs10878640 in DYRK2 (OR = 2.39, 95% CI: 1.32-4.30; P(dominant) = 0.003), and for rs12765929, rs9836340, rs4707795 in BMPR1A, EPHA3 and EPHA7, respectively (ERα tumor status P(interaction)&lt;0.05). The identification of three novel candidates as EPH receptor genes might indicate a link between perturbed compartmentalization of early neoplastic lesions and breast cancer risk and progression. Together, these data may lay the foundations for replication in additional populations and could potentially increase our knowledge of the underlying molecular mechanisms of breast carcinogenesis.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">11</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/21124932?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Peña, Arantxa</style></author><author><style face="normal" font="default" size="100%">Teeling, Hanno</style></author><author><style face="normal" font="default" size="100%">Huerta-Cepas, Jaime</style></author><author><style face="normal" font="default" size="100%">Santos, Fernando</style></author><author><style face="normal" font="default" size="100%">Yarza, Pablo</style></author><author><style face="normal" font="default" size="100%">Brito-Echeverría, Jocelyn</style></author><author><style face="normal" font="default" size="100%">Lucio, Marianna</style></author><author><style face="normal" font="default" size="100%">Schmitt-Kopplin, Philippe</style></author><author><style face="normal" font="default" size="100%">Meseguer, Inmaculada</style></author><author><style face="normal" font="default" size="100%">Schenowitz, Chantal</style></author><author><style face="normal" font="default" size="100%">Dossat, Carole</style></author><author><style face="normal" font="default" size="100%">Barbe, Valerie</style></author><author><style face="normal" font="default" size="100%">Joaquín Dopazo</style></author><author><style face="normal" font="default" size="100%">Rosselló-Mora, Ramon</style></author><author><style face="normal" font="default" size="100%">Schüler, Margarete</style></author><author><style face="normal" font="default" size="100%">Glöckner, Frank Oliver</style></author><author><style face="normal" font="default" size="100%">Amann, Rudolf</style></author><author><style face="normal" font="default" size="100%">Gabaldón, Toni</style></author><author><style face="normal" font="default" size="100%">Antón, Josefa</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Fine-scale evolution: genomic, phenotypic and ecological differentiation in two coexisting Salinibacter ruber strains.</style></title><secondary-title><style face="normal" font="default" size="100%">The ISME journal</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010 Feb 18</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Genomic and metagenomic data indicate a high degree of genomic variation within microbial populations, although the ecological and evolutive meaning of this microdiversity remains unknown. Microevolution analyses, including genomic and experimental approaches, are so far very scarce for non-pathogenic bacteria. In this study, we compare the genomes, metabolomes and selected ecological traits of the strains M8 and M31 of the hyperhalophilic bacterium Salinibacter ruber that contain ribosomal RNA (rRNA) gene and intergenic regions that are identical in sequence and were simultaneously isolated from a Mediterranean solar saltern. Comparative analyses indicate that S. ruber genomes present a mosaic structure with conserved and hypervariable regions (HVRs). The HVRs or genomic islands, are enriched in transposases, genes related to surface properties, strain-specific genes and highly divergent orthologous. However, the many indels outside the HVRs indicate that genome plasticity extends beyond them. Overall, 10% of the genes encoded in the M8 genome are absent from M31 and could stem from recent acquisitions. S. ruber genomes also harbor 34 genes located outside HVRs that are transcribed during standard growth and probably derive from lateral gene transfers with Archaea preceding the M8/M31 divergence. Metabolomic analyses, phage susceptibility and competition experiments indicate that these genomic differences cannot be considered neutral from an ecological perspective. The results point to the avoidance of competition by micro-niche adaptation and response to viral predation as putative major forces that drive microevolution within these Salinibacter strains. In addition, this work highlights the extent of bacterial functional diversity and environmental adaptation, beyond the resolution of the 16S rRNA and internal transcribed spacers regions.The ISME Journal advance online publication, 18 February 2010; doi:10.1038/ismej.2010.6.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Galan, Amparo</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Póo, M Eugenia</style></author><author><style face="normal" font="default" size="100%">Valbuena, Diana</style></author><author><style face="normal" font="default" size="100%">Ruiz, Veronica</style></author><author><style face="normal" font="default" size="100%">Aguilar, Cristóbal</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Simon, Carlos</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Functional genomics of 5- to 8-cell stage human embryos by blastomere single-cell cDNA analysis.</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS One</style></secondary-title><alt-title><style face="normal" font="default" size="100%">PLoS One</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Blastomeres</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA, Complementary</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Oligonucleotide Array Sequence Analysis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010 Oct 26</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">5</style></volume><pages><style face="normal" font="default" size="100%">e13615</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Blastomere fate and embryonic genome activation (EGA) during human embryonic development are unsolved areas of high scientific and clinical interest. Forty-nine blastomeres from 5- to 8-cell human embryos have been investigated following an efficient single-cell cDNA amplification protocol to provide a template for high-density microarray analysis. The previously described markers, characteristic of Inner Cell Mass (ICM) (n = 120), stemness (n = 190) and Trophectoderm (TE) (n = 45), were analyzed, and a housekeeping pattern of 46 genes was established. All the human blastomeres from the 5- to 8-cell stage embryo displayed a common gene expression pattern corresponding to ICM markers (e.g., DDX3, FOXD3, LEFTY1, MYC, NANOG, POU5F1), stemness (e.g., POU5F1, DNMT3B, GABRB3, SOX2, ZFP42, TERT), and TE markers (e.g., GATA6, EOMES, CDX2, LHCGR). The EGA profile was also investigated between the 5-6- and 8-cell stage embryos, and compared to the blastocyst stage. Known genes (n = 92) such as depleted maternal transcripts (e.g., CCNA1, CCNB1, DPPA2) and embryo-specific activation (e.g., POU5F1, CDH1, DPPA4), as well as novel genes, were confirmed. In summary, the global single-cell cDNA amplification microarray analysis of the 5- to 8-cell stage human embryos reveals that blastomere fate is not committed to ICM or TE. Finally, new EGA features in human embryogenesis are presented.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/21049019?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Joaquín Dopazo</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Grützmann, Robert</style></author><author><style face="normal" font="default" size="100%">Pilarsky, Christian</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Functional profiling methods in cancer.</style></title><secondary-title><style face="normal" font="default" size="100%">Methods in molecular biology (Clifton, N.J.)</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">576</style></volume><pages><style face="normal" font="default" size="100%">363-74</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The introduction of new high-throughput methodologies such as DNA microarrays constitutes a major breakthrough in cancer research. The unprecedented amount of data produced by such technologies has opened new avenues for interrogating living systems although, at the same time, it has demanded of the development of new data analytical methods as well as new strategies for testing hypotheses. A history of early successful applications in cancer boosted the use of microarrays and fostered further applications in other fields. Keeping the pace with these technologies, bioinformatics offers new solutions for data analysis and, what is more important, permits the formulation of a new class of hypotheses inspired in systems biology, more oriented to pathways or, in general, to modules of functionally related genes. Although these analytical methodologies are new, some options are already available and are discussed in this chapter.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prado-Lopez, Sonia</style></author><author><style face="normal" font="default" size="100%">Conesa, Ana</style></author><author><style face="normal" font="default" size="100%">Armiñán, Ana</style></author><author><style face="normal" font="default" size="100%">Martínez-Losa, Magdalena</style></author><author><style face="normal" font="default" size="100%">Escobedo-Lucea, Carmen</style></author><author><style face="normal" font="default" size="100%">Gandia, Carolina</style></author><author><style face="normal" font="default" size="100%">Tarazona, Sonia</style></author><author><style face="normal" font="default" size="100%">Melguizo, Dario</style></author><author><style face="normal" font="default" size="100%">Blesa, David</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Sanz-González, Silvia</style></author><author><style face="normal" font="default" size="100%">Sepúlveda, Pilar</style></author><author><style face="normal" font="default" size="100%">Götz, Stefan</style></author><author><style face="normal" font="default" size="100%">O'Connor, José Enrique</style></author><author><style face="normal" font="default" size="100%">Moreno, Ruben</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Burks, Deborah J</style></author><author><style face="normal" font="default" size="100%">Stojkovic, Miodrag</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Hypoxia promotes efficient differentiation of human embryonic stem cells to functional endothelium.</style></title><secondary-title><style face="normal" font="default" size="100%">Stem Cells</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Stem Cells</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Angiopoietin-1</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">biomarkers</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Culture Techniques</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Differentiation</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Hypoxia</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Transplantation</style></keyword><keyword><style  face="normal" font="default" size="100%">Cells, Cultured</style></keyword><keyword><style  face="normal" font="default" size="100%">Down-Regulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Embryonic Stem Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Endothelial Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Myocardial Infarction</style></keyword><keyword><style  face="normal" font="default" size="100%">Neovascularization, Physiologic</style></keyword><keyword><style  face="normal" font="default" size="100%">Oxygen</style></keyword><keyword><style  face="normal" font="default" size="100%">Pluripotent Stem Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Rats</style></keyword><keyword><style  face="normal" font="default" size="100%">Rats, Nude</style></keyword><keyword><style  face="normal" font="default" size="100%">Vascular Endothelial Growth Factor A</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010 Mar 31</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">28</style></volume><pages><style face="normal" font="default" size="100%">407-18</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Early development of mammalian embryos occurs in an environment of relative hypoxia. Nevertheless, human embryonic stem cells (hESC), which are derived from the inner cell mass of blastocyst, are routinely cultured under the same atmospheric conditions (21% O(2)) as somatic cells. We hypothesized that O(2) levels modulate gene expression and differentiation potential of hESC, and thus, we performed gene profiling of hESC maintained under normoxic or hypoxic (1% or 5% O(2)) conditions. Our analysis revealed that hypoxia downregulates expression of pluripotency markers in hESC but increases significantly the expression of genes associated with angio- and vasculogenesis including vascular endothelial growth factor and angiopoitein-like proteins. Consequently, we were able to efficiently differentiate hESC to functional endothelial cells (EC) by varying O(2) levels; after 24 hours at 5% O(2), more than 50% of cells were CD34+. Transplantation of resulting endothelial-like cells improved both systolic function and fractional shortening in a rodent model of myocardial infarction. Moreover, analysis of the infarcted zone revealed that transplanted EC reduced the area of fibrous scar tissue by 50%. Thus, use of hypoxic conditions to specify the endothelial lineage suggests a novel strategy for cellular therapies aimed at repair of damaged vasculature in pathologies such as cerebral ischemia and myocardial infarction.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/20049902?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Németh, Attila</style></author><author><style face="normal" font="default" size="100%">Ana Conesa</style></author><author><style face="normal" font="default" size="100%">Santoyo-López, Javier</style></author><author><style face="normal" font="default" size="100%">Medina, Ignacio</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Péterfia, Bálint</style></author><author><style face="normal" font="default" size="100%">Solovei, Irina</style></author><author><style face="normal" font="default" size="100%">Cremer, Thomas</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Längst, Gernot</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Initial genomics of the human nucleolus.</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS genetics</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">NGS</style></keyword><keyword><style  face="normal" font="default" size="100%">nucleolus</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.1000889</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">6</style></volume><pages><style face="normal" font="default" size="100%">e1000889</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;We report for the first time the genomics of a nuclear compartment of the eukaryotic cell. 454 sequencing and microarray analysis revealed the pattern of nucleolus-associated chromatin domains (NADs) in the linear human genome and identified different gene families and certain satellite repeats as the major building blocks of NADs, which constitute about 4% of the genome. Bioinformatic evaluation showed that NAD-localized genes take part in specific biological processes, like the response to other organisms, odor perception, and tissue development. 3D FISH and immunofluorescence experiments illustrated the spatial distribution of NAD-specific chromatin within interphase nuclei and its alteration upon transcriptional changes. Altogether, our findings describe the nature of DNA sequences associated with the human nucleolus and provide insights into the function of the nucleolus in genome organization and establishment of nuclear architecture.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Shi, Leming</style></author><author><style face="normal" font="default" size="100%">Campbell, Gregory</style></author><author><style face="normal" font="default" size="100%">Jones, Wendell D</style></author><author><style face="normal" font="default" size="100%">Campagne, Fabien</style></author><author><style face="normal" font="default" size="100%">Wen, Zhining</style></author><author><style face="normal" font="default" size="100%">Walker, Stephen J</style></author><author><style face="normal" font="default" size="100%">Su, Zhenqiang</style></author><author><style face="normal" font="default" size="100%">Chu, Tzu-Ming</style></author><author><style face="normal" font="default" size="100%">Goodsaid, Federico M</style></author><author><style face="normal" font="default" size="100%">Pusztai, Lajos</style></author><author><style face="normal" font="default" size="100%">Shaughnessy, John D</style></author><author><style face="normal" font="default" size="100%">Oberthuer, André</style></author><author><style face="normal" font="default" size="100%">Thomas, Russell S</style></author><author><style face="normal" font="default" size="100%">Paules, Richard S</style></author><author><style face="normal" font="default" size="100%">Fielden, Mark</style></author><author><style face="normal" font="default" size="100%">Barlogie, Bart</style></author><author><style face="normal" font="default" size="100%">Chen, Weijie</style></author><author><style face="normal" font="default" size="100%">Du, Pan</style></author><author><style face="normal" font="default" size="100%">Fischer, Matthias</style></author><author><style face="normal" font="default" size="100%">Furlanello, Cesare</style></author><author><style face="normal" font="default" size="100%">Gallas, Brandon D</style></author><author><style face="normal" font="default" size="100%">Ge, Xijin</style></author><author><style face="normal" font="default" size="100%">Megherbi, Dalila B</style></author><author><style face="normal" font="default" size="100%">Symmans, W Fraser</style></author><author><style face="normal" font="default" size="100%">Wang, May D</style></author><author><style face="normal" font="default" size="100%">Zhang, John</style></author><author><style face="normal" font="default" size="100%">Bitter, Hans</style></author><author><style face="normal" font="default" size="100%">Brors, Benedikt</style></author><author><style face="normal" font="default" size="100%">Bushel, Pierre R</style></author><author><style face="normal" font="default" size="100%">Bylesjo, Max</style></author><author><style face="normal" font="default" size="100%">Chen, Minjun</style></author><author><style face="normal" font="default" size="100%">Cheng, Jie</style></author><author><style face="normal" font="default" size="100%">Cheng, Jing</style></author><author><style face="normal" font="default" size="100%">Chou, Jeff</style></author><author><style face="normal" font="default" size="100%">Davison, Timothy S</style></author><author><style face="normal" font="default" size="100%">Delorenzi, Mauro</style></author><author><style face="normal" font="default" size="100%">Deng, Youping</style></author><author><style face="normal" font="default" size="100%">Devanarayan, Viswanath</style></author><author><style face="normal" font="default" size="100%">Dix, David J</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Dorff, Kevin C</style></author><author><style face="normal" font="default" size="100%">Elloumi, Fathi</style></author><author><style face="normal" font="default" size="100%">Fan, Jianqing</style></author><author><style face="normal" font="default" size="100%">Fan, Shicai</style></author><author><style face="normal" font="default" size="100%">Fan, Xiaohui</style></author><author><style face="normal" font="default" size="100%">Fang, Hong</style></author><author><style face="normal" font="default" size="100%">Gonzaludo, Nina</style></author><author><style face="normal" font="default" size="100%">Hess, Kenneth R</style></author><author><style face="normal" font="default" size="100%">Hong, Huixiao</style></author><author><style face="normal" font="default" size="100%">Huan, Jun</style></author><author><style face="normal" font="default" size="100%">Irizarry, Rafael A</style></author><author><style face="normal" font="default" size="100%">Judson, Richard</style></author><author><style face="normal" font="default" size="100%">Juraeva, Dilafruz</style></author><author><style face="normal" font="default" size="100%">Lababidi, Samir</style></author><author><style face="normal" font="default" size="100%">Lambert, Christophe G</style></author><author><style face="normal" font="default" size="100%">Li, Li</style></author><author><style face="normal" font="default" size="100%">Li, Yanen</style></author><author><style face="normal" font="default" size="100%">Li, Zhen</style></author><author><style face="normal" font="default" size="100%">Lin, Simon M</style></author><author><style face="normal" font="default" size="100%">Liu, Guozhen</style></author><author><style face="normal" font="default" size="100%">Lobenhofer, Edward K</style></author><author><style face="normal" font="default" size="100%">Luo, Jun</style></author><author><style face="normal" font="default" size="100%">Luo, Wen</style></author><author><style face="normal" font="default" size="100%">McCall, Matthew N</style></author><author><style face="normal" font="default" size="100%">Nikolsky, Yuri</style></author><author><style face="normal" font="default" size="100%">Pennello, Gene A</style></author><author><style face="normal" font="default" size="100%">Perkins, Roger G</style></author><author><style face="normal" font="default" size="100%">Philip, Reena</style></author><author><style face="normal" font="default" size="100%">Popovici, Vlad</style></author><author><style face="normal" font="default" size="100%">Price, Nathan D</style></author><author><style face="normal" font="default" size="100%">Qian, Feng</style></author><author><style face="normal" font="default" size="100%">Scherer, Andreas</style></author><author><style face="normal" font="default" size="100%">Shi, Tieliu</style></author><author><style face="normal" font="default" size="100%">Shi, Weiwei</style></author><author><style face="normal" font="default" size="100%">Sung, Jaeyun</style></author><author><style face="normal" font="default" size="100%">Thierry-Mieg, Danielle</style></author><author><style face="normal" font="default" size="100%">Thierry-Mieg, Jean</style></author><author><style face="normal" font="default" size="100%">Thodima, Venkata</style></author><author><style face="normal" font="default" size="100%">Trygg, Johan</style></author><author><style face="normal" font="default" size="100%">Vishnuvajjala, Lakshmi</style></author><author><style face="normal" font="default" size="100%">Wang, Sue Jane</style></author><author><style face="normal" font="default" size="100%">Wu, Jianping</style></author><author><style face="normal" font="default" size="100%">Wu, Yichao</style></author><author><style face="normal" font="default" size="100%">Xie, Qian</style></author><author><style face="normal" font="default" size="100%">Yousef, Waleed A</style></author><author><style face="normal" font="default" size="100%">Zhang, Liang</style></author><author><style face="normal" font="default" size="100%">Zhang, Xuegong</style></author><author><style face="normal" font="default" size="100%">Zhong, Sheng</style></author><author><style face="normal" font="default" size="100%">Zhou, Yiming</style></author><author><style face="normal" font="default" size="100%">Zhu, Sheng</style></author><author><style face="normal" font="default" size="100%">Arasappan, Dhivya</style></author><author><style face="normal" font="default" size="100%">Bao, Wenjun</style></author><author><style face="normal" font="default" size="100%">Lucas, Anne Bergstrom</style></author><author><style face="normal" font="default" size="100%">Berthold, Frank</style></author><author><style face="normal" font="default" size="100%">Brennan, Richard J</style></author><author><style face="normal" font="default" size="100%">Buness, Andreas</style></author><author><style face="normal" font="default" size="100%">Catalano, Jennifer G</style></author><author><style face="normal" font="default" size="100%">Chang, Chang</style></author><author><style face="normal" font="default" size="100%">Chen, Rong</style></author><author><style face="normal" font="default" size="100%">Cheng, Yiyu</style></author><author><style face="normal" font="default" size="100%">Cui, Jian</style></author><author><style face="normal" font="default" size="100%">Czika, Wendy</style></author><author><style face="normal" font="default" size="100%">Demichelis, Francesca</style></author><author><style face="normal" font="default" size="100%">Deng, Xutao</style></author><author><style face="normal" font="default" size="100%">Dosymbekov, Damir</style></author><author><style face="normal" font="default" size="100%">Eils, Roland</style></author><author><style face="normal" font="default" size="100%">Feng, Yang</style></author><author><style face="normal" font="default" size="100%">Fostel, Jennifer</style></author><author><style face="normal" font="default" size="100%">Fulmer-Smentek, Stephanie</style></author><author><style face="normal" font="default" size="100%">Fuscoe, James C</style></author><author><style face="normal" font="default" size="100%">Gatto, Laurent</style></author><author><style face="normal" font="default" size="100%">Ge, Weigong</style></author><author><style face="normal" font="default" size="100%">Goldstein, Darlene R</style></author><author><style face="normal" font="default" size="100%">Guo, Li</style></author><author><style face="normal" font="default" size="100%">Halbert, Donald N</style></author><author><style face="normal" font="default" size="100%">Han, Jing</style></author><author><style face="normal" font="default" size="100%">Harris, Stephen C</style></author><author><style face="normal" font="default" size="100%">Hatzis, Christos</style></author><author><style face="normal" font="default" size="100%">Herman, Damir</style></author><author><style face="normal" font="default" size="100%">Huang, Jianping</style></author><author><style face="normal" font="default" size="100%">Jensen, Roderick V</style></author><author><style face="normal" font="default" size="100%">Jiang, Rui</style></author><author><style face="normal" font="default" size="100%">Johnson, Charles D</style></author><author><style face="normal" font="default" size="100%">Jurman, Giuseppe</style></author><author><style face="normal" font="default" size="100%">Kahlert, Yvonne</style></author><author><style face="normal" font="default" size="100%">Khuder, Sadik A</style></author><author><style face="normal" font="default" size="100%">Kohl, Matthias</style></author><author><style face="normal" font="default" size="100%">Li, Jianying</style></author><author><style face="normal" font="default" size="100%">Li, Li</style></author><author><style face="normal" font="default" size="100%">Li, Menglong</style></author><author><style face="normal" font="default" size="100%">Li, Quan-Zhen</style></author><author><style face="normal" font="default" size="100%">Li, Shao</style></author><author><style face="normal" font="default" size="100%">Li, Zhiguang</style></author><author><style face="normal" font="default" size="100%">Liu, Jie</style></author><author><style face="normal" font="default" size="100%">Liu, Ying</style></author><author><style face="normal" font="default" size="100%">Liu, Zhichao</style></author><author><style face="normal" font="default" size="100%">Meng, Lu</style></author><author><style face="normal" font="default" size="100%">Madera, Manuel</style></author><author><style face="normal" font="default" size="100%">Martinez-Murillo, Francisco</style></author><author><style face="normal" font="default" size="100%">Medina, Ignacio</style></author><author><style face="normal" font="default" size="100%">Meehan, Joseph</style></author><author><style face="normal" font="default" size="100%">Miclaus, Kelci</style></author><author><style face="normal" font="default" size="100%">Moffitt, Richard A</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Mukherjee, Piali</style></author><author><style face="normal" font="default" size="100%">Mulligan, George J</style></author><author><style face="normal" font="default" size="100%">Neville, Padraic</style></author><author><style face="normal" font="default" size="100%">Nikolskaya, Tatiana</style></author><author><style face="normal" font="default" size="100%">Ning, Baitang</style></author><author><style face="normal" font="default" size="100%">Page, Grier P</style></author><author><style face="normal" font="default" size="100%">Parker, Joel</style></author><author><style face="normal" font="default" size="100%">Parry, R Mitchell</style></author><author><style face="normal" font="default" size="100%">Peng, Xuejun</style></author><author><style face="normal" font="default" size="100%">Peterson, Ron L</style></author><author><style face="normal" font="default" size="100%">Phan, John H</style></author><author><style face="normal" font="default" size="100%">Quanz, Brian</style></author><author><style face="normal" font="default" size="100%">Ren, Yi</style></author><author><style face="normal" font="default" size="100%">Riccadonna, Samantha</style></author><author><style face="normal" font="default" size="100%">Roter, Alan H</style></author><author><style face="normal" font="default" size="100%">Samuelson, Frank W</style></author><author><style face="normal" font="default" size="100%">Schumacher, Martin M</style></author><author><style face="normal" font="default" size="100%">Shambaugh, Joseph D</style></author><author><style face="normal" font="default" size="100%">Shi, Qiang</style></author><author><style face="normal" font="default" size="100%">Shippy, Richard</style></author><author><style face="normal" font="default" size="100%">Si, Shengzhu</style></author><author><style face="normal" font="default" size="100%">Smalter, Aaron</style></author><author><style face="normal" font="default" size="100%">Sotiriou, Christos</style></author><author><style face="normal" font="default" size="100%">Soukup, Mat</style></author><author><style face="normal" font="default" size="100%">Staedtler, Frank</style></author><author><style face="normal" font="default" size="100%">Steiner, Guido</style></author><author><style face="normal" font="default" size="100%">Stokes, Todd H</style></author><author><style face="normal" font="default" size="100%">Sun, Qinglan</style></author><author><style face="normal" font="default" size="100%">Tan, Pei-Yi</style></author><author><style face="normal" font="default" size="100%">Tang, Rong</style></author><author><style face="normal" font="default" size="100%">Tezak, Zivana</style></author><author><style face="normal" font="default" size="100%">Thorn, Brett</style></author><author><style face="normal" font="default" size="100%">Tsyganova, Marina</style></author><author><style face="normal" font="default" size="100%">Turpaz, Yaron</style></author><author><style face="normal" font="default" size="100%">Vega, Silvia C</style></author><author><style face="normal" font="default" size="100%">Visintainer, Roberto</style></author><author><style face="normal" font="default" size="100%">von Frese, Juergen</style></author><author><style face="normal" font="default" size="100%">Wang, Charles</style></author><author><style face="normal" font="default" size="100%">Wang, Eric</style></author><author><style face="normal" font="default" size="100%">Wang, Junwei</style></author><author><style face="normal" font="default" size="100%">Wang, Wei</style></author><author><style face="normal" font="default" size="100%">Westermann, Frank</style></author><author><style face="normal" font="default" size="100%">Willey, James C</style></author><author><style face="normal" font="default" size="100%">Woods, Matthew</style></author><author><style face="normal" font="default" size="100%">Wu, Shujian</style></author><author><style face="normal" font="default" size="100%">Xiao, Nianqing</style></author><author><style face="normal" font="default" size="100%">Xu, Joshua</style></author><author><style face="normal" font="default" size="100%">Xu, Lei</style></author><author><style face="normal" font="default" size="100%">Yang, Lun</style></author><author><style face="normal" font="default" size="100%">Zeng, Xiao</style></author><author><style face="normal" font="default" size="100%">Zhang, Jialu</style></author><author><style face="normal" font="default" size="100%">Zhang, Li</style></author><author><style face="normal" font="default" size="100%">Zhang, Min</style></author><author><style face="normal" font="default" size="100%">Zhao, Chen</style></author><author><style face="normal" font="default" size="100%">Puri, Raj K</style></author><author><style face="normal" font="default" size="100%">Scherf, Uwe</style></author><author><style face="normal" font="default" size="100%">Tong, Weida</style></author><author><style face="normal" font="default" size="100%">Wolfinger, Russell D</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.</style></title><secondary-title><style face="normal" font="default" size="100%">Nature biotechnology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010 Aug</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.nature.com/nbt/journal/v28/n8/full/nbt.1665.html</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">28</style></volume><pages><style face="normal" font="default" size="100%">827-38</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Gene expression data from microarrays are being applied to predict preclinical and clinical endpoints, but the reliability of these predictions has not been established. In the MAQC-II project, 36 independent teams analyzed six microarray data sets to generate predictive models for classifying a sample with respect to one of 13 endpoints indicative of lung or liver toxicity in rodents, or of breast cancer, multiple myeloma or neuroblastoma in humans. In total, &amp;gt;30,000 models were built using many combinations of analytical methods. The teams generated predictive models without knowing the biological meaning of some of the endpoints and, to mimic clinical reality, tested the models on data that had not been used for training. We found that model performance depended largely on the endpoint and team proficiency and that different approaches generated models of similar performance. The conclusions and recommendations from MAQC-II should be useful for regulatory agencies, study committees and independent investigators that evaluate methods for global gene expression analysis.&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Barragán, Isabel</style></author><author><style face="normal" font="default" size="100%">Borrego, Salud</style></author><author><style face="normal" font="default" size="100%">Pieras, Juan Ignacio</style></author><author><style face="normal" font="default" size="100%">González-del Pozo, María</style></author><author><style face="normal" font="default" size="100%">Santoyo, Javier</style></author><author><style face="normal" font="default" size="100%">Ayuso, Carmen</style></author><author><style face="normal" font="default" size="100%">Baiget, Montserrat</style></author><author><style face="normal" font="default" size="100%">Millán, José M</style></author><author><style face="normal" font="default" size="100%">Mena, Marcela</style></author><author><style face="normal" font="default" size="100%">Abd El-Aziz, Mai M</style></author><author><style face="normal" font="default" size="100%">Audo, Isabelle</style></author><author><style face="normal" font="default" size="100%">Zeitz, Christina</style></author><author><style face="normal" font="default" size="100%">Littink, Karin W</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Bhattacharya, Shomi S</style></author><author><style face="normal" font="default" size="100%">Antiňolo, Guillermo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Mutation spectrum of EYS in Spanish patients with autosomal recessive retinitis pigmentosa.</style></title><secondary-title><style face="normal" font="default" size="100%">Hum Mutat</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Hum Mutat</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Amino Acid Sequence</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Case-Control Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA Mutational Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Drosophila Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Evolution, Molecular</style></keyword><keyword><style  face="normal" font="default" size="100%">Eye Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Genes, Recessive</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Variation</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Sequence Data</style></keyword><keyword><style  face="normal" font="default" size="100%">mutation</style></keyword><keyword><style  face="normal" font="default" size="100%">Pedigree</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Structure, Tertiary</style></keyword><keyword><style  face="normal" font="default" size="100%">Retinitis pigmentosa</style></keyword><keyword><style  face="normal" font="default" size="100%">Spain</style></keyword><keyword><style  face="normal" font="default" size="100%">Structural Homology, Protein</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010 Nov</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">31</style></volume><pages><style face="normal" font="default" size="100%">E1772-800</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Retinitis pigmentosa (RP) is a heterogeneous group of inherited retinal dystrophies characterised ultimately by the loss of photoreceptor cells. We have recently identified a new gene(EYS) encoding an ortholog of Drosophila space maker (spam) as a commonly mutated gene in autosomal recessive RP. In the present study, we report the identification of 73 sequence variations in EYS, of which 28 are novel. Of these, 42.9% (12/28) are very likely pathogenic, 17.9% (5/28)are possibly pathogenic, whereas 39.3% (11/28) are SNPs. In addition, we have detected 3 pathogenic changes previously reported in other populations. We are also presenting the characterisation of EYS homologues in different species, and a detailed analysis of the EYS domains, with the identification of an interesting novel feature: a putative coiled-coil domain.Majority of the mutations in the arRP patients have been found within the domain structures of EYS. The minimum observed prevalence of distinct EYS mutations in our group of patients is of 15.9% (15/94), confirming a major involvement of EYS in the pathogenesis of arRP in the Spanish population. Along with the detection of three recurrent mutations in Caucasian population, our hypothesis of EYS being the first prevalent gene in arRP has been reinforced in the present study.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">11</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/21069908?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Aggarwal, Mohit</style></author><author><style face="normal" font="default" size="100%">Sánchez-Beato, Margarita</style></author><author><style face="normal" font="default" size="100%">Gómez-López, Gonzalo</style></author><author><style face="normal" font="default" size="100%">Al-Shahrour, Fátima</style></author><author><style face="normal" font="default" size="100%">Martínez, Nerea</style></author><author><style face="normal" font="default" size="100%">Rodríguez, Antonia</style></author><author><style face="normal" font="default" size="100%">Ruiz-Ballesteros, Elena</style></author><author><style face="normal" font="default" size="100%">Camacho, Francisca I</style></author><author><style face="normal" font="default" size="100%">Pérez-Rosado, Alberto</style></author><author><style face="normal" font="default" size="100%">de la Cueva, Paloma</style></author><author><style face="normal" font="default" size="100%">Artiga, María J</style></author><author><style face="normal" font="default" size="100%">Pisano, David G</style></author><author><style face="normal" font="default" size="100%">Kimby, Eva</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Villuendas, Raquel</style></author><author><style face="normal" font="default" size="100%">Piris, Miguel A</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Functional signatures identified in B-cell non-Hodgkin lymphoma profiles.</style></title><secondary-title><style face="normal" font="default" size="100%">Leuk Lymphoma</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Leuk Lymphoma</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Cluster Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation, Leukemic</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Heterogeneity</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Lymphoma, B-Cell</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Oligonucleotide Array Sequence Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Neoplasm</style></keyword><keyword><style  face="normal" font="default" size="100%">Transcription, Genetic</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009 Oct</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">50</style></volume><pages><style face="normal" font="default" size="100%">1699-708</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Gene-expression profiling in B-cell lymphomas has provided crucial data on specific lymphoma types, which can contribute to the identification of essential lymphoma survival genes and pathways. In this study, the gene-expression profiling data of all major B-cell lymphoma types were analyzed by unsupervised clustering. The transcriptome classification so obtained, was explored using gene set enrichment analysis generating a heatmap for B-cell lymphoma that identifies common lymphoma survival mechanisms and potential therapeutic targets, recognizing sets of coregulated genes and functional pathways expressed in different lymphoma types. Some of the most relevant signatures (stroma, cell cycle, B-cell receptor (BCR)) are shared by multiple lymphoma types or subclasses. A specific attention was paid to the analysis of BCR and coregulated pathways, defining molecular heterogeneity within multiple B-cell lymphoma types.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/19863341?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Medina, Ignacio</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Bonifaci, Núria</style></author><author><style face="normal" font="default" size="100%">Pujana, Miguel Angel</style></author><author><style face="normal" font="default" size="100%">Carbonell, José</style></author><author><style face="normal" font="default" size="100%">Tárraga, Joaquín</style></author><author><style face="normal" font="default" size="100%">Al-Shahrour, Fátima</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Gene set-based analysis of polymorphisms: finding pathways or biological processes associated to traits in genome-wide association studies.</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Biological Phenomena</style></keyword><keyword><style  face="normal" font="default" size="100%">Breast Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Genes</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Variation</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome-Wide Association Study</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style  face="normal" font="default" size="100%">Software</style></keyword><keyword><style  face="normal" font="default" size="100%">User-Computer Interface</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009 Jul</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">37</style></volume><pages><style face="normal" font="default" size="100%">W340-4</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Genome-wide association studies have become a popular strategy to find associations of genes to traits of interest. Despite the high-resolution available today to carry out genotyping studies, the success of its application in real studies has been limited by the testing strategy used. As an alternative to brute force solutions involving the use of very large cohorts, we propose the use of the Gene Set Analysis (GSA), a different analysis strategy based on testing the association of modules of functionally related genes. We show here how the Gene Set-based Analysis of Polymorphisms (GeSBAP), which is a simple implementation of the GSA strategy for the analysis of genome-wide association studies, provides a significant increase in the power testing for this type of studies. GeSBAP is freely available at http://bioinfo.cipf.es/gesbap/.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">Web Server issue</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/19502494?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Medina, Ignacio</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Bonifaci, Núria</style></author><author><style face="normal" font="default" size="100%">Pujana, Miguel Angel</style></author><author><style face="normal" font="default" size="100%">Carbonell, José</style></author><author><style face="normal" font="default" size="100%">Tárraga, Joaquín</style></author><author><style face="normal" font="default" size="100%">Fatima Al-Shahrour</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Gene set-based analysis of polymorphisms: finding pathways or biological processes associated to traits in genome-wide association studies</style></title><secondary-title><style face="normal" font="default" size="100%">Nucl. Acids Res.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">babelomics</style></keyword><keyword><style  face="normal" font="default" size="100%">gene set</style></keyword><keyword><style  face="normal" font="default" size="100%">GESBAP</style></keyword><keyword><style  face="normal" font="default" size="100%">pathway-based analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">SNP</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://nar.oxfordjournals.org/cgi/content/abstract/37/suppl_2/W340</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">suppl_2</style></number><volume><style face="normal" font="default" size="100%">37</style></volume><pages><style face="normal" font="default" size="100%">W340-344</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Genome-wide association studies have become a popular strategy to find associations of genes to traits of interest. Despite the high-resolution available today to carry out genotyping studies, the success of its application in real studies has been limited by the testing strategy used. As an alternative to brute force solutions involving the use of very large cohorts, we propose the use of the Gene Set Analysis (GSA), a different analysis strategy based on testing the association of modules of functionally related genes. We show here how the Gene Set-based Analysis of Polymorphisms (GeSBAP), which is a simple implementation of the GSA strategy for the analysis of genome-wide association studies, provides a significant increase in the power testing for this type of studies. GeSBAP is freely available at http://bioinfo.cipf.es/gesbap/&lt;/p&gt;</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Orti, L.</style></author><author><style face="normal" font="default" size="100%">Carbajo, R. J.</style></author><author><style face="normal" font="default" size="100%">Pieper, U.</style></author><author><style face="normal" font="default" size="100%">Eswar, N.</style></author><author><style face="normal" font="default" size="100%">Maurer, S. M.</style></author><author><style face="normal" font="default" size="100%">Rai, A. K.</style></author><author><style face="normal" font="default" size="100%">Taylor, G.</style></author><author><style face="normal" font="default" size="100%">Todd, M. H.</style></author><author><style face="normal" font="default" size="100%">Pineda-Lucena, A.</style></author><author><style face="normal" font="default" size="100%">Sali, A.</style></author><author><style face="normal" font="default" size="100%">M. A. Marti-Renom</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A kernel for open source drug discovery in tropical diseases</style></title><secondary-title><style face="normal" font="default" size="100%">PLoS Negl Trop Dis</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=19381286</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">3</style></volume><pages><style face="normal" font="default" size="100%">e418</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: Conventional patent-based drug development incentives work badly for the developing world, where commercial markets are usually small to non-existent. For this reason, the past decade has seen extensive experimentation with alternative R&amp;D institutions ranging from private-public partnerships to development prizes. Despite extensive discussion, however, one of the most promising avenues-open source drug discovery-has remained elusive. We argue that the stumbling block has been the absence of a critical mass of preexisting work that volunteers can improve through a series of granular contributions. Historically, open source software collaborations have almost never succeeded without such &quot;kernels&quot;. METHODOLOGY/PRINCIPAL FINDINGS: HERE, WE USE A COMPUTATIONAL PIPELINE FOR: (i) comparative structure modeling of target proteins, (ii) predicting the localization of ligand binding sites on their surfaces, and (iii) assessing the similarity of the predicted ligands to known drugs. Our kernel currently contains 143 and 297 protein targets from ten pathogen genomes that are predicted to bind a known drug or a molecule similar to a known drug, respectively. The kernel provides a source of potential drug targets and drug candidates around which an online open source community can nucleate. Using NMR spectroscopy, we have experimentally tested our predictions for two of these targets, confirming one and invalidating the other. CONCLUSIONS/SIGNIFICANCE: The TDI kernel, which is being offered under the Creative Commons attribution share-alike license for free and unrestricted use, can be accessed on the World Wide Web at http://www.tropicaldisease.org. We hope that the kernel will facilitate collaborative efforts towards the discovery of new drugs against parasites that cause tropical diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Orti, Leticia Carbajo, Rodrigo J Pieper, Ursula Eswar, Narayanan Maurer, Stephen M Rai, Arti K Taylor, Ginger Todd, Matthew H Pineda-Lucena, Antonio Sali, Andrej Marti-Renom, Marc A United States PLoS neglected tropical diseases PLoS Negl Trop Dis. 2009;3(4):e418. Epub 2009 Apr 21.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Orti, L.</style></author><author><style face="normal" font="default" size="100%">Carbajo, R. J.</style></author><author><style face="normal" font="default" size="100%">Pieper, U.</style></author><author><style face="normal" font="default" size="100%">Eswar, N.</style></author><author><style face="normal" font="default" size="100%">Maurer, S. M.</style></author><author><style face="normal" font="default" size="100%">Rai, A. K.</style></author><author><style face="normal" font="default" size="100%">Taylor, G.</style></author><author><style face="normal" font="default" size="100%">Todd, M. H.</style></author><author><style face="normal" font="default" size="100%">Pineda-Lucena, A.</style></author><author><style face="normal" font="default" size="100%">Sali, A.</style></author><author><style face="normal" font="default" size="100%">M. A. Marti-Renom</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A kernel for the Tropical Disease Initiative</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Biotechnol</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=19352362</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">27</style></volume><pages><style face="normal" font="default" size="100%">320-1</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><notes><style face="normal" font="default" size="100%">&lt;p&gt;Orti, Leticia Carbajo, Rodrigo J Pieper, Ursula Eswar, Narayanan Maurer, Stephen M Rai, Arti K Taylor, Ginger Todd, Matthew H Pineda-Lucena, Antonio Sali, Andrej Marti-Renom, Marc A P01 AI035707/AI/NIAID NIH HHS/United States P01 GM71790/GM/NIGMS NIH HHS/United States R01 GM54762/GM/NIGMS NIH HHS/United States U54 GM074945/GM/NIGMS NIH HHS/United States Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t United States Nature biotechnology Nat Biotechnol. 2009 Apr;27(4):320-1.&lt;/p&gt;</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pieper, U.</style></author><author><style face="normal" font="default" size="100%">Eswar, N.</style></author><author><style face="normal" font="default" size="100%">Webb, B. M.</style></author><author><style face="normal" font="default" size="100%">Eramian, D.</style></author><author><style face="normal" font="default" size="100%">Kelly, L.</style></author><author><style face="normal" font="default" size="100%">Barkan, D. T.</style></author><author><style face="normal" font="default" size="100%">Carter, H.</style></author><author><style face="normal" font="default" size="100%">Mankoo, P.</style></author><author><style face="normal" font="default" size="100%">Karchin, R.</style></author><author><style face="normal" font="default" size="100%">M. A. Marti-Renom</style></author><author><style face="normal" font="default" size="100%">Davis, F. P.</style></author><author><style face="normal" font="default" size="100%">Sali, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">MODBASE, a database of annotated comparative protein structure models and associated resources</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Databases</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Mutation Polymorphism</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Genomics Humans Ligands *Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein User-Computer Interface</style></keyword><keyword><style  face="normal" font="default" size="100%">Single Nucleotide Protein Folding Protein Interaction Domains and Motifs *Protein Structure</style></keyword><keyword><style  face="normal" font="default" size="100%">Tertiary Proteins/genetics *Structural Homology</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=18948282</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">Database issue</style></number><volume><style face="normal" font="default" size="100%">37</style></volume><pages><style face="normal" font="default" size="100%">D347-54</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">MODBASE (http://salilab.org/modbase) is a database of annotated comparative protein structure models. The models are calculated by MODPIPE, an automated modeling pipeline that relies primarily on MODELLER for fold assignment, sequence-structure alignment, model building and model assessment (http:/salilab.org/modeller). MODBASE currently contains 5,152,695 reliable models for domains in 1,593,209 unique protein sequences; only models based on statistically significant alignments and/or models assessed to have the correct fold are included. MODBASE also allows users to calculate comparative models on demand, through an interface to the MODWEB modeling server (http://salilab.org/modweb). Other resources integrated with MODBASE include databases of multiple protein structure alignments (DBAli), structurally defined ligand binding sites (LIGBASE), predicted ligand binding sites (AnnoLyze), structurally defined binary domain interfaces (PIBASE) and annotated single nucleotide polymorphisms and somatic mutations found in human proteins (LS-SNP, LS-Mut). MODBASE models are also available through the Protein Model Portal (http://www.proteinmodelportal.org/).</style></abstract><notes><style face="normal" font="default" size="100%">Pieper, Ursula Eswar, Narayanan Webb, Ben M Eramian, David Kelly, Libusha Barkan, David T Carter, Hannah Mankoo, Parminder Karchin, Rachel Marti-Renom, Marc A Davis, Fred P Sali, Andrej GM08284/GM/NIGMS NIH HHS/United States P01 GM71790/GM/NIGMS NIH HHS/United States R01 GM54762/GM/NIGMS NIH HHS/United States U01 GM61390/GM/NIGMS NIH HHS/United States U54 GM074929/GM/NIGMS NIH HHS/United States U54 GM074945/GM/NIGMS NIH HHS/United States Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S. England Nucleic acids research Nucleic Acids Res. 2009 Jan;37(Database issue):D347-54. Epub 2008 Oct 23.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Andrew R Jones</style></author><author><style face="normal" font="default" size="100%">Allyson L Lister</style></author><author><style face="normal" font="default" size="100%">Leandro Hermida</style></author><author><style face="normal" font="default" size="100%">Peter Wilkinson</style></author><author><style face="normal" font="default" size="100%">Martin Eisenacher</style></author><author><style face="normal" font="default" size="100%">Khalid Belhajjame</style></author><author><style face="normal" font="default" size="100%">Frank Gibson</style></author><author><style face="normal" font="default" size="100%">Phil Lord</style></author><author><style face="normal" font="default" size="100%">Matthew Pocock</style></author><author><style face="normal" font="default" size="100%">Heiko Rosenfelder</style></author><author><style face="normal" font="default" size="100%">Santoyo-López, Javier</style></author><author><style face="normal" font="default" size="100%">Anil Wipat</style></author><author><style face="normal" font="default" size="100%">Norman W Paton</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Modeling and managing experimental data using FuGE.</style></title><secondary-title><style face="normal" font="default" size="100%">OMICS</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year></dates><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">13</style></volume><pages><style face="normal" font="default" size="100%">239-51</style></pages><language><style face="normal" font="default" size="100%">eng</style></language></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>47</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Silbiger, Vivian</style></author><author><style face="normal" font="default" size="100%">Luchessi, André</style></author><author><style face="normal" font="default" size="100%">Hirata, Rosario</style></author><author><style face="normal" font="default" size="100%">Carracedo, Ángel</style></author><author><style face="normal" font="default" size="100%">Brión, Maria</style></author><author><style face="normal" font="default" size="100%">Lima Neto, Lidio</style></author><author><style face="normal" font="default" size="100%">P. Pastorelli, C</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Garcia, F</style></author><author><style face="normal" font="default" size="100%">P. Sampaio, M</style></author><author><style face="normal" font="default" size="100%">P. Pereira, M</style></author><author><style face="normal" font="default" size="100%">S. Santos, E</style></author><author><style face="normal" font="default" size="100%">Armaganijan, Dikran</style></author><author><style face="normal" font="default" size="100%">Hirata, Mario</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Peripheral blood cells transcriptome to study new biomarkers for myocardial infarction follow up</style></title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">06</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">eng</style></language></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bonifaci, N.</style></author><author><style face="normal" font="default" size="100%">Berenguer, A.</style></author><author><style face="normal" font="default" size="100%">Diez, J.</style></author><author><style face="normal" font="default" size="100%">Reina, O.</style></author><author><style face="normal" font="default" size="100%">Medina, Ignacio</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Moreno, V.</style></author><author><style face="normal" font="default" size="100%">Pujana, M. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Biological processes, properties and molecular wiring diagrams of candidate low-penetrance breast cancer susceptibility genes</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Med Genomics</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">gene set</style></keyword><keyword><style  face="normal" font="default" size="100%">GWAS</style></keyword><keyword><style  face="normal" font="default" size="100%">SNP</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=19094230</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">1</style></volume><pages><style face="normal" font="default" size="100%">62</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;ABSTRACT: BACKGROUND: Recent advances in whole-genome association studies (WGASs) for human cancer risk are beginning to provide the part lists of low-penetrance susceptibility genes. However, statistical analysis in these studies is complicated by the vast number of genetic variants examined and the weak effects observed, as a result of which constraints must be incorporated into the study design and analytical approach. In this scenario, biological attributes beyond the adjusted statistics generally receive little attention and, more importantly, the fundamental biological characteristics of low-penetrance susceptibility genes have yet to be determined. METHODS: We applied an integrative approach for identifying candidate low-penetrance breast cancer susceptibility genes, their characteristics and molecular networks through the analysis of diverse sources of biological evidence. RESULTS: First, examination of the distribution of Gene Ontology terms in ordered WGAS results identified asymmetrical distribution of Cell Communication and Cell Death processes linked to risk. Second, analysis of 11 different types of molecular or functional relationships in genomic and proteomic data sets defined the &amp;quot;omic&amp;quot; properties of candidate genes: i/ differential expression in tumors relative to normal tissue; ii/ somatic genomic copy number changes correlating with gene expression levels; iii/ differentially expressed across age at diagnosis; and iv/ expression changes after BRCA1 perturbation. Finally, network modeling of the effects of variants on germline gene expression showed higher connectivity than expected by chance between novel candidates and with known susceptibility genes, which supports functional relationships and provides mechanistic hypotheses of risk. CONCLUSION: This study proposes that cell communication and cell death are major biological processes perturbed in risk of breast cancer conferred by low-penetrance variants, and defines the common omic properties, molecular interactions and possible functional effects of candidate genes and proteins.&lt;/p&gt;</style></abstract><notes><style face="normal" font="default" size="100%">&lt;p&gt;Bonifaci, Nuria Berenguer, Antoni Diez, Javier Reina, Oscar Medina, Ignacio Dopazo, Joaquin Moreno, Victor Pujana, Miguel Angel England BMC medical genomics BMC Med Genomics. 2008 Dec 18;1:62.&lt;/p&gt;</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Valls, J.</style></author><author><style face="normal" font="default" size="100%">Grau, M.</style></author><author><style face="normal" font="default" size="100%">Sole, X.</style></author><author><style face="normal" font="default" size="100%">Hernandez, P.</style></author><author><style face="normal" font="default" size="100%">Montaner, D.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Peinado, M. A.</style></author><author><style face="normal" font="default" size="100%">Capella, G.</style></author><author><style face="normal" font="default" size="100%">Moreno, V.</style></author><author><style face="normal" font="default" size="100%">Pujana, M. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">CLEAR-test: combining inference for differential expression and variability in microarray data analysis</style></title><secondary-title><style face="normal" font="default" size="100%">J Biomed Inform</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Algorithms Artificial Intelligence *Data Interpretation</style></keyword><keyword><style  face="normal" font="default" size="100%">Statistical Gene Expression Profiling/*methods Gene Expression Regulation/*physiology Oligonucleotide Array Sequence Analysis/*methods Proteome/*metabolism Signal Transduction/*physiology</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=17597009</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">41</style></volume><pages><style face="normal" font="default" size="100%">33-45</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;A common goal of microarray experiments is to detect genes that are differentially expressed under distinct experimental conditions. Several statistical tests have been proposed to determine whether the observed changes in gene expression are significant. The t-test assigns a score to each gene on the basis of changes in its expression relative to its estimated variability, in such a way that genes with a higher score (in absolute values) are more likely to be significant. Most variants of the t-test use the complete set of genes to influence the variance estimate for each single gene. However, no inference is made in terms of the variability itself. Here, we highlight the problem of low observed variances in the t-test, when genes with relatively small changes are declared differentially expressed. Alternatively, the z-test could be used although, unlike the t-test, it can declare differentially expressed genes with high observed variances. To overcome this, we propose to combine the z-test, which focuses on large changes, with a chi(2) test to evaluate variability. We call this procedure CLEAR-test and we provide a combined p-value that offers a compromise between both aspects. Analysis of three publicly available microarray datasets reveals the greater performance of the CLEAR-test relative to the t-test and alternative methods. Finally, empirical and simulated data analyses demonstrate the greater reproducibility and statistical power of the CLEAR-test and z-test with respect to current alternative methods. In addition, the CLEAR-test improves the z-test by capturing reproducible genes with high variability.&lt;/p&gt;</style></abstract><notes><style face="normal" font="default" size="100%">&lt;p&gt;Valls, Joan Grau, Monica Sole, Xavier Hernandez, Pilar Montaner, David Dopazo, Joaquin Peinado, Miguel A Capella, Gabriel Moreno, Victor Pujana, Miguel Angel Comparative Study Research Support, Non-U.S. Gov’t United States Journal of biomedical informatics J Biomed Inform. 2008 Feb;41(1):33-45. Epub 2007 May 17.&lt;/p&gt;</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Horcajadas, J. A.</style></author><author><style face="normal" font="default" size="100%">Minguez, P.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Esteban, F. J.</style></author><author><style face="normal" font="default" size="100%">Dominguez, F.</style></author><author><style face="normal" font="default" size="100%">Giudice, L. C.</style></author><author><style face="normal" font="default" size="100%">Pellicer, A.</style></author><author><style face="normal" font="default" size="100%">Simon, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Controlled ovarian stimulation induces a functional genomic delay of the endometrium with potential clinical implications</style></title><secondary-title><style face="normal" font="default" size="100%">J Clin Endocrinol Metab</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Algorithms Chorionic Gonadotropin/genetics Endometrium/cytology/pathology/*physiology/physiopathology Female Gene Expression Regulation Genome</style></keyword><keyword><style  face="normal" font="default" size="100%">Human Glutathione Peroxidase/genetics Humans Insulin-Like Growth Factor Binding Proteins/genetics Luteal Phase/physiology Luteinizing Hormone/genetics Menstrual Cycle Oligonucleotide Array Sequence Analysis Ovulation Induction/*methods RNA/genetics/isola</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=18697870</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">11</style></number><volume><style face="normal" font="default" size="100%">93</style></volume><pages><style face="normal" font="default" size="100%">4500-10</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;CONTEXT: Controlled ovarian stimulation induces morphological, biochemical, and functional genomic modifications of the human endometrium during the window of implantation. OBJECTIVE: Our objective was to compare the gene expression profile of the human endometrium in natural vs. controlled ovarian stimulation cycles throughout the early-mid secretory transition using microarray technology. METHOD: Microarray data from 49 endometrial biopsies obtained from LH+1 to LH+9 (n=25) in natural cycles and from human chorionic gonadotropin (hCG) +1 to hCG+9 in controlled ovarian stimulation cycles (n=24) were analyzed using different methods, such as clustering, profiling of biological processes, and selection of differentially expressed genes, as implemented in Gene Expression Pattern Analysis Suite and Babelomics programs. RESULTS: Endometria from natural cycles followed different genomic patterns compared with controlled ovarian stimulation cycles in the transition from the pre-receptive (days LH/hCG+1 until LH/hCG+5) to the receptive phase (day LH+7/hCG+7). Specifically, we have demonstrated the existence of a 2-d delay in the activation/repression of two clusters composed by 218 and 133 genes, respectively, on day hCG+7 vs. LH+7. Many of these delayed genes belong to the class window of implantation genes affecting basic biological processes in the receptive endometrium. CONCLUSIONS: These results demonstrate that gene expression profiling of the endometrium is different between natural and controlled ovarian stimulation cycles in the receptive phase. Identification of these differentially regulated genes can be used to understand the different developmental profiles of receptive endometrium during controlled ovarian stimulation and to search for the best controlled ovarian stimulation treatment in terms of minimal endometrial impact.&lt;/p&gt;</style></abstract><notes><style face="normal" font="default" size="100%">&lt;p&gt;Horcajadas, Jose A Minguez, Pablo Dopazo, Joaquin Esteban, Francisco J Dominguez, Francisco Giudice, Linda C Pellicer, Antonio Simon, Carlos Research Support, Non-U.S. Gov’t United States The Journal of clinical endocrinology and metabolism J Clin Endocrinol Metab. 2008 Nov;93(11):4500-10. Epub 2008 Aug 12.&lt;/p&gt;</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gabaldón, T.</style></author><author><style face="normal" font="default" size="100%">Gil, R.</style></author><author><style face="normal" font="default" size="100%">Peretó, J.</style></author><author><style face="normal" font="default" size="100%">Latorre, A.</style></author><author><style face="normal" font="default" size="100%">Moya, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The core of a minimal gene set: insights from natural reduced genomes</style></title><secondary-title><style face="normal" font="default" size="100%">Protocells: Bridging nonliving and living matter</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year></dates><publisher><style face="normal" font="default" size="100%">The MIT Press</style></publisher><pub-location><style face="normal" font="default" size="100%">USA</style></pub-location><pages><style face="normal" font="default" size="100%">347-366</style></pages><language><style face="normal" font="default" size="100%">eng</style></language></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Conesa, Ana</style></author><author><style face="normal" font="default" size="100%">Bro, Rasmus</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, Francisco</style></author><author><style face="normal" font="default" size="100%">Prats, José Manuel</style></author><author><style face="normal" font="default" size="100%">Götz, Stefan</style></author><author><style face="normal" font="default" size="100%">Kjeldahl, Karin</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Direct functional assessment of the composite phenotype through multivariate projection strategies.</style></title><secondary-title><style face="normal" font="default" size="100%">Genomics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Genomics</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Breast Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Databases, Genetic</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Mathematical Computing</style></keyword><keyword><style  face="normal" font="default" size="100%">Multivariate Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Phenotype</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008 Dec</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">92</style></volume><pages><style face="normal" font="default" size="100%">373-83</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;We present a novel approach for the analysis of transcriptomics data that integrates functional annotation of gene sets with expression values in a multivariate fashion, and directly assesses the relation of functional features to a multivariate space of response phenotypical variables. Multivariate projection methods are used to obtain new correlated variables for a set of genes that share a given function. These new functional variables are then related to the response variables of interest. The analysis of the principal directions of the multivariate regression allows for the identification of gene function features correlated with the phenotype. Two different transcriptomics studies are used to illustrate the statistical and interpretative aspects of the methodology. We demonstrate the superiority of the proposed method over equivalent approaches.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/18652888?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">A. Conesa</style></author><author><style face="normal" font="default" size="100%">Bro, R.</style></author><author><style face="normal" font="default" size="100%">Garcia-Garcia, F.</style></author><author><style face="normal" font="default" size="100%">Prats, J. M.</style></author><author><style face="normal" font="default" size="100%">Gotz, S.</style></author><author><style face="normal" font="default" size="100%">Kjeldahl, K.</style></author><author><style face="normal" font="default" size="100%">Montaner, D.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Direct functional assessment of the composite phenotype through multivariate projection strategies</style></title><secondary-title><style face="normal" font="default" size="100%">Genomics</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Breast Neoplasms/genetics Computational Biology/*methods Databases</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Female Gene Expression Profiling/*statistics &amp; numerical data Humans Mathematical Computing Multivariate Analysis Phenotype</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=18652888</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">92</style></volume><pages><style face="normal" font="default" size="100%">373-83</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;We present a novel approach for the analysis of transcriptomics data that integrates functional annotation of gene sets with expression values in a multivariate fashion, and directly assesses the relation of functional features to a multivariate space of response phenotypical variables. Multivariate projection methods are used to obtain new correlated variables for a set of genes that share a given function. These new functional variables are then related to the response variables of interest. The analysis of the principal directions of the multivariate regression allows for the identification of gene function features correlated with the phenotype. Two different transcriptomics studies are used to illustrate the statistical and interpretative aspects of the methodology. We demonstrate the superiority of the proposed method over equivalent approaches.&lt;/p&gt;</style></abstract><notes><style face="normal" font="default" size="100%">&lt;p&gt;Conesa, Ana Bro, Rasmus Garcia-Garcia, Francisco Prats, Jose Manuel Gotz, Stefan Kjeldahl, Karin Montaner, David Dopazo, Joaquin Evaluation Studies Research Support, Non-U.S. Gov’t United States Genomics Genomics. 2008 Dec;92(6):373-83. Epub 2008 Sep 13.&lt;/p&gt;</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Panjkovich, A.</style></author><author><style face="normal" font="default" size="100%">Melo, F.</style></author><author><style face="normal" font="default" size="100%">M. A. Marti-Renom</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Evolutionary potentials: structure specific knowledge-based potentials exploiting the evolutionary record of sequence homologs</style></title><secondary-title><style face="normal" font="default" size="100%">Genome Biol</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=18397517</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">9</style></volume><pages><style face="normal" font="default" size="100%">R68</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">ABSTRACT: We introduce a new type of knowledge-based potentials for protein structure prediction, called ’evolutionary potentials’, which are derived using a single experimental protein structure and all three-dimensional models of its homologous sequences. The new potentials have been benchmarked against other knowledge-based potentials, resulting in a significant increase in accuracy for model assessment. In contrast to standard knowledge-based potentials, we propose that evolutionary potentials capture key determinants of thermodynamic stability and specific sequence constraints required for fast folding.</style></abstract><notes><style face="normal" font="default" size="100%">Journal article Genome biology Genome Biol. 2008 Apr 8;9(4):R68.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wilkinson, Mark D</style></author><author><style face="normal" font="default" size="100%">Senger, Martin</style></author><author><style face="normal" font="default" size="100%">Kawas, Edward</style></author><author><style face="normal" font="default" size="100%">Bruskiewich, Richard</style></author><author><style face="normal" font="default" size="100%">Gouzy, Jerome</style></author><author><style face="normal" font="default" size="100%">Noirot, Celine</style></author><author><style face="normal" font="default" size="100%">Bardou, Philippe</style></author><author><style face="normal" font="default" size="100%">Ng, Ambrose</style></author><author><style face="normal" font="default" size="100%">Haase, Dirk</style></author><author><style face="normal" font="default" size="100%">Saiz, Enrique de Andres</style></author><author><style face="normal" font="default" size="100%">Wang, Dennis</style></author><author><style face="normal" font="default" size="100%">Gibbons, Frank</style></author><author><style face="normal" font="default" size="100%">Gordon, Paul M K</style></author><author><style face="normal" font="default" size="100%">Sensen, Christoph W</style></author><author><style face="normal" font="default" size="100%">Carrasco, Jose Manuel Rodriguez</style></author><author><style face="normal" font="default" size="100%">Fernández, José M</style></author><author><style face="normal" font="default" size="100%">Shen, Lixin</style></author><author><style face="normal" font="default" size="100%">Links, Matthew</style></author><author><style face="normal" font="default" size="100%">Ng, Michael</style></author><author><style face="normal" font="default" size="100%">Opushneva, Nina</style></author><author><style face="normal" font="default" size="100%">Neerincx, Pieter B T</style></author><author><style face="normal" font="default" size="100%">Leunissen, Jack A M</style></author><author><style face="normal" font="default" size="100%">Ernst, Rebecca</style></author><author><style face="normal" font="default" size="100%">Twigger, Simon</style></author><author><style face="normal" font="default" size="100%">Usadel, Bjorn</style></author><author><style face="normal" font="default" size="100%">Good, Benjamin</style></author><author><style face="normal" font="default" size="100%">Wong, Yan</style></author><author><style face="normal" font="default" size="100%">Stein, Lincoln</style></author><author><style face="normal" font="default" size="100%">Crosby, William</style></author><author><style face="normal" font="default" size="100%">Karlsson, Johan</style></author><author><style face="normal" font="default" size="100%">Royo, Romina</style></author><author><style face="normal" font="default" size="100%">Párraga, Iván</style></author><author><style face="normal" font="default" size="100%">Ramírez, Sergio</style></author><author><style face="normal" font="default" size="100%">Gelpi, Josep Lluis</style></author><author><style face="normal" font="default" size="100%">Trelles, Oswaldo</style></author><author><style face="normal" font="default" size="100%">Pisano, David G</style></author><author><style face="normal" font="default" size="100%">Jimenez, Natalia</style></author><author><style face="normal" font="default" size="100%">Kerhornou, Arnaud</style></author><author><style face="normal" font="default" size="100%">Rosset, Roman</style></author><author><style face="normal" font="default" size="100%">Zamacola, Leire</style></author><author><style face="normal" font="default" size="100%">Tárraga, Joaquín</style></author><author><style face="normal" font="default" size="100%">Huerta-Cepas, Jaime</style></author><author><style face="normal" font="default" size="100%">Carazo, Jose María</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Guigó, Roderic</style></author><author><style face="normal" font="default" size="100%">Navarro, Arcadi</style></author><author><style face="normal" font="default" size="100%">Orozco, Modesto</style></author><author><style face="normal" font="default" size="100%">Valencia, Alfonso</style></author><author><style face="normal" font="default" size="100%">Claros, M Gonzalo</style></author><author><style face="normal" font="default" size="100%">Pérez, Antonio J</style></author><author><style face="normal" font="default" size="100%">Aldana, Jose</style></author><author><style face="normal" font="default" size="100%">Rojano, M  Mar</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santa Cruz, Raul</style></author><author><style face="normal" font="default" size="100%">Navas, Ismael</style></author><author><style face="normal" font="default" size="100%">Schiltz, Gary</style></author><author><style face="normal" font="default" size="100%">Farmer, Andrew</style></author><author><style face="normal" font="default" size="100%">Gessler, Damian</style></author><author><style face="normal" font="default" size="100%">Schoof, Heiko</style></author><author><style face="normal" font="default" size="100%">Groscurth, Andreas</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">BioMoby Consortium</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Interoperability with Moby 1.0--it's better than sharing your toothbrush!</style></title><secondary-title><style face="normal" font="default" size="100%">Brief Bioinform</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Brief Bioinform</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Database Management Systems</style></keyword><keyword><style  face="normal" font="default" size="100%">Databases, Factual</style></keyword><keyword><style  face="normal" font="default" size="100%">Information Storage and Retrieval</style></keyword><keyword><style  face="normal" font="default" size="100%">Internet</style></keyword><keyword><style  face="normal" font="default" size="100%">Programming Languages</style></keyword><keyword><style  face="normal" font="default" size="100%">Systems Integration</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008 May</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">9</style></volume><pages><style face="normal" font="default" size="100%">220-31</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The BioMoby project was initiated in 2001 from within the model organism database community. It aimed to standardize methodologies to facilitate information exchange and access to analytical resources, using a consensus driven approach. Six years later, the BioMoby development community is pleased to announce the release of the 1.0 version of the interoperability framework, registry Application Programming Interface and supporting Perl and Java code-bases. Together, these provide interoperable access to over 1400 bioinformatics resources worldwide through the BioMoby platform, and this number continues to grow. Here we highlight and discuss the features of BioMoby that make it distinct from other Semantic Web Service and interoperability initiatives, and that have been instrumental to its deployment and use by a wide community of bioinformatics service providers. The standard, client software, and supporting code libraries are all freely available at http://www.biomoby.org/.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/18238804?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Wilkinson, M. D.</style></author><author><style face="normal" font="default" size="100%">Senger, M.</style></author><author><style face="normal" font="default" size="100%">Kawas, E.</style></author><author><style face="normal" font="default" size="100%">Bruskiewich, R.</style></author><author><style face="normal" font="default" size="100%">Gouzy, J.</style></author><author><style face="normal" font="default" size="100%">Noirot, C.</style></author><author><style face="normal" font="default" size="100%">Bardou, P.</style></author><author><style face="normal" font="default" size="100%">Ng, A.</style></author><author><style face="normal" font="default" size="100%">Haase, D.</style></author><author><style face="normal" font="default" size="100%">Saiz Ede, A.</style></author><author><style face="normal" font="default" size="100%">Wang, D.</style></author><author><style face="normal" font="default" size="100%">Gibbons, F.</style></author><author><style face="normal" font="default" size="100%">Gordon, P. M.</style></author><author><style face="normal" font="default" size="100%">Sensen, C. W.</style></author><author><style face="normal" font="default" size="100%">Carrasco, J. M.</style></author><author><style face="normal" font="default" size="100%">Fernandez, J. M.</style></author><author><style face="normal" font="default" size="100%">Shen, L.</style></author><author><style face="normal" font="default" size="100%">Links, M.</style></author><author><style face="normal" font="default" size="100%">Ng, M.</style></author><author><style face="normal" font="default" size="100%">Opushneva, N.</style></author><author><style face="normal" font="default" size="100%">Neerincx, P. B.</style></author><author><style face="normal" font="default" size="100%">Leunissen, J. A.</style></author><author><style face="normal" font="default" size="100%">Ernst, R.</style></author><author><style face="normal" font="default" size="100%">Twigger, S.</style></author><author><style face="normal" font="default" size="100%">Usadel, B.</style></author><author><style face="normal" font="default" size="100%">Good, B.</style></author><author><style face="normal" font="default" size="100%">Wong, Y.</style></author><author><style face="normal" font="default" size="100%">Stein, L.</style></author><author><style face="normal" font="default" size="100%">Crosby, W.</style></author><author><style face="normal" font="default" size="100%">Karlsson, J.</style></author><author><style face="normal" font="default" size="100%">Royo, R.</style></author><author><style face="normal" font="default" size="100%">Parraga, I.</style></author><author><style face="normal" font="default" size="100%">Ramirez, S.</style></author><author><style face="normal" font="default" size="100%">Gelpi, J. L.</style></author><author><style face="normal" font="default" size="100%">Trelles, O.</style></author><author><style face="normal" font="default" size="100%">Pisano, D. G.</style></author><author><style face="normal" font="default" size="100%">Jimenez, N.</style></author><author><style face="normal" font="default" size="100%">Kerhornou, A.</style></author><author><style face="normal" font="default" size="100%">Rosset, R.</style></author><author><style face="normal" font="default" size="100%">Zamacola, L.</style></author><author><style face="normal" font="default" size="100%">Tarraga, J.</style></author><author><style face="normal" font="default" size="100%">Huerta-Cepas, J.</style></author><author><style face="normal" font="default" size="100%">Carazo, J. M.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">R. Guigo</style></author><author><style face="normal" font="default" size="100%">Navarro, A.</style></author><author><style face="normal" font="default" size="100%">Orozco, M.</style></author><author><style face="normal" font="default" size="100%">Valencia, A.</style></author><author><style face="normal" font="default" size="100%">Claros, M. G.</style></author><author><style face="normal" font="default" size="100%">Perez, A. J.</style></author><author><style face="normal" font="default" size="100%">Aldana, J.</style></author><author><style face="normal" font="default" size="100%">Rojano, M. M.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Santa Cruz, R.</style></author><author><style face="normal" font="default" size="100%">Navas, I.</style></author><author><style face="normal" font="default" size="100%">Schiltz, G.</style></author><author><style face="normal" font="default" size="100%">Farmer, A.</style></author><author><style face="normal" font="default" size="100%">Gessler, D.</style></author><author><style face="normal" font="default" size="100%">Schoof, H.</style></author><author><style face="normal" font="default" size="100%">Groscurth, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Interoperability with Moby 1.0–it’s better than sharing your toothbrush!</style></title><secondary-title><style face="normal" font="default" size="100%">Brief Bioinform</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Computational Biology/*methods *Database Management Systems *Databases</style></keyword><keyword><style  face="normal" font="default" size="100%">Factual Information Storage and Retrieval/*methods *Internet *Programming Languages Systems Integration</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=18238804</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">9</style></volume><pages><style face="normal" font="default" size="100%">220-31</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The BioMoby project was initiated in 2001 from within the model organism database community. It aimed to standardize methodologies to facilitate information exchange and access to analytical resources, using a consensus driven approach. Six years later, the BioMoby development community is pleased to announce the release of the 1.0 version of the interoperability framework, registry Application Programming Interface and supporting Perl and Java code-bases. Together, these provide interoperable access to over 1400 bioinformatics resources worldwide through the BioMoby platform, and this number continues to grow. Here we highlight and discuss the features of BioMoby that make it distinct from other Semantic Web Service and interoperability initiatives, and that have been instrumental to its deployment and use by a wide community of bioinformatics service providers. The standard, client software, and supporting code libraries are all freely available at http://www.biomoby.org/.&lt;/p&gt;</style></abstract><notes><style face="normal" font="default" size="100%">&lt;p&gt;BioMoby Consortium Wilkinson, Mark D Senger, Martin Kawas, Edward Bruskiewich, Richard Gouzy, Jerome Noirot, Celine Bardou, Philippe Ng, Ambrose Haase, Dirk Saiz, Enrique de Andres Wang, Dennis Gibbons, Frank Gordon, Paul M K Sensen, Christoph W Carrasco, Jose Manuel Rodriguez Fernandez, Jose M Shen, Lixin Links, Matthew Ng, Michael Opushneva, Nina Neerincx, Pieter B T Leunissen, Jack A M Ernst, Rebecca Twigger, Simon Usadel, Bjorn Good, Benjamin Wong, Yan Stein, Lincoln Crosby, William Karlsson, Johan Royo, Romina Parraga, Ivan Ramirez, Sergio Gelpi, Josep Lluis Trelles, Oswaldo Pisano, David G Jimenez, Natalia Kerhornou, Arnaud Rosset, Roman Zamacola, Leire Tarraga, Joaquin Huerta-Cepas, Jaime Carazo, Jose Maria Dopazo, Joaquin Guigo, Roderic Navarro, Arcadi Orozco, Modesto Valencia, Alfonso Claros, M Gonzalo Perez, Antonio J Aldana, Jose Rojano, M Mar Fernandez-Santa Cruz, Raul Navas, Ismael Schiltz, Gary Farmer, Andrew Gessler, Damian Schoof, Heiko Groscurth, Andreas Research Support, Non-U.S. Gov’t Review England Briefings in bioinformatics Brief Bioinform. 2008 May;9(3):220-31. Epub 2008 Jan 31.&lt;/p&gt;</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">K. Saar</style></author><author><style face="normal" font="default" size="100%">A. Beck</style></author><author><style face="normal" font="default" size="100%">M. T. Bihoreau</style></author><author><style face="normal" font="default" size="100%">E. Birney</style></author><author><style face="normal" font="default" size="100%">D. Brocklebank</style></author><author><style face="normal" font="default" size="100%">Y. Chen</style></author><author><style face="normal" font="default" size="100%">E. Cuppen</style></author><author><style face="normal" font="default" size="100%">S. Demonchy</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">P. Flicek</style></author><author><style face="normal" font="default" size="100%">M. Foglio</style></author><author><style face="normal" font="default" size="100%">A. Fujiyama</style></author><author><style face="normal" font="default" size="100%">I. G. Gut</style></author><author><style face="normal" font="default" size="100%">D. Gauguier</style></author><author><style face="normal" font="default" size="100%">R. Guigo</style></author><author><style face="normal" font="default" size="100%">V. Guryev</style></author><author><style face="normal" font="default" size="100%">M. Heinig</style></author><author><style face="normal" font="default" size="100%">O. Hummel</style></author><author><style face="normal" font="default" size="100%">N. Jahn</style></author><author><style face="normal" font="default" size="100%">S. Klages</style></author><author><style face="normal" font="default" size="100%">V. Kren</style></author><author><style face="normal" font="default" size="100%">M. Kube</style></author><author><style face="normal" font="default" size="100%">H. Kuhl</style></author><author><style face="normal" font="default" size="100%">Kuramoto, T.</style></author><author><style face="normal" font="default" size="100%">Kuroki, Y.</style></author><author><style face="normal" font="default" size="100%">Lechner, D.</style></author><author><style face="normal" font="default" size="100%">Lee, Y. A.</style></author><author><style face="normal" font="default" size="100%">Lopez-Bigas, N.</style></author><author><style face="normal" font="default" size="100%">Lathrop, G. M.</style></author><author><style face="normal" font="default" size="100%">Mashimo, T.</style></author><author><style face="normal" font="default" size="100%">Medina, Ignacio</style></author><author><style face="normal" font="default" size="100%">Mott, R.</style></author><author><style face="normal" font="default" size="100%">Patone, G.</style></author><author><style face="normal" font="default" size="100%">Perrier-Cornet, J. A.</style></author><author><style face="normal" font="default" size="100%">Platzer, M.</style></author><author><style face="normal" font="default" size="100%">Pravenec, M.</style></author><author><style face="normal" font="default" size="100%">Reinhardt, R.</style></author><author><style face="normal" font="default" size="100%">Sakaki, Y.</style></author><author><style face="normal" font="default" size="100%">Schilhabel, M.</style></author><author><style face="normal" font="default" size="100%">Schulz, H.</style></author><author><style face="normal" font="default" size="100%">Serikawa, T.</style></author><author><style face="normal" font="default" size="100%">Shikhagaie, M.</style></author><author><style face="normal" font="default" size="100%">Tatsumoto, S.</style></author><author><style face="normal" font="default" size="100%">Taudien, S.</style></author><author><style face="normal" font="default" size="100%">Toyoda, A.</style></author><author><style face="normal" font="default" size="100%">Voigt, B.</style></author><author><style face="normal" font="default" size="100%">Zelenika, D.</style></author><author><style face="normal" font="default" size="100%">Zimdahl, H.</style></author><author><style face="normal" font="default" size="100%">Hubner, N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">SNP and haplotype mapping for genetic analysis in the rat</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Genet</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals Chromosome Mapping *Databases</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Genome *Haplotypes Linkage Disequilibrium Phylogeny *Polymorphism</style></keyword><keyword><style  face="normal" font="default" size="100%">Inbred Strains/*genetics Recombination</style></keyword><keyword><style  face="normal" font="default" size="100%">Single Nucleotide *Quantitative Trait Loci Rats/*genetics Rats</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=18443594</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">40</style></volume><pages><style face="normal" font="default" size="100%">560-6</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The laboratory rat is one of the most extensively studied model organisms. Inbred laboratory rat strains originated from limited Rattus norvegicus founder populations, and the inherited genetic variation provides an excellent resource for the correlation of genotype to phenotype. Here, we report a survey of genetic variation based on almost 3 million newly identified SNPs. We obtained accurate and complete genotypes for a subset of 20,238 SNPs across 167 distinct inbred rat strains, two rat recombinant inbred panels and an F2 intercross. Using 81% of these SNPs, we constructed high-density genetic maps, creating a large dataset of fully characterized SNPs for disease gene mapping. Our data characterize the population structure and illustrate the degree of linkage disequilibrium. We provide a detailed SNP map and demonstrate its utility for mapping of quantitative trait loci. This community resource is openly available and augments the genetic tools for this workhorse of physiological studies.&lt;/p&gt;</style></abstract><notes><style face="normal" font="default" size="100%">&lt;p&gt;STAR Consortium Saar, Kathrin Beck, Alfred Bihoreau, Marie-Therese Birney, Ewan Brocklebank, Denise Chen, Yuan Cuppen, Edwin Demonchy, Stephanie Dopazo, Joaquin Flicek, Paul Foglio, Mario Fujiyama, Asao Gut, Ivo G Gauguier, Dominique Guigo, Roderic Guryev, Victor Heinig, Matthias Hummel, Oliver Jahn, Niels Klages, Sven Kren, Vladimir Kube, Michael Kuhl, Heiner Kuramoto, Takashi Kuroki, Yoko Lechner, Doris Lee, Young-Ae Lopez-Bigas, Nuria Lathrop, G Mark Mashimo, Tomoji Medina, Ignacio Mott, Richard Patone, Giannino Perrier-Cornet, Jeanne-Antide Platzer, Matthias Pravenec, Michal Reinhardt, Richard Sakaki, Yoshiyuki Schilhabel, Markus Schulz, Herbert Serikawa, Tadao Shikhagaie, Medya Tatsumoto, Shouji Taudien, Stefan Toyoda, Atsushi Voigt, Birger Zelenika, Diana Zimdahl, Heike Hubner, Norbert 057733/Z/99/A/Wellcome Trust/United Kingdom 066780/Z/01/Z/Wellcome Trust/United Kingdom Research Support, Non-U.S. Gov’t Technical Report United States Nature genetics Nat Genet. 2008 May;40(5):560-6.&lt;/p&gt;</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Saar, Kathrin</style></author><author><style face="normal" font="default" size="100%">Beck, Alfred</style></author><author><style face="normal" font="default" size="100%">Bihoreau, Marie-Thérèse</style></author><author><style face="normal" font="default" size="100%">Birney, Ewan</style></author><author><style face="normal" font="default" size="100%">Brocklebank, Denise</style></author><author><style face="normal" font="default" size="100%">Chen, Yuan</style></author><author><style face="normal" font="default" size="100%">Cuppen, Edwin</style></author><author><style face="normal" font="default" size="100%">Demonchy, Stephanie</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Flicek, Paul</style></author><author><style face="normal" font="default" size="100%">Foglio, Mario</style></author><author><style face="normal" font="default" size="100%">Fujiyama, Asao</style></author><author><style face="normal" font="default" size="100%">Gut, Ivo G</style></author><author><style face="normal" font="default" size="100%">Gauguier, Dominique</style></author><author><style face="normal" font="default" size="100%">Guigó, Roderic</style></author><author><style face="normal" font="default" size="100%">Guryev, Victor</style></author><author><style face="normal" font="default" size="100%">Heinig, Matthias</style></author><author><style face="normal" font="default" size="100%">Hummel, Oliver</style></author><author><style face="normal" font="default" size="100%">Jahn, Niels</style></author><author><style face="normal" font="default" size="100%">Klages, Sven</style></author><author><style face="normal" font="default" size="100%">Kren, Vladimir</style></author><author><style face="normal" font="default" size="100%">Kube, Michael</style></author><author><style face="normal" font="default" size="100%">Kuhl, Heiner</style></author><author><style face="normal" font="default" size="100%">Kuramoto, Takashi</style></author><author><style face="normal" font="default" size="100%">Kuroki, Yoko</style></author><author><style face="normal" font="default" size="100%">Lechner, Doris</style></author><author><style face="normal" font="default" size="100%">Lee, Young-Ae</style></author><author><style face="normal" font="default" size="100%">Lopez-Bigas, Nuria</style></author><author><style face="normal" font="default" size="100%">Lathrop, G Mark</style></author><author><style face="normal" font="default" size="100%">Mashimo, Tomoji</style></author><author><style face="normal" font="default" size="100%">Medina, Ignacio</style></author><author><style face="normal" font="default" size="100%">Mott, Richard</style></author><author><style face="normal" font="default" size="100%">Patone, Giannino</style></author><author><style face="normal" font="default" size="100%">Perrier-Cornet, Jeanne-Antide</style></author><author><style face="normal" font="default" size="100%">Platzer, Matthias</style></author><author><style face="normal" font="default" size="100%">Pravenec, Michal</style></author><author><style face="normal" font="default" size="100%">Reinhardt, Richard</style></author><author><style face="normal" font="default" size="100%">Sakaki, Yoshiyuki</style></author><author><style face="normal" font="default" size="100%">Schilhabel, Markus</style></author><author><style face="normal" font="default" size="100%">Schulz, Herbert</style></author><author><style face="normal" font="default" size="100%">Serikawa, Tadao</style></author><author><style face="normal" font="default" size="100%">Shikhagaie, Medya</style></author><author><style face="normal" font="default" size="100%">Tatsumoto, Shouji</style></author><author><style face="normal" font="default" size="100%">Taudien, Stefan</style></author><author><style face="normal" font="default" size="100%">Toyoda, Atsushi</style></author><author><style face="normal" font="default" size="100%">Voigt, Birger</style></author><author><style face="normal" font="default" size="100%">Zelenika, Diana</style></author><author><style face="normal" font="default" size="100%">Zimdahl, Heike</style></author><author><style face="normal" font="default" size="100%">Hubner, Norbert</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">STAR Consortium</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">SNP and haplotype mapping for genetic analysis in the rat.</style></title><secondary-title><style face="normal" font="default" size="100%">Nat Genet</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nat Genet</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Chromosome Mapping</style></keyword><keyword><style  face="normal" font="default" size="100%">Databases, Genetic</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome</style></keyword><keyword><style  face="normal" font="default" size="100%">Haplotypes</style></keyword><keyword><style  face="normal" font="default" size="100%">Linkage Disequilibrium</style></keyword><keyword><style  face="normal" font="default" size="100%">Phylogeny</style></keyword><keyword><style  face="normal" font="default" size="100%">Polymorphism, Single Nucleotide</style></keyword><keyword><style  face="normal" font="default" size="100%">Quantitative Trait Loci</style></keyword><keyword><style  face="normal" font="default" size="100%">Rats</style></keyword><keyword><style  face="normal" font="default" size="100%">Rats, Inbred Strains</style></keyword><keyword><style  face="normal" font="default" size="100%">Recombination, Genetic</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008 May</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">40</style></volume><pages><style face="normal" font="default" size="100%">560-6</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The laboratory rat is one of the most extensively studied model organisms. Inbred laboratory rat strains originated from limited Rattus norvegicus founder populations, and the inherited genetic variation provides an excellent resource for the correlation of genotype to phenotype. Here, we report a survey of genetic variation based on almost 3 million newly identified SNPs. We obtained accurate and complete genotypes for a subset of 20,238 SNPs across 167 distinct inbred rat strains, two rat recombinant inbred panels and an F2 intercross. Using 81% of these SNPs, we constructed high-density genetic maps, creating a large dataset of fully characterized SNPs for disease gene mapping. Our data characterize the population structure and illustrate the degree of linkage disequilibrium. We provide a detailed SNP map and demonstrate its utility for mapping of quantitative trait loci. This community resource is openly available and augments the genetic tools for this workhorse of physiological studies.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/18443594?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Agudo, M.</style></author><author><style face="normal" font="default" size="100%">Perez-Marin, M. C.</style></author><author><style face="normal" font="default" size="100%">Lonngren, U.</style></author><author><style face="normal" font="default" size="100%">Sobrado, P.</style></author><author><style face="normal" font="default" size="100%">A. Conesa</style></author><author><style face="normal" font="default" size="100%">Canovas, I.</style></author><author><style face="normal" font="default" size="100%">Salinas-Navarro, M.</style></author><author><style face="normal" font="default" size="100%">Miralles-Imperial, J.</style></author><author><style face="normal" font="default" size="100%">Hallbook, F.</style></author><author><style face="normal" font="default" size="100%">Vidal-Sanz, M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Time course profiling of the retinal transcriptome after optic nerve transection and optic nerve crush</style></title><secondary-title><style face="normal" font="default" size="100%">Mol Vis</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals Cell Death Cluster Analysis Female *Gene Expression Profiling Gene Expression Regulation *Nerve Crush Optic Nerve/*metabolism/*pathology Optic Nerve Injuries/*genetics Rats Rats</style></keyword><keyword><style  face="normal" font="default" size="100%">Sprague-Dawley Reproducibility of Results Retina/*metabolism/*pathology Time Factors</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=18552980</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">1050-63</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">PURPOSE: A time-course analysis of gene regulation in the adult rat retina after intraorbital nerve crush (IONC) and intraorbital nerve transection (IONT). METHODS: RNA was extracted from adult rat retinas undergoing either IONT or IONC at increasing times post-lesion. Affymetrix RAE230.2 arrays were hybridized and analyzed. Statistically regulated genes were annotated and functionally clustered. Arrays were validated by means of quantative reverse transcription polymerase chain reaction (qRT-PCR) on ten regulated genes at two times post-lesion. Western blotting and immunohistofluorescence for four pro-apoptotic proteins were performed on naive and injured retinas. Finally, custom signaling maps for IONT- and IONC-induced death response were generated (MetaCore, Genego Inc.). RESULTS: Here we show that over time, 3,219 sequences were regulated after IONT and 1,996 after IONC. Out of the total of regulated sequences, 1,078 were commonly regulated by both injuries. Interestingly, while IONT mainly triggers a gene upregulation-sustained over time, IONC causes a transitory downregulation. Functional clustering identified the regulation of high interest biologic processes, most importantly cell death wherein apoptosis was the most significant cluster. Ten death-related genes upregulated by both injuries were used for array validation by means of qRT-PCR. In addition, western blotting and immunohistofluorescence of total and active Caspase 3 (Casp3), tumor necrosis factor receptor type 1 associated death domain (TRADD), tumor necrosis factor receptor superfamily member 1a (TNFR1a), and c-fos were performed to confirm their protein regulation and expression pattern in naive and injured retinas. These analyses demonstrated that for these genes, protein regulation followed transcriptional regulation and that these pro-apoptotic proteins were expressed by retinal ganglion cells (RGCs). MetaCore-based death-signaling maps show that several apoptotic cascades were regulated in the retina following optic nerve injury and highlight the similarities and differences between IONT and IONC in cell death profiling. CONCLUSIONS: This comprehensive time course retinal transcriptome study comparing IONT and IONC lesions provides a unique valuable tool to understand the molecular mechanisms underlying optic nerve injury and to design neuroprotective protocols.</style></abstract><notes><style face="normal" font="default" size="100%">Agudo, Marta Perez-Marin, Maria Cruz Lonngren, Ulrika Sobrado, Paloma Conesa, Ana Canovas, Isabel Salinas-Navarro, Manuel Miralles-Imperial, Jaime Hallbook, Finn Vidal-Sanz, Manuel Research Support, Non-U.S. Gov’t United States Molecular vision Mol Vis. 2008 Jun 3;14:1050-63.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Stierum, R.</style></author><author><style face="normal" font="default" size="100%">A. Conesa</style></author><author><style face="normal" font="default" size="100%">Heijne, W.</style></author><author><style face="normal" font="default" size="100%">Ommen, B.</style></author><author><style face="normal" font="default" size="100%">Junker, K.</style></author><author><style face="normal" font="default" size="100%">Scott, M. P.</style></author><author><style face="normal" font="default" size="100%">Price, R. J.</style></author><author><style face="normal" font="default" size="100%">Meredith, C.</style></author><author><style face="normal" font="default" size="100%">Lake, B. G.</style></author><author><style face="normal" font="default" size="100%">Groten, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Transcriptome analysis provides new insights into liver changes induced in the rat upon dietary administration of the food additives butylated hydroxytoluene, curcumin, propyl gallate and thiabendazole</style></title><secondary-title><style face="normal" font="default" size="100%">Food Chem Toxicol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals Aryl Hydrocarbon Hydroxylases/metabolism Body Weight/drug effects Butylated Hydroxytoluene/toxicity Curcumin/toxicity Cytochrome P-450 CYP1A2/metabolism Cytochrome P-450 CYP2B1/metabolism DNA</style></keyword><keyword><style  face="normal" font="default" size="100%">Complementary/biosynthesis/genetics Data Interpretation</style></keyword><keyword><style  face="normal" font="default" size="100%">Sprague-Dawley Reverse Transcriptase Polymerase Chain Reaction Steroid Hydroxylases/metabolism Thiabendazole/toxicity</style></keyword><keyword><style  face="normal" font="default" size="100%">Statistical *Diet Food Additives/*toxicity Gene Expression/drug effects *Gene Expression Profiling Glutathione Transferase/metabolism Liver/*drug effects Male Organ Size/drug effects Oxidation-Reduction Palmitoyl Coenzyme A/metabolism Propyl Gallate/toxi</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=18539377</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">46</style></volume><pages><style face="normal" font="default" size="100%">2616-28</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Transcriptomics was performed to gain insight into mechanisms of food additives butylated hydroxytoluene (BHT), curcumin (CC), propyl gallate (PG), and thiabendazole (TB), additives for which interactions in the liver can not be excluded. Additives were administered in diets for 28 days to Sprague-Dawley rats and cDNA microarray experiments were performed on hepatic RNA. BHT induced changes in the expression of 10 genes, including phase I (CYP2B1/2; CYP3A9; CYP2C6) and phase II metabolism (GST mu2). The CYP2B1/2 and GST expression findings were confirmed by real time RT-PCR, western blotting, and increased GST activity towards DCNB. CC altered the expression of 12 genes. Three out of these were related to peroxisomes (phytanoyl-CoA dioxygenase, enoyl-CoA hydratase; CYP4A3). Increased cyanide insensitive palmitoyl-CoA oxidation was observed, suggesting that CC is a weak peroxisome proliferator. TB changed the expression of 12 genes, including CYP1A2. In line, CYP1A2 protein expression was increased. The expression level of five genes, associated with p53 was found to change upon TB treatment, including p53 itself, GADD45alpha, DN-7, protein kinase C beta and serum albumin. These array experiments led to the novel finding that TB is capable of inducing p53 at the protein level, at least at the highest dose levels employed above the current NOAEL. The expression of eight genes changed upon PG administration. This study shows the value of gene expression profiling in food toxicology in terms of generating novel hypotheses on the mechanisms of action of food additives in relation to pathology.</style></abstract><notes><style face="normal" font="default" size="100%">Stierum, Rob Conesa, Ana Heijne, Wilbert Ommen, Ben van Junker, Karin Scott, Mary P Price, Roger J Meredith, Clive Lake, Brian G Groten, John Research Support, Non-U.S. Gov’t England Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association Food Chem Toxicol. 2008 Aug;46(8):2616-28. Epub 2008 Apr 25.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">M. A. Marti-Renom</style></author><author><style face="normal" font="default" size="100%">Rossi, A.</style></author><author><style face="normal" font="default" size="100%">Fatima Al-Shahrour</style></author><author><style face="normal" font="default" size="100%">Davis, F. P.</style></author><author><style face="normal" font="default" size="100%">Pieper, U.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Sali, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The AnnoLite and AnnoLyze programs for comparative annotation of protein structures</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Bioinformatics</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Algorithms Amino Acid Sequence Confidence Intervals Data Interpretation</style></keyword><keyword><style  face="normal" font="default" size="100%">Amino Acid *Software Structure-Activity Relationship</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Information Storage and Retrieval/methods Molecular Sequence Data Proteins/*chemistry/classification/*metabolism Sensitivity and Specificity Sequence Alignment/*methods Sequence Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein/*methods Sequence Homology</style></keyword><keyword><style  face="normal" font="default" size="100%">Statistical *Databases</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=17570147</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">8 Suppl 4</style></volume><pages><style face="normal" font="default" size="100%">S4</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: Advances in structural biology, including structural genomics, have resulted in a rapid increase in the number of experimentally determined protein structures. However, about half of the structures deposited by the structural genomics consortia have little or no information about their biological function. Therefore, there is a need for tools for automatically and comprehensively annotating the function of protein structures. We aim to provide such tools by applying comparative protein structure annotation that relies on detectable relationships between protein structures to transfer functional annotations. Here we introduce two programs, AnnoLite and AnnoLyze, which use the structural alignments deposited in the DBAli database. DESCRIPTION: AnnoLite predicts the SCOP, CATH, EC, InterPro, PfamA, and GO terms with an average sensitivity of  90% and average precision of  80%. AnnoLyze predicts ligand binding site and domain interaction patches with an average sensitivity of  70% and average precision of  30%, correctly localizing binding sites for small molecules in  95% of its predictions. CONCLUSION: The AnnoLite and AnnoLyze programs for comparative annotation of protein structures can reliably and automatically annotate new protein structures. The programs are fully accessible via the Internet as part of the DBAli suite of tools at http://salilab.org/DBAli/.</style></abstract><notes><style face="normal" font="default" size="100%">Marti-Renom, Marc A Rossi, Andrea Al-Shahrour, Fatima Davis, Fred P Pieper, Ursula Dopazo, Joaquin Sali, Andrej Research Support, Non-U.S. Gov’t England BMC bioinformatics BMC Bioinformatics. 2007 May 22;8 Suppl 4:S4.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ruiz-Llorente, S.</style></author><author><style face="normal" font="default" size="100%">Montero-Conde, C.</style></author><author><style face="normal" font="default" size="100%">Milne, R. L.</style></author><author><style face="normal" font="default" size="100%">Moya, C. M.</style></author><author><style face="normal" font="default" size="100%">Cebrian, A.</style></author><author><style face="normal" font="default" size="100%">Leton, R.</style></author><author><style face="normal" font="default" size="100%">Cascon, A.</style></author><author><style face="normal" font="default" size="100%">Mercadillo, F.</style></author><author><style face="normal" font="default" size="100%">Landa, I.</style></author><author><style face="normal" font="default" size="100%">Borrego, S.</style></author><author><style face="normal" font="default" size="100%">Perez de Nanclares, G.</style></author><author><style face="normal" font="default" size="100%">Alvarez-Escola, C.</style></author><author><style face="normal" font="default" size="100%">Diaz-Perez, J. A.</style></author><author><style face="normal" font="default" size="100%">Carracedo, A.</style></author><author><style face="normal" font="default" size="100%">Urioste, M.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Neira, A.</style></author><author><style face="normal" font="default" size="100%">Benitez, J.</style></author><author><style face="normal" font="default" size="100%">Santisteban, P.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Ponder, B. A.</style></author><author><style face="normal" font="default" size="100%">M. Robledo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Association study of 69 genes in the ret pathway identifies low-penetrance loci in sporadic medullary thyroid carcinoma</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Res</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">80 and over Carcinoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Adolescent Adult Aged Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Proto-Oncogene Proteins c-ret/*genetics/metabolism Signal Transduction Thyroid Neoplasms/*genetics/metabolism Transcription</style></keyword><keyword><style  face="normal" font="default" size="100%">Medullary/*genetics/metabolism Case-Control Studies Cyclin-Dependent Kinase Inhibitor p15/biosynthesis/genetics Female Genetic Predisposition to Disease Germ-Line Mutation Haplotypes Humans Male Middle Aged Penetrance Polymorphism</style></keyword><keyword><style  face="normal" font="default" size="100%">Single Nucleotide Promoter Regions</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=17909067</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">19</style></number><volume><style face="normal" font="default" size="100%">67</style></volume><pages><style face="normal" font="default" size="100%">9561-7</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">To date, few association studies have been done to better understand the genetic basis for the development of sporadic medullary thyroid carcinoma (sMTC). To identify additional low-penetrance genes, we have done a two-stage case-control study in two European populations using high-throughput genotyping. We selected 417 single nucleotide polymorphisms (SNP) belonging to 69 genes either related to RET signaling pathway/functions or involved in key processes for cancer development. TagSNPs and functional variants were included where possible. These SNPs were initially studied in the largest known series of sMTC cases (n = 266) and controls (n = 422), all of Spanish origin. In stage II, an independent British series of 155 sMTC patients and 531 controls was included to validate the previous results. Associations were assessed by an exhaustive analysis of individual SNPs but also considering gene- and linkage disequilibrium-based haplotypes. This strategy allowed us to identify seven low-penetrance genes, six of them (STAT1, AURKA, BCL2, CDKN2B, CDK6, and COMT) consistently associated with sMTC risk in the two case-control series and a seventh (HRAS) with individual SNPs and haplotypes associated with sMTC in the Spanish data set. The potential role of CDKN2B was confirmed by a functional assay showing a role of a SNP (rs7044859) in the promoter region in altering the binding of the transcription factor HNF1. These results highlight the utility of association studies using homogeneous series of cases for better understanding complex diseases.</style></abstract><notes><style face="normal" font="default" size="100%">Ruiz-Llorente, Sergio Montero-Conde, Cristina Milne, Roger L Moya, Christian M Cebrian, Arancha Leton, Rocio Cascon, Alberto Mercadillo, Fatima Landa, Inigo Borrego, Salud Perez de Nanclares, Guiomar Alvarez-Escola, Cristina Diaz-Perez, Jose Angel Carracedo, Angel Urioste, Miguel Gonzalez-Neira, Anna Benitez, Javier Santisteban, Pilar Dopazo, Joaquin Ponder, Bruce A Robledo, Mercedes Medullary Thyroid Carcinoma Clinical Group Research Support, Non-U.S. Gov’t United States Cancer research Cancer Res. 2007 Oct 1;67(19):9561-7.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Marti-Renom, Marc A</style></author><author><style face="normal" font="default" size="100%">Pieper, Ursula</style></author><author><style face="normal" font="default" size="100%">Madhusudhan, M S</style></author><author><style face="normal" font="default" size="100%">Rossi, Andrea</style></author><author><style face="normal" font="default" size="100%">Eswar, Narayanan</style></author><author><style face="normal" font="default" size="100%">Davis, Fred P</style></author><author><style face="normal" font="default" size="100%">Al-Shahrour, Fátima</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Sali, Andrej</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">DBAli tools: mining the protein structure space.</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Algorithms</style></keyword><keyword><style  face="normal" font="default" size="100%">Amino Acid Sequence</style></keyword><keyword><style  face="normal" font="default" size="100%">Computational Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Data Interpretation, Statistical</style></keyword><keyword><style  face="normal" font="default" size="100%">Databases, Protein</style></keyword><keyword><style  face="normal" font="default" size="100%">Internet</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Sequence Data</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Conformation</style></keyword><keyword><style  face="normal" font="default" size="100%">Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Pseudomonas aeruginosa</style></keyword><keyword><style  face="normal" font="default" size="100%">Sequence Alignment</style></keyword><keyword><style  face="normal" font="default" size="100%">Sequence Analysis, Protein</style></keyword><keyword><style  face="normal" font="default" size="100%">Sequence Homology, Amino Acid</style></keyword><keyword><style  face="normal" font="default" size="100%">Software</style></keyword><keyword><style  face="normal" font="default" size="100%">Structure-Activity Relationship</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007 Jul</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">35</style></volume><pages><style face="normal" font="default" size="100%">W393-7</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The DBAli tools use a comprehensive set of structural alignments in the DBAli database to leverage the structural information deposited in the Protein Data Bank (PDB). These tools include (i) the DBAlit program that allows users to input the 3D coordinates of a protein structure for comparison by MAMMOTH against all chains in the PDB; (ii) the AnnoLite and AnnoLyze programs that annotate a target structure based on its stored relationships to other structures; (iii) the ModClus program that clusters structures by sequence and structure similarities; (iv) the ModDom program that identifies domains as recurrent structural fragments and (v) an implementation of the COMPARER method in the SALIGN command in MODELLER that creates a multiple structure alignment for a set of related protein structures. Thus, the DBAli tools, which are freely accessible via the World Wide Web at http://salilab.org/DBAli/, allow users to mine the protein structure space by establishing relationships between protein structures and their functions.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">Web Server issue</style></issue><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/17478513?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">M. A. Marti-Renom</style></author><author><style face="normal" font="default" size="100%">Pieper, U.</style></author><author><style face="normal" font="default" size="100%">Madhusudhan, M. S.</style></author><author><style face="normal" font="default" size="100%">Rossi, A.</style></author><author><style face="normal" font="default" size="100%">Eswar, N.</style></author><author><style face="normal" font="default" size="100%">Davis, F. P.</style></author><author><style face="normal" font="default" size="100%">Fatima Al-Shahrour</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Sali, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">DBAli tools: mining the protein structure space</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Algorithms Amino Acid Sequence Computational Biology/*methods Data Interpretation</style></keyword><keyword><style  face="normal" font="default" size="100%">Amino Acid *Software Structure-Activity Relationship</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Internet Molecular Sequence Data Protein Conformation Proteins/*chemistry/classification/*metabolism Pseudomonas aeruginosa/*metabolism Sequence Alignment/*methods Sequence Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein/*methods Sequence Homology</style></keyword><keyword><style  face="normal" font="default" size="100%">Statistical *Databases</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=17478513</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">Web Server issue</style></number><volume><style face="normal" font="default" size="100%">35</style></volume><pages><style face="normal" font="default" size="100%">W393-7</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The DBAli tools use a comprehensive set of structural alignments in the DBAli database to leverage the structural information deposited in the Protein Data Bank (PDB). These tools include (i) the DBAlit program that allows users to input the 3D coordinates of a protein structure for comparison by MAMMOTH against all chains in the PDB; (ii) the AnnoLite and AnnoLyze programs that annotate a target structure based on its stored relationships to other structures; (iii) the ModClus program that clusters structures by sequence and structure similarities; (iv) the ModDom program that identifies domains as recurrent structural fragments and (v) an implementation of the COMPARER method in the SALIGN command in MODELLER that creates a multiple structure alignment for a set of related protein structures. Thus, the DBAli tools, which are freely accessible via the World Wide Web at http://salilab.org/DBAli/, allow users to mine the protein structure space by establishing relationships between protein structures and their functions.</style></abstract><notes><style face="normal" font="default" size="100%">Marti-Renom, Marc A Pieper, Ursula Madhusudhan, M S Rossi, Andrea Eswar, Narayanan Davis, Fred P Al-Shahrour, Fatima Dopazo, Joaquin Sali, Andrej GM 62529/GM/NIGMS NIH HHS/United States GM074929/GM/NIGMS NIH HHS/United States GM54762/GM/NIGMS NIH HHS/United States GM71790/GM/NIGMS NIH HHS/United States Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t England Nucleic acids research Nucleic Acids Res. 2007 Jul;35(Web Server issue):W393-7. Epub 2007 May 3.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hernandez, P.</style></author><author><style face="normal" font="default" size="100%">Huerta-Cepas, J.</style></author><author><style face="normal" font="default" size="100%">Montaner, D.</style></author><author><style face="normal" font="default" size="100%">Fatima Al-Shahrour</style></author><author><style face="normal" font="default" size="100%">Valls, J.</style></author><author><style face="normal" font="default" size="100%">Gomez, L.</style></author><author><style face="normal" font="default" size="100%">Capella, G.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Pujana, M. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Evidence for systems-level molecular mechanisms of tumorigenesis</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Genomics</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Cell Transformation</style></keyword><keyword><style  face="normal" font="default" size="100%">Biological Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Messenger/metabolism Signal Transduction Systems Biology</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplastic *Gene Expression Profiling *Gene Expression Regulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplastic Humans Male Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Statistical Neoplasm Proteins/*physiology Neoplasms/etiology/*genetics Prostatic Neoplasms/genetics Protein Interaction Mapping RNA</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=17584915</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">8</style></volume><pages><style face="normal" font="default" size="100%">185</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: Cancer arises from the consecutive acquisition of genetic alterations. Increasing evidence suggests that as a consequence of these alterations, molecular interactions are reprogrammed in the context of highly connected and regulated cellular networks. Coordinated reprogramming would allow the cell to acquire the capabilities for malignant growth. RESULTS: Here, we determine the coordinated function of cancer gene products (i.e., proteins encoded by differentially expressed genes in tumors relative to healthy tissue counterparts, hereafter referred to as &quot;CGPs&quot;) defined as their topological properties and organization in the interactome network. We show that CGPs are central to information exchange and propagation and that they are specifically organized to promote tumorigenesis. Centrality is identified by both local (degree) and global (betweenness and closeness) measures, and systematically appears in down-regulated CGPs. Up-regulated CGPs do not consistently exhibit centrality, but both types of cancer products determine the overall integrity of the network structure. In addition to centrality, down-regulated CGPs show topological association that correlates with common biological processes and pathways involved in tumorigenesis. CONCLUSION: Given the current limited coverage of the human interactome, this study proposes that tumorigenesis takes place in a specific and organized way at the molecular systems-level and suggests a model that comprises the precise down-regulation of groups of topologically-associated proteins involved in particular functions, orchestrated with the up-regulation of specific proteins.</style></abstract><notes><style face="normal" font="default" size="100%">Hernandez, Pilar Huerta-Cepas, Jaime Montaner, David Al-Shahrour, Fatima Valls, Joan Gomez, Laia Capella, Gabriel Dopazo, Joaquin Pujana, Miguel Angel Research Support, Non-U.S. Gov’t England BMC genomics BMC Genomics. 2007 Jun 20;8:185.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hernández, Pilar</style></author><author><style face="normal" font="default" size="100%">Huerta-Cepas, Jaime</style></author><author><style face="normal" font="default" size="100%">Montaner, David</style></author><author><style face="normal" font="default" size="100%">Al-Shahrour, Fátima</style></author><author><style face="normal" font="default" size="100%">Valls, Joan</style></author><author><style face="normal" font="default" size="100%">Gómez, Laia</style></author><author><style face="normal" font="default" size="100%">Capellà, Gabriel</style></author><author><style face="normal" font="default" size="100%">Dopazo, Joaquin</style></author><author><style face="normal" font="default" size="100%">Pujana, Miguel Angel</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Evidence for systems-level molecular mechanisms of tumorigenesis.</style></title><secondary-title><style face="normal" font="default" size="100%">BMC Genomics</style></secondary-title><alt-title><style face="normal" font="default" size="100%">BMC Genomics</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Cell Transformation, Neoplastic</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Profiling</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation, Neoplastic</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Models, Biological</style></keyword><keyword><style  face="normal" font="default" size="100%">Models, Genetic</style></keyword><keyword><style  face="normal" font="default" size="100%">Models, Statistical</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm Proteins</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Prostatic Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Interaction Mapping</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Messenger</style></keyword><keyword><style  face="normal" font="default" size="100%">Signal Transduction</style></keyword><keyword><style  face="normal" font="default" size="100%">Systems biology</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007 Jun 20</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">8</style></volume><pages><style face="normal" font="default" size="100%">185</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;BACKGROUND: &lt;/b&gt;Cancer arises from the consecutive acquisition of genetic alterations. Increasing evidence suggests that as a consequence of these alterations, molecular interactions are reprogrammed in the context of highly connected and regulated cellular networks. Coordinated reprogramming would allow the cell to acquire the capabilities for malignant growth.&lt;/p&gt;&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;Here, we determine the coordinated function of cancer gene products (i.e., proteins encoded by differentially expressed genes in tumors relative to healthy tissue counterparts, hereafter referred to as &quot;CGPs&quot;) defined as their topological properties and organization in the interactome network. We show that CGPs are central to information exchange and propagation and that they are specifically organized to promote tumorigenesis. Centrality is identified by both local (degree) and global (betweenness and closeness) measures, and systematically appears in down-regulated CGPs. Up-regulated CGPs do not consistently exhibit centrality, but both types of cancer products determine the overall integrity of the network structure. In addition to centrality, down-regulated CGPs show topological association that correlates with common biological processes and pathways involved in tumorigenesis.&lt;/p&gt;&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;Given the current limited coverage of the human interactome, this study proposes that tumorigenesis takes place in a specific and organized way at the molecular systems-level and suggests a model that comprises the precise down-regulation of groups of topologically-associated proteins involved in particular functions, orchestrated with the up-regulation of specific proteins.&lt;/p&gt;</style></abstract><custom1><style face="normal" font="default" size="100%">https://www.ncbi.nlm.nih.gov/pubmed/17584915?dopt=Abstract</style></custom1></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Schluter, A.</style></author><author><style face="normal" font="default" size="100%">Fourcade, S.</style></author><author><style face="normal" font="default" size="100%">Domenech-Estevez, E.</style></author><author><style face="normal" font="default" size="100%">Gabaldón, T.</style></author><author><style face="normal" font="default" size="100%">Huerta-Cepas, J.</style></author><author><style face="normal" font="default" size="100%">Berthommier, G.</style></author><author><style face="normal" font="default" size="100%">Ripp, R.</style></author><author><style face="normal" font="default" size="100%">Wanders, R. J.</style></author><author><style face="normal" font="default" size="100%">Poch, O.</style></author><author><style face="normal" font="default" size="100%">Pujol, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">PeroxisomeDB: a database for the peroxisomal proteome, functional genomics and disease</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals *Databases</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Genomics Humans Internet Mice Peroxisomal Disorders/*genetics Peroxisomes/*metabolism Protein Sorting Signals Proteome/chemistry/*genetics/*physiology Rats Saccharomyces cerevisiae Proteins/genetics/physiology Software User-Computer Interface</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=17135190</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">Database issue</style></number><volume><style face="normal" font="default" size="100%">35</style></volume><pages><style face="normal" font="default" size="100%">D815-22</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Peroxisomes are essential organelles of eukaryotic origin, ubiquitously distributed in cells and organisms, playing key roles in lipid and antioxidant metabolism. Loss or malfunction of peroxisomes causes more than 20 fatal inherited conditions. We have created a peroxisomal database (http://www.peroxisomeDB.org) that includes the complete peroxisomal proteome of Homo sapiens and Saccharomyces cerevisiae, by gathering, updating and integrating the available genetic and functional information on peroxisomal genes. PeroxisomeDB is structured in interrelated sections ’Genes’, ’Functions’, ’Metabolic pathways’ and ’Diseases’, that include hyperlinks to selected features of NCBI, ENSEMBL and UCSC databases. We have designed graphical depictions of the main peroxisomal metabolic routes and have included updated flow charts for diagnosis. Precomputed BLAST, PSI-BLAST, multiple sequence alignment (MUSCLE) and phylogenetic trees are provided to assist in direct multispecies comparison to study evolutionary conserved functions and pathways. Highlights of the PeroxisomeDB include new tools developed for facilitating (i) identification of novel peroxisomal proteins, by means of identifying proteins carrying peroxisome targeting signal (PTS) motifs, (ii) detection of peroxisomes in silico, particularly useful for screening the deluge of newly sequenced genomes. PeroxisomeDB should contribute to the systematic characterization of the peroxisomal proteome and facilitate system biology approaches on the organelle.</style></abstract><notes><style face="normal" font="default" size="100%">Schluter, Agatha Fourcade, Stephane Domenech-Estevez, Enric Gabaldon, Toni Huerta-Cepas, Jaime Berthommier, Guillaume Ripp, Raymond Wanders, Ronald J A Poch, Olivier Pujol, Aurora Research Support, Non-U.S. Gov’t England Nucleic acids research Nucleic Acids Res. 2007 Jan;35(Database issue):D815-22. Epub 2006 Nov 28.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gabaldón, T.</style></author><author><style face="normal" font="default" size="100%">Peretó, J.</style></author><author><style face="normal" font="default" size="100%">Montero, F.</style></author><author><style face="normal" font="default" size="100%">Gil, R.</style></author><author><style face="normal" font="default" size="100%">Latorre, A.</style></author><author><style face="normal" font="default" size="100%">Moya, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Structural analyses of a hypothetical minimal metabolism</style></title><secondary-title><style face="normal" font="default" size="100%">Philos Trans R Soc Lond B Biol Sci</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Cell Physiological Phenomena Cells/*metabolism Cluster Analysis *Computer Simulation *Metabolic Networks and Pathways *Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Biological Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Statistical</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=17510022</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">1486</style></number><volume><style face="normal" font="default" size="100%">362</style></volume><pages><style face="normal" font="default" size="100%">1751-62</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">By integrating data from comparative genomics and large-scale deletion studies, we previously proposed a minimal gene set comprising 206 protein-coding genes. To evaluate the consistency of the metabolism encoded by such a minimal genome, we have carried out a series of computational analyses. Firstly, the topology of the minimal metabolism was compared with that of the reconstructed networks from natural bacterial genomes. Secondly, the robustness of the metabolic network was evaluated by simulated mutagenesis and, finally, the stoichiometric consistency was assessed by automatically deriving the steady-state solutions from the reaction set. The results indicated that the proposed minimal metabolism presents stoichiometric consistency and that it is organized as a complex power-law network with topological parameters falling within the expected range for a natural metabolism of its size. The robustness analyses revealed that most random mutations do not alter the topology of the network significantly, but do cause significant damage by preventing the synthesis of several compounds or compromising the stoichiometric consistency of the metabolism. The implications that these results have on the origins of metabolic complexity and the theoretical design of an artificial minimal cell are discussed.</style></abstract><notes><style face="normal" font="default" size="100%">Gabaldon, Toni Pereto, Juli Montero, Francisco Gil, Rosario Latorre, Amparo Moya, Andres Research Support, Non-U.S. Gov’t England Philosophical transactions of the Royal Society of London. Series B, Biological sciences Philos Trans R Soc Lond B Biol Sci. 2007 Oct 29;362(1486):1751-62.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gandia, M.</style></author><author><style face="normal" font="default" size="100%">A. Conesa</style></author><author><style face="normal" font="default" size="100%">Ancillo, G.</style></author><author><style face="normal" font="default" size="100%">J. Gadea</style></author><author><style face="normal" font="default" size="100%">J. Forment</style></author><author><style face="normal" font="default" size="100%">Pallas, V.</style></author><author><style face="normal" font="default" size="100%">Flores, R.</style></author><author><style face="normal" font="default" size="100%">Duran-Vila, N.</style></author><author><style face="normal" font="default" size="100%">Moreno, P.</style></author><author><style face="normal" font="default" size="100%">Guerri, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Transcriptional response of Citrus aurantifolia to infection by Citrus tristeza virus</style></title><secondary-title><style face="normal" font="default" size="100%">Virology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Citrus/*genetics/physiology/virology Closterovirus/genetics/*physiology Genes</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic</style></keyword><keyword><style  face="normal" font="default" size="100%">Plant Oligonucleotide Array Sequence Analysis Reverse Transcriptase Polymerase Chain Reaction *Transcription</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=17617431</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">367</style></volume><pages><style face="normal" font="default" size="100%">298-306</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Changes in gene expression of Mexican lime plants in response to infection with a severe (T305) or a mild (T385) isolate of Citrus tristeza virus (CTV) were analyzed using a cDNA microarray containing 12,672 probes to 6875 different citrus genes. Statistically significant (P&lt;0.01) expression changes of 334 genes were detected in response to infection with isolate T305, whereas infection with T385 induced no significant change. Induced genes included 145 without significant similarity with known sequences and 189 that were classified in seven functional categories. Genes related with response to stress and defense were the main category and included 28% of the genes induced. Selected transcription changes detected by microarray analysis were confirmed by quantitative real-time RT-PCR. Changes detected in the transcriptome upon infecting lime with T305 may be associated either with symptom expression, with a strain-specific defense mechanism, or with a general response to stress.</style></abstract><notes><style face="normal" font="default" size="100%">Gandia, Monica Conesa, Ana Ancillo, Gema Gadea, Jose Forment, Javier Pallas, Vicente Flores, Ricardo Duran-Vila, Nuria Moreno, Pedro Guerri, Jose Research Support, Non-U.S. Gov’t United States Virology Virology. 2007 Oct 25;367(2):298-306. Epub 2007 Jul 9.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eswar, N.</style></author><author><style face="normal" font="default" size="100%">Webb, B.</style></author><author><style face="normal" font="default" size="100%">M. A. Marti-Renom</style></author><author><style face="normal" font="default" size="100%">Madhusudhan, M. S.</style></author><author><style face="normal" font="default" size="100%">Eramian, D.</style></author><author><style face="normal" font="default" size="100%">Shen, M. Y.</style></author><author><style face="normal" font="default" size="100%">Pieper, U.</style></author><author><style face="normal" font="default" size="100%">Sali, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparative protein structure modeling using Modeller</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Protoc Bioinformatics</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Algorithms Amino Acid Sequence Computer Simulation Crystallography/*methods *Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Chemical *Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Molecular Sequence Data Protein Conformation Protein Folding Proteins/*chemistry/*ultrastructure Sequence Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein/*methods *Software</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2006</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=18428767</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">Chapter 5</style></volume><pages><style face="normal" font="default" size="100%">Unit 5 6</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Functional characterization of a protein sequence is one of the most frequent problems in biology. This task is usually facilitated by accurate three-dimensional (3-D) structure of the studied protein. In the absence of an experimentally determined structure, comparative or homology modeling can sometimes provide a useful 3-D model for a protein that is related to at least one known protein structure. Comparative modeling predicts the 3-D structure of a given protein sequence (target) based primarily on its alignment to one or more proteins of known structure (templates). The prediction process consists of fold assignment, target-template alignment, model building, and model evaluation. This unit describes how to calculate comparative models using the program MODELLER and discusses all four steps of comparative modeling, frequently observed errors, and some applications. Modeling lactate dehydrogenase from Trichomonas vaginalis (TvLDH) is described as an example. The download and installation of the MODELLER software is also described.</style></abstract><notes><style face="normal" font="default" size="100%">Eswar, Narayanan Webb, Ben Marti-Renom, Marc A Madhusudhan, M S Eramian, David Shen, Min-Yi Pieper, Ursula Sali, Andrej P01 A135707/PHS HHS/United States P01 GM71790/GM/NIGMS NIH HHS/United States R01 GM54762/GM/NIGMS NIH HHS/United States U54 GM62529/GM/NIGMS NIH HHS/United States Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t United States Current protocols in bioinformatics / editoral board, Andreas D. Baxevanis ... [et al.] Curr Protoc Bioinformatics. 2006 Oct;Chapter 5:Unit 5.6.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pieper, U.</style></author><author><style face="normal" font="default" size="100%">Eswar, N.</style></author><author><style face="normal" font="default" size="100%">Davis, F. P.</style></author><author><style face="normal" font="default" size="100%">Braberg, H.</style></author><author><style face="normal" font="default" size="100%">Madhusudhan, M. S.</style></author><author><style face="normal" font="default" size="100%">Rossi, A.</style></author><author><style face="normal" font="default" size="100%">M. A. Marti-Renom</style></author><author><style face="normal" font="default" size="100%">Karchin, R.</style></author><author><style face="normal" font="default" size="100%">Webb, B. M.</style></author><author><style face="normal" font="default" size="100%">Eramian, D.</style></author><author><style face="normal" font="default" size="100%">Shen, M. Y.</style></author><author><style face="normal" font="default" size="100%">Kelly, L.</style></author><author><style face="normal" font="default" size="100%">Melo, F.</style></author><author><style face="normal" font="default" size="100%">Sali, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">MODBASE: a database of annotated comparative protein structure models and associated resources</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Binding Sites *Databases</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Polymorphism</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Humans Internet Ligands *Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Systems Integration User-Computer Interface</style></keyword><keyword><style  face="normal" font="default" size="100%">Single Nucleotide Protein Structure</style></keyword><keyword><style  face="normal" font="default" size="100%">Tertiary Proteins/*chemistry/genetics/metabolism Software *Structural Homology</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2006</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=16381869</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">Database issue</style></number><volume><style face="normal" font="default" size="100%">34</style></volume><pages><style face="normal" font="default" size="100%">D291-5</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">MODBASE (http://salilab.org/modbase) is a database of annotated comparative protein structure models for all available protein sequences that can be matched to at least one known protein structure. The models are calculated by MODPIPE, an automated modeling pipeline that relies on MODELLER for fold assignment, sequence-structure alignment, model building and model assessment (http:/salilab.org/modeller). MODBASE is updated regularly to reflect the growth in protein sequence and structure databases, and improvements in the software for calculating the models. MODBASE currently contains 3 094 524 reliable models for domains in 1 094 750 out of 1 817 889 unique protein sequences in the UniProt database (July 5, 2005); only models based on statistically significant alignments and models assessed to have the correct fold despite insignificant alignments are included. MODBASE also allows users to generate comparative models for proteins of interest with the automated modeling server MODWEB (http://salilab.org/modweb). Our other resources integrated with MODBASE include comprehensive databases of multiple protein structure alignments (DBAli, http://salilab.org/dbali), structurally defined ligand binding sites and structurally defined binary domain interfaces (PIBASE, http://salilab.org/pibase) as well as predictions of ligand binding sites, interactions between yeast proteins, and functional consequences of human nsSNPs (LS-SNP, http://salilab.org/LS-SNP).</style></abstract><notes><style face="normal" font="default" size="100%">Pieper, Ursula Eswar, Narayanan Davis, Fred P Braberg, Hannes Madhusudhan, M S Rossi, Andrea Marti-Renom, Marc Karchin, Rachel Webb, Ben M Eramian, David Shen, Min-Yi Kelly, Libusha Melo, Francisco Sali, Andrej GM 08284/GM/NIGMS NIH HHS/United States P50 GM62529/GM/NIGMS NIH HHS/United States R01 GM 54762/GM/NIGMS NIH HHS/United States R33 CA84699/CA/NCI NIH HHS/United States U54 GM074945/GM/NIGMS NIH HHS/United States Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t England Nucleic acids research Nucleic Acids Res. 2006 Jan 1;34(Database issue):D291-5.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Montaner, D.</style></author><author><style face="normal" font="default" size="100%">Tarraga, J.</style></author><author><style face="normal" font="default" size="100%">Huerta-Cepas, J.</style></author><author><style face="normal" font="default" size="100%">Burguet, J.</style></author><author><style face="normal" font="default" size="100%">Vaquerizas, J. M.</style></author><author><style face="normal" font="default" size="100%">L. Conde</style></author><author><style face="normal" font="default" size="100%">Minguez, P.</style></author><author><style face="normal" font="default" size="100%">Vera, J.</style></author><author><style face="normal" font="default" size="100%">Mukherjee, S.</style></author><author><style face="normal" font="default" size="100%">Valls, J.</style></author><author><style face="normal" font="default" size="100%">Pujana, M. A.</style></author><author><style face="normal" font="default" size="100%">Alloza, E.</style></author><author><style face="normal" font="default" size="100%">Herrero, J.</style></author><author><style face="normal" font="default" size="100%">Fatima Al-Shahrour</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Next station in microarray data analysis: GEPAS</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">gepas</style></keyword><keyword><style  face="normal" font="default" size="100%">microarray data analysis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2006</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=16845056</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">34</style></volume><pages><style face="normal" font="default" size="100%">W486-91</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The Gene Expression Profile Analysis Suite (GEPAS) has been running for more than four years. During this time it has evolved to keep pace with the new interests and trends in the still changing world of microarray data analysis. GEPAS has been designed to provide an intuitive although powerful web-based interface that offers diverse analysis options from the early step of preprocessing (normalization of Affymetrix and two-colour microarray experiments and other preprocessing options), to the final step of the functional annotation of the experiment (using Gene Ontology, pathways, PubMed abstracts etc.), and include different possibilities for clustering, gene selection, class prediction and array-comparative genomic hybridization management. GEPAS is extensively used by researchers of many countries and its records indicate an average usage rate of 400 experiments per day. The web-based pipeline for microarray gene expression data, GEPAS, is available at http://www.gepas.org.&lt;/p&gt;</style></abstract><notes><style face="normal" font="default" size="100%">&lt;p&gt;Montaner, David Tarraga, Joaquin Huerta-Cepas, Jaime Burguet, Jordi Vaquerizas, Juan M Conde, Lucia Minguez, Pablo Vera, Javier Mukherjee, Sach Valls, Joan Pujana, Miguel A G Alloza, Eva Herrero, Javier Al-Shahrour, Fatima Dopazo, Joaquin Research Support, Non-U.S. Gov’t England Nucleic acids research Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W486-91.&lt;/p&gt;</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Arbiza, L.</style></author><author><style face="normal" font="default" size="100%">Duchi, S.</style></author><author><style face="normal" font="default" size="100%">Montaner, D.</style></author><author><style face="normal" font="default" size="100%">Burguet, J.</style></author><author><style face="normal" font="default" size="100%">Pantoja-Uceda, D.</style></author><author><style face="normal" font="default" size="100%">Pineda-Lucena, A.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">H. Dopazo</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Selective pressures at a codon-level predict deleterious mutations in human disease genes</style></title><secondary-title><style face="normal" font="default" size="100%">J Mol Biol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Amino Acid Sequence Amino Acid Substitution Codon/*genetics Databases</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Evolution</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Human Humans Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Inborn/*genetics Genome</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Genes</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Molecular Sequence Data *Mutation Neoplasms/genetics Proteins/genetics *Selection (Genetics) Tumor Suppressor Protein p53/chemistry/genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">p53 Genetic Diseases</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2006</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=16584746</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">358</style></volume><pages><style face="normal" font="default" size="100%">1390-404</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Deleterious mutations affecting biological function of proteins are constantly being rejected by purifying selection from the gene pool. The non-synonymous/synonymous substitution rate ratio (omega) is a measure of selective pressure on amino acid replacement mutations for protein-coding genes. Different methods have been developed in order to predict non-synonymous changes affecting gene function. However, none has considered the estimation of selective constraints acting on protein residues. Here, we have used codon-based maximum likelihood models in order to estimate the selective pressures on the individual amino acid residues of a well-known model protein: p53. We demonstrate that the number of residues under strong purifying selection in p53 is much higher than those that are strictly conserved during the evolution of the species. In agreement with theoretical expectations, residues that have been noted to be of structural relevance, or in direct association with DNA, were among those showing the highest signals of purifying selection. Conversely, those changing according to a neutral, or nearly neutral mode of evolution, were observed to be irrelevant for protein function. Finally, using more than 40 human disease genes, we demonstrate that residues evolving under strong selective pressures (omega&lt;0.1) are significantly associated (p&lt;0.01) with human disease. We hypothesize that non-synonymous change on amino acids showing omega&lt;0.1 will most likely affect protein function. The application of this evolutionary prediction at a genomic scale will provide an a priori hypothesis of the phenotypic effect of non-synonymous coding single nucleotide polymorphisms (SNPs) in the human genome.</style></abstract><notes><style face="normal" font="default" size="100%">Arbiza, Leonardo Duchi, Serena Montaner, David Burguet, Jordi Pantoja-Uceda, David Pineda-Lucena, Antonio Dopazo, Joaquin Dopazo, Hernan Research Support, Non-U.S. Gov’t England Journal of molecular biology J Mol Biol. 2006 May 19;358(5):1390-404. Epub 2006 Mar 15.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">J. Forment</style></author><author><style face="normal" font="default" size="100%">J. Gadea</style></author><author><style face="normal" font="default" size="100%">Huerta, L.</style></author><author><style face="normal" font="default" size="100%">Abizanda, L.</style></author><author><style face="normal" font="default" size="100%">Agusti, J.</style></author><author><style face="normal" font="default" size="100%">Alamar, S.</style></author><author><style face="normal" font="default" size="100%">Alos, E.</style></author><author><style face="normal" font="default" size="100%">Andres, F.</style></author><author><style face="normal" font="default" size="100%">Arribas, R.</style></author><author><style face="normal" font="default" size="100%">Beltran, J. P.</style></author><author><style face="normal" font="default" size="100%">Berbel, A.</style></author><author><style face="normal" font="default" size="100%">Blazquez, M. A.</style></author><author><style face="normal" font="default" size="100%">Brumos, J.</style></author><author><style face="normal" font="default" size="100%">Canas, L. A.</style></author><author><style face="normal" font="default" size="100%">Cercos, M.</style></author><author><style face="normal" font="default" size="100%">Colmenero-Flores, J. M.</style></author><author><style face="normal" font="default" size="100%">A. Conesa</style></author><author><style face="normal" font="default" size="100%">Estables, B.</style></author><author><style face="normal" font="default" size="100%">Gandia, M.</style></author><author><style face="normal" font="default" size="100%">Garcia-Martinez, J. L.</style></author><author><style face="normal" font="default" size="100%">Gimeno, J.</style></author><author><style face="normal" font="default" size="100%">Gisbert, A.</style></author><author><style face="normal" font="default" size="100%">Gomez, G.</style></author><author><style face="normal" font="default" size="100%">Gonzalez-Candelas, L.</style></author><author><style face="normal" font="default" size="100%">Granell, A.</style></author><author><style face="normal" font="default" size="100%">Guerri, J.</style></author><author><style face="normal" font="default" size="100%">Lafuente, M. T.</style></author><author><style face="normal" font="default" size="100%">Madueno, F.</style></author><author><style face="normal" font="default" size="100%">Marcos, J. F.</style></author><author><style face="normal" font="default" size="100%">Marques, M. C.</style></author><author><style face="normal" font="default" size="100%">Martinez, F.</style></author><author><style face="normal" font="default" size="100%">Martinez-Godoy, M. A.</style></author><author><style face="normal" font="default" size="100%">Miralles, S.</style></author><author><style face="normal" font="default" size="100%">Moreno, P.</style></author><author><style face="normal" font="default" size="100%">Navarro, L.</style></author><author><style face="normal" font="default" size="100%">Pallas, V.</style></author><author><style face="normal" font="default" size="100%">Perez-Amador, M. A.</style></author><author><style face="normal" font="default" size="100%">Perez-Valle, J.</style></author><author><style face="normal" font="default" size="100%">Pons, C.</style></author><author><style face="normal" font="default" size="100%">Rodrigo, I.</style></author><author><style face="normal" font="default" size="100%">Rodriguez, P. L.</style></author><author><style face="normal" font="default" size="100%">Royo, C.</style></author><author><style face="normal" font="default" size="100%">Serrano, R.</style></author><author><style face="normal" font="default" size="100%">Soler, G.</style></author><author><style face="normal" font="default" size="100%">Tadeo, F.</style></author><author><style face="normal" font="default" size="100%">Talon, M.</style></author><author><style face="normal" font="default" size="100%">Terol, J.</style></author><author><style face="normal" font="default" size="100%">Trenor, M.</style></author><author><style face="normal" font="default" size="100%">Vaello, L.</style></author><author><style face="normal" font="default" size="100%">Vicente, O.</style></author><author><style face="normal" font="default" size="100%">Vidal, Ch</style></author><author><style face="normal" font="default" size="100%">Zacarias, L.</style></author><author><style face="normal" font="default" size="100%">Conejero, V.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Development of a citrus genome-wide EST collection and cDNA microarray as resources for genomic studies</style></title><secondary-title><style face="normal" font="default" size="100%">Plant Mol Biol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Citrus/*genetics DNA</style></keyword><keyword><style  face="normal" font="default" size="100%">Complementary/chemistry/genetics *Expressed Sequence Tags Gene Expression Profiling Gene Library *Genome</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA</style></keyword><keyword><style  face="normal" font="default" size="100%">Plant Genomics/*methods Molecular Sequence Data Oligonucleotide Array Sequence Analysis/*methods RNA</style></keyword><keyword><style  face="normal" font="default" size="100%">Plant/genetics/metabolism Reproducibility of Results Sequence Analysis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2005</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=15830128</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">57</style></volume><pages><style face="normal" font="default" size="100%">375-91</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">A functional genomics project has been initiated to approach the molecular characterization of the main biological and agronomical traits of citrus. As a key part of this project, a citrus EST collection has been generated from 25 cDNA libraries covering different tissues, developmental stages and stress conditions. The collection includes a total of 22,635 high-quality ESTs, grouped in 11,836 putative unigenes, which represent at least one third of the estimated number of genes in the citrus genome. Functional annotation of unigenes which have Arabidopsis orthologues (68% of all unigenes) revealed gene representation in every major functional category, suggesting that a genome-wide EST collection was obtained. A Citrus clementina Hort. ex Tan. cv. Clemenules genomic library, that will contribute to further characterization of relevant genes, has also been constructed. To initiate the analysis of citrus transcriptome, we have developed a cDNA microarray containing 12,672 probes corresponding to 6875 putative unigenes of the collection. Technical characterization of the microarray showed high intra- and inter-array reproducibility, as well as a good range of sensitivity. We have also validated gene expression data achieved with this microarray through an independent technique such as RNA gel blot analysis.</style></abstract><notes><style face="normal" font="default" size="100%">Forment, J Gadea, J Huerta, L Abizanda, L Agusti, J Alamar, S Alos, E Andres, F Arribas, R Beltran, J P Berbel, A Blazquez, M A Brumos, J Canas, L A Cercos, M Colmenero-Flores, J M Conesa, A Estables, B Gandia, M Garcia-Martinez, J L Gimeno, J Gisbert, A Gomez, G Gonzalez-Candelas, L Granell, A Guerri, J Lafuente, M T Madueno, F Marcos, J F Marques, M C Martinez, F Martinez-Godoy, M A Miralles, S Moreno, P Navarro, L Pallas, V Perez-Amador, M A Perez-Valle, J Pons, C Rodrigo, I Rodriguez, P L Royo, C Serrano, R Soler, G Tadeo, F Talon, M Terol, J Trenor, M Vaello, L Vicente, O Vidal, Ch Zacarias, L Conejero, V Comparative Study Research Support, U.S. Gov’t, Non-P.H.S. Netherlands Plant molecular biology Plant Mol Biol. 2005 Feb;57(3):375-91.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Palacios, J.</style></author><author><style face="normal" font="default" size="100%">Honrado, E.</style></author><author><style face="normal" font="default" size="100%">Osorio, A.</style></author><author><style face="normal" font="default" size="100%">Cazorla, A.</style></author><author><style face="normal" font="default" size="100%">Sarrio, D.</style></author><author><style face="normal" font="default" size="100%">Barroso, A.</style></author><author><style face="normal" font="default" size="100%">Rodriguez, S.</style></author><author><style face="normal" font="default" size="100%">Cigudosa, J. C.</style></author><author><style face="normal" font="default" size="100%">Diez, O.</style></author><author><style face="normal" font="default" size="100%">Alonso, C.</style></author><author><style face="normal" font="default" size="100%">Lerma, E.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Rivas, C.</style></author><author><style face="normal" font="default" size="100%">Benitez, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers</style></title><secondary-title><style face="normal" font="default" size="100%">Breast Cancer Res Treat</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult Apoptosis Breast Neoplasms/*genetics/*pathology Cell Cycle Proteins Cluster Analysis Female *Genes</style></keyword><keyword><style  face="normal" font="default" size="100%">Biological/genetics/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">BRCA1 *Genes</style></keyword><keyword><style  face="normal" font="default" size="100%">BRCA2 Humans Immunohistochemistry In Situ Hybridization</style></keyword><keyword><style  face="normal" font="default" size="100%">Fluorescence Phenotype Spain *Tissue Array Analysis *Tumor Markers</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2005</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=15770521</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">90</style></volume><pages><style face="normal" font="default" size="100%">5-14</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Familial breast cancers that are associated with BRCA1 or BRCA2 germline mutations differ in both their morphological and immunohistochemical characteristics. To further characterize the molecular difference between genotypes, the authors evaluated the expression of 37 immunohistochemical markers in a tissue microarray (TMA) containing cores from 20 BRCA1, 14 BRCA2, and 59 sporadic age-matched breast carcinomas. Markers analyzed included, amog others, common markers in breast cancer, such as hormone receptors, p53 and HER2, along with 15 molecules involved in cell cycle regulation, such as cyclins, cyclin dependent kinases (CDK) and CDK inhibitors (CDKI), apoptosis markers, such as BCL2 and active caspase 3, and two basal/myoepithelial markers (CK 5/6 and P-cadherin). In addition, we analyzed the amplification of CCND1, CCNE, HER2 and MYC by FISH.Unsupervised cluster data analysis of both hereditary and sporadic cases using the complete set of immunohistochemical markers demonstrated that most BRCA1-associated carcinomas grouped in a branch of ER-, HER2-negative tumors that expressed basal cell markers and/or p53 and had higher expression of activated caspase 3. The cell cycle proteins associated with these tumors were E2F6, cyclins A, B1 and E, SKP2 and Topo IIalpha. In contrast, most BRCA2-associated carcinomas grouped in a branch composed by ER/PR/BCL2-positive tumors with a higher expression of the cell cycle proteins cyclin D1, cyclin D3, p27, p16, p21, CDK4, CDK2 and CDK1. In conclusion, our study in hereditary breast cancer tumors analyzing 37 immunohistochemical markers, define the molecular differences between BRCA1 and BRCA2 tumors with respect to hormonal receptors, cell cycle, apoptosis and basal cell markers.</style></abstract><notes><style face="normal" font="default" size="100%">Palacios, Jose Honrado, Emiliano Osorio, Ana Cazorla, Alicia Sarrio, David Barroso, Alicia Rodriguez, Sandra Cigudosa, Juan C Diez, Orland Alonso, Carmen Lerma, Enrique Dopazo, Joaquin Rivas, Carmen Benitez, Javier Research Support, Non-U.S. Gov’t Netherlands Breast cancer research and treatment Breast Cancer Res Treat. 2005 Mar;90(1):5-14.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Alvarez, S.</style></author><author><style face="normal" font="default" size="100%">Diaz-Uriarte, R.</style></author><author><style face="normal" font="default" size="100%">Osorio, A.</style></author><author><style face="normal" font="default" size="100%">Barroso, A.</style></author><author><style face="normal" font="default" size="100%">Melchor, L.</style></author><author><style face="normal" font="default" size="100%">Paz, M. F.</style></author><author><style face="normal" font="default" size="100%">Honrado, E.</style></author><author><style face="normal" font="default" size="100%">Rodriguez, R.</style></author><author><style face="normal" font="default" size="100%">Urioste, M.</style></author><author><style face="normal" font="default" size="100%">Valle, L.</style></author><author><style face="normal" font="default" size="100%">Diez, O.</style></author><author><style face="normal" font="default" size="100%">Cigudosa, J. C.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Esteller, M.</style></author><author><style face="normal" font="default" size="100%">Benitez, J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Cancer Res</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">BRCA1 Protein/*genetics BRCA2 Protein/*genetics Breast Neoplasms/*genetics/pathology Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic/*genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Human</style></keyword><keyword><style  face="normal" font="default" size="100%">Human Humans Male Mutation Nucleic Acid Hybridization/methods Promoter Regions</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 12/genetics Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 15/genetics Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 18/genetics Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 2/genetics Chromosomes</style></keyword><keyword><style  face="normal" font="default" size="100%">Pair 8/genetics *DNA Methylation Female Genome</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2005</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=15709182</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">11</style></volume><pages><style face="normal" font="default" size="100%">1146-53</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The genetic changes underlying in the development and progression of familial breast cancer are poorly understood. To identify a somatic genetic signature of tumor progression for each familial group, BRCA1, BRCA2, and non-BRCA1/BRCA2 (BRCAX) tumors, by high-resolution comparative genomic hybridization, we have analyzed 77 tumors previously characterized for BRCA1 and BRCA2 germ line mutations. Based on a combination of the somatic genetic changes observed at the six most different chromosomal regions and the status of the estrogen receptor, we developed using random forests a molecular classifier, which assigns to a given tumor a probability to belong either to the BRCA1 or to the BRCA2 class. Because 76.5% (26 of 34) of the BRCAX cases were classified with our predictor to the BRCA1 class with a probability of &gt;50%, we analyzed the BRCA1 promoter region for aberrant methylation in all the BRCAX cases. We found that 15 of the 34 BRCAX analyzed tumors had hypermethylation of the BRCA1 gene. When we considered the predictor, we observed that all the cases with this epigenetic event were assigned to the BRCA1 class with a probability of &gt;50%. Interestingly, 84.6% of the cases (11 of 13) assigned to the BRCA1 class with a probability &gt;80% had an aberrant methylation of the BRCA1 promoter. This fact suggests that somatic BRCA1 inactivation could modify the profile of tumor progression in most of the BRCAX cases.</style></abstract><notes><style face="normal" font="default" size="100%">Alvarez, Sara Diaz-Uriarte, Ramon Osorio, Ana Barroso, Alicia Melchor, Lorenzo Paz, Maria Fe Honrado, Emiliano Rodriguez, Raquel Urioste, Miguel Valle, Laura Diez, Orland Cigudosa, Juan Cruz Dopazo, Joaquin Esteller, Manel Benitez, Javier Comparative Study Research Support, Non-U.S. Gov’t United States Clinical cancer research : an official journal of the American Association for Cancer Research Clin Cancer Res. 2005 Feb 1;11(3):1146-53.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>5</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Antón, J</style></author><author><style face="normal" font="default" size="100%">Peña, A</style></author><author><style face="normal" font="default" size="100%">Valens, M</style></author><author><style face="normal" font="default" size="100%">Santos, F</style></author><author><style face="normal" font="default" size="100%">Glöckner, F.O</style></author><author><style face="normal" font="default" size="100%">Bauer, M</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Herrero, J.</style></author><author><style face="normal" font="default" size="100%">Rosselló-Mora, R</style></author><author><style face="normal" font="default" size="100%">Amann, R</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Salinibacter ruber: genomics and biogeography</style></title><secondary-title><style face="normal" font="default" size="100%">Adaptation to life in high salt concentrations in Archaea, Bacteria and Eukarya</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2005</style></year></dates><publisher><style face="normal" font="default" size="100%">Nina Gunde-Cimerman, Ana Plemenitas, and Aharon Oren. Kluwer Academic Publishers</style></publisher><pub-location><style face="normal" font="default" size="100%">Dordrecht, Netherlands</style></pub-location><volume><style face="normal" font="default" size="100%">9</style></volume><pages><style face="normal" font="default" size="100%">257-266</style></pages><language><style face="normal" font="default" size="100%">eng</style></language></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pieper, U.</style></author><author><style face="normal" font="default" size="100%">Eswar, N.</style></author><author><style face="normal" font="default" size="100%">Braberg, H.</style></author><author><style face="normal" font="default" size="100%">Madhusudhan, M. S.</style></author><author><style face="normal" font="default" size="100%">Davis, F. P.</style></author><author><style face="normal" font="default" size="100%">Stuart, A. C.</style></author><author><style face="normal" font="default" size="100%">Mirkovic, N.</style></author><author><style face="normal" font="default" size="100%">Rossi, A.</style></author><author><style face="normal" font="default" size="100%">M. A. Marti-Renom</style></author><author><style face="normal" font="default" size="100%">Fiser, A.</style></author><author><style face="normal" font="default" size="100%">Webb, B.</style></author><author><style face="normal" font="default" size="100%">Greenblatt, D.</style></author><author><style face="normal" font="default" size="100%">Huang, C. C.</style></author><author><style face="normal" font="default" size="100%">Ferrin, T. E.</style></author><author><style face="normal" font="default" size="100%">Sali, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">MODBASE, a database of annotated comparative protein structure models, and associated resources</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Amino Acid Sequence Animals Binding Sites *Computational Biology *Databases</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Molecular Sequence Data Polymorphism</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Genomics Humans Internet Ligands Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Single Nucleotide Protein Binding Protein Conformation Proteins/*chemistry/genetics Sequence Alignment Software User-Computer Interface</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2004</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=14681398</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">Database issue</style></number><volume><style face="normal" font="default" size="100%">32</style></volume><pages><style face="normal" font="default" size="100%">D217-22</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">MODBASE (http://salilab.org/modbase) is a relational database of annotated comparative protein structure models for all available protein sequences matched to at least one known protein structure. The models are calculated by MODPIPE, an automated modeling pipeline that relies on the MODELLER package for fold assignment, sequence-structure alignment, model building and model assessment (http:/salilab.org/modeller). MODBASE uses the MySQL relational database management system for flexible querying and CHIMERA for viewing the sequences and structures (http://www.cgl.ucsf.edu/chimera/). MODBASE is updated regularly to reflect the growth in protein sequence and structure databases, as well as improvements in the software for calculating the models. For ease of access, MODBASE is organized into different data sets. The largest data set contains 1,26,629 models for domains in 659,495 out of 1,182,126 unique protein sequences in the complete Swiss-Prot/TrEMBL database (August 25, 2003); only models based on alignments with significant similarity scores and models assessed to have the correct fold despite insignificant alignments are included. Another model data set supports target selection and structure-based annotation by the New York Structural Genomics Research Consortium; e.g. the 53 new structures produced by the consortium allowed us to characterize structurally 24,113 sequences. MODBASE also contains binding site predictions for small ligands and a set of predicted interactions between pairs of modeled sequences from the same genome. Our other resources associated with MODBASE include a comprehensive database of multiple protein structure alignments (DBALI, http://salilab.org/dbali) as well as web servers for automated comparative modeling with MODPIPE (MODWEB, http://salilab. org/modweb), modeling of loops in protein structures (MODLOOP, http://salilab.org/modloop) and predicting functional consequences of single nucleotide polymorphisms (SNPWEB, http://salilab. org/snpweb).</style></abstract><notes><style face="normal" font="default" size="100%">Pieper, Ursula Eswar, Narayanan Braberg, Hannes Madhusudhan, M S Davis, Fred P Stuart, Ashley C Mirkovic, Nebojsa Rossi, Andrea Marti-Renom, Marc A Fiser, Andras Webb, Ben Greenblatt, Daniel Huang, Conrad C Ferrin, Thomas E Sali, Andrej P41 RR01081/RR/NCRR NIH HHS/United States P50 GM62529/GM/NIGMS NIH HHS/United States R01 GM 54762/GM/NIGMS NIH HHS/United States R33 CA84699/CA/NCI NIH HHS/United States Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S. England Nucleic acids research Nucleic Acids Res. 2004 Jan 1;32(Database issue):D217-22.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Koh, I. Y.</style></author><author><style face="normal" font="default" size="100%">Eyrich, V. A.</style></author><author><style face="normal" font="default" size="100%">M. A. Marti-Renom</style></author><author><style face="normal" font="default" size="100%">Przybylski, D.</style></author><author><style face="normal" font="default" size="100%">Madhusudhan, M. S.</style></author><author><style face="normal" font="default" size="100%">Eswar, N.</style></author><author><style face="normal" font="default" size="100%">Grana, O.</style></author><author><style face="normal" font="default" size="100%">Pazos, F.</style></author><author><style face="normal" font="default" size="100%">Valencia, A.</style></author><author><style face="normal" font="default" size="100%">Sali, A.</style></author><author><style face="normal" font="default" size="100%">Rost, B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">EVA: Evaluation of protein structure prediction servers</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Automation Databases</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Internet *Protein Conformation Protein Folding Protein Structure</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Structural Homology</style></keyword><keyword><style  face="normal" font="default" size="100%">Secondary Proteins/chemistry Reproducibility of Results *Sequence Analysis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2003</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=12824315</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">13</style></number><volume><style face="normal" font="default" size="100%">31</style></volume><pages><style face="normal" font="default" size="100%">3311-5</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">EVA (http://cubic.bioc.columbia.edu/eva/) is a web server for evaluation of the accuracy of automated protein structure prediction methods. The evaluation is updated automatically each week, to cope with the large number of existing prediction servers and the constant changes in the prediction methods. EVA currently assesses servers for secondary structure prediction, contact prediction, comparative protein structure modelling and threading/fold recognition. Every day, sequences of newly available protein structures in the Protein Data Bank (PDB) are sent to the servers and their predictions are collected. The predictions are then compared to the experimental structures once a week; the results are published on the EVA web pages. Over time, EVA has accumulated prediction results for a large number of proteins, ranging from hundreds to thousands, depending on the prediction method. This large sample assures that methods are compared reliably. As a result, EVA provides useful information to developers as well as users of prediction methods.</style></abstract><notes><style face="normal" font="default" size="100%">Koh, Ingrid Y Y Eyrich, Volker A Marti-Renom, Marc A Przybylski, Dariusz Madhusudhan, Mallur S Eswar, Narayanan Grana, Osvaldo Pazos, Florencio Valencia, Alfonso Sali, Andrej Rost, Burkhard 1-P50-GM62413-01/GM/NIGMS NIH HHS/United States 5-P20-LM7276/LM/NLM NIH HHS/United States P50 GM62529/GM/NIGMS NIH HHS/United States R01 GM54762/GM/NIGMS NIH HHS/United States R01-GM63029-01/GM/NIGMS NIH HHS/United States Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S. Research Support, U.S. Gov’t, P.H.S. England Nucleic acids research Nucleic Acids Res. 2003 Jul 1;31(13):3311-5.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yi, X.</style></author><author><style face="normal" font="default" size="100%">A. Conesa</style></author><author><style face="normal" font="default" size="100%">Punt, P. J.</style></author><author><style face="normal" font="default" size="100%">Hager, L. P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Examining the role of glutamic acid 183 in chloroperoxidase catalysis</style></title><secondary-title><style face="normal" font="default" size="100%">J Biol Chem</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aspergillus niger/metabolism Catalase/metabolism Catalysis Chloride Peroxidase/*chemistry/*metabolism Chlorine/metabolism Chromatography</style></keyword><keyword><style  face="normal" font="default" size="100%">Ion Exchange Circular Dichroism Crystallography</style></keyword><keyword><style  face="normal" font="default" size="100%">Polyacrylamide Gel Fungi/enzymology Glutamic Acid/*chemistry Histidine/chemistry/metabolism Hydrogen-Ion Concentration Immunoblotting Isoelectric Focusing Mutation Oxidoreductases/metabolism Plasmids/metabolism</style></keyword><keyword><style  face="normal" font="default" size="100%">X-Ray Electrophoresis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2003</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=12576477</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">16</style></number><volume><style face="normal" font="default" size="100%">278</style></volume><pages><style face="normal" font="default" size="100%">13855-9</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Site-directed mutagenesis has been used to investigate the role of glutamic acid 183 in chloroperoxidase catalysis. Based on the x-ray crystallographic structure of chloroperoxidase, Glu-183 is postulated to function on distal side of the heme prosthetic group as an acid-base catalyst in facilitating the reaction between the peroxidase and hydrogen peroxide with the formation of Compound I. In contrast, the other members of the heme peroxidase family use a histidine residue in this role. Plasmids have now been constructed in which the codon for Glu-183 is replaced with a histidine codon. The mutant recombinant gene has been expressed in Aspergillus niger. An analysis of the produced mutant gene shows that the substitution of Glu-183 with a His residue is detrimental to the chlorination and dismutation activity of chloroperoxidase. The activity is reduced by 85 and 50% of wild type activity, respectively. However, quite unexpectedly, the epoxidation activity of the mutant enzyme is significantly enhanced approximately 2.5-fold. These results show that Glu-183 is important but not essential for the chlorination activity of chloroperoxidase. It is possible that the increased epoxidation of the mutant enzyme is based on an increase in the hydrophobicity of the active site.</style></abstract><notes><style face="normal" font="default" size="100%">Yi, Xianwen Conesa, Ana Punt, Peter J Hager, Lowell P GM 07768/GM/NIGMS NIH HHS/United States Research Support, U.S. Gov’t, P.H.S. United States The Journal of biological chemistry J Biol Chem. 2003 Apr 18;278(16):13855-9. Epub 2003 Feb 7.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">H. Dopazo</style></author><author><style face="normal" font="default" size="100%">Gordon, M. B.</style></author><author><style face="normal" font="default" size="100%">Perazzo, R.</style></author><author><style face="normal" font="default" size="100%">Risau-Gusman, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A model for the emergence of adaptive subsystems</style></title><secondary-title><style face="normal" font="default" size="100%">Bull Math Biol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Adaptation</style></keyword><keyword><style  face="normal" font="default" size="100%">Biological Algorithms Alleles Animals Evolution Genotype Humans *Learning *Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Statistical Neural Networks (Computer) Phenotype Synapses/genetics</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2003</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=12597115</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">65</style></volume><pages><style face="normal" font="default" size="100%">27-56</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">We investigate the interaction of learning and evolution in a changing environment. A stable learning capability is regarded as an emergent adaptive system evolved by natural selection of genetic variants. We consider the evolution of an asexual population. Each genotype can have ’fixed’ and ’flexible’ alleles. The former express themselves as synaptic connections that remain unchanged during ontogeny and the latter as synapses that can be adjusted through a learning algorithm. Evolution is modelled using genetic algorithms and the changing environment is represented by two optimal synaptic patterns that alternate a fixed number of times during the ’life’ of the individuals. The amplitude of the change is related to the Hamming distance between the two optimal patterns and the rate of change to the frequency with which both exchange roles. This model is an extension of that of Hinton and Nowlan in which the fitness is given by a probabilistic measure of the Hamming distance to the optimum. We find that two types of evolutionary pathways are possible depending upon how difficult (costly) it is to cope with the changes of the environment. In one case the population loses the learning ability, and the individuals inherit fixed synapses that are optimal in only one of the environmental states. In the other case a flexible subsystem emerges that allows the individuals to adapt to the changes of the environment. The model helps us to understand how an adaptive subsystem can emerge as the result of the tradeoff between the exploitation of a congenital structure and the exploration of the adaptive capabilities practised by learning.</style></abstract><notes><style face="normal" font="default" size="100%">Dopazo, H Gordon, M B Perazzo, R Risau-Gusman, S Research Support, Non-U.S. Gov’t United States Bulletin of mathematical biology Bull Math Biol. 2003 Jan;65(1):27-56.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ilyin, V. A.</style></author><author><style face="normal" font="default" size="100%">Pieper, U.</style></author><author><style face="normal" font="default" size="100%">Stuart, A. C.</style></author><author><style face="normal" font="default" size="100%">M. A. Marti-Renom</style></author><author><style face="normal" font="default" size="100%">McMahan, L.</style></author><author><style face="normal" font="default" size="100%">Sali, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">ModView, visualization of multiple protein sequences and structures</style></title><secondary-title><style face="normal" font="default" size="100%">Bioinformatics</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">*Database Management Systems Documentation/methods Imaging</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein/*methods *User-Computer Interface</style></keyword><keyword><style  face="normal" font="default" size="100%">Three-Dimensional/methods Protein Conformation Proteins/*chemistry/genetics Sequence Alignment/*methods Sequence Analysis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2003</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=12499313</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">19</style></volume><pages><style face="normal" font="default" size="100%">165-6</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">SUMMARY: We describe ModView, a web application for visualization of multiple protein sequences and structures. ModView integrates a multiple structure viewer, a multiple sequence alignment editor, and a database querying engine. It is possible to interactively manipulate hundreds of proteins, to visualize conservative and variable residues, active and binding sites, fragments, and domains in protein families, as well as to display large macromolecular complexes such as ribosomes or viruses. As a Netscape plug-in, ModView can be included in HTML pages along with text and figures, which makes it useful for teaching and presentations. ModView is also suitable as a graphical interface to various databases because it can be controlled through JavaScript commands and called from CGI scripts. AVAILABILITY: ModView is available at http://guitar.rockefeller.edu/modview.</style></abstract><notes><style face="normal" font="default" size="100%">Ilyin, Valentin A Pieper, Ursula Stuart, Ashley C Marti-Renom, Marc A McMahan, Linda Sali, Andrej P50-GM62529/GM/NIGMS NIH HHS/United States Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S. England Bioinformatics (Oxford, England) Bioinformatics. 2003 Jan;19(1):165-6.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eswar, N.</style></author><author><style face="normal" font="default" size="100%">John, B.</style></author><author><style face="normal" font="default" size="100%">Mirkovic, N.</style></author><author><style face="normal" font="default" size="100%">Fiser, A.</style></author><author><style face="normal" font="default" size="100%">Ilyin, V. A.</style></author><author><style face="normal" font="default" size="100%">Pieper, U.</style></author><author><style face="normal" font="default" size="100%">Stuart, A. C.</style></author><author><style face="normal" font="default" size="100%">M. A. Marti-Renom</style></author><author><style face="normal" font="default" size="100%">Madhusudhan, M. S.</style></author><author><style face="normal" font="default" size="100%">Yerkovich, B.</style></author><author><style face="normal" font="default" size="100%">Sali, A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Tools for comparative protein structure modeling and analysis</style></title><secondary-title><style face="normal" font="default" size="100%">Nucleic Acids Res</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Amino Acid *Software *Structural Homology</style></keyword><keyword><style  face="normal" font="default" size="100%">Internet Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Protein Folding Proteins/chemistry Reproducibility of Results Sequence Alignment Sequence Homology</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Systems Integration</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2003</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=12824331</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">13</style></number><volume><style face="normal" font="default" size="100%">31</style></volume><pages><style face="normal" font="default" size="100%">3375-80</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The following resources for comparative protein structure modeling and analysis are described (http://salilab.org): MODELLER, a program for comparative modeling by satisfaction of spatial restraints; MODWEB, a web server for automated comparative modeling that relies on PSI-BLAST, IMPALA and MODELLER; MODLOOP, a web server for automated loop modeling that relies on MODELLER; MOULDER, a CPU intensive protocol of MODWEB for building comparative models based on distant known structures; MODBASE, a comprehensive database of annotated comparative models for all sequences detectably related to a known structure; MODVIEW, a Netscape plugin for Linux that integrates viewing of multiple sequences and structures; and SNPWEB, a web server for structure-based prediction of the functional impact of a single amino acid substitution.</style></abstract><notes><style face="normal" font="default" size="100%">Eswar, Narayanan John, Bino Mirkovic, Nebojsa Fiser, Andras Ilyin, Valentin A Pieper, Ursula Stuart, Ashley C Marti-Renom, Marc A Madhusudhan, M S Yerkovich, Bozidar Sali, Andrej P50 GM62529/GM/NIGMS NIH HHS/United States R01 GM 54762/GM/NIGMS NIH HHS/United States R33 CA84699/CA/NCI NIH HHS/United States Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S. England Nucleic acids research Nucleic Acids Res. 2003 Jul 1;31(13):3375-80.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">A. Conesa</style></author><author><style face="normal" font="default" size="100%">Jeenes, D.</style></author><author><style face="normal" font="default" size="100%">Archer, D. B.</style></author><author><style face="normal" font="default" size="100%">van den Hondel, C. A.</style></author><author><style face="normal" font="default" size="100%">Punt, P. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Calnexin overexpression increases manganese peroxidase production in Aspergillus niger</style></title><secondary-title><style face="normal" font="default" size="100%">Appl Environ Microbiol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aspergillus niger/*enzymology/genetics Calcium-Binding Proteins/*metabolism Calnexin Culture Media *Fungal Proteins HSP70 Heat-Shock Proteins/metabolism Heme/metabolism Peroxidases/*biosynthesis/genetics Phanerochaete/enzymology/genetics Transformation</style></keyword><keyword><style  face="normal" font="default" size="100%">Genetic</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2002</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=11823227</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">68</style></volume><pages><style face="normal" font="default" size="100%">846-51</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Heme-containing peroxidases from white rot basidiomycetes, in contrast to most proteins of fungal origin, are poorly produced in industrial filamentous fungal strains. Factors limiting peroxidase production are believed to operate at the posttranslational level. In particular, insufficient availability of the prosthetic group which is required for peroxidase biosynthesis has been proposed to be an important bottleneck. In this work, we analyzed the role of two components of the secretion pathway, the chaperones calnexin and binding protein (BiP), in the production of a fungal peroxidase. Expression of the Phanerochaete chrysosporium manganese peroxidase (MnP) in Aspergillus niger resulted in an increase in the expression level of the clxA and bipA genes. In a heme-supplemented medium, where MnP was shown to be overproduced to higher levels, induction of clxA and bipA was also higher. Overexpression of these two chaperones in an MnP-producing strain was analyzed for its effect on MnP production. Whereas bipA overexpression seriously reduced MnP production, overexpression of calnexin resulted in a four- to fivefold increase in the extracellular MnP levels. However, when additional heme was provided in the culture medium, calnexin overexpression had no synergistic effect on MnP production. The possible function of these two chaperones in MnP maturation and production is discussed.</style></abstract><notes><style face="normal" font="default" size="100%">Conesa, Ana Jeenes, David Archer, David B van den Hondel, Cees A M J J Punt, Peter J United States Applied and environmental microbiology Appl Environ Microbiol. 2002 Feb;68(2):846-51.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Punt, P. J.</style></author><author><style face="normal" font="default" size="100%">van Biezen, N.</style></author><author><style face="normal" font="default" size="100%">A. Conesa</style></author><author><style face="normal" font="default" size="100%">Albers, A.</style></author><author><style face="normal" font="default" size="100%">Mangnus, J.</style></author><author><style face="normal" font="default" size="100%">van den Hondel, C.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Filamentous fungi as cell factories for heterologous protein production</style></title><secondary-title><style face="normal" font="default" size="100%">Trends Biotechnol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Fermentation/genetics/physiology Fungi/*genetics/*metabolism Humans Interleukin-6/analysis/*biosynthesis/genetics Peroxidases/analysis/*biosynthesis/genetics Protein Conformation Recombinant Proteins/analysis/*biosynthesis/genetics</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2002</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=11943375</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">20</style></volume><pages><style face="normal" font="default" size="100%">200-6</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Filamentous fungi have been used as sources of metabolites and enzymes for centuries. For about two decades, molecular genetic tools have enabled us to use these organisms to express extra copies of both endogenous and exogenous genes. This review of current practice reveals that molecular tools have enabled several new developments. But it has been process development that has driven the final breakthrough to achieving commercially relevant quantities of protein. Recent research into gene expression in filamentous fungi has explored their wealth of genetic diversity with a view to exploiting them as expression hosts and as a source of new genes. Inevitably, the progress in the ’genomics’ technology will further develop high-throughput technologies for these organisms.</style></abstract><notes><style face="normal" font="default" size="100%">Punt, Peter J van Biezen, Nick Conesa, Ana Albers, Alwin Mangnus, Jeroen van den Hondel, Cees Review England Trends in biotechnology Trends Biotechnol. 2002 May;20(5):200-6.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">A. Conesa</style></author><author><style face="normal" font="default" size="100%">Punt, P. J.</style></author><author><style face="normal" font="default" size="100%">van den Hondel, C. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Fungal peroxidases: molecular aspects and applications</style></title><secondary-title><style face="normal" font="default" size="100%">J Biotechnol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Amino Acid Sequence Binding Sites Biotechnology Catalysis Fungi/*enzymology Molecular Sequence Data Peroxidases/chemistry/*genetics/metabolism Recombinant Proteins Sequence Homology Substrate Specificity</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2002</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=11738721</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">93</style></volume><pages><style face="normal" font="default" size="100%">143-58</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Peroxidases are oxidoreductases that utilize hydrogen peroxide to catalyze oxidative reactions. A large number of peroxidases have been identified in fungal species and are being characterized at the molecular level. In this manuscript we review the current knowledge on the molecular aspects of this type of enzymes. We present an overview of the research efforts undertaken in deciphering the structural basis of the catalytic properties of fungal peroxidases and discuss molecular genetics and protein homology aspects of this enzyme class. Finally, we summarize the potential biotechnological applications of these enzymes and evaluate recent advances on their expression in heterologous systems for production purposes.</style></abstract><notes><style face="normal" font="default" size="100%">Conesa, Ana Punt, Peter J van den Hondel, Cees A M J J Review Netherlands Journal of biotechnology J Biotechnol. 2002 Feb 14;93(2):143-58.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tracey, L.</style></author><author><style face="normal" font="default" size="100%">Villuendas, R.</style></author><author><style face="normal" font="default" size="100%">Ortiz, P.</style></author><author><style face="normal" font="default" size="100%">Dopazo, A.</style></author><author><style face="normal" font="default" size="100%">Spiteri, I.</style></author><author><style face="normal" font="default" size="100%">Lombardia, L.</style></author><author><style face="normal" font="default" size="100%">Rodriguez-Peralto, J. L.</style></author><author><style face="normal" font="default" size="100%">Fernandez-Herrera, J.</style></author><author><style face="normal" font="default" size="100%">Hernandez, A.</style></author><author><style face="normal" font="default" size="100%">Fraga, J.</style></author><author><style face="normal" font="default" size="100%">Dominguez, O.</style></author><author><style face="normal" font="default" size="100%">Herrero, J.</style></author><author><style face="normal" font="default" size="100%">Alonso, M. A.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Piris, M. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma</style></title><secondary-title><style face="normal" font="default" size="100%">Am J Pathol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Antineoplastic Agents/*pharmacology/therapeutic use Carrier Proteins/biosynthesis/genetics DNA-Binding Proteins/biosynthesis/genetics Drug Resistance</style></keyword><keyword><style  face="normal" font="default" size="100%">Biological Oligonucleotide Array Sequence Analysis RNA</style></keyword><keyword><style  face="normal" font="default" size="100%">Cultured</style></keyword><keyword><style  face="normal" font="default" size="100%">Cutaneous/diagnosis/drug therapy/*genetics/metabolism *Membrane Glycoproteins Models</style></keyword><keyword><style  face="normal" font="default" size="100%">Interleukin-1 Reproducibility of Results STAT1 Transcription Factor STAT3 Transcription Factor Trans-Activators/biosynthesis/genetics Tumor Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm Gene Expression Profiling *Gene Expression Regulation</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm/biosynthesis *Receptors</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplastic Humans Interferon-alpha/*pharmacology/therapeutic use Kinetics Lymphoma</style></keyword><keyword><style  face="normal" font="default" size="100%">T-Cell</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2002</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=12414529</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">161</style></volume><pages><style face="normal" font="default" size="100%">1825-37</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Interferon-alpha therapy has been shown to be active in the treatment of mycosis fungoides although the individual response to this therapy is unpredictable and dependent on essentially unknown factors. In an effort to better understand the molecular mechanisms of interferon-alpha resistance we have developed an interferon-alpha resistant variant from a sensitive cutaneous T-cell lymphoma cell line. We have performed expression analysis to detect genes differentially expressed between both variants using a cDNA microarray including 6386 cancer-implicated genes. The experiments showed that resistance to interferon-alpha is consistently associated with changes in the expression of a set of 39 genes, involved in signal transduction, apoptosis, transcription regulation, and cell growth. Additional studies performed confirm that STAT1 and STAT3 expression and interferon-alpha induction and activation are not altered between both variants. The gene MAL, highly overexpressed by resistant cells, was also found to be expressed by tumoral cells in a series of cutaneous T-cell lymphoma patients treated with interferon-alpha and/or photochemotherapy. MAL expression was associated with longer time to complete remission. Time-course experiments of the sensitive and resistant cells showed a differential expression of a subset of genes involved in interferon-response (1 to 4 hours), cell growth and apoptosis (24 to 48 hours.), and signal transduction.</style></abstract><notes><style face="normal" font="default" size="100%">Tracey, Lorraine Villuendas, Raquel Ortiz, Pablo Dopazo, Ana Spiteri, Inmaculada Lombardia, Luis Rodriguez-Peralto, Jose L Fernandez-Herrera, Jesus Hernandez, Almudena Fraga, Javier Dominguez, Orlando Herrero, Javier Alonso, Miguel A Dopazo, Joaquin Piris, Miguel A Research Support, Non-U.S. Gov’t United States The American journal of pathology Am J Pathol. 2002 Nov;161(5):1825-37.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Mendoza, A.</style></author><author><style face="normal" font="default" size="100%">Herrero, J.</style></author><author><style face="normal" font="default" size="100%">Caldara, F.</style></author><author><style face="normal" font="default" size="100%">Humbert, Y.</style></author><author><style face="normal" font="default" size="100%">Friedli, L.</style></author><author><style face="normal" font="default" size="100%">Guerrier, M.</style></author><author><style face="normal" font="default" size="100%">Grand-Schenk, E.</style></author><author><style face="normal" font="default" size="100%">Gandin, C.</style></author><author><style face="normal" font="default" size="100%">de Francesco, M.</style></author><author><style face="normal" font="default" size="100%">Polissi, A.</style></author><author><style face="normal" font="default" size="100%">Buell, G.</style></author><author><style face="normal" font="default" size="100%">Feger, G.</style></author><author><style face="normal" font="default" size="100%">Garcia, E.</style></author><author><style face="normal" font="default" size="100%">Peitsch, M.</style></author><author><style face="normal" font="default" size="100%">Garcia-Bustos, J. F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Annotated draft genomic sequence from a Streptococcus pneumoniae type 19F clinical isolate</style></title><secondary-title><style face="normal" font="default" size="100%">Microb Drug Resist</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Bacterial Molecular Sequence Data Pneumococcal Infections/*microbiology Prokaryotic Cells RNA</style></keyword><keyword><style  face="normal" font="default" size="100%">Bacterial/chemistry/genetics Genes</style></keyword><keyword><style  face="normal" font="default" size="100%">Bacterial/genetics *Genome</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA</style></keyword><keyword><style  face="normal" font="default" size="100%">Transfer/metabolism Streptococcus pneumoniae/*genetics</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2001</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=11442348</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">7</style></volume><pages><style face="normal" font="default" size="100%">99-125</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The public availability of numerous microbial genomes is enabling the analysis of bacterial biology in great detail and with an unprecedented, organism-wide and taxon-wide, broad scope. Streptococcus pneumoniae is one of the most important bacterial pathogens throughout the world. We present here sequences and functional annotations for 2.1-Mbp of pneumococcal DNA, covering more than 90% of the total estimated size of the genome. The sequenced strain is a clinical isolate resistant to macrolides and tetracycline. It carries a type 19F capsular locus, but multilocus sequence typing for several conserved genetic loci suggests that the strain sequenced belongs to a pneumococcal lineage that most often expresses a serotype 15 capsular polysaccharide. A total of 2,046 putative open reading frames (ORFs) longer than 100 amino acids were identified (average of 1,009 bp per ORF), including all described two-component systems and aminoacyl tRNA synthetases. Comparisons to other complete, or nearly complete, bacterial genomes were made and are presented in a graphical form for all the predicted proteins.</style></abstract><notes><style face="normal" font="default" size="100%">Dopazo, J Mendoza, A Herrero, J Caldara, F Humbert, Y Friedli, L Guerrier, M Grand-Schenk, E Gandin, C de Francesco, M Polissi, A Buell, G Feger, G Garcia, E Peitsch, M Garcia-Bustos, J F United States Microbial drug resistance (Larchmont, N.Y.) Microb Drug Resist. 2001 Summer;7(2):99-125.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">A. Conesa</style></author><author><style face="normal" font="default" size="100%">Weelink, G.</style></author><author><style face="normal" font="default" size="100%">van den Hondel, C. A.</style></author><author><style face="normal" font="default" size="100%">Punt, P. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">C-terminal propeptide of the Caldariomyces fumago chloroperoxidase: an intramolecular chaperone?</style></title><secondary-title><style face="normal" font="default" size="100%">FEBS Lett</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Amino Acid Sequence Ascomycota/*enzymology/genetics Aspergillus niger/genetics Base Sequence Chloride Peroxidase/biosynthesis/*chemistry/genetics DNA Primers/genetics Enzyme Precursors/biosynthesis/chemistry/genetics Gene Expression Molecular Chaperones/b</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2001</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=11513866</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">2-3</style></number><volume><style face="normal" font="default" size="100%">503</style></volume><pages><style face="normal" font="default" size="100%">117-20</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The Caldariomyces fumago chloroperoxidase (CPO) is synthesised as a 372-aa precursor which undergoes two proteolytic processing events: removal of a 21-aa N-terminal signal peptide and of a 52-aa C-terminal propeptide. The Aspergillus niger expression system developed for CPO was used to get insight into the function of this C-terminal propeptide. A. niger transformants expressing a CPO protein from which the C-terminal propeptide was deleted failed in producing any extracellular CPO activity, although the CPO polypeptide was synthesised. Expression of the full-length gene in an A. niger strain lacking the KEX2-like protease PclA also resulted in the production of CPO cross-reactive material into the culture medium, but no CPO activity. Based on these results, a function of the C-terminal propeptide in CPO maturation is indicated.</style></abstract><notes><style face="normal" font="default" size="100%">Conesa, A Weelink, G van den Hondel, C A Punt, P J Netherlands FEBS letters FEBS Lett. 2001 Aug 17;503(2-3):117-20.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Eyrich, V. A.</style></author><author><style face="normal" font="default" size="100%">M. A. Marti-Renom</style></author><author><style face="normal" font="default" size="100%">Przybylski, D.</style></author><author><style face="normal" font="default" size="100%">Madhusudhan, M. S.</style></author><author><style face="normal" font="default" size="100%">Fiser, A.</style></author><author><style face="normal" font="default" size="100%">Pazos, F.</style></author><author><style face="normal" font="default" size="100%">Valencia, A.</style></author><author><style face="normal" font="default" size="100%">Sali, A.</style></author><author><style face="normal" font="default" size="100%">Rost, B.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">EVA: continuous automatic evaluation of protein structure prediction servers</style></title><secondary-title><style face="normal" font="default" size="100%">Bioinformatics</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Automation Internet *Protein Conformation Proteins/*analysis *Software</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2001</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=11751240</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">12</style></number><volume><style face="normal" font="default" size="100%">17</style></volume><pages><style face="normal" font="default" size="100%">1242-3</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Evaluation of protein structure prediction methods is difficult and time-consuming. Here, we describe EVA, a web server for assessing protein structure prediction methods, in an automated, continuous and large-scale fashion. Currently, EVA evaluates the performance of a variety of prediction methods available through the internet. Every week, the sequences of the latest experimentally determined protein structures are sent to prediction servers, results are collected, performance is evaluated, and a summary is published on the web. EVA has so far collected data for more than 3000 protein chains. These results may provide valuable insight to both developers and users of prediction methods. AVAILABILITY: http://cubic.bioc.columbia.edu/eva. CONTACT: eva@cubic.bioc.columbia.edu</style></abstract><notes><style face="normal" font="default" size="100%">Eyrich, V A Marti-Renom, M A Przybylski, D Madhusudhan, M S Fiser, A Pazos, F Valencia, A Sali, A Rost, B England Bioinformatics (Oxford, England) Bioinformatics. 2001 Dec;17(12):1242-3.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">A. Conesa</style></author><author><style face="normal" font="default" size="100%">van De Velde, F.</style></author><author><style face="normal" font="default" size="100%">van Rantwijk, F.</style></author><author><style face="normal" font="default" size="100%">Sheldon, R. A.</style></author><author><style face="normal" font="default" size="100%">van den Hondel, C. A.</style></author><author><style face="normal" font="default" size="100%">Punt, P. J.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Expression of the Caldariomyces fumago chloroperoxidase in Aspergillus niger and characterization of the recombinant enzyme</style></title><secondary-title><style face="normal" font="default" size="100%">J Biol Chem</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Aspergillus niger/enzymology/genetics Catalysis Chloride Peroxidase/biosynthesis/*genetics Fungal Proteins/biosynthesis/*genetics Recombinant Proteins/biosynthesis/genetics Substrate Specificity</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2001</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=11278701</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">21</style></number><volume><style face="normal" font="default" size="100%">276</style></volume><pages><style face="normal" font="default" size="100%">17635-40</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The Caldariomyces fumago chloroperoxidase was successfully expressed in Aspergillus niger. The recombinant enzyme was produced in the culture medium as an active protein and could be purified by a three-step purification procedure. The catalytic behavior of recombinant chloroperoxidase (rCPO) was studied and compared with that of native CPO. The specific chlorination activity (47 units/nmol) of rCPO and its pH optimum (pH 2.75) were very similar to those of native CPO. rCPO catalyzes the oxidation of various substrates in comparable yields and selectivities to native CPO. Indole was oxidized to 2-oxindole with 99% selectivity and thioanisole to the corresponding R-sulfoxide (enantiomeric excess &gt;98%). Incorporation of (18)O from labeled H(2)18O(2) into the oxidized products was 100% in both cases.</style></abstract><notes><style face="normal" font="default" size="100%">Conesa, A van De Velde, F van Rantwijk, F Sheldon, R A van Den Hondel, C A Punt, P J Research Support, Non-U.S. Gov’t United States The Journal of biological chemistry J Biol Chem. 2001 May 25;276(21):17635-40. Epub 2001 Feb 22.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nunez, J. I.</style></author><author><style face="normal" font="default" size="100%">Martin, M. J.</style></author><author><style face="normal" font="default" size="100%">Piccone, M. E.</style></author><author><style face="normal" font="default" size="100%">Carrillo, E.</style></author><author><style face="normal" font="default" size="100%">Palma, E. L.</style></author><author><style face="normal" font="default" size="100%">Dopazo, J.</style></author><author><style face="normal" font="default" size="100%">Sobrino, F.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Identification of optimal regions for phylogenetic studies on VP1 gene of foot-and-mouth disease virus: analysis of types A and O Argentinean viruses</style></title><secondary-title><style face="normal" font="default" size="100%">Vet Res</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Amino Acid Sequence Animals Aphthovirus/classification/*genetics Base Sequence Capsid/chemistry/*genetics Capsid Proteins DNA</style></keyword><keyword><style  face="normal" font="default" size="100%">Complementary/chemistry Molecular Sequence Data *Phylogeny Polymerase Chain Reaction RNA</style></keyword><keyword><style  face="normal" font="default" size="100%">Viral/chemistry/genetics Serotyping Viral Proteins/analysis/*genetics</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2001</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=11254175</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">32</style></volume><pages><style face="normal" font="default" size="100%">31-45</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">An analysis of the informative content of sequence stretches on the foot-and-mouth disease virus (FMDV) VPI gene was applied to two important viral serotypes: A and O. Several sequence regions were identified to allow the reconstruction of phylogenetic trees equivalent to those derived from the whole VPI gene. The optimal informative regions for sequence windows of 150 to 250 nt were predicted between positions 250 and 550 of the gene. The sequences spanning the 250 nt of the 3’ end (positions 400 to 650), extensively used for FMDV phylogenetic analyses, showed a lower informative content. In spite of this, the use of sequences from this region allowed the derivation of phylogenetic trees for type A and type O FMDVs which showed topologies similar to those previously reported for the whole VP1 gene. When the sequences determined for viruses isolated in Argentina, between 1990 and 1993, were included in these analyses, the results obtained revealed features of the circulation of type A and type O viruses in the field, in the months that preceded the eradication of the disease in this country. Type A viruses were closely related to an Argentinean vaccine strain, and defined an independent cluster within this serotype. Among the type O viruses analysed, two groups were distinguished; one was closely related to the South American vaccine strains, while the other was grouped with viruses of the O3 subtype. In addition, a detailed phylogeny for type A FMDV is presented.</style></abstract><notes><style face="normal" font="default" size="100%">Nunez, J I Martin, M J Piccone, M E Carrillo, E Palma, E L Dopazo, J Sobrino, F Research Support, Non-U.S. Gov’t France Veterinary research Vet Res. 2001 Jan-Feb;32(1):31-45.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">H. Dopazo</style></author><author><style face="normal" font="default" size="100%">Gordon, M. B.</style></author><author><style face="normal" font="default" size="100%">Perazzo, R.</style></author><author><style face="normal" font="default" size="100%">Risau-Gusman, S.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">A model for the interaction of learning and evolution</style></title><secondary-title><style face="normal" font="default" size="100%">Bull Math Biol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Algorithms Alleles Animals *Evolution Genotype Humans *Learning *Neural Networks (Computer) Numerical Analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Computer-Assisted Phenotype Synapses/genetics</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2001</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=11146879</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">63</style></volume><pages><style face="normal" font="default" size="100%">117-34</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">We present a simple model in order to discuss the interaction of the genetic and behavioral systems throughout evolution. This considers a set of adaptive perceptrons in which some of their synapses can be updated through a learning process. This framework provides an extension of the well-known Hinton and Nowlan model by blending together some learning capability and other (rigid) genetic effects that contribute to the fitness. We find a halting effect in the evolutionary dynamics, in which the transcription of environmental data into genetic information is hindered by learning, instead of stimulated as is usually understood by the so-called Baldwin effect. The present results are discussed and compared with those reported in the literature. An interpretation is provided of the halting effect.</style></abstract><notes><style face="normal" font="default" size="100%">Dopazo, H Gordon, M B Perazzo, R Risau-Gusman, S Comparative Study Research Support, Non-U.S. Gov’t United States Bulletin of mathematical biology Bull Math Biol. 2001 Jan;63(1):117-34.</style></notes></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">A. Conesa</style></author><author><style face="normal" font="default" size="100%">Punt, P. J.</style></author><author><style face="normal" font="default" size="100%">van Luijk, N.</style></author><author><style face="normal" font="default" size="100%">van den Hondel, C. A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The secretion pathway in filamentous fungi: a biotechnological view</style></title><secondary-title><style face="normal" font="default" size="100%">Fungal Genet Biol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals Biotechnology/*methods Fungal Proteins/*genetics/*metabolism Fungi/*genetics/*metabolism Humans Recombinant Proteins/metabolism</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2001</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=11495573</style></url></web-urls></urls><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">33</style></volume><pages><style face="normal" font="default" size="100%">155-71</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The high capacity of the secretion machinery of filamentous fungi has been widely exploited for the production of homologous and heterologous proteins; however, our knowledge of the fungal secretion pathway is still at an early stage. Most of the knowledge comes from models developed in yeast and higher eukaryotes, which have served as reference for the studies on fungal species. In this review we compile the data accumulated in recent years on the molecular basis of fungal secretion, emphasizing the relevance of these data for the biotechnological use of the fungal cell and indicating how this information has been applied in attempts to create improved production strains. We also present recent emerging approaches that promise to provide answers to fundamental questions on the molecular genetics of the fungal secretory pathway.</style></abstract><notes><style face="normal" font="default" size="100%">&lt;p&gt;Conesa, A Punt, P J van Luijk, N van den Hondel, C A Review United States Fungal genetics and biology : FG &amp;amp; B Fungal Genet Biol. 2001 Aug;33(3):155-71.&lt;/p&gt;</style></notes></record></records></xml>